{"1261dc44dc070df92a06237083b8b31370252337": [["IntroductionTuberculosis (TB) is a communicable infectious disease spread through aerosolised droplets of Mycobacterium tuberculosis [1] .", [["IntroductionTuberculosis", "CHEMICAL", 0, 24], ["TB", "DISEASE", 26, 28], ["infectious disease", "DISEASE", 48, 66], ["Mycobacterium tuberculosis", "DISEASE", 106, 132], ["Mycobacterium tuberculosis", "SPECIES", 106, 132], ["Mycobacterium tuberculosis", "SPECIES", 106, 132], ["a communicable infectious disease spread", "PROBLEM", 33, 73], ["Mycobacterium tuberculosis", "PROBLEM", 106, 132], ["Mycobacterium tuberculosis", "OBSERVATION", 106, 132]]], ["In 2017, TB was one of the top ten causes of adult mortality in the world; among children, it was responsible for an estimated one million cases of incident TB and 253 000 reported deaths [2] .", [["TB", "DISEASE", 9, 11], ["TB", "DISEASE", 157, 159], ["deaths", "DISEASE", 181, 187], ["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89]]], ["Reported Philippine national TB estimates of paediatric cases in 2016 were 613 cases per 100 000 (95% CI = 403-822) among individuals 15-19 years old [5] .", [["CI", "TEST", 102, 104]]], ["Prior to our study, there were no known reports of estimates of TB prevalence or incidence in children under age 15 in the Philippines.", [["TB", "DISEASE", 64, 66], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["our study", "TEST", 9, 18]]], ["Addressing paediatric TB is important because children are exposed to adults with active TB and are vulnerable to develop severe disease [6, 7] .", [["TB", "DISEASE", 22, 24], ["TB", "DISEASE", 89, 91], ["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["active TB", "PROBLEM", 82, 91], ["severe disease", "PROBLEM", 122, 136]]], ["Additionally, they can serve as indicators of active TB transmission in the community.IntroductionGlobally, TB in children (<15 years old) make up an estimated 10% of all cases, but this is likely underestimated by at least 15-20% due to challenges in diagnostics, surveillance and control [5] [6] [7] [8] [9] [10] .", [["TB", "DISEASE", 53, 55], ["TB", "DISEASE", 108, 110], ["[5] [6] [7] [8] [9] [10]", "CHEMICAL", 290, 314], ["children", "ORGANISM", 114, 122], ["[5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 290, 314], ["children", "SPECIES", 114, 122], ["diagnostics", "TEST", 252, 263], ["surveillance", "TEST", 265, 277], ["active", "OBSERVATION_MODIFIER", 46, 52], ["TB", "OBSERVATION", 53, 55]]], ["Since the predominate focus of TB prevention and control in the Philippines is on the adult population, limited evidence exists regarding prevalence and risk factors for TB in Filipino children.", [["TB", "DISEASE", 31, 33], ["TB", "DISEASE", 170, 172], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 185, 193], ["TB prevention", "TREATMENT", 31, 44], ["TB", "PROBLEM", 170, 172], ["predominate", "OBSERVATION_MODIFIER", 10, 21], ["focus", "OBSERVATION_MODIFIER", 22, 27], ["TB", "OBSERVATION", 31, 33]]], ["This household-based cluster survey screened 5476 Filipino children for TB and identified a prevalence of positive Mantoux Tuberculin Skin Tests (TST) as high as 29% in some villages.", [["TB", "DISEASE", 72, 74], ["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["TB", "PROBLEM", 72, 74], ["positive Mantoux Tuberculin", "PROBLEM", 106, 133], ["Skin Tests", "TEST", 134, 144], ["TST", "TEST", 146, 149], ["Skin", "ANATOMY", 134, 138]]], ["We wanted to know if these aggregated clusters of TST-positive children were associated with distance to health care facilities and resources.", [["TST", "GENE_OR_GENE_PRODUCT", 50, 53], ["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71]]], ["We hypothesised that living farther from health care resources contributed to TST positivity, which we used as a proxy for latent TB infection (LTBI).IntroductionThe primary health care facilities in the Philippines are Rural Health Units (RHUs), which are public community health clinics stationed in each municipality/town.", [["latent TB infection", "DISEASE", 123, 142], ["LTBI", "DISEASE", 144, 148], ["TST positivity", "PROBLEM", 78, 92], ["latent TB infection", "PROBLEM", 123, 142], ["TB", "OBSERVATION_MODIFIER", 130, 132], ["infection", "OBSERVATION", 133, 142]]], ["The Department of Health's National Tuberculosis Programme (NTP) through its Regional Offices and Provincial Health Office (PHO), is responsible for TB control at the regional and provincial levels, respectively [12] .", [["Tuberculosis", "DISEASE", 36, 48], ["TB", "DISEASE", 149, 151]]], ["The PHO provides support to the RHUs through technical oversight, and the distribution of TB pharmaceutical and diagnostic supplies.", [["TB", "DISEASE", 90, 92], ["PHO", "PROTEIN", 4, 7], ["The PHO", "TREATMENT", 0, 7]]], ["RHUs then provide TB diagnostics and treatment via Direct Observed Therapy, Short Course (DOTS) free of cost [12] [13] [14] .", [["TB", "DISEASE", 18, 20], ["TB diagnostics", "TREATMENT", 18, 32], ["treatment", "TREATMENT", 37, 46], ["Direct Observed Therapy", "TREATMENT", 51, 74]]], ["In Bohol, residents rely on the RHUs for medical care as private health care facilities are expensive and local village clinics, known as barangay health stations (usually manned by a midwife and volunteer barangay health workers), are unable to provide TB specialised care [5] .", [["TB", "DISEASE", 254, 256], ["medical care", "TREATMENT", 41, 53]]], ["In 2016, the National Tuberculosis Prevalence Survey found 76% of adult TB cases sought treatment at their RHU, and 72.3% received their anti-TB medications from them [5] .", [["Tuberculosis", "DISEASE", 22, 34], ["TB", "DISEASE", 72, 74], ["their anti-TB medications", "TREATMENT", 131, 156]]], ["Since RHUs are paramount to the Filipino health infrastructure, they play a critical and salient role in TB identification, prevention and control in the Philippines, especially in areas of poverty.IntroductionBased on our concern that geographic isolation is related to increased risk for TB, we conducted a study to determine if paediatric TST-positive prevalence at the village (barangay) level was associated with travel-distance to health care facilities (RHU) or resources for TB control (PHO).", [["TB", "DISEASE", 105, 107], ["TB", "DISEASE", 290, 292], ["TB", "DISEASE", 483, 485], ["RHUs", "CANCER", 6, 10], ["TB identification", "TEST", 105, 122], ["geographic isolation", "PROBLEM", 236, 256], ["TB", "PROBLEM", 290, 292], ["a study", "TEST", 307, 314], ["paediatric TST", "TEST", 331, 345], ["TB control (PHO", "TREATMENT", 483, 498]]], ["To achieve this, we analysed the geospatial relationship between (a) village TST-positive prevalence and the travel-distance to a healthcare facility (PHO or RHU); (b) municipality TST-positive prevalence and the traveldistance to the PHO; and (c) the influence of socioeconomic determinants of health on travel-distance.MethodsThis study was approved by the Institutional Review Boards of the University of the Philippines Manila and Baylor College of Medicine (Protocol Number: H-37167).", [["H-37167", "CHEMICAL", 480, 487], ["village TST", "TEST", 69, 80], ["TST", "TEST", 181, 184]]], ["Census data of populations within municipality and village were obtained from the Republic of the Philippines Statistics Authority and the Bohol PHO [15] .", [["the Bohol PHO", "TREATMENT", 135, 148]]], ["For the purposes of this study, we define an 'island' as being a piece of land surrounded by a body of water, physically separated but belonging to the geopolitical jurisdiction of a municipality located in mainland Bohol.", [["body", "ANATOMY", 95, 99], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["this study", "TEST", 20, 30]]], ["Data for this study were derived from a large, randomised cluster survey as previously described by Murray et al. [11] .", [["this study", "TEST", 9, 19], ["large", "OBSERVATION_MODIFIER", 40, 45]]], ["The paediatric population was selected using the World Health Organization's EPI methods [16] of population proportion to size cluster sampling among randomly selected households within randomly selected villages between the years 2015 and 2018.", [["EPI methods", "TREATMENT", 77, 88], ["size", "OBSERVATION_MODIFIER", 122, 126]]], ["Children were screened using TSTs, with an induration of \u2a7e10 mm indicating LTBI (as recommended by the American Thoracic Society and Centers for Disease Control and Prevention for use in high-risk settings not considered endemic for HIV [17] ) and were marked as a positive test result.", [["LTBI", "DISEASE", 75, 79], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["HIV", "SPECIES", 233, 236], ["an induration", "PROBLEM", 40, 53], ["LTBI", "PROBLEM", 75, 79], ["Disease Control", "TREATMENT", 145, 160], ["high-risk settings", "TREATMENT", 187, 205], ["HIV", "PROBLEM", 233, 236], ["a positive test result", "PROBLEM", 263, 285], ["induration", "OBSERVATION", 43, 53], ["Thoracic", "ANATOMY", 112, 120]]], ["For this study, we included all TST-positive children in the analysis, which included both LTBI and the 16 active TB disease cases [11] .", [["LTBI", "DISEASE", 91, 95], ["TB disease", "DISEASE", 114, 124], ["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["this study", "TEST", 4, 14], ["all TST", "TEST", 28, 35], ["the analysis", "TEST", 57, 69]]], ["Locations of the villages, municipal RHUs and the PHO included in this study are indicated in Figure 1 .", [["PHO", "DNA", 50, 53], ["the PHO", "TEST", 46, 53], ["this study", "TEST", 66, 76]]], ["Since the island-wide TST-positive prevalence was found to be 6.5% [11] , we used this prevalence as the cut-point and calculated the proportion of villages in each municipality with \u2a7e6.5% as an indicator of high prevalence of LTBI.", [["LTBI", "DISEASE", 227, 231], ["wide TST", "TEST", 17, 25], ["LTBI", "PROBLEM", 227, 231], ["wide", "OBSERVATION_MODIFIER", 17, 21], ["LTBI", "OBSERVATION", 227, 231]]], ["We calculated the prevalence of TST-positivity in the municipalities as an indicator of exposure burdens (Table 1 ) and also calculated TST-positive prevalence by village (Supplemental Table) .MethodsPolitical boundaries of municipalities and villages were obtained through PhilGIS \u00a9 (Philippine GIS Data Clearinghouse, To understand if locations with high prevalence were clusters of TST positivity, we conducted a hot spot analysis of TST-positive prevalence by village using the Optimized Hot Spot Analysis tool in ArcGIS( Fig. 3 ) [19] .", [["TST", "TEST", 32, 35], ["exposure burdens", "PROBLEM", 88, 104], ["calculated TST", "TEST", 125, 139], ["TST positivity", "PROBLEM", 385, 399], ["a hot spot analysis", "TEST", 414, 433], ["TST", "TEST", 437, 440], ["Spot Analysis", "TEST", 496, 509]]], ["The hot spot analysis uses the Getis-Ord Gi* statistic to calculate each point's z-score, P value and confidence level to determine if clusters are spatial in nature or due to random chance [20] [21] [22] [23] .", [["The hot spot analysis", "TEST", 0, 21], ["P value", "TEST", 90, 97], ["confidence level", "TEST", 102, 118]]], ["This tool examines each individual value and then compares to the neighbouring values to determine if there is significant clustering. z-Scores that indicate statistically lower prevalence than expected are considered 'cold spots' and coloured blue, z-scores that statistically high are considered 'hot spots' and coloured red, and z-scores close to zero are considered 'not significant' and coloured grey [22] .", [["This tool", "TEST", 0, 9], ["significant clustering", "PROBLEM", 111, 133], ["z-Scores", "TEST", 135, 143], ["'cold spots'", "PROBLEM", 218, 230], ["coloured blue", "PROBLEM", 235, 248], ["z-scores", "TEST", 332, 340], ["significant", "OBSERVATION_MODIFIER", 111, 122], ["clustering", "OBSERVATION", 123, 133]]], ["Confidence levels are derived from z-scores and are based at 90%, 95% and 99% [23] .MethodsIn a separate analysis, we conducted two regression analyses to analyse predictors of TST positivity in Stata v.14.2 \u00a9 (Statacorp, College Station, TX, USA).", [["Confidence levels", "TEST", 0, 17], ["z-scores", "TEST", 35, 43], ["TST positivity", "TEST", 177, 191], ["Stata", "TEST", 195, 200]]], ["First, we used a linear regression analysis to examine the association between distance to health care facilities and TST-positive prevalence by municipality and village (Fig. 4) .", [["a linear regression analysis", "TEST", 15, 43], ["TST", "TEST", 118, 121]]], ["Distance between points (village to RHU, village to PHO and RHU to PHO) was calculated using travel distance, which we define as the common travel route in physical distance by kilometres (km) and in trip time by minutes (min), known as time-distance, based on the car travel function using Google Maps.", [["PHO", "DNA", 52, 55], ["PHO", "DNA", 67, 70]]], ["To reduce variability in time-distance by car as a result of heavy traffic, car travel times were calculated in one time frame during the middle of the night in Bohol.", [["variability", "OBSERVATION_MODIFIER", 10, 21]]], ["For the island villages of mainland Bohol who were enrolled in the study (16 total), travel distance to RHUs and the PHO combined Euclidean distance over bodies of water connecting each island's ports and the travel distance from the port to the health care facility on mainland Bohol.", [["PHO", "DNA", 117, 120], ["the study", "TEST", 63, 72], ["the PHO combined Euclidean distance over bodies of water connecting each island's ports", "TREATMENT", 113, 200], ["mainland Bohol", "TREATMENT", 270, 284]]], ["All geocoded data including coordinates and distance data were double entered to increase internal reliability and quality assurance.MethodsLastly, our logistic regression combined socioeconomic determinants of health with our distance data to analyse the role of poverty with access to healthcare providers and TST positivity.", [["All geocoded data", "TEST", 0, 17], ["distance data", "TEST", 44, 57], ["TST positivity", "TEST", 312, 326]]], ["Poverty indicators were needed for the delivery of targeted interventions to the most disadvantaged communities through housing development, assistance and resources [25, 26] .", [["the delivery of targeted interventions", "TREATMENT", 35, 73]]], ["The PDMS was implemented from 2004-2010 as a province-wide household-based community survey of Bohol to determine the level of poverty in health (water sources, sanitation, child malnutrition and child mortality), economic (income threshold, food threshold and unemployment) and social factors (housing, school dropouts, land tenure and crime incidence) by both municipality and village [25, 27] .", [["malnutrition", "DISEASE", 179, 191], ["The PDMS", "TREATMENT", 0, 8], ["Bohol", "TREATMENT", 95, 100]]], ["Percentages of poverty indicators and TST-positive prevalence were analysed at the village level for comparisons.", [["poverty indicators", "TEST", 15, 33], ["TST", "TEST", 38, 41]]], ["Each variable was evaluated by univariate analysis to assess their influence in predicting TST positivity.", [["univariate analysis", "TEST", 31, 50]]], ["Variables with P < 0.25 were entered into the multivariate model, and we used a backwards stepwise approach to eliminate variables with the highest P values until the final variables met the P < 0.05 cut-off.", [["a backwards stepwise approach", "TREATMENT", 78, 107]]], ["This approach helped us control for effect modifiers, confounders, identify independent risk factors associated with TST-positivity and estimate variable relationships.ResultsThe distribution of high TST-positive prevalence appeared to be the highest in the municipalities that had the most remote and isolated villages.", [["TST", "PROTEIN", 117, 120], ["effect modifiers", "TREATMENT", 36, 52], ["independent risk factors", "PROBLEM", 76, 100], ["TST", "TEST", 117, 120], ["high TST-positive prevalence", "PROBLEM", 195, 223], ["highest", "OBSERVATION_MODIFIER", 243, 250]]], ["Among the 14 participating municipalities, President Carlos P. Garcia (7/10, 70%), Bien Unido (4/6, 67%) and Inabanga (14/24, 58%) had the highest proportion of villages with a TST-positive prevalence \u2a7e6.5% (Table 1) .", [["Inabanga", "TEST", 109, 117], ["a TST", "TEST", 175, 180]]], ["These three municipalities are coastal and contain 13/16 (81%) of the villages located on islands that were randomly selected for inclusion as clusters in the study.", [["the study", "TEST", 155, 164], ["coastal", "ANATOMY_MODIFIER", 31, 38]]], ["The distribution of village TST-positive prevalence (Supplemental Table) was mapped to visualize the varying burden of disease across Bohol (Fig. 2) .", [["village TST", "TEST", 20, 31], ["Supplemental Table)", "TREATMENT", 53, 72], ["disease", "PROBLEM", 119, 126], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["varying", "OBSERVATION_MODIFIER", 101, 108], ["burden", "OBSERVATION_MODIFIER", 109, 115], ["disease", "OBSERVATION", 119, 126]]], ["The choropleth map showed that villages with the highest prevalence were located on the northeast section of Bohol (with the exception of Inabanga on the northwestern side) and were near the coast.", [["The choropleth map", "TEST", 0, 18], ["Bohol", "TREATMENT", 109, 114], ["highest", "OBSERVATION_MODIFIER", 49, 56], ["coast", "ANATOMY_MODIFIER", 191, 196]]], ["Island villages of Gaus (29%), Campamanog (23%) and Bilangbilangan Diot (22%) were in the top ten for highest TST-positive prevalence [11] .", [["Gaus", "TEST", 19, 23], ["Campamanog", "TEST", 31, 41], ["Bilangbilangan Diot", "TREATMENT", 52, 71], ["highest TST", "TEST", 102, 113], ["Gaus", "ANATOMY", 19, 23]]], ["The hot spot analysis was consistent with burden of TST positivity.", [["The hot spot analysis", "TEST", 0, 21], ["TST positivity", "PROBLEM", 52, 66], ["consistent with", "UNCERTAINTY", 26, 41]]], ["Hot spots clusters were identified in Inabanga, Sagbayan and President Carlos P. Garcia (Fig. 3) .", [["Hot spots clusters", "PROBLEM", 0, 18]]], ["Cold spots The linear regression demonstrated time-distance was a stronger variable than Euclidean distance with regard to the effect of travel on TST-positivity (Fig. 4A-F) .", [["Cold spots", "PROBLEM", 0, 10], ["TST", "TEST", 147, 150], ["spots", "OBSERVATION", 5, 10], ["linear", "OBSERVATION_MODIFIER", 15, 21], ["regression", "OBSERVATION_MODIFIER", 22, 32]]], ["Analysis of RHUs to the PHO in kilometres (P = 0.14, r = 0.42) and time-distance (P = 0.09, r = 0.47) had a weak association with TST-positive prevalence ( Fig. 4A and B) .", [["PHO", "DNA", 24, 27], ["TST", "PROTEIN", 130, 133], ["P", "TEST", 43, 44], ["r", "TEST", 53, 54], ["P", "TEST", 82, 83], ["a weak association", "PROBLEM", 106, 124], ["TST", "TEST", 130, 133]]], ["However, village distance to the PHO both in kilometres (P < 0.001, r = 0.24) and time-distance (P < 0.0001, r = 0.32) had a stronger association and correlation ( Fig. 4C and D) , with one island village with a prevalence of 29% being located 4.7 h away from the PHO.", [["PHO", "DNA", 33, 36], ["PHO", "DNA", 264, 267], ["P", "TEST", 57, 58], ["r", "TEST", 68, 69], ["P", "TEST", 97, 98]]], ["Lastly, village distance to the municipal RHU in kilometres (P = 0.34, r = 0.07) did not have a strong effect on TST positivity but distance in time did (P = 0.006, r = 0.20), indicating a disparity between distance in kilometres and time-distance ( Fig. 4E and F) .ResultsSince socioeconomic factors can also influence access to transportation and ability to seek healthcare, we wanted to determine these influences in a logistic regression prediction model.", [["P", "TEST", 61, 62], ["TST positivity", "TEST", 113, 127], ["P", "TEST", 154, 155]]], ["The majority of the population is below the income threshold (60.8%) and almost half of the population are below the food threshold (45.8%).", [["majority", "OBSERVATION_MODIFIER", 4, 12], ["population", "OBSERVATION_MODIFIER", 20, 30]]], ["Almost 20% of the population do not have access to potable drinking water, experience unemployment and experience total deprivation across all poverty indicators.ResultsBased on univariate analysis, income threshold, school dropouts and total deprivation had an effect on TST-positivity in addition to distance to the PHO in kilometres and minutes.", [["PHO", "DNA", 318, 321], ["total deprivation", "TREATMENT", 114, 131], ["univariate analysis", "TEST", 178, 197], ["total deprivation", "TREATMENT", 237, 254], ["TST", "TEST", 272, 275]]], ["However, due to collinearity of the individual socioeconomic variables, we ran a multivariate logistic regression using total deprivation for all poverty indicators along with geospatial indicators to test for influence on our outcome of villages with TST-positivity \u2a7e6.5% prevalence (Table 3 ).", [["the individual socioeconomic variables", "PROBLEM", 32, 70], ["total deprivation", "TREATMENT", 120, 137], ["geospatial indicators", "TEST", 176, 197], ["TST", "TEST", 252, 255]]], ["Our final model found distance remained significant with travel time in minutes to the PHO with a P = 0.03 (OR = 1.01, 95% CI = 1.00-1.02) and our socioeconomic factors were not independently associated with TST positivity.", [["CI", "TEST", 123, 125], ["our socioeconomic factors", "PROBLEM", 143, 168], ["TST positivity", "PROBLEM", 208, 222], ["distance", "OBSERVATION_MODIFIER", 22, 30], ["significant", "OBSERVATION_MODIFIER", 40, 51]]], ["Total deprivation dropped out of the model with a P = 0.39.", [["Total deprivation", "TEST", 0, 17]]], ["After removing total deprivation from the model, travel time in minutes to the PHO was still significantly associated with villages with a TST positivity \u2a7e6.5% at P = 0.005, OR = 1.01 (95% CI 1.00-1.02).", [["total deprivation", "TREATMENT", 15, 32], ["a TST positivity", "TEST", 137, 153], ["P", "TEST", 163, 164], ["CI", "TEST", 189, 191]]], ["Since, travel time in minutes to the PHO was an independent factor that predicted high TST positivity, we decided to pursue one last analysis to determine what threshold of travel time created a significant increase in TST positive prevalence.", [["PHO", "PROTEIN", 37, 40], ["high TST positivity", "PROBLEM", 82, 101], ["one last analysis", "TEST", 124, 141], ["a significant increase in TST positive prevalence", "PROBLEM", 193, 242], ["significant", "OBSERVATION_MODIFIER", 195, 206], ["increase", "OBSERVATION_MODIFIER", 207, 215]]], ["Based on univariate analysis, we found children who live an hour or more away from the PHO had three times greater odds of TST positivity compared to children who lives less than an hour away from the PHO (P = 0.003, OR = 3.1, 95% CI = 1.5-6.7).DiscussionOur geospatial analysis demonstrates that high paediatric TST-positive prevalence in Bohol, Philippines is associated with living in remote villages.", [["children", "ORGANISM", 39, 47], ["children", "ORGANISM", 150, 158], ["children", "SPECIES", 39, 47], ["children", "SPECIES", 150, 158], ["univariate analysis", "TEST", 9, 28], ["TST positivity", "PROBLEM", 123, 137], ["CI", "TEST", 231, 233], ["geospatial analysis", "TEST", 259, 278], ["high paediatric TST", "TEST", 297, 316]]], ["Increased time-distance from villages to the PHO (the government source of resources for TB prevention and control for the province) is a likely barrier as some island villages were more than 4 h away by car and water taxi.", [["TB", "DISEASE", 89, 91], ["the PHO", "TREATMENT", 41, 48], ["TB prevention", "TREATMENT", 89, 102]]], ["Our analysis highlights that this problem is exacerbated among island villages of Bohol, putting them at higher risk for TST-positivity compared to mainland villages.", [["Our analysis", "TEST", 0, 12], ["Bohol", "TREATMENT", 82, 87], ["TST", "TEST", 121, 124]]], ["The same is also true for health care providers, where these travel constraints could make it difficult to effectively and regularly deliver healthcare services, supplies and resources to the RHUs and village-level Barangay Health Stations, contributing to service and supply shortages.DiscussionTB risk is intertwined with socioeconomic conditions [7] .", [["DiscussionTB", "DISEASE", 286, 298]]], ["Risk of paediatric TB infection increases in relationship to age, poverty, housing structure, overcrowding within and outside of the home, geographic location, community prevalence, immune status and malnutrition [3, 6, 28] .", [["TB infection", "DISEASE", 19, 31], ["malnutrition", "DISEASE", 200, 212], ["paediatric TB infection", "PROBLEM", 8, 31], ["malnutrition", "PROBLEM", 200, 212], ["paediatric", "OBSERVATION_MODIFIER", 8, 18], ["TB", "OBSERVATION", 19, 21]]], ["Previous research from studies in Bohol found poverty and socioeconomic deprivation to be high in the north and northeast side of the province, which supports our finding of high prevalence of TST-positivity in this area (in President Carlos P. Garcia, Bien Unido and Inabanga) [24].", [["Previous research from studies", "TEST", 0, 30], ["socioeconomic deprivation", "PROBLEM", 58, 83], ["TST", "TEST", 193, 196]]], ["Canares [29] explained this is due to an 'urban bias,' meaning resources and funding, particularly from non-governmental organizations (NGOs), are distributed in areas closest to the capital city of Tagbilaran and are inadequate in municipalities and villages that are farther away.", [["Tagbilaran", "TREATMENT", 199, 209]]], ["He showed that island and coastal communities are the farthest from the PHO and have minimal to no NGO presence.", [["communities", "ANATOMY", 34, 45], ["PHO", "DNA", 72, 75]]], ["This funding bias was attributed by Canares [29] to the expenses of transporting healthcare supplies across the island, and in a similar manner, the expense of residents to get to the clinics for the same reasons.", [["island", "OBSERVATION", 112, 118]]], ["MacPherson et al. (2019) also showed a geospatial relationship between an increase in TB transmission as there are increases in poorer neighbourhoods that are farther from the TB clinics [30] .", [["TB", "DISEASE", 86, 88], ["TB", "DISEASE", 176, 178], ["TB transmission", "TREATMENT", 86, 101], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["TB", "OBSERVATION", 86, 88], ["increases", "OBSERVATION_MODIFIER", 115, 124]]], ["We, too, found support for this phenomenon which is known as the 'inverse case law' coined by Hart (1971) in the Lancet [31] .", [["this phenomenon", "PROBLEM", 27, 42]]], ["'Inverse case law' means that people often most in need of specialized care tend to live the farthest from their healthcare providers in rural areas [30, 31] .", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36]]], ["However, more research is needed to better understand how other socioeconomic factors influence access to TB care and subsequently paediatric transmission.DiscussionThis study has some noteworthy limitations.", [["TB", "DISEASE", 106, 108], ["TB care", "TREATMENT", 106, 113], ["This study", "TEST", 165, 175]]], ["First, using Google Maps to calculate time-distance is based on the assumption of travel by private vehicle, limiting our ability to consider multiple modes of travel to a location [20] .", [["Google Maps", "TEST", 13, 24]]], ["Travel time across water may be subject to inconsistencies based on weather, sea conditions and other variables such as the time it takes for the boat to be filled with passengers before it could leave the port.", [["the port", "TREATMENT", 202, 210]]], ["Second, we were unable to build a predictive model of TST-positivity because PDMS poverty variables were largely collinear, thereby impacting our model building strategies.", [["TST", "TEST", 54, 57], ["PDMS poverty variables", "PROBLEM", 77, 99]]], ["Due to this collinearity, we opted to use the variable of total deprivation, which incorporates data from all core poverty indicators.", [["total deprivation", "TREATMENT", 58, 75]]], ["Third, our socioeconomic indicators were based on community-level data collected between 2004 and 2010, while our study was conducted around 10 years later from 2015-2018.", [["our study", "TEST", 110, 119]]], ["A more reliable analysis could be produced if we had data available that was temporally collected at the time of the prevalence survey.", [["A more reliable analysis", "TEST", 0, 24]]], ["Fourth, TST positivity was used as a proxy for LTBI, but could overestimate true prevalence in cases of cross-reaction with BCG vaccination.", [["LTBI", "DISEASE", 47, 51], ["TST positivity", "TEST", 8, 22], ["LTBI", "PROBLEM", 47, 51], ["cross-reaction", "PROBLEM", 104, 118], ["BCG vaccination", "TREATMENT", 124, 139]]], ["As we discussed in our prior publication [11] , cross-reactions should be low since BCG is administered at the time of birth in the Philippines, and TST positivity was significantly associated with older age, indicating true exposure.", [["cross-reactions", "TREATMENT", 48, 63], ["BCG", "TREATMENT", 84, 87], ["TST positivity", "TEST", 149, 163], ["true exposure", "PROBLEM", 220, 233], ["true exposure", "OBSERVATION", 220, 233]]], ["While interferon gamma release assays (IGRA) might improve specificity, the WHO does not support the use of IGRA in low-and middle-income countries due to insufficient data, prohibitive cost and lacking laboratory infrastructure [32] .", [["interferon gamma", "GENE_OR_GENE_PRODUCT", 6, 22], ["interferon gamma", "PROTEIN", 6, 22], ["IGRA", "PROTEIN", 108, 112], ["interferon gamma release assays", "TEST", 6, 37], ["IGRA", "TEST", 108, 112], ["insufficient data", "PROBLEM", 155, 172], ["prohibitive cost", "PROBLEM", 174, 190]]], ["It is also possible that prevalence was underestimated since we used the cut-off of \u2a7e10 mm to determine TST positivity, which would then risk our missing a positive response in malnourished children, where the recommended cut-off is \u2a7e5 mm [17] .", [["children", "ORGANISM", 190, 198], ["children", "SPECIES", 190, 198], ["TST positivity", "TEST", 104, 118], ["also possible", "UNCERTAINTY", 6, 19]]], ["Lastly, we acknowledge distance to health facilities is only one factor associated with TB burden and many other social, economic, political and environmental factors play a role in reduced access to care that are beyond the scope of this study.DiscussionIn conclusion, we found that distance in time, especially if longer than an hour's drive, was significantly associated with high TST-positive prevalence in children, even when controlling for socioeconomic factors.", [["TB", "DISEASE", 88, 90], ["children", "ORGANISM", 411, 419], ["children", "SPECIES", 411, 419], ["TB burden", "PROBLEM", 88, 97], ["this study", "TEST", 234, 244]]], ["Improving access to resources for TB prevention and control should be focused on those villages that are more than an hour drive from the PHO.", [["TB", "DISEASE", 34, 36], ["PHO", "DNA", 138, 141], ["TB prevention", "TREATMENT", 34, 47], ["control", "TREATMENT", 52, 59], ["the PHO", "TREATMENT", 134, 141]]], ["Although many TB control strategies typically focus on older populations, paediatric infections are indicative of adult transmission patterns, and it is critical to identify and treat all age groups exposed.", [["TB", "DISEASE", 14, 16], ["infections", "DISEASE", 85, 95], ["many TB control strategies", "PROBLEM", 9, 35], ["paediatric infections", "PROBLEM", 74, 95], ["adult transmission patterns", "PROBLEM", 114, 141], ["many", "OBSERVATION_MODIFIER", 9, 13], ["TB", "OBSERVATION", 14, 16], ["infections", "OBSERVATION", 85, 95], ["indicative of", "UNCERTAINTY", 100, 113]]], ["It is paramount for health care providers to begin conducting outreach in these high-risk villages in the form of screening and treatment.", [["screening", "TEST", 114, 123], ["treatment", "TREATMENT", 128, 137]]]], "PMC5052580": [["Overexpression of PTEN ameliorates CIA development ::: ResultsTo determine whether PTEN had anti-arthritic effect, CIA induced mice were injected with either PTEN overexpression or mock vector once weekly.", [["CIA", "DISEASE", 35, 38], ["PTEN", "GENE_OR_GENE_PRODUCT", 18, 22], ["CIA", "PATHOLOGICAL_FORMATION", 35, 38], ["PTEN", "GENE_OR_GENE_PRODUCT", 83, 87], ["mice", "ORGANISM", 127, 131], ["PTEN", "GENE_OR_GENE_PRODUCT", 158, 162], ["PTEN", "PROTEIN", 18, 22], ["PTEN", "PROTEIN", 83, 87], ["PTEN", "PROTEIN", 158, 162], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 127, 131], ["PTEN", "PROBLEM", 83, 87], ["anti-arthritic effect", "PROBLEM", 92, 113], ["CIA induced mice", "TREATMENT", 115, 131]]], ["PTEN overexpression significantly downregulated the severity of arthritis in CIA induced mice (Fig. 1A).", [["arthritis", "DISEASE", 64, 73], ["CIA", "DISEASE", 77, 80], ["PTEN", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 89, 93], ["PTEN", "PROTEIN", 0, 4], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["PTEN overexpression", "PROBLEM", 0, 19], ["arthritis", "PROBLEM", 64, 73], ["significantly", "OBSERVATION_MODIFIER", 20, 33], ["downregulated", "OBSERVATION_MODIFIER", 34, 47], ["severity", "OBSERVATION_MODIFIER", 52, 60], ["arthritis", "OBSERVATION", 64, 73], ["CIA", "ANATOMY", 77, 80]]], ["The concentrations of total IgG, IgG1, and IgG2a in the serum were significantly decreased in mice injected with PTEN overexpression compared to mock group (Fig. 1B).", [["serum", "ANATOMY", 56, 61], ["IgG", "GENE_OR_GENE_PRODUCT", 28, 31], ["IgG1", "GENE_OR_GENE_PRODUCT", 33, 37], ["IgG2a", "GENE_OR_GENE_PRODUCT", 43, 48], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["mice", "ORGANISM", 94, 98], ["PTEN", "GENE_OR_GENE_PRODUCT", 113, 117], ["total IgG", "PROTEIN", 22, 31], ["IgG1", "PROTEIN", 33, 37], ["IgG2a", "PROTEIN", 43, 48], ["PTEN", "PROTEIN", 113, 117], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["total IgG", "TEST", 22, 31], ["IgG1", "TREATMENT", 33, 37], ["IgG2a", "TREATMENT", 43, 48], ["the serum", "TEST", 52, 61], ["PTEN overexpression", "PROBLEM", 113, 132], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["PTEN overexpression significantly reduced the degree of inflammation, bone damage, and cartilage damage (Fig. 1C).", [["bone", "ANATOMY", 70, 74], ["cartilage", "ANATOMY", 87, 96], ["inflammation", "DISEASE", 56, 68], ["bone damage", "DISEASE", 70, 81], ["cartilage damage", "DISEASE", 87, 103], ["PTEN", "GENE_OR_GENE_PRODUCT", 0, 4], ["bone", "TISSUE", 70, 74], ["cartilage", "TISSUE", 87, 96], ["PTEN", "PROTEIN", 0, 4], ["PTEN overexpression", "PROBLEM", 0, 19], ["inflammation", "PROBLEM", 56, 68], ["bone damage", "PROBLEM", 70, 81], ["cartilage damage", "PROBLEM", 87, 103], ["significantly", "OBSERVATION_MODIFIER", 20, 33], ["reduced", "OBSERVATION_MODIFIER", 34, 41], ["degree", "OBSERVATION_MODIFIER", 46, 52], ["inflammation", "OBSERVATION", 56, 68], ["bone", "ANATOMY", 70, 74], ["damage", "OBSERVATION", 75, 81], ["cartilage", "ANATOMY", 87, 96], ["damage", "OBSERVATION", 97, 103]]], ["Immunohistochemical analysis revealed that injection with PTEN overexpression vector significantly suppressed the expression of proinflammatory cytokines and osteoclastogenesis related factor such as RANKL and TRAP in joints compared to CIA mice treated with mock vector (Fig. 1D,E).", [["joints", "ANATOMY", 218, 224], ["PTEN", "GENE_OR_GENE_PRODUCT", 58, 62], ["RANKL", "GENE_OR_GENE_PRODUCT", 200, 205], ["TRAP", "GENE_OR_GENE_PRODUCT", 210, 214], ["joints", "MULTI-TISSUE_STRUCTURE", 218, 224], ["mice", "ORGANISM", 241, 245], ["PTEN", "PROTEIN", 58, 62], ["proinflammatory cytokines", "PROTEIN", 128, 153], ["osteoclastogenesis related factor", "PROTEIN", 158, 191], ["RANKL", "PROTEIN", 200, 205], ["TRAP", "PROTEIN", 210, 214], ["mice", "SPECIES", 241, 245], ["mice", "SPECIES", 241, 245], ["Immunohistochemical analysis", "TEST", 0, 28], ["PTEN overexpression vector", "PROBLEM", 58, 84], ["proinflammatory cytokines", "PROBLEM", 128, 153], ["osteoclastogenesis related factor", "PROBLEM", 158, 191], ["RANKL and TRAP in joints", "TREATMENT", 200, 224], ["mock vector", "TREATMENT", 259, 270], ["proinflammatory cytokines", "OBSERVATION", 128, 153], ["joints", "ANATOMY", 218, 224]]], ["Our results suggested that PTEN overexpression could suppress CIA severity, thus reducing inflammatory response and osteoclastogenesis in joint.Overexpression of PTEN regulates reciprocal Th17/Treg balance in CIA ::: ResultsTo determine whether PTEN overexpression could attenuate dysregulated balance between Th17 and Treg, we examined the differentiation of Th17 and Treg in CIA mice.", [["joint", "ANATOMY", 138, 143], ["Th17/Treg", "ANATOMY", 188, 197], ["Th17", "ANATOMY", 310, 314], ["Treg", "ANATOMY", 319, 323], ["Th17", "ANATOMY", 360, 364], ["Treg", "ANATOMY", 369, 373], ["CIA", "DISEASE", 62, 65], ["PTEN", "GENE_OR_GENE_PRODUCT", 27, 31], ["CIA", "GENE_OR_GENE_PRODUCT", 62, 65], ["joint", "MULTI-TISSUE_STRUCTURE", 138, 143], ["PTEN", "GENE_OR_GENE_PRODUCT", 162, 166], ["Treg", "CELL", 193, 197], ["PTEN", "GENE_OR_GENE_PRODUCT", 245, 249], ["Th17", "CELL", 310, 314], ["Treg", "CELL", 319, 323], ["Th17", "CELL", 360, 364], ["Treg", "CELL", 369, 373], ["mice", "ORGANISM", 381, 385], ["PTEN", "PROTEIN", 27, 31], ["PTEN", "PROTEIN", 162, 166], ["PTEN", "PROTEIN", 245, 249], ["Th17", "CELL_TYPE", 310, 314], ["Treg", "CELL_TYPE", 319, 323], ["Th17", "CELL_TYPE", 360, 364], ["Treg", "CELL_TYPE", 369, 373], ["mice", "SPECIES", 381, 385], ["mice", "SPECIES", 381, 385], ["PTEN overexpression", "PROBLEM", 27, 46], ["CIA severity", "PROBLEM", 62, 74], ["reducing inflammatory response", "PROBLEM", 81, 111], ["osteoclastogenesis in joint", "PROBLEM", 116, 143], ["PTEN overexpression", "PROBLEM", 245, 264], ["dysregulated balance", "PROBLEM", 281, 301], ["inflammatory response", "OBSERVATION", 90, 111], ["osteoclastogenesis", "OBSERVATION", 116, 134], ["joint", "ANATOMY", 138, 143], ["CIA", "ANATOMY", 209, 212]]], ["The overexpression of PTEN reduced Th17 differentiation in the spleen tissues of CIA induced mice.", [["Th17", "ANATOMY", 35, 39], ["spleen tissues", "ANATOMY", 63, 77], ["PTEN", "GENE_OR_GENE_PRODUCT", 22, 26], ["Th17", "CELL", 35, 39], ["spleen tissues", "TISSUE", 63, 77], ["mice", "ORGANISM", 93, 97], ["PTEN", "PROTEIN", 22, 26], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["PTEN", "PROBLEM", 22, 26], ["PTEN", "OBSERVATION", 22, 26], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["Th17 differentiation", "OBSERVATION", 35, 55], ["spleen", "ANATOMY", 63, 69], ["tissues", "ANATOMY_MODIFIER", 70, 77], ["CIA", "ANATOMY", 81, 84]]], ["However, the differentiation of Treg cell was promoted in CIA induced mice injected with PTEN overexpression vector (Fig. 2A).", [["Treg cell", "ANATOMY", 32, 41], ["Treg cell", "CELL", 32, 41], ["CIA", "ORGANISM", 58, 61], ["mice", "ORGANISM", 70, 74], ["PTEN", "GENE_OR_GENE_PRODUCT", 89, 93], ["Treg cell", "CELL_TYPE", 32, 41], ["PTEN overexpression vector", "DNA", 89, 115], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["PTEN overexpression vector", "TREATMENT", 89, 115], ["Treg cell", "OBSERVATION", 32, 41]]], ["It is well documented that T cell activation is involved in the pathogenesis of RA18.", [["T cell", "ANATOMY", 27, 33], ["T cell", "CELL", 27, 33], ["RA18", "GENE_OR_GENE_PRODUCT", 80, 84]]], ["In mixed lymphocyte reaction (MLR), the alloreactive T cell response was decreased in LBRM transfected with PTEN overexpression compared to that in the control (Fig. 2B).", [["lymphocyte", "ANATOMY", 9, 19], ["alloreactive T cell", "ANATOMY", 40, 59], ["LBRM", "ANATOMY", 86, 90], ["lymphocyte", "CELL", 9, 19], ["alloreactive T cell", "CELL", 40, 59], ["PTEN", "GENE_OR_GENE_PRODUCT", 108, 112], ["LBRM", "CELL_LINE", 86, 90], ["PTEN", "PROTEIN", 108, 112], ["mixed lymphocyte reaction", "PROBLEM", 3, 28], ["the alloreactive T cell response", "TEST", 36, 68], ["PTEN overexpression", "PROBLEM", 108, 127], ["mixed lymphocyte reaction", "OBSERVATION", 3, 28], ["alloreactive T cell response", "OBSERVATION", 40, 68], ["decreased", "OBSERVATION_MODIFIER", 73, 82]]], ["Additionally, PTEN overexpression decreased the number of IL-17 producing CD4+p-STAT705+ or p-STAT727+ T cells.", [["CD4+p-STAT705+", "ANATOMY", 74, 88], ["p-STAT727+ T cells", "ANATOMY", 92, 110], ["PTEN", "GENE_OR_GENE_PRODUCT", 14, 18], ["IL-17", "GENE_OR_GENE_PRODUCT", 58, 63], ["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["STAT705", "GENE_OR_GENE_PRODUCT", 80, 87], ["PTEN", "PROTEIN", 14, 18], ["CD4", "PROTEIN", 74, 77], ["STAT705", "PROTEIN", 80, 87], ["STAT727", "PROTEIN", 94, 101], ["T cells", "CELL_TYPE", 103, 110], ["PTEN overexpression", "PROBLEM", 14, 33], ["IL", "TEST", 58, 60], ["CD4", "TEST", 74, 77], ["decreased", "OBSERVATION_MODIFIER", 34, 43]]], ["However, the number of CD4+p-Foxp3+ T cells in the spleen tissues of CIA induced mice was significantly upregulated compared to that in the spleen tissues of mice treated with mock vector based on immunofluorescence confocal microscopy (Fig. 2C,D).", [["T cells", "ANATOMY", 36, 43], ["spleen tissues", "ANATOMY", 51, 65], ["spleen tissues", "ANATOMY", 140, 154], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["Foxp3", "GENE_OR_GENE_PRODUCT", 29, 34], ["T cells", "CELL", 36, 43], ["spleen tissues", "TISSUE", 51, 65], ["CIA", "ORGANISM", 69, 72], ["mice", "ORGANISM", 81, 85], ["spleen tissues", "TISSUE", 140, 154], ["mice", "ORGANISM", 158, 162], ["CD4", "PROTEIN", 23, 26], ["Foxp3", "PROTEIN", 29, 34], ["T cells", "CELL_TYPE", 36, 43], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 158, 162], ["mock vector", "TREATMENT", 176, 187], ["immunofluorescence confocal microscopy", "TEST", 197, 235], ["CD4+p-Foxp3", "OBSERVATION", 23, 34], ["spleen", "ANATOMY", 51, 57], ["CIA", "ANATOMY", 69, 72], ["spleen", "ANATOMY", 140, 146]]], ["These data suggested that PTEN overexpression ameliorated the imbalance between Th17 and Treg in CIA.Loss of p53 induces STAT3 activation ::: ResultsPreviously, p53 has been known as a modulator of STAT3 activation through significant reducing STAT3 phosphorylation and STAT3 DNA binding activity19.", [["Th17", "ANATOMY", 80, 84], ["Treg", "ANATOMY", 89, 93], ["PTEN", "GENE_OR_GENE_PRODUCT", 26, 30], ["Th17", "CELL", 80, 84], ["Treg", "CELL", 89, 93], ["p53", "GENE_OR_GENE_PRODUCT", 109, 112], ["STAT3", "GENE_OR_GENE_PRODUCT", 121, 126], ["p53", "GENE_OR_GENE_PRODUCT", 161, 164], ["STAT3", "GENE_OR_GENE_PRODUCT", 198, 203], ["STAT3", "GENE_OR_GENE_PRODUCT", 244, 249], ["STAT3", "GENE_OR_GENE_PRODUCT", 270, 275], ["DNA", "CELLULAR_COMPONENT", 276, 279], ["PTEN", "PROTEIN", 26, 30], ["Th17", "CELL_TYPE", 80, 84], ["Treg", "CELL_TYPE", 89, 93], ["p53", "PROTEIN", 109, 112], ["STAT3", "PROTEIN", 121, 126], ["p53", "PROTEIN", 161, 164], ["STAT3", "PROTEIN", 198, 203], ["STAT3", "PROTEIN", 244, 249], ["STAT3", "PROTEIN", 270, 275], ["These data", "TEST", 0, 10], ["PTEN overexpression", "PROBLEM", 26, 45], ["the imbalance", "PROBLEM", 58, 71], ["STAT3 activation", "PROBLEM", 198, 214], ["significant reducing STAT3 phosphorylation", "TREATMENT", 223, 265], ["STAT3 DNA binding activity", "TEST", 270, 296], ["CIA", "ANATOMY", 97, 100]]], ["The phosphorylation levels of STAT3 Tyr705 and Ser727 in p53 deficient mice splenocytes were increased compared to those of WT mice splenocytes (Fig. 3A,B).", [["splenocytes", "ANATOMY", 76, 87], ["splenocytes", "ANATOMY", 132, 143], ["STAT3", "GENE_OR_GENE_PRODUCT", 30, 35], ["Tyr705", "GENE_OR_GENE_PRODUCT", 36, 42], ["Ser727", "GENE_OR_GENE_PRODUCT", 47, 53], ["p53", "GENE_OR_GENE_PRODUCT", 57, 60], ["mice", "ORGANISM", 127, 131], ["splenocytes", "CELL", 132, 143], ["B", "CELL", 153, 154], ["STAT3 Tyr705", "PROTEIN", 30, 42], ["Ser727", "PROTEIN", 47, 53], ["p53", "PROTEIN", 57, 60], ["splenocytes", "CELL_TYPE", 76, 87], ["splenocytes", "CELL_TYPE", 132, 143], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 127, 131], ["The phosphorylation levels", "TEST", 0, 26], ["STAT3 Tyr705", "TEST", 30, 42], ["p53 deficient mice splenocytes", "PROBLEM", 57, 87], ["increased", "OBSERVATION_MODIFIER", 93, 102]]], ["Cells isolated from WT or p53 deficient mice were cultured under the condition of Th0 or Th17.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["p53", "GENE_OR_GENE_PRODUCT", 26, 29], ["mice", "ORGANISM", 40, 44], ["Th0", "CELL", 82, 85], ["Th17", "CELL", 89, 93], ["p53", "PROTEIN", 26, 29], ["Th0", "CELL_LINE", 82, 85], ["Th17", "CELL_TYPE", 89, 93], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["Cells", "TEST", 0, 5], ["WT", "TEST", 20, 22], ["p53 deficient mice", "TREATMENT", 26, 44]]], ["IL-17 production in p53\u2212/\u2212 mice was significantly increased compared to that in WT mice (Fig. 3C,D).", [["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["p53\u2212", "GENE_OR_GENE_PRODUCT", 20, 24], ["\u2212", "GENE_OR_GENE_PRODUCT", 25, 26], ["WT mice", "ORGANISM", 80, 87], ["IL-17", "PROTEIN", 0, 5], ["p53\u2212", "PROTEIN", 20, 24], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 83, 87], ["IL", "TEST", 0, 2]]], ["Gene expression of IL-17 and CCL20 which causes recruiting of IL\u201317 expressing cells20 in WT mice splenocytes was increased after stimulation with TGF-\u03b2 and IL-6.", [["splenocytes", "ANATOMY", 98, 109], ["IL-17", "GENE_OR_GENE_PRODUCT", 19, 24], ["CCL20", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL\u201317", "GENE_OR_GENE_PRODUCT", 62, 67], ["cells20", "GENE_OR_GENE_PRODUCT", 79, 86], ["WT mice", "ORGANISM", 90, 97], ["splenocytes", "CELL", 98, 109], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 147, 152], ["IL-6", "GENE_OR_GENE_PRODUCT", 157, 161], ["IL-17", "PROTEIN", 19, 24], ["CCL20", "PROTEIN", 29, 34], ["IL\u201317", "PROTEIN", 62, 67], ["cells20", "PROTEIN", 79, 86], ["splenocytes", "CELL_TYPE", 98, 109], ["TGF-\u03b2 and IL-6", "PROTEIN", 147, 161], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["IL", "TEST", 19, 21], ["CCL20", "TREATMENT", 29, 34], ["WT mice splenocytes", "TREATMENT", 90, 109], ["TGF", "TEST", 147, 150], ["IL", "TEST", 157, 159]]], ["But, mRNA expression of IL-17 and CCL20 was reduced significantly by p53 activator, nutlin-3a.", [["IL-17", "GENE_OR_GENE_PRODUCT", 24, 29], ["CCL20", "GENE_OR_GENE_PRODUCT", 34, 39], ["p53", "GENE_OR_GENE_PRODUCT", 69, 72], ["nutlin-3a", "GENE_OR_GENE_PRODUCT", 84, 93], ["IL-17", "PROTEIN", 24, 29], ["CCL20", "PROTEIN", 34, 39], ["p53", "PROTEIN", 69, 72], ["nutlin-3a", "PROTEIN", 84, 93], ["IL", "TEST", 24, 26], ["CCL20", "TEST", 34, 39]]], ["In contrast, bPV(HOpic), the inhibitor of PTEN, promoted gene expression of IL-17 and CCL20 (Fig. 3E).", [["bPV", "CHEMICAL", 13, 16], ["bPV", "CHEMICAL", 13, 16], ["HOpic", "CHEMICAL", 17, 22], ["bPV", "SIMPLE_CHEMICAL", 13, 16], ["HOpic", "SIMPLE_CHEMICAL", 17, 22], ["PTEN", "GENE_OR_GENE_PRODUCT", 42, 46], ["IL-17", "GENE_OR_GENE_PRODUCT", 76, 81], ["CCL20", "GENE_OR_GENE_PRODUCT", 86, 91], ["bPV", "PROTEIN", 13, 16], ["PTEN", "PROTEIN", 42, 46], ["IL-17", "PROTEIN", 76, 81], ["CCL20", "PROTEIN", 86, 91], ["bPV(HOpic)", "TREATMENT", 13, 23], ["the inhibitor of PTEN", "TREATMENT", 25, 46], ["IL", "TEST", 76, 78]]], ["Gene expression of PTEN was enhanced significantly by nutlin-3a.", [["nutlin-3a", "CHEMICAL", 54, 63], ["PTEN", "GENE_OR_GENE_PRODUCT", 19, 23], ["nutlin-3a", "GENE_OR_GENE_PRODUCT", 54, 63], ["PTEN", "PROTEIN", 19, 23], ["nutlin", "PROTEIN", 54, 60], ["PTEN", "PROBLEM", 19, 23], ["PTEN", "OBSERVATION", 19, 23]]], ["However, pifithrin-\u03b1, the inhibitor of p53, significantly decreased the mRNA level of PTEN in mice splenocytes (Fig. 3F).", [["splenocytes", "ANATOMY", 99, 110], ["pifithrin-\u03b1", "CHEMICAL", 9, 20], ["pifithrin-\u03b1", "CHEMICAL", 9, 20], ["pifithrin-\u03b1", "SIMPLE_CHEMICAL", 9, 20], ["p53", "GENE_OR_GENE_PRODUCT", 39, 42], ["PTEN", "GENE_OR_GENE_PRODUCT", 86, 90], ["mice", "ORGANISM", 94, 98], ["splenocytes", "CELL", 99, 110], ["p53", "PROTEIN", 39, 42], ["PTEN", "PROTEIN", 86, 90], ["splenocytes", "CELL_TYPE", 99, 110], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["pifithrin", "TEST", 9, 18], ["the inhibitor of p53", "TEST", 22, 42], ["PTEN in mice splenocytes", "PROBLEM", 86, 110]]], ["These results suggested that the inhibition of p53 under inflammatory milieu of RA might have enhanced inflammation.", [["RA", "DISEASE", 80, 82], ["inflammation", "DISEASE", 103, 115], ["p53", "GENE_OR_GENE_PRODUCT", 47, 50], ["p53", "PROTEIN", 47, 50], ["the inhibition of p53 under inflammatory milieu of RA", "PROBLEM", 29, 82], ["enhanced inflammation", "PROBLEM", 94, 115], ["inflammatory", "OBSERVATION_MODIFIER", 57, 69], ["RA", "ANATOMY", 80, 82], ["enhanced", "OBSERVATION_MODIFIER", 94, 102], ["inflammation", "OBSERVATION", 103, 115]]], ["Additionally, PTEN expression could be regulated by p53 dependent manner.Loss of p53 exacerbates induction of Th17 and reduction of Treg ::: ResultsRecently, p53 has been demonstrated as a mediator of balance between Th17 and Treg in RA17.", [["Treg", "ANATOMY", 132, 136], ["Th17", "ANATOMY", 217, 221], ["Treg", "ANATOMY", 226, 230], ["PTEN", "GENE_OR_GENE_PRODUCT", 14, 18], ["p53", "GENE_OR_GENE_PRODUCT", 52, 55], ["p53", "GENE_OR_GENE_PRODUCT", 81, 84], ["Th17", "CELL", 110, 114], ["Treg", "CELL", 132, 136], ["p53", "GENE_OR_GENE_PRODUCT", 158, 161], ["Th17", "CELL", 217, 221], ["Treg", "CELL", 226, 230], ["PTEN", "PROTEIN", 14, 18], ["p53", "PROTEIN", 52, 55], ["p53", "PROTEIN", 81, 84], ["Treg", "CELL_TYPE", 132, 136], ["p53", "PROTEIN", 158, 161], ["Th17", "CELL_TYPE", 217, 221], ["Treg", "CELL_TYPE", 226, 230], ["RA17", "CELL_LINE", 234, 238], ["PTEN expression", "PROBLEM", 14, 29], ["Loss of p53", "PROBLEM", 73, 84], ["p53", "TEST", 158, 161]]], ["Cells of WT or p53 deficient mice in normal state were cultured under Th0 or Th17 condition.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["p53", "GENE_OR_GENE_PRODUCT", 15, 18], ["mice", "ORGANISM", 29, 33], ["Th0", "CELL", 70, 73], ["Th17", "CELL", 77, 81], ["p53", "PROTEIN", 15, 18], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["WT", "TEST", 9, 11]]], ["The expression of IL-17 was significantly increased (Fig. 4A).", [["IL-17", "GENE_OR_GENE_PRODUCT", 18, 23], ["IL-17", "PROTEIN", 18, 23]]], ["Gene expression of IL-17 in splenocytes isolated from p53 deficient mice was also significantly increased compare to that in WT mice (Fig. 4B).", [["splenocytes", "ANATOMY", 28, 39], ["IL-17", "GENE_OR_GENE_PRODUCT", 19, 24], ["splenocytes", "CELL", 28, 39], ["p53", "GENE_OR_GENE_PRODUCT", 54, 57], ["mice", "ORGANISM", 68, 72], ["WT mice", "ORGANISM", 125, 132], ["Fig. 4B", "ORGANISM", 134, 141], ["IL-17", "PROTEIN", 19, 24], ["splenocytes", "CELL_TYPE", 28, 39], ["p53", "PROTEIN", 54, 57], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 128, 132], ["IL", "TEST", 19, 21], ["splenocytes", "PROBLEM", 28, 39], ["p53 deficient mice", "TREATMENT", 54, 72], ["splenocytes", "ANATOMY", 28, 39], ["increased", "OBSERVATION_MODIFIER", 96, 105]]], ["T cell activation was profoundly upregulated in cells isolated from p53 deficient mice compared to that in WT mice (Fig. 4C).", [["T cell", "ANATOMY", 0, 6], ["cells", "ANATOMY", 48, 53], ["T cell", "CELL", 0, 6], ["cells", "CELL", 48, 53], ["p53", "GENE_OR_GENE_PRODUCT", 68, 71], ["mice", "ORGANISM", 82, 86], ["WT mice", "ORGANISM", 107, 114], ["p53", "PROTEIN", 68, 71], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 110, 114], ["T cell activation", "PROBLEM", 0, 17], ["profoundly upregulated in cells", "PROBLEM", 22, 53], ["p53 deficient mice", "TREATMENT", 68, 86]]], ["Th17 differentiation in p53 deficient mice was significantly increased whereas Treg differentiation was significantly reduced compared to that in WT mice (Fig. 4D).", [["Treg", "ANATOMY", 79, 83], ["Th17", "CELL", 0, 4], ["p53", "GENE_OR_GENE_PRODUCT", 24, 27], ["mice", "ORGANISM", 38, 42], ["Treg", "CELL", 79, 83], ["WT mice", "ORGANISM", 146, 153], ["p53", "PROTEIN", 24, 27], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 149, 153], ["significantly increased", "PROBLEM", 47, 70], ["significantly", "OBSERVATION_MODIFIER", 47, 60], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["significantly", "OBSERVATION_MODIFIER", 104, 117], ["reduced", "OBSERVATION_MODIFIER", 118, 125]]], ["These data suggested that p53 deficiency could lead to T cell activation and imbalance between Th17 and Treg.p53 deficiency exacerbates CIA severity by upregulating inflammation ::: ResultsBased on arthritis scores, it was found that p53 deficiency exacerbated CIA progression in vivo (Fig. 5A).", [["T cell", "ANATOMY", 55, 61], ["CIA", "DISEASE", 136, 139], ["inflammation", "DISEASE", 165, 177], ["arthritis", "DISEASE", 198, 207], ["CIA", "DISEASE", 261, 264], ["p53", "GENE_OR_GENE_PRODUCT", 26, 29], ["T cell", "CELL", 55, 61], ["Th17", "CELL", 95, 99], ["Treg.p53", "GENE_OR_GENE_PRODUCT", 104, 112], ["CIA", "PATHOLOGICAL_FORMATION", 136, 139], ["p53", "GENE_OR_GENE_PRODUCT", 234, 237], ["CIA", "PATHOLOGICAL_FORMATION", 261, 264], ["p53", "PROTEIN", 26, 29], ["p53", "PROTEIN", 234, 237], ["These data", "TEST", 0, 10], ["p53 deficiency", "PROBLEM", 26, 40], ["T cell activation", "PROBLEM", 55, 72], ["imbalance", "PROBLEM", 77, 86], ["Th17", "TEST", 95, 99], ["deficiency exacerbates CIA severity", "PROBLEM", 113, 148], ["upregulating inflammation", "PROBLEM", 152, 177], ["arthritis scores", "PROBLEM", 198, 214], ["p53 deficiency", "PROBLEM", 234, 248], ["CIA progression", "PROBLEM", 261, 276], ["p53 deficiency", "OBSERVATION", 26, 40], ["arthritis", "OBSERVATION", 198, 207], ["p53 deficiency", "OBSERVATION", 234, 248]]], ["Serum levels of total IgG, IgG1, and IgG2a were significantly increased in p53 deficiency mice compared to those in WT mice (Fig. 5B).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["IgG1", "GENE_OR_GENE_PRODUCT", 27, 31], ["IgG2a", "GENE_OR_GENE_PRODUCT", 37, 42], ["p53", "GENE_OR_GENE_PRODUCT", 75, 78], ["mice", "ORGANISM", 90, 94], ["WT mice", "ORGANISM", 116, 123], ["total IgG", "PROTEIN", 16, 25], ["IgG1", "PROTEIN", 27, 31], ["IgG2a", "PROTEIN", 37, 42], ["p53", "PROTEIN", 75, 78], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 119, 123], ["Serum levels", "TEST", 0, 12], ["total IgG", "TEST", 16, 25], ["IgG1", "TEST", 27, 31], ["IgG2a", "TEST", 37, 42], ["p53 deficiency mice", "PROBLEM", 75, 94], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["p53 deficiency", "OBSERVATION", 75, 89]]], ["Moreover, histological analysis showed that paws and ankles of p53 deficiency arthritis mice had higher degree of inflammation with bone damage and cartilage damage (Fig. 5C).", [["paws", "ANATOMY", 44, 48], ["ankles", "ANATOMY", 53, 59], ["bone", "ANATOMY", 132, 136], ["cartilage", "ANATOMY", 148, 157], ["arthritis", "DISEASE", 78, 87], ["inflammation", "DISEASE", 114, 126], ["bone damage", "DISEASE", 132, 143], ["cartilage damage", "DISEASE", 148, 164], ["paws", "ORGANISM_SUBDIVISION", 44, 48], ["ankles", "ORGANISM_SUBDIVISION", 53, 59], ["p53", "GENE_OR_GENE_PRODUCT", 63, 66], ["mice", "ORGANISM", 88, 92], ["bone", "TISSUE", 132, 136], ["cartilage", "TISSUE", 148, 157], ["p53", "PROTEIN", 63, 66], ["mice", "SPECIES", 88, 92], ["histological analysis", "TEST", 10, 31], ["paws", "PROBLEM", 44, 48], ["p53 deficiency arthritis mice", "PROBLEM", 63, 92], ["inflammation", "PROBLEM", 114, 126], ["bone damage", "PROBLEM", 132, 143], ["cartilage damage", "PROBLEM", 148, 164], ["ankles", "ANATOMY", 53, 59], ["p53 deficiency", "OBSERVATION", 63, 77], ["higher degree", "OBSERVATION_MODIFIER", 97, 110], ["inflammation", "OBSERVATION", 114, 126], ["bone", "ANATOMY", 132, 136], ["damage", "OBSERVATION", 137, 143], ["cartilage", "ANATOMY", 148, 157]]], ["The expression of proinflammatory cytokines in joints were significantly upregulated in p53 deficiency arthritis mice compared to that in WT mice (Fig. 5D).", [["joints", "ANATOMY", 47, 53], ["arthritis", "DISEASE", 103, 112], ["joints", "MULTI-TISSUE_STRUCTURE", 47, 53], ["p53", "GENE_OR_GENE_PRODUCT", 88, 91], ["mice", "ORGANISM", 113, 117], ["WT mice", "ORGANISM", 138, 145], ["proinflammatory cytokines", "PROTEIN", 18, 43], ["p53", "PROTEIN", 88, 91], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 141, 145], ["proinflammatory cytokines in joints", "PROBLEM", 18, 53], ["p53 deficiency arthritis mice", "PROBLEM", 88, 117], ["proinflammatory cytokines", "OBSERVATION", 18, 43], ["joints", "ANATOMY", 47, 53], ["p53 deficiency", "OBSERVATION", 88, 102]]], ["Our results suggested that p53 deficiency might have failed to regulate inflammatory response, thus worsening local inflammatory milieu.p53 deficiency decreases PTEN expression and induces imbalance between Th17 and Treg ::: ResultsSince PTEN expression is regulated by p5316, we investigated PTEN expression in p53 deficiency mice with CIA.", [["Treg", "ANATOMY", 216, 220], ["CIA", "DISEASE", 337, 340], ["p53", "GENE_OR_GENE_PRODUCT", 27, 30], ["p53", "GENE_OR_GENE_PRODUCT", 136, 139], ["PTEN", "GENE_OR_GENE_PRODUCT", 161, 165], ["Th17", "CELL", 207, 211], ["Treg", "CELL", 216, 220], ["PTEN", "GENE_OR_GENE_PRODUCT", 238, 242], ["p5316", "GENE_OR_GENE_PRODUCT", 270, 275], ["PTEN", "GENE_OR_GENE_PRODUCT", 293, 297], ["p53", "GENE_OR_GENE_PRODUCT", 312, 315], ["mice", "ORGANISM", 327, 331], ["p53", "PROTEIN", 27, 30], ["p53", "PROTEIN", 136, 139], ["PTEN", "PROTEIN", 161, 165], ["Th17", "CELL_TYPE", 207, 211], ["Treg", "CELL_TYPE", 216, 220], ["PTEN", "PROTEIN", 238, 242], ["p5316", "PROTEIN", 270, 275], ["PTEN", "PROTEIN", 293, 297], ["p53", "PROTEIN", 312, 315], ["mice", "SPECIES", 327, 331], ["p53 deficiency", "PROBLEM", 27, 41], ["inflammatory response", "PROBLEM", 72, 93], ["worsening local inflammatory milieu", "PROBLEM", 100, 135], ["p53 deficiency", "PROBLEM", 136, 150], ["PTEN expression", "PROBLEM", 161, 176], ["PTEN expression in p53 deficiency", "PROBLEM", 293, 326], ["CIA", "PROBLEM", 337, 340], ["p53 deficiency", "OBSERVATION", 27, 41], ["inflammatory", "OBSERVATION_MODIFIER", 72, 84], ["worsening", "OBSERVATION_MODIFIER", 100, 109], ["local", "OBSERVATION_MODIFIER", 110, 115], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["p53 deficiency", "OBSERVATION", 312, 326]]], ["Gene expression levels of PTEN in splenic CD4+ T cells, splenocytes, and draining lymph nodes isolated from p53 deficiency mice with CIA were decreased significantly compared to those in WT mice with CIA (Fig. 6A).", [["splenic CD4+ T cells", "ANATOMY", 34, 54], ["splenocytes", "ANATOMY", 56, 67], ["lymph nodes", "ANATOMY", 82, 93], ["PTEN", "GENE_OR_GENE_PRODUCT", 26, 30], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["splenocytes", "CELL", 56, 67], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 82, 93], ["p53", "GENE_OR_GENE_PRODUCT", 108, 111], ["mice", "ORGANISM", 123, 127], ["mice", "ORGANISM", 190, 194], ["PTEN", "PROTEIN", 26, 30], ["splenic CD4+ T cells", "CELL_TYPE", 34, 54], ["splenocytes", "CELL_TYPE", 56, 67], ["p53", "PROTEIN", 108, 111], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 190, 194], ["Gene expression levels", "TEST", 0, 22], ["PTEN", "PROBLEM", 26, 30], ["splenic CD4", "TEST", 34, 45], ["T cells", "PROBLEM", 47, 54], ["splenocytes", "TEST", 56, 67], ["draining lymph nodes", "PROBLEM", 73, 93], ["p53 deficiency mice", "PROBLEM", 108, 127], ["CIA", "PROBLEM", 133, 136], ["splenic", "ANATOMY", 34, 41], ["CD4+ T cells", "OBSERVATION", 42, 54], ["splenocytes", "ANATOMY", 56, 67], ["draining", "OBSERVATION_MODIFIER", 73, 81], ["lymph nodes", "OBSERVATION", 82, 93], ["p53 deficiency", "OBSERVATION", 108, 122], ["CIA", "OBSERVATION_MODIFIER", 133, 136], ["decreased", "OBSERVATION_MODIFIER", 142, 151]]], ["Since RA can result in dysregulated balance of Th17/Treg1, we also measured the balance between Th17 and Treg.", [["Th17", "ANATOMY", 96, 100], ["Treg", "ANATOMY", 105, 109], ["Th17", "GENE_OR_GENE_PRODUCT", 47, 51], ["Treg1", "GENE_OR_GENE_PRODUCT", 52, 57], ["Th17", "CELL", 96, 100], ["Treg", "CELL", 105, 109], ["Th17", "PROTEIN", 47, 51], ["Treg1", "PROTEIN", 52, 57], ["Th17", "CELL_TYPE", 96, 100], ["Treg", "CELL_TYPE", 105, 109], ["dysregulated balance", "OBSERVATION", 23, 43]]], ["The mRNA level of Th17 related molecules including IL-17 was increased, whereas the mRNA expression of Treg cell-related molecules such as Foxp3 was enhanced in p53 deficiency mice with CIA (Fig. 6B).", [["Treg cell", "ANATOMY", 103, 112], ["IL-17", "GENE_OR_GENE_PRODUCT", 51, 56], ["Treg cell", "CELL", 103, 112], ["Foxp3", "GENE_OR_GENE_PRODUCT", 139, 144], ["p53", "GENE_OR_GENE_PRODUCT", 161, 164], ["mice", "ORGANISM", 176, 180], ["Th17 related molecules", "PROTEIN", 18, 40], ["IL-17", "PROTEIN", 51, 56], ["Treg cell-related molecules", "PROTEIN", 103, 130], ["Foxp3", "PROTEIN", 139, 144], ["p53", "PROTEIN", 161, 164], ["mice", "SPECIES", 176, 180], ["mice", "SPECIES", 176, 180], ["IL", "TEST", 51, 53], ["Treg cell-related molecules", "PROBLEM", 103, 130], ["p53 deficiency", "PROBLEM", 161, 175], ["Treg cell", "OBSERVATION", 103, 112], ["p53 deficiency", "OBSERVATION", 161, 175]]], ["In addition, the number of CD4+p-STAT5+ T cells in the spleen tissues of p53 deficiency mice with CIA was significantly downregulated compared to that in the spleen tissues of WT mice with CIA based on immunofluorescence confocal microscopy (Fig. 6C).", [["CD4+p-STAT5+ T cells", "ANATOMY", 27, 47], ["spleen tissues", "ANATOMY", 55, 69], ["spleen tissues", "ANATOMY", 158, 172], ["CD4", "GENE_OR_GENE_PRODUCT", 27, 30], ["STAT5", "GENE_OR_GENE_PRODUCT", 33, 38], ["spleen tissues", "TISSUE", 55, 69], ["p53", "GENE_OR_GENE_PRODUCT", 73, 76], ["mice", "ORGANISM", 88, 92], ["spleen tissues", "TISSUE", 158, 172], ["mice", "ORGANISM", 179, 183], ["CD4", "PROTEIN", 27, 30], ["STAT5", "PROTEIN", 33, 38], ["T cells", "CELL_TYPE", 40, 47], ["p53", "PROTEIN", 73, 76], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 179, 183], ["CD4", "TEST", 27, 30], ["T cells", "PROBLEM", 40, 47], ["p53 deficiency", "PROBLEM", 73, 87], ["CIA", "PROBLEM", 98, 101], ["immunofluorescence confocal microscopy", "TEST", 202, 240], ["spleen", "ANATOMY", 55, 61], ["p53 deficiency", "OBSERVATION", 73, 87], ["CIA", "OBSERVATION_MODIFIER", 98, 101], ["spleen", "ANATOMY", 158, 164]]], ["However, loss of p53 promoted the number of IL-17 producing CD4+p-STAT705+ or p-STAT727+ T cells in the spleen tissues based on immunofluorescence confocal microscopy (Fig. 6D).", [["T cells", "ANATOMY", 89, 96], ["spleen tissues", "ANATOMY", 104, 118], ["p53", "GENE_OR_GENE_PRODUCT", 17, 20], ["IL-17", "GENE_OR_GENE_PRODUCT", 44, 49], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["p-STAT727", "SIMPLE_CHEMICAL", 78, 87], ["T cells", "CELL", 89, 96], ["spleen tissues", "TISSUE", 104, 118], ["p53", "PROTEIN", 17, 20], ["IL-17", "PROTEIN", 44, 49], ["CD4", "PROTEIN", 60, 63], ["STAT705", "PROTEIN", 66, 73], ["STAT727", "DNA", 80, 87], ["T cells", "CELL_TYPE", 89, 96], ["loss of p53", "PROBLEM", 9, 20], ["IL", "TEST", 44, 46], ["CD4", "TEST", 60, 63], ["T cells in the spleen tissues", "PROBLEM", 89, 118], ["immunofluorescence confocal microscopy", "TEST", 128, 166], ["spleen", "ANATOMY", 104, 110]]], ["Moreover, PTEN expression was significantly downregulated in p53 deficient mice compared to that in WT mice (Fig. 6E).", [["PTEN", "GENE_OR_GENE_PRODUCT", 10, 14], ["p53", "GENE_OR_GENE_PRODUCT", 61, 64], ["mice", "ORGANISM", 75, 79], ["WT mice", "ORGANISM", 100, 107], ["PTEN", "PROTEIN", 10, 14], ["p53", "PROTEIN", 61, 64], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 103, 107], ["PTEN expression", "PROBLEM", 10, 25]]], ["These results demonstrated that p53 deficiency could accelerate the imbalance between Th17 and Treg in CIA.DiscussionUntil now, PTEN has been investigated extensively as a tumor suppressor with a role in cell metabolism, motility, and tumor microenvironment21.", [["Th17", "ANATOMY", 86, 90], ["Treg", "ANATOMY", 95, 99], ["tumor", "ANATOMY", 172, 177], ["cell", "ANATOMY", 204, 208], ["tumor", "ANATOMY", 235, 240], ["tumor", "DISEASE", 172, 177], ["tumor", "DISEASE", 235, 240], ["p53", "GENE_OR_GENE_PRODUCT", 32, 35], ["Th17", "CELL", 86, 90], ["Treg", "CELL", 95, 99], ["PTEN", "GENE_OR_GENE_PRODUCT", 128, 132], ["tumor", "CANCER", 172, 177], ["cell", "CELL", 204, 208], ["tumor", "CANCER", 235, 240], ["p53", "PROTEIN", 32, 35], ["Th17", "CELL_TYPE", 86, 90], ["Treg", "CELL_TYPE", 95, 99], ["PTEN", "PROTEIN", 128, 132], ["p53 deficiency", "PROBLEM", 32, 46], ["the imbalance", "PROBLEM", 64, 77], ["a tumor suppressor", "TREATMENT", 170, 188], ["tumor microenvironment21", "TREATMENT", 235, 259], ["p53 deficiency", "OBSERVATION", 32, 46], ["CIA", "ANATOMY", 103, 106], ["tumor", "OBSERVATION", 172, 177]]], ["Recently, PTEN has been observed to be associated with cell differentiation as a phosphatase22.", [["cell", "ANATOMY", 55, 59], ["PTEN", "GENE_OR_GENE_PRODUCT", 10, 14], ["cell", "CELL", 55, 59], ["phosphatase22", "GENE_OR_GENE_PRODUCT", 81, 94], ["PTEN", "PROTEIN", 10, 14], ["phosphatase22", "PROTEIN", 81, 94], ["PTEN", "PROBLEM", 10, 14], ["cell differentiation", "PROBLEM", 55, 75], ["a phosphatase22", "TREATMENT", 79, 94], ["cell differentiation", "OBSERVATION", 55, 75]]], ["In addition, PTEN is revealed to have therapeutic effect in rat with CIA23.", [["PTEN", "GENE_OR_GENE_PRODUCT", 13, 17], ["rat", "ORGANISM", 60, 63], ["PTEN", "PROTEIN", 13, 17], ["rat", "SPECIES", 60, 63], ["rat", "SPECIES", 60, 63], ["CIA23", "TREATMENT", 69, 74], ["therapeutic effect", "OBSERVATION", 38, 56]]], ["However, little is known about the process of PTEN function associated with p53 in RA.", [["RA", "DISEASE", 83, 85], ["PTEN", "GENE_OR_GENE_PRODUCT", 46, 50], ["p53", "GENE_OR_GENE_PRODUCT", 76, 79], ["RA", "CANCER", 83, 85], ["PTEN", "PROTEIN", 46, 50], ["p53", "PROTEIN", 76, 79], ["PTEN function", "PROBLEM", 46, 59], ["p53 in RA", "TREATMENT", 76, 85], ["RA", "ANATOMY", 83, 85]]], ["Here, we studied the therapeutic activity of PTEN in RA and identified a new mechanism of RA regulation.DiscussionThe most notable observation of this investigation is that PTEN can attenuate RA via reciprocal differentiation of Th17/Treg.", [["Th17/Treg", "ANATOMY", 229, 238], ["RA", "DISEASE", 53, 55], ["RA", "DISEASE", 192, 194], ["PTEN", "GENE_OR_GENE_PRODUCT", 45, 49], ["RA", "GENE_OR_GENE_PRODUCT", 90, 92], ["PTEN", "GENE_OR_GENE_PRODUCT", 173, 177], ["RA", "CANCER", 192, 194], ["Th17", "CELL", 229, 233], ["Treg", "CELL", 234, 238], ["PTEN", "PROTEIN", 45, 49], ["PTEN", "PROTEIN", 173, 177], ["Th17", "CELL_TYPE", 229, 233], ["Treg", "CELL_TYPE", 234, 238], ["PTEN in RA", "TREATMENT", 45, 55], ["RA regulation", "TREATMENT", 90, 103], ["this investigation", "TEST", 146, 164], ["PTEN", "PROBLEM", 173, 177], ["Th17/Treg", "TREATMENT", 229, 238], ["RA", "ANATOMY", 53, 55], ["RA", "ANATOMY", 90, 92]]], ["To our knowledge, this is the first research to provide evidence that PTEN could be used for RA therapy through regulating Th17/Treg balance.", [["Th17/Treg", "ANATOMY", 123, 132], ["PTEN", "GENE_OR_GENE_PRODUCT", 70, 74], ["Th17", "CELL", 123, 127], ["Treg", "CELL", 128, 132], ["PTEN", "PROTEIN", 70, 74], ["PTEN", "PROBLEM", 70, 74], ["RA therapy", "TREATMENT", 93, 103], ["Th17/Treg balance", "TREATMENT", 123, 140]]], ["Previously, a number of documents have demonstrated that imbalance between Th17 and Treg can contribute to RA124.", [["Treg", "ANATOMY", 84, 88], ["Th17", "CELL", 75, 79], ["Treg", "CELL", 84, 88], ["RA124", "GENE_OR_GENE_PRODUCT", 107, 112], ["Th17", "CELL_TYPE", 75, 79], ["Treg", "CELL_TYPE", 84, 88], ["RA124", "PROTEIN", 107, 112]]], ["Modulation of Th17 and Treg cells has an important role in RA therapy1025.", [["Th17", "ANATOMY", 14, 18], ["Treg cells", "ANATOMY", 23, 33], ["RA", "DISEASE", 59, 61], ["Th17", "CELL", 14, 18], ["Treg cells", "CELL", 23, 33], ["Th17 and Treg cells", "CELL_TYPE", 14, 33], ["Modulation of Th17 and Treg cells", "TREATMENT", 0, 33], ["RA therapy", "TREATMENT", 59, 69], ["Th17", "ANATOMY", 14, 18], ["Treg cells", "OBSERVATION", 23, 33], ["RA", "ANATOMY", 59, 61]]], ["The activation of STAT5 prolongs Foxp3 production in Treg, while STAT3 activation increases the differentiation of Th17 cells26.", [["Treg", "ANATOMY", 53, 57], ["Th17 cells", "ANATOMY", 115, 125], ["STAT5", "GENE_OR_GENE_PRODUCT", 18, 23], ["Foxp3", "GENE_OR_GENE_PRODUCT", 33, 38], ["Treg", "CELL", 53, 57], ["STAT3", "GENE_OR_GENE_PRODUCT", 65, 70], ["Th17 cells", "CELL", 115, 125], ["STAT5", "PROTEIN", 18, 23], ["Foxp3", "PROTEIN", 33, 38], ["Treg", "CELL_TYPE", 53, 57], ["STAT3", "PROTEIN", 65, 70], ["Th17 cells26", "CELL_LINE", 115, 127], ["STAT5 prolongs Foxp3 production", "TREATMENT", 18, 49], ["STAT3 activation", "PROBLEM", 65, 81], ["Th17 cells", "TEST", 115, 125], ["Th17 cells", "OBSERVATION", 115, 125]]], ["Moreover, binding of p-STAT3 and p-STAT5 can competitively regulate IL-17 transcription27.", [["p-STAT3", "GENE_OR_GENE_PRODUCT", 21, 28], ["p-STAT5", "GENE_OR_GENE_PRODUCT", 33, 40], ["IL-17", "GENE_OR_GENE_PRODUCT", 68, 73], ["p", "PROTEIN", 21, 22], ["STAT3", "PROTEIN", 23, 28], ["STAT5", "PROTEIN", 35, 40], ["IL-17 transcription27", "PROTEIN", 68, 89]]], ["Our results demonstrated that Foxp3+ T cells were induced by PTEN overexpression while p53 deficiency significantly induced p-STAT3+ T cells.", [["Foxp3+ T cells", "ANATOMY", 30, 44], ["p-STAT3+ T cells", "ANATOMY", 124, 140], ["Foxp3", "GENE_OR_GENE_PRODUCT", 30, 35], ["PTEN", "GENE_OR_GENE_PRODUCT", 61, 65], ["p53", "GENE_OR_GENE_PRODUCT", 87, 90], ["STAT3", "GENE_OR_GENE_PRODUCT", 126, 131], ["Foxp3", "PROTEIN", 30, 35], ["T cells", "CELL_TYPE", 37, 44], ["PTEN", "PROTEIN", 61, 65], ["p53", "PROTEIN", 87, 90], ["STAT3", "PROTEIN", 126, 131], ["T cells", "CELL_TYPE", 133, 140], ["Foxp3+ T cells", "PROBLEM", 30, 44], ["PTEN overexpression", "PROBLEM", 61, 80], ["p53 deficiency", "PROBLEM", 87, 101], ["STAT3+ T cells", "PROBLEM", 126, 140]]], ["This could be due to the diminishment of T cell transcriptional regulators such as Foxp3 and SOCS3 and the enhancement of ROR\u03b3t, RUNX1, and BATF.", [["T cell", "ANATOMY", 41, 47], ["T cell", "CELL", 41, 47], ["Foxp3", "GENE_OR_GENE_PRODUCT", 83, 88], ["SOCS3", "GENE_OR_GENE_PRODUCT", 93, 98], ["ROR\u03b3t", "GENE_OR_GENE_PRODUCT", 122, 127], ["RUNX1", "GENE_OR_GENE_PRODUCT", 129, 134], ["BATF", "GENE_OR_GENE_PRODUCT", 140, 144], ["T cell transcriptional regulators", "PROTEIN", 41, 74], ["Foxp3", "PROTEIN", 83, 88], ["SOCS3", "PROTEIN", 93, 98], ["ROR\u03b3t", "PROTEIN", 122, 127], ["RUNX1", "PROTEIN", 129, 134], ["BATF", "PROTEIN", 140, 144], ["T cell transcriptional regulators", "PROBLEM", 41, 74], ["Foxp3 and SOCS3", "TREATMENT", 83, 98], ["could be due to", "UNCERTAINTY", 5, 20], ["cell", "OBSERVATION", 43, 47], ["enhancement", "OBSERVATION_MODIFIER", 107, 118]]], ["In addition, PTEN decreased the number of Treg cells while Th17 differentiation was promoted in RA mice model.", [["Treg cells", "ANATOMY", 42, 52], ["PTEN", "GENE_OR_GENE_PRODUCT", 13, 17], ["Treg cells", "CELL", 42, 52], ["Th17", "CELL", 59, 63], ["mice", "ORGANISM", 99, 103], ["PTEN", "PROTEIN", 13, 17], ["Treg cells", "CELL_TYPE", 42, 52], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["PTEN", "PROBLEM", 13, 17], ["decreased", "OBSERVATION_MODIFIER", 18, 27], ["Treg cells", "OBSERVATION", 42, 52]]], ["Hence, PTEN might be another efficient mechanism regulated by which p53 through controlling Th17/Treg balance.DiscussionTumor protein 53 (p53), a tumor suppressor factor, is essential for cellular response to DNA damage.", [["Th17/Treg", "ANATOMY", 92, 101], ["tumor", "ANATOMY", 146, 151], ["cellular", "ANATOMY", 188, 196], ["tumor", "DISEASE", 146, 151], ["PTEN", "GENE_OR_GENE_PRODUCT", 7, 11], ["p53", "GENE_OR_GENE_PRODUCT", 68, 71], ["Th17", "GENE_OR_GENE_PRODUCT", 92, 96], ["Treg", "CELL", 97, 101], ["DiscussionTumor protein 53", "GENE_OR_GENE_PRODUCT", 110, 136], ["p53", "GENE_OR_GENE_PRODUCT", 138, 141], ["tumor", "CANCER", 146, 151], ["cellular", "CELL", 188, 196], ["DNA", "CELLULAR_COMPONENT", 209, 212], ["PTEN", "PROTEIN", 7, 11], ["p53", "PROTEIN", 68, 71], ["DiscussionTumor protein 53", "PROTEIN", 110, 136], ["p53", "PROTEIN", 138, 141], ["tumor suppressor factor", "PROTEIN", 146, 169], ["DiscussionTumor protein", "TEST", 110, 133], ["a tumor suppressor factor", "PROBLEM", 144, 169], ["DNA damage", "PROBLEM", 209, 219]]], ["It plays a key role in several gene expression as a resourceful transcription factor under stressful conditions.", [["transcription factor", "PROTEIN", 64, 84]]], ["It has been demonstrated that p53 is involved in a variety of cellular signal pathways, cell proliferation, and apoptosis282930.", [["cellular", "ANATOMY", 62, 70], ["cell", "ANATOMY", 88, 92], ["p53", "GENE_OR_GENE_PRODUCT", 30, 33], ["cellular", "CELL", 62, 70], ["cell", "CELL", 88, 92], ["apoptosis282930", "GENE_OR_GENE_PRODUCT", 112, 127], ["p53", "PROTEIN", 30, 33], ["apoptosis282930", "PROTEIN", 112, 127], ["p53", "PROBLEM", 30, 33], ["cell proliferation", "PROBLEM", 88, 106], ["p53", "OBSERVATION", 30, 33], ["variety", "OBSERVATION_MODIFIER", 51, 58], ["cellular signal", "OBSERVATION", 62, 77], ["cell proliferation", "OBSERVATION", 88, 106]]], ["Although p53 function has been recognized mainly in the cell cycle, emerging evidence has suggested that p53 has important role not only in apoptosis, cell differentiation, and DNA repair, but also in the modulation of STAT-mediated Th17 cells17.", [["cell", "ANATOMY", 56, 60], ["cell", "ANATOMY", 151, 155], ["Th17 cells", "ANATOMY", 233, 243], ["p53", "GENE_OR_GENE_PRODUCT", 9, 12], ["cell", "CELL", 56, 60], ["p53", "GENE_OR_GENE_PRODUCT", 105, 108], ["cell", "CELL", 151, 155], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["STAT", "GENE_OR_GENE_PRODUCT", 219, 223], ["Th17 cells", "CELL", 233, 243], ["p53", "PROTEIN", 9, 12], ["p53", "PROTEIN", 105, 108], ["STAT", "PROTEIN", 219, 223], ["Th17 cells17", "CELL_LINE", 233, 245], ["p53 function", "TEST", 9, 21], ["DNA repair", "TREATMENT", 177, 187], ["mainly", "OBSERVATION_MODIFIER", 42, 48], ["cell cycle", "OBSERVATION", 56, 66], ["cell differentiation", "OBSERVATION", 151, 171], ["DNA repair", "OBSERVATION", 177, 187]]], ["Loss of p53 can promote the progression of antigen-induced arthritis and increase activated T cell differentiation31.", [["T cell", "ANATOMY", 92, 98], ["arthritis", "DISEASE", 59, 68], ["p53", "GENE_OR_GENE_PRODUCT", 8, 11], ["antigen", "GENE_OR_GENE_PRODUCT", 43, 50], ["T cell", "CELL", 92, 98], ["p53", "PROTEIN", 8, 11], ["Loss of p53", "PROBLEM", 0, 11], ["antigen-induced arthritis", "PROBLEM", 43, 68], ["activated T cell differentiation31", "TREATMENT", 82, 116], ["progression", "OBSERVATION_MODIFIER", 28, 39], ["arthritis", "OBSERVATION", 59, 68]]], ["In this study, PTEN expression was found to be regulated in p53 dependent manner.", [["PTEN", "GENE_OR_GENE_PRODUCT", 15, 19], ["p53", "GENE_OR_GENE_PRODUCT", 60, 63], ["PTEN", "PROTEIN", 15, 19], ["p53", "PROTEIN", 60, 63], ["this study", "TEST", 3, 13], ["PTEN expression", "PROBLEM", 15, 30]]], ["Additionally, p53 deficiency aggravated CIA severity and reduced PTEN expression.", [["CIA", "DISEASE", 40, 43], ["p53", "GENE_OR_GENE_PRODUCT", 14, 17], ["CIA", "PATHOLOGICAL_FORMATION", 40, 43], ["PTEN", "GENE_OR_GENE_PRODUCT", 65, 69], ["p53", "PROTEIN", 14, 17], ["PTEN", "PROTEIN", 65, 69], ["p53 deficiency aggravated CIA severity", "PROBLEM", 14, 52], ["reduced PTEN expression", "PROBLEM", 57, 80], ["p53 deficiency", "OBSERVATION", 14, 28], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["PTEN expression", "OBSERVATION", 65, 80]]], ["These results suggested that PTEN could have therapeutic effect in autoimmune arthritis through p53.DiscussionIL-17 is a typical proinflammatory cytokine inducing the expression of IL-6, -21 and TNF-\u03b1323334.", [["autoimmune arthritis", "DISEASE", 67, 87], ["PTEN", "GENE_OR_GENE_PRODUCT", 29, 33], ["p53", "GENE_OR_GENE_PRODUCT", 96, 99], ["DiscussionIL-17", "GENE_OR_GENE_PRODUCT", 100, 115], ["IL-6", "GENE_OR_GENE_PRODUCT", 181, 185], ["-21", "GENE_OR_GENE_PRODUCT", 187, 190], ["TNF-\u03b1323334", "GENE_OR_GENE_PRODUCT", 195, 206], ["PTEN", "PROTEIN", 29, 33], ["p53", "PROTEIN", 96, 99], ["DiscussionIL-17", "PROTEIN", 100, 115], ["proinflammatory cytokine", "PROTEIN", 129, 153], ["IL", "PROTEIN", 181, 183], ["TNF", "PROTEIN", 195, 198], ["PTEN", "PROBLEM", 29, 33], ["autoimmune arthritis through p53", "PROBLEM", 67, 99], ["IL", "TEST", 181, 183], ["TNF", "TEST", 195, 198], ["autoimmune arthritis", "OBSERVATION", 67, 87]]], ["It has been documented that IL-17 can upregulate proinflammatory cytokines including IL-6 and IL-8 and aggravate joint inflammation of RA through activating CD4+ T cells3536.", [["joint", "ANATOMY", 113, 118], ["RA", "ANATOMY", 135, 137], ["CD4+ T cells", "ANATOMY", 157, 169], ["inflammation", "DISEASE", 119, 131], ["RA", "DISEASE", 135, 137], ["IL-17", "GENE_OR_GENE_PRODUCT", 28, 33], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL-8", "GENE_OR_GENE_PRODUCT", 94, 98], ["joint", "PATHOLOGICAL_FORMATION", 113, 118], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["IL-17", "PROTEIN", 28, 33], ["proinflammatory cytokines", "PROTEIN", 49, 74], ["IL-6", "PROTEIN", 85, 89], ["IL-8", "PROTEIN", 94, 98], ["CD4", "PROTEIN", 157, 160], ["IL", "TEST", 28, 30], ["proinflammatory cytokines", "TEST", 49, 74], ["IL", "TEST", 85, 87], ["IL", "TEST", 94, 96], ["aggravate joint inflammation of RA", "PROBLEM", 103, 137], ["aggravate", "UNCERTAINTY", 103, 112], ["joint", "ANATOMY", 113, 118], ["inflammation", "OBSERVATION", 119, 131], ["RA", "ANATOMY", 135, 137]]], ["Th17 secreting IL-17 performs a key role in the pathogenesis of RA.", [["RA", "DISEASE", 64, 66], ["IL-17", "GENE_OR_GENE_PRODUCT", 15, 20], ["RA", "CANCER", 64, 66], ["Th17", "PROTEIN", 0, 4], ["IL-17", "PROTEIN", 15, 20], ["RA", "ANATOMY", 64, 66]]], ["Th17 frequency and IL-17 level are strikingly correlated with RA development.", [["RA", "DISEASE", 62, 64], ["IL-17", "GENE_OR_GENE_PRODUCT", 19, 24], ["IL", "TEST", 19, 21]]], ["It has been documented that Th17 can result in excessive inflammation in patients with RA3.", [["inflammation", "DISEASE", 57, 69], ["Th17", "CELL", 28, 32], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["excessive inflammation in patients with RA3", "PROBLEM", 47, 90], ["excessive", "OBSERVATION_MODIFIER", 47, 56], ["inflammation", "OBSERVATION", 57, 69]]], ["Our data revealed that PTEN overexpression reduced the activation of T cells and that the loss of p53 enhanced the proliferation of Th17 cells.", [["T cells", "ANATOMY", 69, 76], ["Th17 cells", "ANATOMY", 132, 142], ["PTEN", "GENE_OR_GENE_PRODUCT", 23, 27], ["T cells", "CELL", 69, 76], ["p53", "GENE_OR_GENE_PRODUCT", 98, 101], ["Th17 cells", "CELL", 132, 142], ["PTEN", "PROTEIN", 23, 27], ["T cells", "CELL_TYPE", 69, 76], ["p53", "PROTEIN", 98, 101], ["Th17 cells", "CELL_TYPE", 132, 142], ["Our data", "TEST", 0, 8], ["PTEN overexpression", "PROBLEM", 23, 42], ["T cells", "PROBLEM", 69, 76], ["the loss of p53", "PROBLEM", 86, 101], ["Th17 cells", "PROBLEM", 132, 142], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["loss", "OBSERVATION_MODIFIER", 90, 94], ["proliferation", "OBSERVATION_MODIFIER", 115, 128], ["Th17 cells", "OBSERVATION", 132, 142]]], ["Since IL-17 expression is well known to induce RA development, suggesting a novel therapeutic strategy to modulate RA via PTEN expression.DiscussionGranulocyte-macrophage colony-stimulating factor (GM-CSF), an immune modulatory cytokine, performs a significant role in immune tolerance and attenuates autoimmune disorder37.", [["autoimmune disorder37", "DISEASE", 301, 322], ["IL-17", "GENE_OR_GENE_PRODUCT", 6, 11], ["PTEN", "GENE_OR_GENE_PRODUCT", 122, 126], ["Granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 148, 196], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 198, 204], ["IL-17", "PROTEIN", 6, 11], ["PTEN", "PROTEIN", 122, 126], ["Granulocyte-macrophage colony-stimulating factor", "PROTEIN", 148, 196], ["GM", "PROTEIN", 198, 200], ["CSF", "PROTEIN", 201, 204], ["immune modulatory cytokine", "PROTEIN", 210, 236], ["a novel therapeutic strategy", "TREATMENT", 74, 102], ["Granulocyte", "TEST", 148, 159], ["macrophage colony", "TEST", 160, 177], ["stimulating factor", "PROBLEM", 178, 196], ["immune tolerance", "PROBLEM", 269, 285], ["attenuates autoimmune disorder37", "PROBLEM", 290, 322], ["RA", "ANATOMY", 115, 117], ["macrophage colony", "OBSERVATION", 160, 177], ["immune tolerance", "OBSERVATION", 269, 285]]], ["It has been suggested that GM-CSF suppressed progression of autoimmune disease via induction of Tregs38.", [["GM", "CHEMICAL", 27, 29], ["autoimmune disease", "DISEASE", 60, 78], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 27, 33], ["Tregs38", "GENE_OR_GENE_PRODUCT", 96, 103], ["CSF", "PROTEIN", 30, 33], ["Tregs38", "PROTEIN", 96, 103], ["GM", "TEST", 27, 29], ["autoimmune disease", "PROBLEM", 60, 78], ["induction of Tregs38", "TREATMENT", 83, 103], ["autoimmune disease", "OBSERVATION", 60, 78]]], ["Previously, immune tolerance can be a good strategy for CIA therapy.", [["CIA", "DISEASE", 56, 59], ["CIA therapy", "TREATMENT", 56, 67]]], ["Indeed, immune tolerance induction using CII showed therapeutic effect in vivo and in vitro39.", [["CII", "GENE_OR_GENE_PRODUCT", 41, 44], ["CII", "PROTEIN", 41, 44], ["immune tolerance induction", "TREATMENT", 8, 34], ["vitro39", "TREATMENT", 86, 93]]], ["CD8+ Tregs can reveal therapeutic implications in CII involved-disease inducing immune tolerance40.", [["CD8+ Tregs", "ANATOMY", 0, 10], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["CII", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD8", "PROTEIN", 0, 3], ["Tregs", "CELL_TYPE", 5, 10], ["CII", "PROTEIN", 50, 53], ["disease inducing immune tolerance40", "PROBLEM", 63, 98]]], ["The therapeutic effect of PTEN in CIA may be involved in upregulation of GM-CSF and immune tolerance.", [["CIA", "DISEASE", 34, 37], ["GM", "CHEMICAL", 73, 75], ["PTEN", "GENE_OR_GENE_PRODUCT", 26, 30], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 73, 79], ["PTEN", "PROTEIN", 26, 30], ["PTEN in CIA", "PROBLEM", 26, 37], ["GM-CSF", "TEST", 73, 79]]], ["Thus, further study will be needed to confirm therapeutic activity of PTEN related with GM-CSF expression and immune tolerance.DiscussionWe analyzed the gene expression of p53 and STAT3 in CD4+ T cells of healthy individuals and RA patients from the National Center for Biotechnology Information Gene Expression Omnibus database (GSE4588).", [["CD4+", "ANATOMY", 189, 193], ["T cells", "ANATOMY", 194, 201], ["GM", "CHEMICAL", 88, 90], ["PTEN", "GENE_OR_GENE_PRODUCT", 70, 74], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 88, 94], ["p53", "GENE_OR_GENE_PRODUCT", 172, 175], ["STAT3", "GENE_OR_GENE_PRODUCT", 180, 185], ["CD4", "GENE_OR_GENE_PRODUCT", 189, 192], ["T cells", "CELL", 194, 201], ["patients", "ORGANISM", 232, 240], ["PTEN", "PROTEIN", 70, 74], ["CSF", "PROTEIN", 91, 94], ["p53", "PROTEIN", 172, 175], ["STAT3", "PROTEIN", 180, 185], ["CD4", "PROTEIN", 189, 192], ["T cells", "CELL_TYPE", 194, 201], ["patients", "SPECIES", 232, 240], ["further study", "TEST", 6, 19], ["PTEN", "PROBLEM", 70, 74], ["GM-CSF expression", "TREATMENT", 88, 105], ["RA", "ANATOMY", 229, 231]]], ["The GSE4588 database contains 10 healthy subjects and 8 RA patients with clinic and pathological information.", [["RA", "DISEASE", 56, 58], ["patients", "ORGANISM", 59, 67], ["GSE4588", "PROTEIN", 4, 11], ["patients", "SPECIES", 59, 67], ["10 healthy", "OBSERVATION_MODIFIER", 30, 40]]], ["We observed that the relative mRNA level of STAT3 of RA patients was promoted significantly compared to that of healthy individuals in this database.", [["STAT3", "GENE_OR_GENE_PRODUCT", 44, 49], ["patients", "ORGANISM", 56, 64], ["STAT3", "PROTEIN", 44, 49], ["patients", "SPECIES", 56, 64], ["RA", "ANATOMY", 53, 55]]], ["The mRNA expression of p53 in RA patients was downregulated significantly compared to that in healthy individuals.", [["p53", "GENE_OR_GENE_PRODUCT", 23, 26], ["patients", "ORGANISM", 33, 41], ["p53", "PROTEIN", 23, 26], ["patients", "SPECIES", 33, 41], ["p53 in RA", "TREATMENT", 23, 32], ["RA", "ANATOMY", 30, 32]]], ["The lack of p53 might have aggravated RA progression and induced STAT3 activation.", [["RA", "DISEASE", 38, 40], ["p53", "GENE_OR_GENE_PRODUCT", 12, 15], ["STAT3", "GENE_OR_GENE_PRODUCT", 65, 70], ["p53", "PROTEIN", 12, 15], ["STAT3", "PROTEIN", 65, 70], ["aggravated RA progression", "PROBLEM", 27, 52], ["induced STAT3 activation", "PROBLEM", 57, 81], ["STAT3 activation", "OBSERVATION", 65, 81]]], ["In this study, we demonstrated that PTEN overexpression could reduce CIA progression and that the loss of p53 enhanced the expression of STAT3.DiscussionThe function of PTEN and p53 in STAT3 activation has already been studied in previous investigations1319.", [["PTEN", "GENE_OR_GENE_PRODUCT", 36, 40], ["CIA", "PATHOLOGICAL_FORMATION", 69, 72], ["p53", "GENE_OR_GENE_PRODUCT", 106, 109], ["STAT3", "GENE_OR_GENE_PRODUCT", 137, 142], ["PTEN", "GENE_OR_GENE_PRODUCT", 169, 173], ["p53", "GENE_OR_GENE_PRODUCT", 178, 181], ["STAT3", "GENE_OR_GENE_PRODUCT", 185, 190], ["PTEN", "PROTEIN", 36, 40], ["p53", "PROTEIN", 106, 109], ["STAT3", "PROTEIN", 137, 142], ["PTEN", "PROTEIN", 169, 173], ["p53", "PROTEIN", 178, 181], ["STAT3", "PROTEIN", 185, 190], ["this study", "TEST", 3, 13], ["PTEN overexpression", "PROBLEM", 36, 55], ["CIA progression", "PROBLEM", 69, 84], ["the loss of p53", "PROBLEM", 94, 109], ["PTEN", "PROBLEM", 169, 173], ["previous investigations", "TEST", 230, 253], ["loss", "OBSERVATION_MODIFIER", 98, 102]]], ["Recently, p53 deficiency has revealed correlation with RA severity inducing Th17 differentiation17.", [["RA", "DISEASE", 55, 57], ["p53", "GENE_OR_GENE_PRODUCT", 10, 13], ["p53", "PROTEIN", 10, 13], ["p53 deficiency", "PROBLEM", 10, 24], ["RA severity", "TEST", 55, 66], ["Th17 differentiation17", "TREATMENT", 76, 98], ["p53 deficiency", "OBSERVATION", 10, 24]]], ["However, our study demonstrated significant mechanism of PTEN associated with p53 in the development of CIA via reciprocally regulating Th17 and Treg.", [["Th17", "ANATOMY", 136, 140], ["Treg", "ANATOMY", 145, 149], ["CIA", "DISEASE", 104, 107], ["PTEN", "GENE_OR_GENE_PRODUCT", 57, 61], ["p53", "GENE_OR_GENE_PRODUCT", 78, 81], ["CIA", "CANCER", 104, 107], ["Th17", "CELL", 136, 140], ["Treg", "CELL", 145, 149], ["PTEN", "PROTEIN", 57, 61], ["p53", "PROTEIN", 78, 81], ["Th17", "CELL_TYPE", 136, 140], ["Treg", "CELL_TYPE", 145, 149], ["our study", "TEST", 9, 18], ["PTEN", "PROBLEM", 57, 61], ["p53", "PROBLEM", 78, 81], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["PTEN", "OBSERVATION", 57, 61], ["CIA", "ANATOMY", 104, 107], ["Th17", "OBSERVATION", 136, 140]]], ["This preliminary evidence suggested that upregulating PTEN could be a strong therapeutic strategy for the treatment of RA.Ethics statement ::: Materials and MethodsThe Animal Care Committee of The Catholic University of Korea approved the experimental protocol, and all the experimental procedures were carried out in accordance with the protocols approved by the Animal Research Ethics Committee at the Catholic University of Korea.", [["RA", "DISEASE", 119, 121], ["PTEN", "GENE_OR_GENE_PRODUCT", 54, 58], ["PTEN", "PROTEIN", 54, 58], ["upregulating PTEN", "PROBLEM", 41, 58], ["a strong therapeutic strategy", "TREATMENT", 68, 97], ["the treatment of RA", "TREATMENT", 102, 121], ["the experimental protocol", "TREATMENT", 235, 260], ["the experimental procedures", "TEST", 270, 297], ["RA", "ANATOMY", 119, 121]]], ["All procedures performed followed the ethical guidelines for animal studies.Animals ::: Materials and MethodsMale DBA1/J mice and C57BL/6 mice at 6\u20138 weeks old (Orient, Korea) were maintained in groups of five in polycarbonate cages in a specific pathogen-free environment.", [["polycarbonate", "CHEMICAL", 213, 226], ["DBA1/J mice", "ORGANISM", 114, 125], ["C57BL/6 mice", "ORGANISM", 130, 142], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 138, 142], ["All procedures", "TREATMENT", 0, 14], ["animal studies", "TEST", 61, 75], ["polycarbonate cages", "TREATMENT", 213, 232]]], ["They were provided free access to standard mouse chow (Ralston Purina, Gray Summit, MO) and water ad libitum.", [["mouse", "ORGANISM", 43, 48], ["chow", "ORGANISM_SUBDIVISION", 49, 53], ["mouse", "SPECIES", 43, 48], ["mouse", "SPECIES", 43, 48]]], ["Mice harboring the p53-null allele with a C57BL/6 mice background (B6.129S2-Trp53tm1Tyj/J) were obtained from The Jackson Laboratory.Induction of arthritis and injection of agents ::: Materials and MethodsCollagen-induced arthritis (CIA) was induced in DBA1/J mice (each group: n = 10).", [["129S2-Trp", "CHEMICAL", 70, 79], ["arthritis", "DISEASE", 146, 155], ["MethodsCollagen", "CHEMICAL", 198, 213], ["arthritis", "DISEASE", 222, 231], ["CIA", "DISEASE", 233, 236], ["Trp", "CHEMICAL", 76, 79], ["Mice", "ORGANISM", 0, 4], ["p53", "GENE_OR_GENE_PRODUCT", 19, 22], ["C57BL/6 mice", "ORGANISM", 42, 54], ["DBA1/J mice", "ORGANISM", 253, 264], ["p53-null allele", "DNA", 19, 34], ["129S2", "PROTEIN", 70, 75], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 260, 264], ["DBA1/J mice", "SPECIES", 253, 264], ["arthritis", "PROBLEM", 146, 155], ["injection of agents", "TREATMENT", 160, 179], ["Materials", "TREATMENT", 184, 193], ["MethodsCollagen", "TREATMENT", 198, 213], ["arthritis", "PROBLEM", 222, 231], ["arthritis", "OBSERVATION", 146, 155], ["arthritis", "OBSERVATION", 222, 231]]], ["Mice were immunized with 100 \u03bcg of chicken CII (Chondrex Inc., Redmond, WA, USA) dissolved overnight in 0.1N acetic acid (4 mg/ml) in complete Freund\u2019s adjuvant or incomplete Freund\u2019s adjuvant (Chondrex Inc).", [["0.1N acetic acid", "CHEMICAL", 104, 120], ["N acetic acid", "CHEMICAL", 107, 120], ["Mice", "ORGANISM", 0, 4], ["chicken", "ORGANISM", 35, 42], ["acetic acid", "SIMPLE_CHEMICAL", 109, 120], ["Mice", "SPECIES", 0, 4], ["chicken", "SPECIES", 35, 42], ["chicken", "SPECIES", 35, 42], ["chicken CII", "TREATMENT", 35, 46], ["acetic acid", "TREATMENT", 109, 120], ["complete Freund\u2019s adjuvant", "TREATMENT", 134, 160], ["incomplete Freund\u2019s adjuvant", "TREATMENT", 164, 192], ["Chondrex Inc", "TREATMENT", 194, 206]]], ["The immunization was performed intradermally into the base of the tail.", [["intradermally", "ANATOMY", 31, 44], ["tail", "ANATOMY", 66, 70], ["tail", "ORGANISM_SUBDIVISION", 66, 70], ["The immunization", "TREATMENT", 0, 16], ["base", "ANATOMY_MODIFIER", 54, 58], ["tail", "ANATOMY", 66, 70]]], ["CIA was induced in the p53\u2212/\u2212 strain mice as described previously41.", [["CIA", "GENE_OR_GENE_PRODUCT", 0, 3], ["p53\u2212", "GENE_OR_GENE_PRODUCT", 23, 27], ["mice", "ORGANISM", 37, 41], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41]]], ["Eight days after immunization, mice were injected intravenously with 100 \u03bcg of PTEN or mock vector in 2 ml of saline over a 10-second period.", [["intravenously", "ANATOMY", 50, 63], ["mice", "ORGANISM", 31, 35], ["PTEN", "GENE_OR_GENE_PRODUCT", 79, 83], ["saline", "SIMPLE_CHEMICAL", 110, 116], ["PTEN", "PROTEIN", 79, 83], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["immunization", "TREATMENT", 17, 29], ["PTEN or mock vector", "TREATMENT", 79, 98], ["saline", "TREATMENT", 110, 116]]], ["After 8 days, the same mice received intramuscular injection of 50 \u03bcg of PTEN or mock vector in the left leg with electrical stimulation (electroporation) using a 31-gauge needle insulin syringe for hydrodynamic-based procedures.", [["intramuscular", "ANATOMY", 37, 50], ["left leg", "ANATOMY", 100, 108], ["mice", "ORGANISM", 23, 27], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["PTEN", "GENE_OR_GENE_PRODUCT", 73, 77], ["leg", "ORGAN", 105, 108], ["insulin", "GENE_OR_GENE_PRODUCT", 179, 186], ["PTEN", "PROTEIN", 73, 77], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["intramuscular injection", "TREATMENT", 37, 60], ["PTEN or mock vector", "TREATMENT", 73, 92], ["electrical stimulation (electroporation", "TREATMENT", 114, 153], ["a 31-gauge needle insulin syringe", "TREATMENT", 161, 194], ["hydrodynamic-based procedures", "TREATMENT", 199, 228], ["left leg", "ANATOMY", 100, 108]]], ["Two days later, mice received an intramuscular injection of 50 \u03bcg of PTEN or mock in the right leg through electroporation.Clinical scoring and histological assessment of arthritis ::: Materials and MethodsArthritis score was measured visually twice per week based on the appearance of arthritis in the joints and graded according to Williams et al.42.", [["intramuscular", "ANATOMY", 33, 46], ["right leg", "ANATOMY", 89, 98], ["joints", "ANATOMY", 303, 309], ["arthritis", "DISEASE", 171, 180], ["arthritis", "DISEASE", 286, 295], ["mice", "ORGANISM", 16, 20], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["PTEN", "GENE_OR_GENE_PRODUCT", 69, 73], ["leg", "ORGAN", 95, 98], ["joints", "MULTI-TISSUE_STRUCTURE", 303, 309], ["PTEN", "PROTEIN", 69, 73], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["an intramuscular injection", "TREATMENT", 30, 56], ["PTEN", "TREATMENT", 69, 73], ["Clinical scoring", "TEST", 123, 139], ["histological assessment", "TEST", 144, 167], ["arthritis", "PROBLEM", 171, 180], ["MethodsArthritis score", "TEST", 199, 221], ["arthritis in the joints", "PROBLEM", 286, 309], ["right", "ANATOMY_MODIFIER", 89, 94], ["leg", "ANATOMY", 95, 98], ["arthritis", "OBSERVATION", 171, 180], ["arthritis", "OBSERVATION", 286, 295], ["joints", "ANATOMY", 303, 309]]], ["The joints of each mouse were fixed in 10% formalin, decalcified in 10% EDTA, and embedded in paraffin wax for histological analysis.", [["joints", "ANATOMY", 4, 10], ["formalin", "CHEMICAL", 43, 51], ["formalin", "CHEMICAL", 43, 51], ["EDTA", "CHEMICAL", 72, 76], ["paraffin", "CHEMICAL", 94, 102], ["joints", "MULTI-TISSUE_STRUCTURE", 4, 10], ["mouse", "ORGANISM", 19, 24], ["formalin", "SIMPLE_CHEMICAL", 43, 51], ["EDTA", "SIMPLE_CHEMICAL", 72, 76], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["decalcified in 10% EDTA", "TREATMENT", 53, 76], ["histological analysis", "TEST", 111, 132], ["joints", "ANATOMY", 4, 10]]], ["Hematoxylin-eosin (H&E) stained sections were scored for inflammation, destruction of cartilage, and bone damage according to published criteria4344.Real-time polymerase chain reaction (PCR) ::: Materials and MethodsTotal RNA was isolated using TRI Reagent (Molecular Research Center, Inc. Cincinnati, OH, USA) according to the manufacturer\u2019s instructions.", [["sections", "ANATOMY", 32, 40], ["cartilage", "ANATOMY", 86, 95], ["bone", "ANATOMY", 101, 105], ["inflammation", "DISEASE", 57, 69], ["bone damage", "DISEASE", 101, 112], ["TRI", "CHEMICAL", 245, 248], ["Hematoxylin", "CHEMICAL", 0, 11], ["eosin", "CHEMICAL", 12, 17], ["Hematoxylin-eosin", "SIMPLE_CHEMICAL", 0, 17], ["H&E", "SIMPLE_CHEMICAL", 19, 22], ["cartilage", "TISSUE", 86, 95], ["bone", "TISSUE", 101, 105], ["MethodsTotal RNA", "RNA", 209, 225], ["Hematoxylin", "TEST", 0, 11], ["stained sections", "TEST", 24, 40], ["inflammation", "PROBLEM", 57, 69], ["destruction of cartilage", "PROBLEM", 71, 95], ["bone damage", "PROBLEM", 101, 112], ["MethodsTotal RNA", "TREATMENT", 209, 225], ["TRI Reagent", "TREATMENT", 245, 256], ["inflammation", "OBSERVATION", 57, 69], ["cartilage", "ANATOMY", 86, 95], ["bone", "ANATOMY", 101, 105]]], ["Complementary DNA was synthesized using SuperScript Reverse Transcription system (Takara).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["Complementary DNA", "PROBLEM", 0, 17]]], ["A Light-Cycler 2.0 instrument (software version 4.0; Roche Diagnostics) was used for PCR amplification.", [["A Light-Cycler 2.0 instrument", "TREATMENT", 0, 29], ["software version", "TEST", 31, 47], ["Roche Diagnostics", "TEST", 53, 70], ["PCR amplification", "TREATMENT", 85, 102]]], ["All reactions were performed using LightCycler FastStart DNA Master SYBR Green I mix (Takara) following the manufacturer instructions.", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["All reactions", "PROBLEM", 0, 13], ["the manufacturer instructions", "TREATMENT", 104, 133]]], ["Primer sequences used to amplify mouse genes are listed in Supplementary Table 1.Flow cytometry ::: Materials and MethodsFlow cytometry was conducted as described previously4546.", [["mouse", "ORGANISM", 33, 38], ["Primer sequences", "DNA", 0, 16], ["mouse genes", "DNA", 33, 44], ["mouse", "SPECIES", 33, 38], ["mouse", "SPECIES", 33, 38], ["Primer sequences", "TEST", 0, 16], ["MethodsFlow cytometry", "TEST", 114, 135]]], ["Cells were immunostained with various combinations of fluorescent antibodies against CD4, CD25, FOXP3, IFN-\u03b3, IL-4, and IL-17 (eBioscience, San Diego, CA, USA).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 85, 88], ["CD25", "GENE_OR_GENE_PRODUCT", 90, 94], ["FOXP3", "GENE_OR_GENE_PRODUCT", 96, 101], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-4", "GENE_OR_GENE_PRODUCT", 110, 114], ["IL-17", "GENE_OR_GENE_PRODUCT", 120, 125], ["fluorescent antibodies", "PROTEIN", 54, 76], ["CD4", "PROTEIN", 85, 88], ["CD25", "PROTEIN", 90, 94], ["FOXP3", "PROTEIN", 96, 101], ["IFN", "PROTEIN", 103, 106], ["IL", "PROTEIN", 110, 112], ["IL", "PROTEIN", 120, 122], ["Cells", "TEST", 0, 5], ["fluorescent antibodies", "TEST", 54, 76], ["CD4", "TEST", 85, 88], ["CD25", "TEST", 90, 94], ["FOXP3", "TEST", 96, 101], ["IFN", "TEST", 103, 106], ["IL", "TEST", 110, 112], ["IL", "TEST", 120, 122]]], ["Prior to intracellular staining, cells were restimulated with phorbol myristate acetate (PMA; 25 ng/mL) and ionomycin (250 ng/mL) for 4 hours in the presence of GolgiSTOP (BD Biosciences).", [["intracellular", "ANATOMY", 9, 22], ["cells", "ANATOMY", 33, 38], ["phorbol myristate acetate", "CHEMICAL", 62, 87], ["PMA", "CHEMICAL", 89, 92], ["ionomycin", "CHEMICAL", 108, 117], ["GolgiSTOP", "CHEMICAL", 161, 170], ["phorbol myristate acetate", "CHEMICAL", 62, 87], ["PMA", "CHEMICAL", 89, 92], ["ionomycin", "CHEMICAL", 108, 117], ["GolgiSTOP", "CHEMICAL", 161, 170], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 9, 22], ["cells", "CELL", 33, 38], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 62, 87], ["PMA", "SIMPLE_CHEMICAL", 89, 92], ["ionomycin", "SIMPLE_CHEMICAL", 108, 117], ["intracellular staining", "TEST", 9, 31], ["phorbol myristate acetate (PMA", "TREATMENT", 62, 92], ["ionomycin", "TREATMENT", 108, 117], ["GolgiSTOP (BD Biosciences", "TREATMENT", 161, 186], ["staining", "OBSERVATION", 23, 31]]], ["For analysis of Treg cells, cells were surface labeled with CD4 and CD25, followed by fixation, permeabilization and intracellular staining with Foxp3 was perfirmed per the manufaturer\u2019s protocol.", [["Treg cells", "ANATOMY", 16, 26], ["cells", "ANATOMY", 28, 33], ["surface", "ANATOMY", 39, 46], ["intracellular", "ANATOMY", 117, 130], ["Treg cells", "CELL", 16, 26], ["cells", "CELL", 28, 33], ["surface", "CELLULAR_COMPONENT", 39, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["CD25", "GENE_OR_GENE_PRODUCT", 68, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["Foxp3", "GENE_OR_GENE_PRODUCT", 145, 150], ["Treg cells", "CELL_TYPE", 16, 26], ["CD4", "PROTEIN", 60, 63], ["CD25", "PROTEIN", 68, 72], ["Foxp3", "PROTEIN", 145, 150], ["Treg cells", "PROBLEM", 16, 26], ["CD4", "TEST", 60, 63], ["CD25", "TEST", 68, 72], ["fixation", "TREATMENT", 86, 94], ["permeabilization", "TREATMENT", 96, 112], ["intracellular staining", "TEST", 117, 139], ["Foxp3", "TREATMENT", 145, 150], ["Treg cells", "OBSERVATION", 16, 26]]], ["Flow cytometry was performed on a FACSCalibur flow cytometer (BD Biosciences).", [["Flow cytometry", "TEST", 0, 14], ["a FACSCalibur flow cytometer", "TREATMENT", 32, 60]]], ["The data was analyzed using the FlowJo software (Tree Star, Ashland, OR,USA).ELISA ::: Materials and MethodsEnzyme-linked immunosorbent assay (ELISA) was conducted as described previously4748.", [["MethodsEnzyme", "TEST", 101, 114], ["immunosorbent assay", "TEST", 122, 141], ["ELISA", "TEST", 143, 148]]], ["Briefly, blood was obtained from the orbital sinus of mice.", [["blood", "ANATOMY", 9, 14], ["orbital sinus", "ANATOMY", 37, 50], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["orbital sinus", "MULTI-TISSUE_STRUCTURE", 37, 50], ["mice", "ORGANISM", 54, 58], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["orbital sinus", "ANATOMY", 37, 50]]], ["Serum levels of IgG antibodies were measured using a commercially available ELISA kit (Bethyl Laboratories, Montgomery, TX, USA).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 16, 30], ["IgG antibodies", "PROTEIN", 16, 30], ["Serum levels", "TEST", 0, 12], ["IgG antibodies", "TEST", 16, 30]]], ["Horseradish peroxidase (HRP) activity was measured using tetramethyl benzidine as substrate (eBioscience, San Diego, CA, USA).Staining for confocal microscopy analysis ::: Materials and MethodsTissue cryosections (7 \u03bcm thick) were fixed with acetone and stained with FITC-, PE-, PerCP-Cy5.5-, or APC-conjugated monoclonal antibodies against mouse CD4, pSTAT3 (Tyr 705, Ser 727), pSTAT5, IL-17, and FOXP3 (eBioscience).", [["cryosections", "ANATOMY", 200, 212], ["tetramethyl benzidine", "CHEMICAL", 57, 78], ["acetone", "CHEMICAL", 242, 249], ["tetramethyl benzidine", "CHEMICAL", 57, 78], ["acetone", "CHEMICAL", 242, 249], ["FITC", "CHEMICAL", 267, 271], ["APC", "CHEMICAL", 296, 299], ["Tyr", "CHEMICAL", 360, 363], ["Ser", "CHEMICAL", 369, 372], ["Horseradish peroxidase", "GENE_OR_GENE_PRODUCT", 0, 22], ["HRP", "GENE_OR_GENE_PRODUCT", 24, 27], ["tetramethyl benzidine", "SIMPLE_CHEMICAL", 57, 78], ["acetone", "SIMPLE_CHEMICAL", 242, 249], ["FITC", "SIMPLE_CHEMICAL", 267, 271], ["PE", "SIMPLE_CHEMICAL", 274, 276], ["PerCP-Cy5.5", "SIMPLE_CHEMICAL", 279, 290], ["APC", "GENE_OR_GENE_PRODUCT", 296, 299], ["mouse", "ORGANISM", 341, 346], ["CD4", "GENE_OR_GENE_PRODUCT", 347, 350], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 352, 358], ["Tyr 705", "AMINO_ACID", 360, 367], ["Ser 727", "AMINO_ACID", 369, 376], ["pSTAT5", "GENE_OR_GENE_PRODUCT", 379, 385], ["IL-17", "GENE_OR_GENE_PRODUCT", 387, 392], ["FOXP3", "GENE_OR_GENE_PRODUCT", 398, 403], ["eBioscience", "GENE_OR_GENE_PRODUCT", 405, 416], ["Horseradish peroxidase", "PROTEIN", 0, 22], ["HRP", "PROTEIN", 24, 27], ["Cy5.5", "PROTEIN", 285, 290], ["APC", "PROTEIN", 296, 299], ["conjugated monoclonal antibodies", "PROTEIN", 300, 332], ["mouse CD4", "PROTEIN", 341, 350], ["pSTAT3", "PROTEIN", 352, 358], ["Tyr 705", "PROTEIN", 360, 367], ["pSTAT5", "PROTEIN", 379, 385], ["IL-17", "PROTEIN", 387, 392], ["FOXP3", "PROTEIN", 398, 403], ["eBioscience", "PROTEIN", 405, 416], ["Horseradish", "SPECIES", 0, 11], ["mouse", "SPECIES", 341, 346], ["Horseradish", "SPECIES", 0, 11], ["mouse", "SPECIES", 341, 346], ["tetramethyl benzidine", "TREATMENT", 57, 78], ["confocal microscopy analysis", "TEST", 139, 167], ["MethodsTissue cryosections", "TREATMENT", 186, 212], ["acetone", "TREATMENT", 242, 249], ["FITC", "TEST", 267, 271], ["PE", "TEST", 274, 276], ["PerCP", "TEST", 279, 284], ["Cy5.5", "TEST", 285, 290], ["APC", "TEST", 296, 299], ["conjugated monoclonal antibodies", "TEST", 300, 332], ["mouse CD4", "TEST", 341, 350], ["pSTAT3", "TEST", 352, 358], ["Tyr", "TEST", 360, 363], ["Ser", "TEST", 369, 372], ["pSTAT5", "TEST", 379, 385], ["IL", "TEST", 387, 389], ["PE", "OBSERVATION", 274, 276]]], ["After incubation at 4 \u00b0C overnight, stained sections were visualized through confocal microscopy (LSM 510 Meta; Zeiss, G\u00f6ttingen, Germany).Immunohistochemistry ::: Materials and MethodsImmunohistochemistry was performed using the Vectastain ABC kit.", [["sections", "ANATOMY", 44, 52], ["Vectastain", "GENE_OR_GENE_PRODUCT", 230, 240], ["stained sections", "TEST", 36, 52], ["confocal microscopy", "TEST", 77, 96], ["MethodsImmunohistochemistry", "TEST", 178, 205]]], ["Tissues were first incubated with primary anti-c-Jun and anti-c-Fos antibodies overnight at 4 \u00b0C. The primary antibody was detected with a biotinylated secondary antibody followed by incubation with a streptavidin-peroxidase complex for 1 h.", [["Tissues", "ANATOMY", 0, 7], ["Tissues", "CANCER", 0, 7], ["anti-c-Jun", "GENE_OR_GENE_PRODUCT", 42, 52], ["anti-c-Fos", "GENE_OR_GENE_PRODUCT", 57, 67], ["streptavidin", "GENE_OR_GENE_PRODUCT", 201, 213], ["peroxidase", "GENE_OR_GENE_PRODUCT", 214, 224], ["primary anti-c-Jun and anti-c-Fos antibodies", "PROTEIN", 34, 78], ["primary antibody", "PROTEIN", 102, 118], ["biotinylated secondary antibody", "PROTEIN", 139, 170], ["streptavidin-peroxidase complex", "PROTEIN", 201, 232], ["primary anti-c-Jun", "TREATMENT", 34, 52], ["anti-c-Fos antibodies", "TEST", 57, 78], ["The primary antibody", "TEST", 98, 118], ["a biotinylated secondary antibody", "TREATMENT", 137, 170], ["a streptavidin-peroxidase complex", "TREATMENT", 199, 232]]], ["DAB chromogen was added to obtain colored product.Transfection ::: Materials and MethodsPTEN vector purchased from Addgene (plasmid#22231) was used to generate the overexpression of PTEN.", [["DAB chromogen", "CHEMICAL", 0, 13], ["DAB chromogen", "CHEMICAL", 0, 13], ["DAB chromogen", "SIMPLE_CHEMICAL", 0, 13], ["Addgene", "GENE_OR_GENE_PRODUCT", 115, 122], ["PTEN", "GENE_OR_GENE_PRODUCT", 182, 186], ["MethodsPTEN vector", "DNA", 81, 99], ["Addgene", "DNA", 115, 122], ["PTEN", "PROTEIN", 182, 186], ["DAB chromogen", "TEST", 0, 13], ["MethodsPTEN vector", "TREATMENT", 81, 99], ["Addgene (plasmid", "TREATMENT", 115, 131], ["PTEN", "PROBLEM", 182, 186]]], ["Mock and PTEN vector constructs were transfected into LBRM (mice T lymphoma cell line) cells using Amaxa 4D-Nucleofector X unit according to the manufacturer\u2019s recommendations with program DN-100 (Lonza).Murine T cell isolation and alloreactive T cell responses in vitro ::: Materials and MethodsSplenocytes were harvested in ACK lysis buffer, washed, and resuspended in complete culture medium (RPMI 1640 supplemented with 10% [v/v] heat-inactivated fetal calf serum).", [["LBRM", "ANATOMY", 54, 58], ["T lymphoma cell line) cells", "ANATOMY", 65, 92], ["T cell", "ANATOMY", 211, 217], ["alloreactive T cell", "ANATOMY", 232, 251], ["fetal calf serum", "ANATOMY", 451, 467], ["PTEN", "GENE_OR_GENE_PRODUCT", 9, 13], ["LBRM", "CELL", 54, 58], ["mice", "ORGANISM", 60, 64], ["T lymphoma cell line) cells", "CELL", 65, 92], ["Murine", "ORGANISM", 204, 210], ["T cell", "CELL", 211, 217], ["alloreactive T cell", "CELL", 232, 251], ["MethodsSplenocytes", "CELL", 289, 307], ["ACK", "ORGANISM_SUBSTANCE", 326, 329], ["fetal calf", "MULTI-TISSUE_STRUCTURE", 451, 461], ["serum", "ORGANISM_SUBSTANCE", 462, 467], ["Mock and PTEN vector constructs", "DNA", 0, 31], ["LBRM (mice T lymphoma cell line) cells", "CELL_LINE", 54, 92], ["Nucleofector X unit", "DNA", 108, 127], ["mice", "SPECIES", 60, 64], ["Murine", "SPECIES", 204, 210], ["calf", "SPECIES", 457, 461], ["Mock and PTEN vector constructs", "TREATMENT", 0, 31], ["mice T lymphoma cell line) cells", "TREATMENT", 60, 92], ["Amaxa 4D", "TREATMENT", 99, 107], ["Nucleofector", "TREATMENT", 108, 120], ["Murine T cell isolation", "TREATMENT", 204, 227], ["MethodsSplenocytes", "TREATMENT", 289, 307], ["ACK lysis buffer", "TREATMENT", 326, 342], ["heat", "TEST", 434, 438], ["fetal calf serum", "TEST", 451, 467], ["cell isolation", "OBSERVATION", 213, 227], ["alloreactive T cell", "OBSERVATION", 232, 251], ["calf", "ANATOMY", 457, 461]]], ["To purify splenic CD4+ T cells, splenocytes were incubated with anti-CD4-coated magnetic beads, and CD4+ T cells were isolated using magnetic-activated cell sorting (MACS) separation columns (Miltenyi Biotec).", [["splenic CD4+ T cells", "ANATOMY", 10, 30], ["splenocytes", "ANATOMY", 32, 43], ["CD4+ T cells", "ANATOMY", 100, 112], ["cell", "ANATOMY", 152, 156], ["CD4", "GENE_OR_GENE_PRODUCT", 18, 21], ["splenocytes", "CELL", 32, 43], ["anti-CD4", "SIMPLE_CHEMICAL", 64, 72], ["CD4", "GENE_OR_GENE_PRODUCT", 100, 103], ["cell", "CELL", 152, 156], ["splenic CD4+ T cells", "CELL_TYPE", 10, 30], ["splenocytes", "CELL_TYPE", 32, 43], ["anti-CD4", "PROTEIN", 64, 72], ["CD4", "PROTEIN", 100, 103], ["T cells", "CELL_TYPE", 105, 112], ["Miltenyi Biotec", "PROTEIN", 192, 207], ["T cells", "PROBLEM", 23, 30], ["splenocytes", "PROBLEM", 32, 43], ["anti-CD4", "TEST", 64, 72], ["coated magnetic beads", "TEST", 73, 94], ["CD4+ T cells", "PROBLEM", 100, 112], ["splenic", "ANATOMY", 10, 17], ["CD4+ T cells", "OBSERVATION", 18, 30], ["splenocytes", "ANATOMY", 32, 43]]], ["The cells were pretreated with Pifithrin-\u03b1, Nutlin-3a (Cayman Chemical) or bPV(HOpic) (Santa Cruz Biotechnology) and then stimulated under the required polarizing conditions.", [["cells", "ANATOMY", 4, 9], ["Pifithrin-\u03b1", "CHEMICAL", 31, 42], ["Nutlin-3a", "CHEMICAL", 44, 53], ["Pifithrin-\u03b1", "CHEMICAL", 31, 42], ["bPV", "CHEMICAL", 75, 78], ["cells", "CELL", 4, 9], ["Pifithrin-\u03b1", "SIMPLE_CHEMICAL", 31, 42], ["Nutlin-3a", "SIMPLE_CHEMICAL", 44, 53], ["Cayman Chemical", "SIMPLE_CHEMICAL", 55, 70], ["bPV", "SIMPLE_CHEMICAL", 75, 78], ["HOpic", "SIMPLE_CHEMICAL", 79, 84], ["Santa Cruz Biotechnology", "PROTEIN", 87, 111], ["Pifithrin", "TREATMENT", 31, 40], ["Nutlin", "TREATMENT", 44, 50]]], ["Aliquots of 2 \u00d7 105 CD4+ T cells (responders) were cultured with 2 \u00d7 105 irradiated (2,500 cGy) APCs in 96-well plates containing 200 \u03bcl/well of complete medium, at 37 \u00b0C in a humidified 5% (v/v) CO2/air atmosphere.", [["Aliquots", "ANATOMY", 0, 8], ["CD4+ T cells", "ANATOMY", 20, 32], ["APCs", "ANATOMY", 96, 100], ["CO2", "CHEMICAL", 196, 199], ["CO2", "CHEMICAL", 196, 199], ["APCs", "CELL", 96, 100], ["CO2", "SIMPLE_CHEMICAL", 196, 199], ["CD4", "PROTEIN", 20, 23], ["T cells", "CELL_TYPE", 25, 32], ["APCs", "CELL_TYPE", 96, 100], ["Aliquots", "TEST", 0, 8], ["APCs", "TEST", 96, 100], ["a humidified", "TREATMENT", 174, 186], ["CO2/air atmosphere", "TREATMENT", 196, 214], ["air atmosphere", "OBSERVATION", 200, 214]]], ["Cells were pulsed with 1 \u03bcCi of tritiated thymidine (3[H]-TdR; NEN Life Science Products Inc., Boston, MA, USA) 18 h before harvesting, and counted with an automated harvester (PHD Cell Harvester; Cambridge Technology, Inc., Cambridge, MA, USA).", [["Cells", "ANATOMY", 0, 5], ["thymidine", "CHEMICAL", 42, 51], ["thymidine", "CHEMICAL", 42, 51], ["3[H]-TdR", "CHEMICAL", 53, 61], ["NEN", "CHEMICAL", 63, 66], ["Cells", "CELL", 0, 5], ["thymidine", "SIMPLE_CHEMICAL", 42, 51], ["3[H]-TdR", "SIMPLE_CHEMICAL", 53, 61], ["pulsed", "TEST", 11, 17], ["Ci", "TEST", 26, 28], ["tritiated thymidine", "TEST", 32, 51], ["TdR", "TEST", 58, 61]]], ["Results are expressed as the mean cpm values of triplicate samples.Western blot ::: Materials and MethodsWestern blot was performed as described previously4849.", [["the mean cpm values", "TEST", 25, 44], ["triplicate samples", "TEST", 48, 66], ["MethodsWestern blot", "TEST", 98, 117]]], ["Proteins were loaded onto 10% polyacrylamide gels and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by transferring to nitrocellulose membranes (Invitrogen Life Technologies, Carlsbad, CA, USA).", [["Proteins", "ANATOMY", 0, 8], ["membranes", "ANATOMY", 168, 177], ["sodium dodecyl sulfate", "CHEMICAL", 67, 89], ["polyacrylamide", "CHEMICAL", 30, 44], ["sodium dodecyl sulfate", "CHEMICAL", 67, 89], ["polyacrylamide", "CHEMICAL", 90, 104], ["nitrocellulose", "CHEMICAL", 153, 167], ["sodium dodecyl sulfate polyacrylamide", "SIMPLE_CHEMICAL", 67, 104], ["Proteins", "TEST", 0, 8], ["10% polyacrylamide gels", "TREATMENT", 26, 49], ["sodium dodecyl sulfate polyacrylamide gel electrophoresis", "TREATMENT", 67, 124], ["nitrocellulose membranes", "TREATMENT", 153, 177]]], ["Membranes were blocked with 5% (w/v) non-fat milk in Tris-buffered saline containing 0.1% Tween-20 for 1 h followed by incubation with antibodies against p-STAT3 Y705, p-STAT3 S727, t-STAT3 (Cell signaling), and \u03b2-actin (Santa Cruz Biotechnology) overnight at 4 \u00b0C. Immunoreactivity was determined using enhanced chemiluminescence reagents (Amersham Biosciences, Piscataway, NJ, USA).Statistical analysis ::: Materials and MethodsData were presented as means \u00b1 standard deviations (SD).", [["Membranes", "ANATOMY", 0, 9], ["fat milk", "ANATOMY", 41, 49], ["Cell", "ANATOMY", 191, 195], ["Tween-20", "CHEMICAL", 90, 98], ["Tris", "CHEMICAL", 53, 57], ["Tween-20", "CHEMICAL", 90, 98], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["fat milk", "ORGANISM_SUBSTANCE", 41, 49], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 53, 73], ["Tween-20", "SIMPLE_CHEMICAL", 90, 98], ["STAT3", "GENE_OR_GENE_PRODUCT", 156, 161], ["STAT3", "GENE_OR_GENE_PRODUCT", 170, 175], ["t-", "GENE_OR_GENE_PRODUCT", 182, 184], ["STAT3", "GENE_OR_GENE_PRODUCT", 184, 189], ["Cell", "CELL", 191, 195], ["\u03b2-actin", "SIMPLE_CHEMICAL", 212, 219], ["STAT3 Y705", "PROTEIN", 156, 166], ["STAT3 S727", "PROTEIN", 170, 180], ["STAT3", "PROTEIN", 184, 189], ["\u03b2-actin", "PROTEIN", 212, 219], ["Santa Cruz Biotechnology", "PROTEIN", 221, 245], ["5% (w/v) non-fat milk in Tris-buffered saline", "TREATMENT", 28, 73], ["antibodies", "TEST", 135, 145], ["Immunoreactivity", "TEST", 266, 282], ["enhanced chemiluminescence reagents", "TREATMENT", 304, 339], ["MethodsData", "TEST", 423, 434]]], ["Statistical analysis was performed with nonparametric Mann-Whitney U test using Graphpad Prism v.5.01.", [["Statistical analysis", "TEST", 0, 20], ["Graphpad Prism", "TEST", 80, 94]]], ["One-way analysis of variance (ANOVA) and Bonferroni\u2019s post hoc test were used for multiple comparisons.", [["Bonferroni\u2019s post hoc test", "TEST", 41, 67], ["multiple comparisons", "TEST", 82, 102]]], ["Statistical significance was considered when p value was less than 0.05.Additional InformationHow to cite this article: Lee, S. H. et al. PTEN ameliorates autoimmune arthritis through down-regulating STAT3 activation with reciprocal balance of Th17 and Tregs.", [["Th17", "ANATOMY", 244, 248], ["Tregs", "ANATOMY", 253, 258], ["autoimmune arthritis", "DISEASE", 155, 175], ["PTEN", "GENE_OR_GENE_PRODUCT", 138, 142], ["STAT3", "GENE_OR_GENE_PRODUCT", 200, 205], ["Th17", "CELL", 244, 248], ["Tregs", "CELL", 253, 258], ["PTEN", "PROTEIN", 138, 142], ["STAT3", "PROTEIN", 200, 205], ["Th17", "CELL_TYPE", 244, 248], ["Tregs", "CELL_TYPE", 253, 258], ["p value", "TEST", 45, 52], ["PTEN ameliorates autoimmune arthritis", "PROBLEM", 138, 175], ["STAT3 activation", "TREATMENT", 200, 216], ["reciprocal balance of Th17 and Tregs", "TREATMENT", 222, 258], ["autoimmune arthritis", "OBSERVATION", 155, 175]]]], "PMC7302543": [["In terms of 3D representation, modelling chairs of different styles from large public domain 3D CAD models was proposed by [1].", [["CAD", "DISEASE", 96, 99], ["large public domain 3D CAD models", "TREATMENT", 73, 106], ["large", "OBSERVATION_MODIFIER", 73, 78]]], ["[25] applied Deep Belief Network to create representation of volumetric shapes.", [["volumetric shapes", "OBSERVATION", 61, 78]]], ["Furthermore, the application of CNN extended into rendering techniques, such as enabling global illumination fast rendering in a single scene [19], and Image based relighting from small number of images [18].", [["CNN", "PROTEIN", 32, 35], ["Image", "TEST", 152, 157], ["images", "TEST", 196, 202], ["small", "OBSERVATION_MODIFIER", 180, 185]]], ["Another application filters Monte Carlo noise using a non-linear regression model [8].", [["Another application filters", "TREATMENT", 0, 27], ["a non-linear regression model", "TREATMENT", 52, 81]]]], "PMC7424619": [["Expertise in Intense Political SemiosisRobin Wagner-Pacifi (2018) sees an event as a process of intensified political semiosis, an unpredictable whirl of meanings, where three aspects of public speech and action intertwine.", [["semiosis", "DISEASE", 118, 126], ["public speech", "TREATMENT", 187, 200], ["action intertwine", "TREATMENT", 205, 222], ["Intense", "OBSERVATION_MODIFIER", 13, 20], ["Political", "OBSERVATION_MODIFIER", 21, 30], ["SemiosisRobin Wagner", "OBSERVATION", 31, 51], ["political semiosis", "OBSERVATION", 108, 126]]], ["Demonstrative aspects of words and gestures signal and shape relationships in time, in space and between people (e.g., referring to coronavirus as the \u201cChinese virus).\u201d", [["coronavirus", "DISEASE", 132, 143], ["people", "ORGANISM", 105, 111], ["coronavirus", "ORGANISM", 132, 143], ["people", "SPECIES", 105, 111], ["coronavirus", "PROBLEM", 132, 143]]], ["Speech acts also function as representation, they craft interpretations for circulation (e.g., comparing the pandemic to a \u201cwar\u201d) (Wagner-Pacifi, 2018, pp. 16\u201332).Expertise in Intense Political SemiosisThe heightened political semiosis of events is unpredictable for all actors drawn into its orbit.", [["orbit", "ANATOMY", 293, 298], ["orbit", "ORGAN", 293, 298], ["The heightened political semiosis of events", "PROBLEM", 202, 245], ["Intense", "OBSERVATION_MODIFIER", 176, 183], ["Political Semiosis", "OBSERVATION", 184, 202], ["heightened", "OBSERVATION_MODIFIER", 206, 216], ["political semiosis", "OBSERVATION", 217, 235], ["orbit", "ANATOMY", 293, 298]]], ["Despite this tension, national epidemiologists in many countries have gained almost a celebrity status.", [["this tension", "PROBLEM", 8, 20]]], ["In the spring, some Swedes had the face of a chief epidemiologist, Anders Tegnell, tattooed on their bodies.Expertise in Intense Political SemiosisAt first sight, this celebrated image of the scientist comes in sharp contrast to the way expertise has been troubled by the obstacles of the communicating of the climate crisis: the messaging and lobbying power of industry, the challenge of presenting scientific uncertainty without jeopardizing the larger unassailable findings, or the thorny connections between ideology, identity, and necessary climate action.", [["Intense", "OBSERVATION_MODIFIER", 121, 128]]], ["The climate crisis has not turned scientists into national figure heads, and the idea of ongoing press briefings with climatologist and presidents or prime ministers seems indeed a bit far-fetched.Expertise in Intense Political SemiosisHowever, the further the epidemic has spread, the more we have come to witness the tension between politics and expertise.", [["The climate crisis", "PROBLEM", 0, 18], ["climate crisis", "OBSERVATION", 4, 18], ["Intense", "OBSERVATION_MODIFIER", 210, 217], ["Political SemiosisHowever", "OBSERVATION", 218, 243]]], ["Nowhere has this been so obvious as in the fragmented, polarized, combative\u2014and vulnerable\u2014political-media ecosystem of the United States.", [["fragmented", "OBSERVATION_MODIFIER", 43, 53], ["polarized", "OBSERVATION_MODIFIER", 55, 64]]], ["Here\u2019s one example among many:Unveiling details of \u201cOperation Warp Speed,\u201d a name that references a concept popularised by Star Trek and other science fiction, [President] Trump said ( . . . the) \u201cobjective is to finish developing and then manufacture and distribute a proven coronavirus vaccine as fast as possible.", [["coronavirus", "DISEASE", 276, 287], ["coronavirus", "ORGANISM", 276, 287], ["a proven coronavirus vaccine", "TREATMENT", 267, 295]]], ["We\u2019d love to see if we can do it prior to the end of the year.\u201dStanding just behind him, Anthony Fauci, an infectious diseases expert wearing a face mask, cast his glance down and reached to adjust his tie.", [["infectious diseases", "DISEASE", 107, 126], ["a face mask", "TREATMENT", 142, 153], ["infectious", "OBSERVATION", 107, 117]]], ["Trump did not wear a face mask.", [["face", "ANATOMY", 21, 25], ["a face mask", "TREATMENT", 19, 30]]], ["(The Guardian, May 14, 2020)Expertise in Intense Political SemiosisYou don\u2019t have to be an expert on political semiosis to see the spin: the sci-fi-laced language overselling science for short-term political gain and the hijacking of Fauci\u2019s expertise as theatrical prop to bolster authority.", [["Intense", "OBSERVATION_MODIFIER", 41, 48], ["Political Semiosis", "OBSERVATION", 49, 67]]], ["But you also see the polyphony: the face masks as a metaphor for muted experts, the journalist\u2019s professional room of maneuver \u201conly\u201d to report the small gesture of Fauci, letting us read it as a demonstrative signal of an expert taken hostage.Expertise in Intense Political SemiosisThis is a snapshot of what Kenneth Cmiel and John Durham Peters (2020) call the era of \u201cpromiscuous knowledge,\u201d where we no longer expect anything \u201cbeyond the mix of the popular and professional, political actor and credentialed expert\u201d (p.", [["Intense", "OBSERVATION_MODIFIER", 257, 264], ["Political Semiosis", "OBSERVATION", 265, 283]]], ["At the same time, the scene is symptomatic of a broken public discourse, indeed highlighting the need to think beyond the paradigm of a polyphony vague plurality of \u201cknowledges.\u201d", [["symptomatic", "PROBLEM", 31, 42], ["symptomatic", "OBSERVATION_MODIFIER", 31, 42]]], ["Without a claim for an epistemic dimension for public discourse\u2014a capacity to come to terms with the world, and to know what should be done\u2014both journalism and public expertise will wither.Transformation of Structures: What Will (Nation) States Come to Mean?Thinking about systemic crises raises questions about structures.", [["public discourse\u2014a capacity", "PROBLEM", 47, 74], ["systemic crises", "PROBLEM", 273, 288]]], ["In Logics of History, William Sewell (2005) argues that existing \u201cdislocated structures\u201d always underlie such moments, providing a space for collective action to make a lasting difference.", [["dislocated structures", "PROBLEM", 66, 87], ["collective action", "TREATMENT", 141, 158], ["dislocated", "OBSERVATION", 66, 76]]], ["His narrative of the French Revolution proceeds from the unstable conjuncture that saw the King and National Assembly present rival views of power and new ideas about the authority of popular will and, from there, moves to the material, existential crisis of everyday life in which the food supplies left the masses starving and desperate.", [["existential crisis", "PROBLEM", 237, 255], ["left the masses", "PROBLEM", 300, 315], ["left", "ANATOMY_MODIFIER", 300, 304], ["masses", "OBSERVATION", 309, 315]]], ["It was a lasting transformation of symbolic structures, shaping future agency (Sewell, 2005, pp. 226\u2013270).Transformation of Structures: What Will (Nation) States Come to Mean?The Covid-19 pandemic highlights existing structural fissures in the political order.", [["fissures", "PATHOLOGICAL_FORMATION", 228, 236], ["a lasting transformation of symbolic structures", "PROBLEM", 7, 54], ["The Covid", "TEST", 175, 184], ["lasting", "OBSERVATION_MODIFIER", 9, 16], ["transformation", "OBSERVATION_MODIFIER", 17, 31], ["symbolic structures", "OBSERVATION", 35, 54], ["fissures", "OBSERVATION_MODIFIER", 228, 236]]], ["Most obviously, the virus has entered a context where the twentieth-century commonly held distinction between left and right is being replaced by the polarity that features \u201cnationalists-conservatives\u201d and \u201ccosmopolitan-liberals\u201d\u2014a polarity moving into place long before the coronavirus began moving through the neighborhoods of Wuhan.Transformation of Structures: What Will (Nation) States Come to Mean?Journalism routinely leans toward nationalism, particularly in moments of crises, and the coverage of the pandemic has centered much on the actions taken by national governments to protect national populations.", [["left", "ANATOMY", 110, 114], ["coronavirus", "ORGANISM", 275, 286], ["the virus", "PROBLEM", 16, 25], ["the coronavirus", "PROBLEM", 271, 286], ["crises", "PROBLEM", 478, 484], ["virus", "OBSERVATION", 20, 25], ["left", "ANATOMY_MODIFIER", 110, 114], ["right", "ANATOMY_MODIFIER", 119, 124], ["replaced", "OBSERVATION", 134, 142]]], ["On the other hand, this frame can also cover up crucial differences and moral discrepancies between nations and among diverse populations within nations.", [["moral discrepancies", "PROBLEM", 72, 91], ["diverse", "OBSERVATION_MODIFIER", 118, 125], ["populations", "OBSERVATION_MODIFIER", 126, 137]]], ["It can easily empower the latest arguments against rapid climate action, arguing that climate change might indeed be real, but it makes little sense for \u201cus\u201d to change our ways\u2014because (for instance) of China\u2019s raising emissions and increasing overpopulation.", [["increasing overpopulation", "PROBLEM", 233, 258], ["increasing", "OBSERVATION_MODIFIER", 233, 243], ["overpopulation", "OBSERVATION", 244, 258]]], ["As such narrow-minded and short-sighted political realism gains strength, the position of journalism addressing the climate crisis weakens.Transformation of Structures: What Will (Nation) States Come to Mean?This is not to recommend more of hollow praise cosmopolitanism and the blessings of globalization.", [["the climate crisis weakens", "PROBLEM", 112, 138], ["narrow", "OBSERVATION_MODIFIER", 8, 14]]], ["Instead, journalists should be pushed to do work that looks inside the nationalistic frames from which they report virus contagion numbers and death tolls\u2014or the emission footprints, drought, flood damage, and species die-offs of the climate change era.", [["death", "DISEASE", 143, 148], ["flood damage", "DISEASE", 192, 204], ["flood damage", "PROBLEM", 192, 204]]], ["Covering the pandemic is a key moment for re-articulating what \u201cnations\u201d and \u201cstates\u201d mean in the era of systemic, global crises.", [["global crises", "PROBLEM", 115, 128], ["systemic", "ANATOMY", 105, 113], ["global crises", "OBSERVATION", 115, 128]]], ["In this sense, Covid-19 coverage plows the soil for future climate coverage.A New Horizon: Everyday Life in a Low-Carbon SocietyHannah Arendt\u2019s (1958) The Human Condition argues that events have no causes.", [["Human", "ORGANISM", 155, 160], ["Human", "SPECIES", 155, 160], ["Covid", "TEST", 15, 20], ["the soil", "TREATMENT", 39, 47], ["future climate coverage", "TREATMENT", 52, 75], ["New", "OBSERVATION_MODIFIER", 78, 81]]], ["Rather, they take place where contingent material things intervene with developing human interpretations.", [["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88]]], ["In this line of reasoning, it was Galileo\u2019s telescope (rather than the man himself) that pushed the emerging modern world around a corner, giving \u201can earth-bound creature\u201d the chance to see itself from the perspective of the vast universe.", [["man", "SPECIES", 71, 74], ["Galileo\u2019s telescope", "TREATMENT", 34, 53]]], ["Although the Copernican revolution was already developing as \u201cspeculation and imagination,\u201d the telescope turned it into a sense-related, material observation (Arendt, 1958, p.", [["the telescope", "TREATMENT", 92, 105]]], ["260).A New Horizon: Everyday Life in a Low-Carbon SocietyYou do not have to be much of a philosopher to see the analogue to the virus.", [["Carbon", "CHEMICAL", 43, 49], ["a Low-Carbon Society", "TREATMENT", 37, 57], ["New", "OBSERVATION_MODIFIER", 7, 10]]], ["The virus drills another wormhole into the modern bulwark between social and natural order and shows how a material factor becomes an actor in our social and political networks.", [["political networks", "MULTI-TISSUE_STRUCTURE", 158, 176], ["The virus drills", "TREATMENT", 0, 16], ["virus", "OBSERVATION", 4, 9]]], ["For the media-Covid19-climate intersection, however, the point is not only to fuel a higher awareness of a global post-human condition.A New Horizon: Everyday Life in a Low-Carbon SocietyPerhaps for journalism, the key lesson is more mundane: the acute, material power of the pandemic to change our everyday life.", [["Carbon", "CHEMICAL", 173, 179], ["a global post-human condition", "PROBLEM", 105, 134], ["a Low-Carbon Society", "TREATMENT", 167, 187], ["New", "OBSERVATION_MODIFIER", 137, 140], ["acute", "OBSERVATION_MODIFIER", 247, 252]]], ["It has forced in a glimpse of a new perspective: how routines of individuals, institutions, and nations can be redefined in a systemic crisis.", [["a systemic crisis", "PROBLEM", 124, 141], ["forced", "OBSERVATION_MODIFIER", 7, 13], ["systemic crisis", "OBSERVATION", 126, 141]]], ["When the background of everyday expectation shifts, what counts as \u201cnews\u201d or worthy journalistic storytelling changes too.A New Horizon: Everyday Life in a Low-Carbon SocietyConcern about public expertise and worry about legacy of narrow nationalism are important\u2014but they are also drawn from the usual repertoire of critical media scholarship.", [["New", "OBSERVATION_MODIFIER", 124, 127], ["Horizon", "OBSERVATION_MODIFIER", 128, 135]]], ["The idea of pandemic as a \u201cdress rehearsal\u201d raises a somewhat new question.", [["pandemic", "PROBLEM", 12, 20]]], ["How might journalism help us imagine a different kind of everyday life that a low-carbon society will demand?", [["carbon", "CHEMICAL", 82, 88], ["a low-carbon society", "TREATMENT", 76, 96]]]], "c22797189381e2ac79cdc3e1f3c6b3e5f3f0f455": [["Other conditions may present similarly or concomitantly to AECOPD, such as pulmonary embolism, pneumonia, cardiac ischemia, or congestive heart failure.", [["pulmonary", "ANATOMY", 75, 84], ["cardiac", "ANATOMY", 106, 113], ["heart", "ANATOMY", 138, 143], ["AECOPD", "DISEASE", 59, 65], ["pulmonary embolism", "DISEASE", 75, 93], ["pneumonia", "DISEASE", 95, 104], ["cardiac ischemia", "DISEASE", 106, 122], ["congestive heart failure", "DISEASE", 127, 151], ["pulmonary", "ORGAN", 75, 84], ["cardiac", "ORGAN", 106, 113], ["heart", "ORGAN", 138, 143], ["AECOPD", "PROBLEM", 59, 65], ["pulmonary embolism", "PROBLEM", 75, 93], ["pneumonia", "PROBLEM", 95, 104], ["cardiac ischemia", "PROBLEM", 106, 122], ["congestive heart failure", "PROBLEM", 127, 151], ["AECOPD", "OBSERVATION", 59, 65], ["pulmonary", "ANATOMY", 75, 84], ["embolism", "OBSERVATION", 85, 93], ["pneumonia", "OBSERVATION", 95, 104], ["cardiac", "ANATOMY", 106, 113], ["ischemia", "OBSERVATION", 114, 122], ["congestive", "OBSERVATION_MODIFIER", 127, 137], ["heart", "ANATOMY", 138, 143], ["failure", "OBSERVATION", 144, 151]]], ["These entities must be identified promptly; however, from a clinical perspective further pursuit of the etiology is usually not relevant to the approach to acute treatment (but may be of value in preventing subsequent episodes and in improving chronic symptoms and treatment).INITIAL EVALUATION AND DECISION FOR ADMISSIONWhat other conditions need to be considered in the evaluation of AECOPD?INITIAL EVALUATION AND DECISION FOR ADMISSIONThe presentation of AECOPD is nonspecific, and must be distinguished from other lifethreatening cardiopulmonary conditions including congestive heart failure, cardiac ischemia, pneumonia, and pulmonary embolism.", [["heart", "ANATOMY", 582, 587], ["cardiac", "ANATOMY", 597, 604], ["pulmonary", "ANATOMY", 630, 639], ["AECOPD", "DISEASE", 386, 392], ["AECOPD", "DISEASE", 458, 464], ["congestive heart failure", "DISEASE", 571, 595], ["cardiac ischemia", "DISEASE", 597, 613], ["pneumonia", "DISEASE", 615, 624], ["pulmonary embolism", "DISEASE", 630, 648], ["heart", "ORGAN", 582, 587], ["cardiac", "ORGAN", 597, 604], ["pulmonary", "ORGAN", 630, 639], ["acute treatment", "TREATMENT", 156, 171], ["subsequent episodes", "PROBLEM", 207, 226], ["improving chronic symptoms", "PROBLEM", 234, 260], ["treatment", "TREATMENT", 265, 274], ["INITIAL EVALUATION", "TEST", 276, 294], ["the evaluation", "TEST", 368, 382], ["AECOPD", "PROBLEM", 386, 392], ["INITIAL EVALUATION", "TEST", 393, 411], ["AECOPD", "PROBLEM", 458, 464], ["other lifethreatening cardiopulmonary conditions", "PROBLEM", 512, 560], ["congestive heart failure", "PROBLEM", 571, 595], ["cardiac ischemia", "PROBLEM", 597, 613], ["pneumonia", "PROBLEM", 615, 624], ["pulmonary embolism", "PROBLEM", 630, 648], ["chronic", "OBSERVATION_MODIFIER", 244, 251], ["AECOPD", "OBSERVATION", 386, 392], ["AECOPD", "OBSERVATION", 458, 464], ["nonspecific", "OBSERVATION_MODIFIER", 468, 479], ["congestive", "OBSERVATION_MODIFIER", 571, 581], ["heart", "ANATOMY", 582, 587], ["failure", "OBSERVATION", 588, 595], ["cardiac", "ANATOMY", 597, 604], ["ischemia", "OBSERVATION", 605, 613], ["pneumonia", "OBSERVATION", 615, 624], ["pulmonary", "ANATOMY", 630, 639], ["embolism", "OBSERVATION", 640, 648]]], ["An analysis published in 2009 suggested that the prevalence of pulmonary embolism among patients hospitalized for acute COPD was 25%, although the limitations of the studies and analysis make clinical interpretation and application of these findings difficult.", [["pulmonary", "ANATOMY", 63, 72], ["pulmonary embolism", "DISEASE", 63, 81], ["COPD", "DISEASE", 120, 124], ["pulmonary", "ORGAN", 63, 72], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["An analysis", "TEST", 0, 11], ["pulmonary embolism", "PROBLEM", 63, 81], ["acute COPD", "PROBLEM", 114, 124], ["the studies", "TEST", 162, 173], ["analysis", "TEST", 178, 186], ["clinical interpretation", "TEST", 192, 215], ["these findings", "TEST", 235, 249], ["pulmonary", "ANATOMY", 63, 72], ["embolism", "OBSERVATION", 73, 81], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["COPD", "OBSERVATION", 120, 124]]], ["7 What tests are supported by guidelines?INITIAL EVALUATION AND DECISION FOR ADMISSIONThe initial approach to AECOPD should be to determine the physiologic severity of respiratory distress, to evaluate for concomitant (or contributory) cardiac and pulmonary conditions, and to make an accurate triage decision for further care.", [["respiratory", "ANATOMY", 168, 179], ["cardiac", "ANATOMY", 236, 243], ["pulmonary", "ANATOMY", 248, 257], ["AECOPD", "DISEASE", 110, 116], ["respiratory distress", "DISEASE", 168, 188], ["cardiac and pulmonary conditions", "DISEASE", 236, 268], ["cardiac", "ORGAN", 236, 243], ["pulmonary", "ORGAN", 248, 257], ["INITIAL EVALUATION", "TEST", 41, 59], ["AECOPD", "PROBLEM", 110, 116], ["respiratory distress", "PROBLEM", 168, 188], ["concomitant (or contributory) cardiac and pulmonary conditions", "PROBLEM", 206, 268], ["further care", "TREATMENT", 314, 326], ["respiratory distress", "OBSERVATION", 168, 188], ["pulmonary", "ANATOMY", 248, 257]]], ["In addition to the history and physical examination, basic laboratory studies, and electrocardiogram, the following diagnostic interventions may be considered, in descending order.INITIAL EVALUATION AND DECISION FOR ADMISSIONChest radiographs are recommended by existing guidelines in the evaluation of AECOPD, based on data from observational studies of patients presenting with presumed AECOPD; up to 21% of such patients' chest films suggest a change in treatment or alternative or concomitant diagnosis (eg, heart failure or pneumonia).", [["heart", "ANATOMY", 512, 517], ["AECOPD", "DISEASE", 303, 309], ["AECOPD", "DISEASE", 389, 395], ["heart failure", "DISEASE", 512, 525], ["pneumonia", "DISEASE", 529, 538], ["patients", "ORGANISM", 355, 363], ["patients", "ORGANISM", 415, 423], ["chest", "ORGANISM_SUBDIVISION", 425, 430], ["heart", "ORGAN", 512, 517], ["patients", "SPECIES", 355, 363], ["patients", "SPECIES", 415, 423], ["physical examination", "TEST", 31, 51], ["basic laboratory studies", "TEST", 53, 77], ["electrocardiogram", "TEST", 83, 100], ["INITIAL EVALUATION", "TEST", 180, 198], ["ADMISSIONChest radiographs", "TEST", 216, 242], ["the evaluation", "TEST", 285, 299], ["AECOPD", "PROBLEM", 303, 309], ["observational studies", "TEST", 330, 351], ["AECOPD", "PROBLEM", 389, 395], ["such patients' chest films", "TEST", 410, 436], ["treatment", "TREATMENT", 457, 466], ["heart failure", "PROBLEM", 512, 525], ["pneumonia", "PROBLEM", 529, 538], ["AECOPD", "OBSERVATION", 303, 309], ["AECOPD", "OBSERVATION", 389, 395], ["chest", "ANATOMY", 425, 430], ["heart", "ANATOMY", 512, 517], ["failure", "OBSERVATION", 518, 525], ["pneumonia", "OBSERVATION", 529, 538]]], ["8 Arterial blood gas analysis should be performed in most patients to assess the degree of hypoxemia and hypercarbia, to assess indications for noninvasive ventilation, and to assess the effectiveness of supplemental oxygen therapy.", [["Arterial blood", "ANATOMY", 2, 16], ["hypoxemia", "DISEASE", 91, 100], ["hypercarbia", "DISEASE", 105, 116], ["oxygen", "CHEMICAL", 217, 223], ["oxygen", "CHEMICAL", 217, 223], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["patients", "ORGANISM", 58, 66], ["oxygen", "SIMPLE_CHEMICAL", 217, 223], ["patients", "SPECIES", 58, 66], ["Arterial blood gas analysis", "TEST", 2, 29], ["hypoxemia", "PROBLEM", 91, 100], ["hypercarbia", "PROBLEM", 105, 116], ["noninvasive ventilation", "TREATMENT", 144, 167], ["supplemental oxygen therapy", "TREATMENT", 204, 231], ["hypoxemia", "OBSERVATION", 91, 100], ["hypercarbia", "OBSERVATION", 105, 116], ["oxygen therapy", "OBSERVATION", 217, 231]]], ["Testing for influenza viruses may be seasonally appropriate and could affect choice of treatment.INITIAL EVALUATION AND DECISION FOR ADMISSIONIn addition, sputum culture is generally not indicated because of the lack of specificity of findings, chronic colonization of COPD patients' airways, and ubiquity of contamination.", [["airways", "ANATOMY", 284, 291], ["influenza viruses", "DISEASE", 12, 29], ["COPD", "DISEASE", 269, 273], ["patients", "ORGANISM", 274, 282], ["airways", "MULTI-TISSUE_STRUCTURE", 284, 291], ["patients", "SPECIES", 274, 282], ["influenza viruses", "PROBLEM", 12, 29], ["treatment", "TREATMENT", 87, 96], ["INITIAL EVALUATION", "TEST", 97, 115], ["sputum culture", "TEST", 155, 169], ["chronic colonization of COPD patients' airways", "PROBLEM", 245, 291], ["contamination", "PROBLEM", 309, 322], ["chronic", "OBSERVATION_MODIFIER", 245, 252], ["colonization", "OBSERVATION_MODIFIER", 253, 265], ["COPD", "OBSERVATION", 269, 273], ["airways", "ANATOMY", 284, 291]]], ["Likewise, spirometry is of dubious benefit because there are only limited data to show that clinical outcomes correlate with spirometry in the acute setting.Are there established criteria to guide the decision to admit patients with AECOPD?There are no evidence-based guidelines or \"severity indices\" that sufficiently and accurately distinguish patients who can be safely treated as outpatients from those who benefit from hospitalization.", [["AECOPD", "DISEASE", 233, 239], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 346, 354], ["spirometry", "TEST", 125, 135], ["AECOPD", "PROBLEM", 233, 239], ["\"severity indices", "PROBLEM", 282, 299], ["AECOPD", "OBSERVATION", 233, 239], ["no evidence", "UNCERTAINTY", 250, 261]]], ["Therefore, the decision to admit patients to the hospital is a clinical decision.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]], ["The initial clinical determination should assess for actual or imminent respiratory failure or other end-organ instability, which could prompt assisted ventilation and admission to intensive care.Are there established criteria to guide the decision to admit patients with AECOPD?In 2004, the American Thoracic Society published guidelines to guide the decision to hospitalize patients with AECOPD 9 :Are there established criteria to guide the decision to admit patients with AECOPD?High-risk comorbidities including pneumonia, cardiac arrhythmia, heart failure, diabetes mellitus, renal or liver failure Inadequate response of symptoms to outpatient management Marked increase in dyspnea Inability to eat or sleep owing to symptoms Worsening hypoxemia Worsening hypercapnia Changes in mental status Inability to care for oneself (lack of home support) Uncertain diagnosisWhat therapies for AECOPD are supported by evidence?There are numerous guidelines available to guide therapy for AECOPD in hospitalized patients.", [["respiratory", "ANATOMY", 72, 83], ["organ", "ANATOMY", 105, 110], ["cardiac", "ANATOMY", 528, 535], ["heart", "ANATOMY", 548, 553], ["renal", "ANATOMY", 582, 587], ["liver", "ANATOMY", 591, 596], ["respiratory failure", "DISEASE", 72, 91], ["AECOPD", "DISEASE", 272, 278], ["AECOPD", "DISEASE", 390, 396], ["AECOPD", "DISEASE", 476, 482], ["pneumonia", "DISEASE", 517, 526], ["cardiac arrhythmia", "DISEASE", 528, 546], ["heart failure", "DISEASE", 548, 561], ["diabetes mellitus", "DISEASE", 563, 580], ["renal or liver failure", "DISEASE", 582, 604], ["dyspnea", "DISEASE", 681, 688], ["hypoxemia", "DISEASE", 743, 752], ["hypercapnia", "DISEASE", 763, 774], ["AECOPD", "DISEASE", 891, 897], ["AECOPD", "DISEASE", 985, 991], ["organ", "ORGAN", 105, 110], ["patients", "ORGANISM", 258, 266], ["patients", "ORGANISM", 376, 384], ["patients", "ORGANISM", 462, 470], ["cardiac", "ORGAN", 528, 535], ["heart", "ORGAN", 548, 553], ["renal", "ORGAN", 582, 587], ["liver", "ORGAN", 591, 596], ["patients", "ORGANISM", 1008, 1016], ["patients", "SPECIES", 258, 266], ["patients", "SPECIES", 376, 384], ["patients", "SPECIES", 462, 470], ["patients", "SPECIES", 1008, 1016], ["imminent respiratory failure", "PROBLEM", 63, 91], ["other end-organ instability", "PROBLEM", 95, 122], ["prompt assisted ventilation", "TREATMENT", 136, 163], ["intensive care", "TREATMENT", 181, 195], ["AECOPD", "PROBLEM", 272, 278], ["AECOPD", "PROBLEM", 476, 482], ["High-risk comorbidities", "PROBLEM", 483, 506], ["pneumonia", "PROBLEM", 517, 526], ["cardiac arrhythmia", "PROBLEM", 528, 546], ["heart failure", "PROBLEM", 548, 561], ["diabetes mellitus", "PROBLEM", 563, 580], ["renal or liver failure", "PROBLEM", 582, 604], ["symptoms", "PROBLEM", 628, 636], ["outpatient management", "TREATMENT", 640, 661], ["Marked increase", "PROBLEM", 662, 677], ["dyspnea", "PROBLEM", 681, 688], ["Inability to eat or sleep", "PROBLEM", 689, 714], ["symptoms", "PROBLEM", 724, 732], ["Worsening hypoxemia", "PROBLEM", 733, 752], ["Worsening hypercapnia", "PROBLEM", 753, 774], ["Changes in mental status", "PROBLEM", 775, 799], ["home support", "TREATMENT", 839, 851], ["AECOPD", "PROBLEM", 891, 897], ["therapy", "TREATMENT", 973, 980], ["AECOPD", "PROBLEM", 985, 991], ["respiratory failure", "OBSERVATION", 72, 91], ["organ", "ANATOMY", 105, 110], ["instability", "OBSERVATION", 111, 122], ["AECOPD", "OBSERVATION", 272, 278], ["Thoracic", "ANATOMY", 301, 309], ["pneumonia", "OBSERVATION", 517, 526], ["cardiac", "ANATOMY", 528, 535], ["arrhythmia", "OBSERVATION", 536, 546], ["heart", "ANATOMY", 548, 553], ["failure", "OBSERVATION", 554, 561], ["diabetes mellitus", "OBSERVATION", 563, 580], ["renal", "ANATOMY", 582, 587], ["liver", "ANATOMY", 591, 596], ["failure", "OBSERVATION", 597, 604], ["dyspnea", "OBSERVATION", 681, 688], ["hypercapnia", "OBSERVATION", 763, 774]]], ["The principal therapies for the majority of patients include bronchodilators, corticosteroids, antibiotics, oxygen therapy, and early consideration for noninvasive positive-pressure ventilation (NIPPV).", [["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 108, 114], ["patients", "ORGANISM", 44, 52], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["patients", "SPECIES", 44, 52], ["The principal therapies", "TREATMENT", 0, 23], ["bronchodilators", "TREATMENT", 61, 76], ["corticosteroids", "TREATMENT", 78, 93], ["antibiotics", "TREATMENT", 95, 106], ["oxygen therapy", "TREATMENT", 108, 122], ["noninvasive positive-pressure ventilation", "TREATMENT", 152, 193], ["NIPPV", "TREATMENT", 195, 200], ["pressure ventilation", "OBSERVATION", 173, 193]]], ["In addition, prophylaxis against venous thromboembolism (VTE) and evaluation for influenza and pneumococcal vaccination are appropriate and evidence based.Which bronchodilators should be administered?Short-acting bronchodilators alleviate dyspnea and improve airflow obstruction during AECOPD.", [["venous", "ANATOMY", 33, 39], ["venous thromboembolism", "DISEASE", 33, 55], ["VTE", "DISEASE", 57, 60], ["influenza", "DISEASE", 81, 90], ["dyspnea", "DISEASE", 239, 246], ["airflow obstruction", "DISEASE", 259, 278], ["AECOPD", "DISEASE", 286, 292], ["venous", "MULTI-TISSUE_STRUCTURE", 33, 39], ["pneumococcal", "SPECIES", 95, 107], ["prophylaxis", "TREATMENT", 13, 24], ["venous thromboembolism", "PROBLEM", 33, 55], ["VTE", "PROBLEM", 57, 60], ["evaluation", "TEST", 66, 76], ["influenza", "PROBLEM", 81, 90], ["pneumococcal vaccination", "TREATMENT", 95, 119], ["bronchodilators", "TREATMENT", 161, 176], ["Short-acting bronchodilators", "TREATMENT", 200, 228], ["dyspnea", "PROBLEM", 239, 246], ["airflow obstruction", "PROBLEM", 259, 278], ["AECOPD", "PROBLEM", 286, 292], ["venous", "ANATOMY", 33, 39], ["thromboembolism", "OBSERVATION", 40, 55], ["airflow", "OBSERVATION_MODIFIER", 259, 266], ["obstruction", "OBSERVATION", 267, 278], ["AECOPD", "OBSERVATION", 286, 292]]], ["Either b 2 -adrenergic agonists or anticholinergic agents may be administered in this setting.", [["b 2 -adrenergic agonists", "SIMPLE_CHEMICAL", 7, 31], ["anticholinergic agents", "SIMPLE_CHEMICAL", 35, 57], ["b 2 -adrenergic agonists", "TREATMENT", 7, 31], ["anticholinergic agents", "TREATMENT", 35, 57]]], ["Both types of agents act rapidly and may be administered in nebulized form or in a metered dose inhaler (MDI).", [["agents", "TREATMENT", 14, 20], ["a metered dose inhaler (MDI", "TREATMENT", 81, 108]]], ["There is no compelling evidence that nebulizers are superior to MDI, although administration of nebulizers to anxious and dyspneic patients may be easier and better tolerated.Which bronchodilators should be administered?A systematic review of methylxanthine bronchodilators in AECOPD suggested a trend toward shorter length of stay (LOS) in hospital but also more symptomatic relapses at 1 week, and more adverse effects such as nausea, palpitations, and arrhythmias.", [["anxious", "DISEASE", 110, 117], ["dyspneic", "DISEASE", 122, 130], ["methylxanthine", "CHEMICAL", 243, 257], ["AECOPD", "DISEASE", 277, 283], ["nausea", "DISEASE", 429, 435], ["palpitations", "DISEASE", 437, 449], ["arrhythmias", "DISEASE", 455, 466], ["methylxanthine", "CHEMICAL", 243, 257], ["patients", "ORGANISM", 131, 139], ["methylxanthine", "SIMPLE_CHEMICAL", 243, 257], ["patients", "SPECIES", 131, 139], ["nebulizers", "TREATMENT", 37, 47], ["MDI", "TREATMENT", 64, 67], ["nebulizers", "TREATMENT", 96, 106], ["anxious", "PROBLEM", 110, 117], ["dyspneic", "PROBLEM", 122, 130], ["bronchodilators", "TREATMENT", 181, 196], ["methylxanthine bronchodilators", "TREATMENT", 243, 273], ["AECOPD", "PROBLEM", 277, 283], ["nausea", "PROBLEM", 429, 435], ["palpitations", "PROBLEM", 437, 449], ["arrhythmias", "PROBLEM", 455, 466], ["no compelling evidence", "UNCERTAINTY", 9, 31], ["nebulizers", "OBSERVATION", 37, 47], ["symptomatic", "OBSERVATION_MODIFIER", 364, 375], ["relapses", "OBSERVATION", 376, 384]]], ["10 The anticholinergic ipratropium bromide is also effective in AECOPD.", [["ipratropium bromide", "CHEMICAL", 23, 42], ["AECOPD", "DISEASE", 64, 70], ["ipratropium bromide", "CHEMICAL", 23, 42], ["anticholinergic ipratropium bromide", "SIMPLE_CHEMICAL", 7, 42], ["The anticholinergic ipratropium bromide", "TREATMENT", 3, 42], ["AECOPD", "PROBLEM", 64, 70], ["AECOPD", "OBSERVATION", 64, 70]]], ["Combination therapy with both b2-agonist and anticholinergic agents has not consistently shown a benefit in AECOPD, and a 2008 systematic review concluded that there was no evidence to support simultaneous therapy, or to suggest superiority of b 2 -agonists over anticholinergics.", [["AECOPD", "DISEASE", 108, 114], ["b2-agonist", "GENE_OR_GENE_PRODUCT", 30, 40], ["b 2 -agonists", "SIMPLE_CHEMICAL", 244, 257], ["anticholinergics", "SIMPLE_CHEMICAL", 263, 279], ["Combination therapy", "TREATMENT", 0, 19], ["both b2-agonist", "TREATMENT", 25, 40], ["anticholinergic agents", "TREATMENT", 45, 67], ["AECOPD", "PROBLEM", 108, 114], ["simultaneous therapy", "TREATMENT", 193, 213], ["b 2 -agonists", "TREATMENT", 244, 257], ["anticholinergics", "TREATMENT", 263, 279], ["no evidence to", "UNCERTAINTY", 170, 184]]], ["11 Is there evidence to support the choice or dose of bronchodilator?Which bronchodilators should be administered?The optimal dose and interval of bronchodilators has not been established by formal study.", [["bronchodilator", "TREATMENT", 54, 68], ["bronchodilators", "TREATMENT", 75, 90], ["bronchodilators", "TREATMENT", 147, 162], ["formal study", "TEST", 191, 203]]], ["Albuterol is a common b 2 -agonist, administered via nebulizer as a 2.5-mg dose.", [["Albuterol", "CHEMICAL", 0, 9], ["Albuterol", "CHEMICAL", 0, 9], ["Albuterol", "SIMPLE_CHEMICAL", 0, 9], ["b 2 -agonist", "SIMPLE_CHEMICAL", 22, 34], ["Albuterol", "TREATMENT", 0, 9], ["a common b 2 -agonist", "TREATMENT", 13, 34]]], ["Increasing the dose to 5 mg has not been shown to improve lung function or reduce hospital LOS.In hospitalized patients with AECOPD, what are the expected benefits of treatment with systemic glucocorticoids?Even before there were data to support the practice, systemic corticosteroid treatment was adopted as a standard part of the treatment of AECOPD.", [["lung", "ANATOMY", 58, 62], ["AECOPD", "DISEASE", 125, 131], ["glucocorticoids", "CHEMICAL", 191, 206], ["AECOPD", "DISEASE", 345, 351], ["lung", "ORGAN", 58, 62], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["AECOPD", "PROBLEM", 125, 131], ["treatment", "TREATMENT", 167, 176], ["systemic glucocorticoids", "TREATMENT", 182, 206], ["the practice", "TREATMENT", 246, 258], ["systemic corticosteroid treatment", "TREATMENT", 260, 293], ["the treatment", "TREATMENT", 328, 341], ["AECOPD", "PROBLEM", 345, 351], ["lung", "ANATOMY", 58, 62], ["AECOPD", "OBSERVATION", 125, 131], ["systemic glucocorticoids", "OBSERVATION", 182, 206], ["AECOPD", "OBSERVATION", 345, 351]]], ["This decision was based, presumably, on the clinical similarities between COPD and asthma, and the recognition of the important role that systemic corticosteroids played in reversing the airway inflammation in asthma.", [["airway", "ANATOMY", 187, 193], ["COPD", "DISEASE", 74, 78], ["asthma", "DISEASE", 83, 89], ["corticosteroids", "CHEMICAL", 147, 162], ["airway inflammation", "DISEASE", 187, 206], ["asthma", "DISEASE", 210, 216], ["corticosteroids", "CHEMICAL", 147, 162], ["airway", "MULTI-TISSUE_STRUCTURE", 187, 193], ["COPD", "PROBLEM", 74, 78], ["asthma", "PROBLEM", 83, 89], ["systemic corticosteroids", "TREATMENT", 138, 162], ["the airway inflammation", "PROBLEM", 183, 206], ["asthma", "PROBLEM", 210, 216], ["COPD", "OBSERVATION", 74, 78], ["asthma", "OBSERVATION", 83, 89], ["airway", "ANATOMY", 187, 193], ["inflammation", "OBSERVATION", 194, 206], ["asthma", "OBSERVATION", 210, 216]]], ["However, over time it became clear that the inflammatory processes involved in these 2 diseases were different, and that the clinical effect of glucocorticoids in COPD was much smaller than in asthma.", [["glucocorticoids", "CHEMICAL", 144, 159], ["COPD", "DISEASE", 163, 167], ["asthma", "DISEASE", 193, 199], ["glucocorticoids", "SIMPLE_CHEMICAL", 144, 159], ["the inflammatory processes", "PROBLEM", 40, 66], ["these 2 diseases", "PROBLEM", 79, 95], ["glucocorticoids", "TREATMENT", 144, 159], ["COPD", "PROBLEM", 163, 167], ["asthma", "PROBLEM", 193, 199], ["inflammatory", "OBSERVATION", 44, 56], ["COPD", "OBSERVATION", 163, 167], ["smaller", "OBSERVATION_MODIFIER", 177, 184], ["asthma", "OBSERVATION", 193, 199]]], ["12 In the largest randomized controlled trial addressing this question (a trial sponsored by the Veterans Administration [VA] published in 1999), 13 271 patients hospitalized for an AECOPD were randomized to receive systemic glucocorticoid treatment or placebo.", [["AECOPD", "DISEASE", 182, 188], ["patients", "ORGANISM", 153, 161], ["glucocorticoid", "SIMPLE_CHEMICAL", 225, 239], ["patients", "SPECIES", 153, 161], ["an AECOPD", "PROBLEM", 179, 188], ["systemic glucocorticoid treatment", "TREATMENT", 216, 249], ["placebo", "TREATMENT", 253, 260], ["largest", "OBSERVATION_MODIFIER", 10, 17]]], ["All were treated with broad-spectrum antibiotics and bronchodilators.", [["broad-spectrum antibiotics", "TREATMENT", 22, 48], ["bronchodilators", "TREATMENT", 53, 68]]], ["The primary outcome was treatment failure, defined as 1 of the following: death from any cause, need for intubation/mechanical ventilation, readmission for COPD, or intensification of pharmacologic treatment.", [["death", "DISEASE", 74, 79], ["COPD", "DISEASE", 156, 160], ["treatment failure", "PROBLEM", 24, 41], ["death", "PROBLEM", 74, 79], ["intubation", "TREATMENT", 105, 115], ["mechanical ventilation", "TREATMENT", 116, 138], ["COPD", "PROBLEM", 156, 160], ["pharmacologic treatment", "TREATMENT", 184, 207], ["COPD", "OBSERVATION", 156, 160], ["pharmacologic treatment", "OBSERVATION", 184, 207]]], ["The results showed that patients treated with systemic glucocorticoids experienced a lower rate of treatment failure, but this was mostly related to the need for intensification of treatment in the placebo group (mainly adding glucocorticoids).", [["glucocorticoids", "CHEMICAL", 55, 70], ["glucocorticoids", "CHEMICAL", 227, 242], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["systemic glucocorticoids", "TREATMENT", 46, 70], ["treatment failure", "PROBLEM", 99, 116], ["treatment", "TREATMENT", 181, 190], ["the placebo group", "TREATMENT", 194, 211], ["glucocorticoids", "TREATMENT", 227, 242], ["failure", "OBSERVATION", 109, 116]]], ["Therefore the benefit of adding systemic corticosteroids early was, primarily, that one would avoid having to add them later.", [["corticosteroids", "CHEMICAL", 41, 56], ["systemic corticosteroids", "TREATMENT", 32, 56]]], ["However, the steroid group also had a 1.2-day shorter LOS and a significant improvement in FEV 1 on the day after enrollment, but also had significantly higher rates of hyperglycemia requiring medical therapy, in comparison with the control group.", [["steroid", "CHEMICAL", 13, 20], ["hyperglycemia", "DISEASE", 169, 182], ["steroid", "CHEMICAL", 13, 20], ["steroid", "SIMPLE_CHEMICAL", 13, 20], ["hyperglycemia", "PROBLEM", 169, 182], ["medical therapy", "TREATMENT", 193, 208], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["improvement", "OBSERVATION_MODIFIER", 76, 87], ["hyperglycemia", "OBSERVATION", 169, 182]]], ["The investigators concluded that glucocorticoids offer a modest benefit in patients hospitalized with COPD, at the cost of significant hyperglycemia in some patients.In hospitalized patients with AECOPD, what are the expected benefits of treatment with systemic glucocorticoids?There have been several other studies and meta-analyses examining the use of glucocorticoids in the treatment of AECOPD that have, for the most part, supported similar conclusions.", [["glucocorticoids", "CHEMICAL", 33, 48], ["COPD", "DISEASE", 102, 106], ["hyperglycemia", "DISEASE", 135, 148], ["AECOPD", "DISEASE", 196, 202], ["glucocorticoids", "CHEMICAL", 262, 277], ["glucocorticoids", "CHEMICAL", 355, 370], ["AECOPD", "DISEASE", 391, 397], ["glucocorticoids", "SIMPLE_CHEMICAL", 33, 48], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 182, 190], ["glucocorticoids", "TREATMENT", 33, 48], ["COPD", "PROBLEM", 102, 106], ["significant hyperglycemia", "PROBLEM", 123, 148], ["AECOPD", "PROBLEM", 196, 202], ["treatment", "TREATMENT", 238, 247], ["systemic glucocorticoids", "TREATMENT", 253, 277], ["several other studies", "TEST", 294, 315], ["meta-analyses", "TEST", 320, 333], ["glucocorticoids", "TREATMENT", 355, 370], ["AECOPD", "PROBLEM", 391, 397], ["COPD", "OBSERVATION", 102, 106], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["hyperglycemia", "OBSERVATION", 135, 148], ["AECOPD", "OBSERVATION", 196, 202], ["systemic glucocorticoids", "OBSERVATION", 253, 277], ["AECOPD", "OBSERVATION", 391, 397]]], ["14,15 A Cochrane Collaboration meta-analysis 14 found that patients with AECOPD who were treated with systemic glucocorticoids experienced significantly fewer treatment failures (odds ratio [OR] 0.5, 95% confidence interval [CI] 0.36-0.69) than those treated with placebo ( Fig. 1 ).", [["AECOPD", "DISEASE", 73, 79], ["glucocorticoids", "CHEMICAL", 111, 126], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["AECOPD", "PROBLEM", 73, 79], ["systemic glucocorticoids", "TREATMENT", 102, 126], ["CI", "TEST", 225, 227], ["placebo", "TREATMENT", 264, 271], ["AECOPD", "OBSERVATION", 73, 79]]], ["Based on these data, 10 patients with AECOPD would need to receive steroids to prevent 1 treatment failure.", [["AECOPD", "DISEASE", 38, 44], ["steroids", "CHEMICAL", 67, 75], ["steroids", "CHEMICAL", 67, 75], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["these data", "TEST", 9, 19], ["AECOPD", "PROBLEM", 38, 44], ["steroids", "TREATMENT", 67, 75], ["1 treatment failure", "PROBLEM", 87, 106], ["failure", "OBSERVATION", 99, 106]]], ["[16] [17] [18] Another meta-analysis found that patients with AECOPD treated with systemic glucocorticoids experienced shorter hospital LOS (1.22 days shorter, 95% CI 2.26-0.18).", [["AECOPD", "DISEASE", 62, 68], ["glucocorticoids", "CHEMICAL", 91, 106], ["[16] [17] [18", "SIMPLE_CHEMICAL", 0, 13], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Another meta-analysis", "TEST", 15, 36], ["AECOPD", "PROBLEM", 62, 68], ["systemic glucocorticoids", "TREATMENT", 82, 106], ["CI", "TEST", 164, 166], ["AECOPD", "OBSERVATION", 62, 68]]], ["Some studies have also found steroids to be associated with improvements in FEV 1 , decreases in breathlessness, and improvements in blood gas abnormalities in this population.", [["blood", "ANATOMY", 133, 138], ["steroids", "CHEMICAL", 29, 37], ["breathlessness", "DISEASE", 97, 111], ["blood gas abnormalities", "DISEASE", 133, 156], ["steroids", "CHEMICAL", 29, 37], ["steroids", "SIMPLE_CHEMICAL", 29, 37], ["FEV 1", "GENE_OR_GENE_PRODUCT", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["Some studies", "TEST", 0, 12], ["steroids", "TREATMENT", 29, 37], ["breathlessness", "PROBLEM", 97, 111], ["blood gas abnormalities", "PROBLEM", 133, 156], ["decreases", "OBSERVATION_MODIFIER", 84, 93], ["blood", "ANATOMY", 133, 138], ["gas abnormalities", "OBSERVATION", 139, 156]]], ["However, steroids have never demonstrated any mortality benefit in AECOPD.In hospitalized patients with AECOPD, what are the expected benefits of treatment with systemic glucocorticoids?Most of the studies of glucocorticoids in AECOPD have been performed in noncritically ill populations.", [["steroids", "CHEMICAL", 9, 17], ["AECOPD", "DISEASE", 67, 73], ["AECOPD", "DISEASE", 104, 110], ["glucocorticoids", "CHEMICAL", 170, 185], ["glucocorticoids", "CHEMICAL", 209, 224], ["AECOPD", "DISEASE", 228, 234], ["steroids", "CHEMICAL", 9, 17], ["steroids", "SIMPLE_CHEMICAL", 9, 17], ["patients", "ORGANISM", 90, 98], ["glucocorticoids", "SIMPLE_CHEMICAL", 209, 224], ["patients", "SPECIES", 90, 98], ["steroids", "TREATMENT", 9, 17], ["AECOPD", "PROBLEM", 67, 73], ["AECOPD", "PROBLEM", 104, 110], ["treatment", "TREATMENT", 146, 155], ["systemic glucocorticoids", "TREATMENT", 161, 185], ["the studies", "TEST", 194, 205], ["glucocorticoids", "TREATMENT", 209, 224], ["AECOPD", "PROBLEM", 228, 234], ["AECOPD", "OBSERVATION", 67, 73], ["AECOPD", "OBSERVATION", 104, 110], ["systemic glucocorticoids", "OBSERVATION", 161, 185], ["glucocorticoids", "ANATOMY", 209, 224], ["AECOPD", "OBSERVATION", 228, 234]]], ["However, recently, a study of patients in the intensive care unit demonstrated a decreased rate of noninvasive ventilation failure and a shorter duration of mechanical ventilation in those treated with glucocorticoids compared with placebo, suggesting that the benefits of this treatment extend to this population as well.", [["ventilation failure", "DISEASE", 111, 130], ["glucocorticoids", "CHEMICAL", 202, 217], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["a study", "TEST", 19, 26], ["a decreased rate of noninvasive ventilation failure", "PROBLEM", 79, 130], ["mechanical ventilation", "TREATMENT", 157, 179], ["glucocorticoids", "TREATMENT", 202, 217], ["placebo", "TREATMENT", 232, 239], ["this treatment", "TREATMENT", 273, 287], ["decreased", "OBSERVATION", 81, 90], ["noninvasive", "OBSERVATION_MODIFIER", 99, 110], ["ventilation failure", "OBSERVATION", 111, 130], ["shorter", "OBSERVATION_MODIFIER", 137, 144], ["mechanical ventilation", "OBSERVATION", 157, 179]]], ["19 What are the risks associated with glucocorticoid treatment in AECOPD?In hospitalized patients with AECOPD, what are the expected benefits of treatment with systemic glucocorticoids?The use of systemic glucocorticoids in this patient population is not without risks.", [["AECOPD", "DISEASE", 66, 72], ["AECOPD", "DISEASE", 103, 109], ["glucocorticoids", "CHEMICAL", 169, 184], ["glucocorticoids", "CHEMICAL", 205, 220], ["glucocorticoid", "SIMPLE_CHEMICAL", 38, 52], ["patients", "ORGANISM", 89, 97], ["patient", "ORGANISM", 229, 236], ["patients", "SPECIES", 89, 97], ["patient", "SPECIES", 229, 236], ["glucocorticoid treatment", "TREATMENT", 38, 62], ["AECOPD", "PROBLEM", 66, 72], ["AECOPD", "PROBLEM", 103, 109], ["treatment", "TREATMENT", 145, 154], ["systemic glucocorticoids", "TREATMENT", 160, 184], ["systemic glucocorticoids", "TREATMENT", 196, 220], ["AECOPD", "OBSERVATION", 66, 72], ["AECOPD", "OBSERVATION", 103, 109], ["systemic glucocorticoids", "OBSERVATION", 160, 184], ["systemic glucocorticoids", "OBSERVATION", 196, 220], ["not without", "UNCERTAINTY", 251, 262]]], ["The adverse effects of these drugs include psychosis, osteoporosis, hyperglycemia, muscle wasting, insomnia, and increased appetite/weight gain.", [["muscle", "ANATOMY", 83, 89], ["psychosis", "DISEASE", 43, 52], ["osteoporosis", "DISEASE", 54, 66], ["hyperglycemia", "DISEASE", 68, 81], ["muscle wasting", "DISEASE", 83, 97], ["insomnia", "DISEASE", 99, 107], ["weight gain", "DISEASE", 132, 143], ["muscle", "ORGAN", 83, 89], ["these drugs", "TREATMENT", 23, 34], ["psychosis", "PROBLEM", 43, 52], ["osteoporosis", "PROBLEM", 54, 66], ["hyperglycemia", "PROBLEM", 68, 81], ["muscle wasting", "PROBLEM", 83, 97], ["insomnia", "PROBLEM", 99, 107], ["increased appetite", "PROBLEM", 113, 131], ["weight gain", "PROBLEM", 132, 143], ["osteoporosis", "OBSERVATION", 54, 66], ["hyperglycemia", "OBSERVATION", 68, 81], ["muscle", "ANATOMY", 83, 89], ["wasting", "OBSERVATION", 90, 97]]], ["14, 20 Chronic Obstructive Pulmonary Disease One in every 6 patients treated with glucocorticoids will experience an adverse effect, the most common of which is hyperglycemia (1 in every 13 patients).Which patients should receive glucocorticoids during an AECOPD?Overall, systemic glucocorticoids have a modest but significant treatment benefit in AECOPD, but are complicated by relatively frequent, but often manageable complications.", [["Obstructive Pulmonary Disease", "DISEASE", 15, 44], ["glucocorticoids", "CHEMICAL", 82, 97], ["hyperglycemia", "DISEASE", 161, 174], ["glucocorticoids", "CHEMICAL", 230, 245], ["glucocorticoids", "CHEMICAL", 281, 296], ["AECOPD", "DISEASE", 348, 354], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 190, 198], ["patients", "ORGANISM", 206, 214], ["glucocorticoids", "SIMPLE_CHEMICAL", 281, 296], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 190, 198], ["patients", "SPECIES", 206, 214], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 7, 44], ["glucocorticoids", "TREATMENT", 82, 97], ["an adverse effect", "PROBLEM", 114, 131], ["hyperglycemia", "PROBLEM", 161, 174], ["glucocorticoids", "TREATMENT", 230, 245], ["an AECOPD", "PROBLEM", 253, 262], ["systemic glucocorticoids", "TREATMENT", 272, 296], ["AECOPD", "PROBLEM", 348, 354], ["often manageable complications", "PROBLEM", 404, 434], ["Chronic", "OBSERVATION_MODIFIER", 7, 14], ["Obstructive", "OBSERVATION", 15, 26], ["Pulmonary", "ANATOMY", 27, 36], ["Disease", "OBSERVATION", 37, 44], ["hyperglycemia", "OBSERVATION", 161, 174], ["AECOPD", "OBSERVATION", 256, 262], ["systemic glucocorticoids", "OBSERVATION", 272, 296], ["significant", "OBSERVATION_MODIFIER", 315, 326], ["treatment", "OBSERVATION", 327, 336], ["AECOPD", "OBSERVATION", 348, 354]]], ["For every 10 patients treated, a treatment failure will be prevented (and hospitalization duration will be reduced) but nearly 2 medication complications will occur (with hyperglycemia being most common).Which patients should receive glucocorticoids during an AECOPD?The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend that glucocorticoids be prescribed for hospitalized patients with AECOPD.", [["Lung", "ANATOMY", 318, 322], ["hyperglycemia", "DISEASE", 171, 184], ["glucocorticoids", "CHEMICAL", 234, 249], ["Chronic Obstructive Lung Disease", "DISEASE", 298, 330], ["glucocorticoids", "CHEMICAL", 364, 379], ["AECOPD", "DISEASE", 425, 431], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 210, 218], ["Lung", "ORGAN", 318, 322], ["glucocorticoids", "SIMPLE_CHEMICAL", 364, 379], ["patients", "ORGANISM", 411, 419], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 411, 419], ["a treatment failure", "PROBLEM", 31, 50], ["nearly 2 medication complications", "PROBLEM", 120, 153], ["hyperglycemia", "PROBLEM", 171, 184], ["glucocorticoids", "TREATMENT", 234, 249], ["an AECOPD", "PROBLEM", 257, 266], ["Chronic Obstructive Lung Disease", "PROBLEM", 298, 330], ["glucocorticoids", "TREATMENT", 364, 379], ["AECOPD", "PROBLEM", 425, 431], ["AECOPD", "OBSERVATION", 260, 266], ["Chronic", "OBSERVATION_MODIFIER", 298, 305], ["Obstructive", "OBSERVATION_MODIFIER", 306, 317], ["Lung", "ANATOMY", 318, 322], ["Disease", "OBSERVATION", 323, 330]]], ["1 The authors concur with this recommendation for most patients, although clinical judgment is required for situations whereby the risk/benefit ratio is altered (eg, a clinically mild exacerbations coupled with a high risk for side effects from glucocorticoids).Which patients should receive glucocorticoids during an AECOPD?What are the optimal glucocorticoid dose, duration, and route of delivery for the treatment of patients hospitalized with AECOPD?Which patients should receive glucocorticoids during an AECOPD?The questions about dose and duration are especially important, because many of the adverse effects of glucocorticoid use, including psychiatric effects, osteoporosis, and hyperglycemia, correlate with the degree of exposure to the glucocorticoid medications.", [["glucocorticoids", "CHEMICAL", 245, 260], ["glucocorticoids", "CHEMICAL", 292, 307], ["AECOPD", "DISEASE", 447, 453], ["glucocorticoids", "CHEMICAL", 484, 499], ["psychiatric", "DISEASE", 650, 661], ["osteoporosis", "DISEASE", 671, 683], ["hyperglycemia", "DISEASE", 689, 702], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 268, 276], ["patients", "ORGANISM", 420, 428], ["patients", "ORGANISM", 460, 468], ["glucocorticoid", "SIMPLE_CHEMICAL", 620, 634], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 268, 276], ["patients", "SPECIES", 420, 428], ["patients", "SPECIES", 460, 468], ["altered (eg", "PROBLEM", 153, 164], ["a clinically mild exacerbations", "PROBLEM", 166, 197], ["side effects", "PROBLEM", 227, 239], ["glucocorticoids", "TREATMENT", 245, 260], ["glucocorticoids", "TREATMENT", 292, 307], ["an AECOPD", "PROBLEM", 315, 324], ["delivery", "TREATMENT", 390, 398], ["the treatment", "TREATMENT", 403, 416], ["AECOPD", "PROBLEM", 447, 453], ["glucocorticoids", "TREATMENT", 484, 499], ["an AECOPD", "PROBLEM", 507, 516], ["glucocorticoid use", "TREATMENT", 620, 638], ["psychiatric effects", "PROBLEM", 650, 669], ["osteoporosis", "PROBLEM", 671, 683], ["hyperglycemia", "PROBLEM", 689, 702], ["the glucocorticoid medications", "TREATMENT", 745, 775], ["AECOPD", "OBSERVATION", 318, 324], ["AECOPD", "OBSERVATION", 447, 453], ["AECOPD", "OBSERVATION", 510, 516], ["osteoporosis", "OBSERVATION", 671, 683], ["hyperglycemia", "OBSERVATION", 689, 702]]], ["20 Therefore, it is prudent to use the lowest dose and the shortest course of these medications that will achieve the desired benefit.", [["the lowest dose", "TREATMENT", 35, 50], ["these medications", "TREATMENT", 78, 95]]], ["Unfortunately no clinical trials have directly compared the efficacy of high-, medium-, or low-dose regimens.", [["low-dose regimens", "TREATMENT", 91, 108]]], ["Doses ranging from 30 mg of methylprednisolone daily up to 125 mg of solumedrol every 6 hours (followed by a tapering dose) have shown beneficial effects.", [["methylprednisolone", "CHEMICAL", 28, 46], ["solumedrol", "CHEMICAL", 69, 79], ["methylprednisolone", "CHEMICAL", 28, 46], ["solumedrol", "CHEMICAL", 69, 79], ["methylprednisolone", "SIMPLE_CHEMICAL", 28, 46], ["solumedrol", "SIMPLE_CHEMICAL", 69, 79], ["methylprednisolone", "TREATMENT", 28, 46], ["solumedrol", "TREATMENT", 69, 79], ["a tapering dose", "TREATMENT", 107, 122]]], ["15 ,20 A large observational study (which examined data on almost 80,000 patients) did not find any difference in outcomes (including initiation of mechanical ventilation, mortality, or readmission) in patients treated with high-dose (equivalent to 120-800 mg/d prednisone) versus low-dose (equivalent to 20-80 mg/d prednisone) glucocorticoids for the first 2 days of admission.", [["prednisone", "CHEMICAL", 262, 272], ["prednisone", "CHEMICAL", 316, 326], ["glucocorticoids", "CHEMICAL", 328, 343], ["prednisone", "CHEMICAL", 262, 272], ["prednisone", "CHEMICAL", 316, 326], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 202, 210], ["prednisone", "SIMPLE_CHEMICAL", 262, 272], ["prednisone", "SIMPLE_CHEMICAL", 316, 326], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 202, 210], ["A large observational study", "TEST", 7, 34], ["mechanical ventilation", "TREATMENT", 148, 170], ["prednisone", "TREATMENT", 262, 272], ["prednisone) glucocorticoids", "TREATMENT", 316, 343], ["large", "OBSERVATION_MODIFIER", 9, 14]]], ["21 These data suggest that very high initial doses of glucocorticoids are not advantageous, but the optimal dosing of glucocorticoids in AECOPD remains uncertain.", [["glucocorticoids", "CHEMICAL", 54, 69], ["glucocorticoids", "CHEMICAL", 118, 133], ["AECOPD", "DISEASE", 137, 143], ["glucocorticoids", "SIMPLE_CHEMICAL", 54, 69], ["These data", "TEST", 3, 13], ["glucocorticoids", "TREATMENT", 54, 69], ["glucocorticoids", "TREATMENT", 118, 133], ["AECOPD", "PROBLEM", 137, 143], ["very", "OBSERVATION_MODIFIER", 27, 31], ["high", "OBSERVATION_MODIFIER", 32, 36], ["AECOPD", "OBSERVATION", 137, 143]]], ["The GOLD guidelines recommend 30 to 40 mg of oral prednisolone daily.", [["oral", "ANATOMY", 45, 49], ["prednisolone", "CHEMICAL", 50, 62], ["prednisolone", "CHEMICAL", 50, 62], ["oral", "ORGANISM_SUBDIVISION", 45, 49], ["prednisolone", "SIMPLE_CHEMICAL", 50, 62], ["oral prednisolone", "TREATMENT", 45, 62]]], ["1 Optimal duration of treatment is also unknown based on the available evidence.", [["treatment", "TREATMENT", 22, 31]]], ["The VA study (discussed earlier) compared a 2-week course of treatment with an 8-week course of treatment, and found no benefit with the longer course.", [["The VA study", "TEST", 0, 12], ["treatment", "TREATMENT", 61, 70], ["treatment", "TREATMENT", 96, 105], ["no", "UNCERTAINTY", 117, 119]]], ["A small study of hospitalized patients demonstrated that a 10-day course of glucocorticoids resulted in better improvements in spirometric measurement, dyspnea on exertion, and PaCO 2 levels than did a 3-day course.", [["glucocorticoids", "CHEMICAL", 76, 91], ["dyspnea", "DISEASE", 152, 159], ["PaCO 2", "CHEMICAL", 177, 183], ["patients", "ORGANISM", 30, 38], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 177, 183], ["patients", "SPECIES", 30, 38], ["A small study", "TEST", 0, 13], ["glucocorticoids", "TREATMENT", 76, 91], ["spirometric measurement", "TEST", 127, 150], ["dyspnea", "PROBLEM", 152, 159], ["exertion", "TEST", 163, 171], ["PaCO 2 levels", "TEST", 177, 190], ["small", "OBSERVATION_MODIFIER", 2, 7]]], ["22 A Cochrane Collaboration meta-analysis was able to identify only 4 studies that compared the duration of corticosteroid treatment in AECOPD, 2 of which were only published as abstracts.Which patients should receive glucocorticoids during an AECOPD?Therefore, the available data do not allow for firm conclusions regarding the optimal duration of glucocorticoid treatment in AECOPD.", [["AECOPD", "DISEASE", 136, 142], ["glucocorticoids", "CHEMICAL", 218, 233], ["AECOPD", "DISEASE", 377, 383], ["patients", "ORGANISM", 194, 202], ["glucocorticoid", "SIMPLE_CHEMICAL", 349, 363], ["patients", "SPECIES", 194, 202], ["corticosteroid treatment", "TREATMENT", 108, 132], ["AECOPD", "PROBLEM", 136, 142], ["glucocorticoids", "TREATMENT", 218, 233], ["an AECOPD", "PROBLEM", 241, 250], ["glucocorticoid treatment", "TREATMENT", 349, 373], ["AECOPD", "PROBLEM", 377, 383], ["AECOPD", "OBSERVATION", 136, 142], ["AECOPD", "OBSERVATION", 244, 250], ["glucocorticoid treatment", "OBSERVATION", 349, 373], ["AECOPD", "OBSERVATION", 377, 383]]], ["1Which glucocorticoid type and route is best?There is no evidence that any steroid preparation is better than another when used at equivalent dosing.", [["steroid", "CHEMICAL", 75, 82], ["steroid", "CHEMICAL", 75, 82], ["glucocorticoid type", "GENE_OR_GENE_PRODUCT", 7, 26], ["steroid", "SIMPLE_CHEMICAL", 75, 82], ["any steroid preparation", "TREATMENT", 71, 94], ["no evidence", "UNCERTAINTY", 54, 65]]], ["It is also not clear if the route of administration (eg, intravenous vs Chronic Obstructive Pulmonary Disease e175 oral) is important.", [["intravenous", "ANATOMY", 57, 68], ["Pulmonary", "ANATOMY", 92, 101], ["oral", "ANATOMY", 115, 119], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 72, 109], ["oral", "ORGANISM_SUBDIVISION", 115, 119], ["administration (eg", "TREATMENT", 37, 55], ["intravenous", "TREATMENT", 57, 68], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 72, 109], ["Obstructive", "OBSERVATION_MODIFIER", 80, 91], ["Pulmonary", "ANATOMY", 92, 101], ["Disease", "OBSERVATION", 102, 109]]], ["Oral glucocorticoids are highly bioavailable, and the intravenous administration of these medications should be reserved for when the patient is unable to take the medications by mouth, or when there is suspicion that the oral medication might not be absorbed for some other reason.", [["Oral", "ANATOMY", 0, 4], ["intravenous", "ANATOMY", 54, 65], ["mouth", "ANATOMY", 179, 184], ["oral", "ANATOMY", 222, 226], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 65], ["patient", "ORGANISM", 134, 141], ["mouth", "ORGANISM_SUBDIVISION", 179, 184], ["oral", "ORGANISM_SUBDIVISION", 222, 226], ["patient", "SPECIES", 134, 141], ["Oral glucocorticoids", "TREATMENT", 0, 20], ["the intravenous administration", "TREATMENT", 50, 80], ["these medications", "TREATMENT", 84, 101], ["the medications", "TREATMENT", 160, 175], ["the oral medication", "TREATMENT", 218, 237], ["glucocorticoids", "OBSERVATION", 5, 20]]], ["20 The large observational study (discussed earlier) was not able to show a difference in outcomes when comparing oral and intravenous treatments.", [["oral", "ANATOMY", 114, 118], ["intravenous", "ANATOMY", 123, 134], ["oral", "ORGANISM_SUBDIVISION", 114, 118], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 134], ["The large observational study", "TEST", 3, 32], ["oral and intravenous treatments", "TREATMENT", 114, 145], ["large", "OBSERVATION_MODIFIER", 7, 12]]], ["21 The GOLD guidelines recommend a standard course of 30 to 40 mg of oral prednisolone daily for 7 to 10 days.", [["oral", "ANATOMY", 69, 73], ["prednisolone", "CHEMICAL", 74, 86], ["prednisolone", "CHEMICAL", 74, 86], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["prednisolone", "SIMPLE_CHEMICAL", 74, 86], ["oral prednisolone", "TREATMENT", 69, 86]]], ["1 Should glucocorticoids be gradually tapered when they are prescribed for AECOPD, or can they be discontinued abruptly?Which glucocorticoid type and route is best?This question has not been well studied, and applies to many other diseases that are treated with brief bursts of glucocorticoid medications.", [["AECOPD", "DISEASE", 75, 81], ["glucocorticoids", "SIMPLE_CHEMICAL", 9, 24], ["glucocorticoid type", "GENE_OR_GENE_PRODUCT", 126, 145], ["glucocorticoids", "TREATMENT", 9, 24], ["AECOPD", "PROBLEM", 75, 81], ["many other diseases", "PROBLEM", 220, 239], ["glucocorticoid medications", "TREATMENT", 278, 304], ["glucocorticoid type", "OBSERVATION", 126, 145], ["diseases", "OBSERVATION", 231, 239]]], ["Although even brief courses of glucocorticoids do suppress the pituitary-adrenal axis, this suppression is not likely to be of clinical significance, and appears to be of short duration.", [["pituitary", "ANATOMY", 63, 72], ["pituitary", "ORGAN", 63, 72], ["adrenal", "ORGAN", 73, 80], ["glucocorticoids", "TREATMENT", 31, 46], ["adrenal axis", "ANATOMY", 73, 85], ["not likely to be", "UNCERTAINTY", 107, 123], ["appears to be", "UNCERTAINTY", 154, 167]]], ["[24] [25] [26] Therefore, glucocorticoid regimens for AECOPD that are comparable to the one recommended here do not require a taper and can be abruptly discontinued at the end of the course.", [["AECOPD", "DISEASE", 54, 60], ["[24] [25] [26]", "SIMPLE_CHEMICAL", 0, 14], ["glucocorticoid regimens", "TREATMENT", 26, 49], ["AECOPD", "PROBLEM", 54, 60], ["a taper", "TREATMENT", 124, 131]]], ["20What are the most frequent bacteria implicated in AECOPD?Bacterial infections are the most frequently identified precipitant of acute exacerbations of COPD, and are implicated in up to 50% of cases.", [["AECOPD", "DISEASE", 52, 58], ["Bacterial infections", "DISEASE", 59, 79], ["COPD", "DISEASE", 153, 157], ["the most frequent bacteria", "PROBLEM", 11, 37], ["AECOPD", "PROBLEM", 52, 58], ["Bacterial infections", "PROBLEM", 59, 79], ["acute exacerbations", "PROBLEM", 130, 149], ["COPD", "PROBLEM", 153, 157], ["AECOPD", "OBSERVATION", 52, 58], ["infections", "OBSERVATION", 69, 79], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["exacerbations", "OBSERVATION", 136, 149], ["COPD", "OBSERVATION", 153, 157]]], ["27, 28 The 3 most common are Moraxella catarrhalis, Haemophilus influenzae, and Streptococcus pneumoniae.", [["Moraxella catarrhalis", "DISEASE", 29, 50], ["Haemophilus influenzae", "DISEASE", 52, 74], ["Streptococcus pneumoniae", "DISEASE", 80, 104], ["Moraxella catarrhalis", "ORGANISM", 29, 50], ["Haemophilus influenzae", "ORGANISM", 52, 74], ["Streptococcus pneumoniae", "ORGANISM", 80, 104], ["Moraxella catarrhalis", "SPECIES", 29, 50], ["Haemophilus influenzae", "SPECIES", 52, 74], ["Streptococcus pneumoniae", "SPECIES", 80, 104], ["Moraxella catarrhalis", "SPECIES", 29, 50], ["Haemophilus influenzae", "SPECIES", 52, 74], ["Streptococcus pneumoniae", "SPECIES", 80, 104], ["Moraxella catarrhalis", "PROBLEM", 29, 50], ["Haemophilus influenzae", "PROBLEM", 52, 74], ["Streptococcus pneumoniae", "PROBLEM", 80, 104], ["Moraxella catarrhalis", "OBSERVATION", 29, 50], ["Haemophilus influenzae", "OBSERVATION", 52, 74], ["Streptococcus pneumoniae", "OBSERVATION", 80, 104]]], ["[29] [30] [31] Pseudomonas aeruginosa is an important pathogen in patients with severe COPD (FEV 1 <50% of predicted).", [["[29] [30] [31", "CHEMICAL", 0, 13], ["COPD", "DISEASE", 87, 91], ["[29] [30] [31] Pseudomonas aeruginosa", "SIMPLE_CHEMICAL", 0, 37], ["patients", "ORGANISM", 66, 74], ["Pseudomonas aeruginosa", "SPECIES", 15, 37], ["patients", "SPECIES", 66, 74], ["Pseudomonas aeruginosa", "SPECIES", 15, 37], ["Pseudomonas aeruginosa", "PROBLEM", 15, 37], ["severe COPD", "PROBLEM", 80, 91], ["FEV", "TEST", 93, 96], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["COPD", "OBSERVATION", 87, 91]]], ["32 Atypical bacteria, such as Chlamydophila, Legionella, and Mycoplasma, are uncommon pathogens, as is Staphylococcus aureus, which is not frequently isolated from patients with acute exacerbations of COPD.", [["Chlamydophila, Legionella", "DISEASE", 30, 55], ["Staphylococcus aureus", "DISEASE", 103, 124], ["COPD", "DISEASE", 201, 205], ["Chlamydophila", "ORGANISM", 30, 43], ["Staphylococcus aureus", "ORGANISM", 103, 124], ["patients", "ORGANISM", 164, 172], ["Chlamydophila", "SPECIES", 30, 43], ["Staphylococcus aureus", "SPECIES", 103, 124], ["patients", "SPECIES", 164, 172], ["Staphylococcus aureus", "SPECIES", 103, 124], ["Atypical bacteria", "PROBLEM", 3, 20], ["Chlamydophila", "PROBLEM", 30, 43], ["Legionella", "PROBLEM", 45, 55], ["Mycoplasma", "PROBLEM", 61, 71], ["uncommon pathogens", "PROBLEM", 77, 95], ["Staphylococcus aureus", "PROBLEM", 103, 124], ["acute exacerbations", "PROBLEM", 178, 197], ["COPD", "PROBLEM", 201, 205], ["Atypical", "OBSERVATION_MODIFIER", 3, 11], ["bacteria", "OBSERVATION", 12, 20], ["Staphylococcus aureus", "OBSERVATION", 103, 124], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["exacerbations", "OBSERVATION", 184, 197], ["COPD", "OBSERVATION", 201, 205]]], ["Acquisition of new bacterial strains is correlated with exacerbations of COPD.", [["COPD", "DISEASE", 73, 77], ["new bacterial strains", "PROBLEM", 15, 36], ["COPD", "PROBLEM", 73, 77], ["new", "OBSERVATION_MODIFIER", 15, 18], ["bacterial strains", "OBSERVATION", 19, 36], ["COPD", "OBSERVATION", 73, 77]]], ["33 Viral infections are also frequent contributors to acute exacerbations of COPD [34] [35] [36] ; rhinovirus is most frequently isolated, and seasonal influenza, parainfluenza, and coronavirus are also frequent contributors.When should patients with acute exacerbations of COPD be treated with antibiotics?Because up to half of all acute exacerbations of COPD are triggered by bacterial infections, 29-31 most patients hospitalized for acute exacerbations of COPD should be treated with antibiotics.", [["Viral infections", "DISEASE", 3, 19], ["COPD", "DISEASE", 77, 81], ["influenza, parainfluenza, and coronavirus", "DISEASE", 152, 193], ["COPD", "DISEASE", 274, 278], ["COPD", "DISEASE", 356, 360], ["bacterial infections", "DISEASE", 378, 398], ["COPD", "DISEASE", 460, 464], ["Viral", "ORGANISM", 3, 8], ["rhinovirus", "ORGANISM", 99, 109], ["parainfluenza", "ORGANISM", 163, 176], ["patients", "ORGANISM", 237, 245], ["patients", "ORGANISM", 411, 419], ["parainfluenza", "SPECIES", 163, 176], ["coronavirus", "SPECIES", 182, 193], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 411, 419], ["Viral infections", "PROBLEM", 3, 19], ["acute exacerbations of COPD", "PROBLEM", 54, 81], ["rhinovirus", "PROBLEM", 99, 109], ["seasonal influenza", "PROBLEM", 143, 161], ["parainfluenza", "PROBLEM", 163, 176], ["coronavirus", "PROBLEM", 182, 193], ["acute exacerbations", "PROBLEM", 251, 270], ["COPD", "PROBLEM", 274, 278], ["antibiotics", "TREATMENT", 295, 306], ["all acute exacerbations", "PROBLEM", 329, 352], ["COPD", "PROBLEM", 356, 360], ["bacterial infections", "PROBLEM", 378, 398], ["acute exacerbations", "PROBLEM", 437, 456], ["COPD", "PROBLEM", 460, 464], ["antibiotics", "TREATMENT", 488, 499], ["infections", "OBSERVATION", 9, 19], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["exacerbations", "OBSERVATION", 60, 73], ["COPD", "OBSERVATION", 77, 81], ["COPD", "OBSERVATION", 274, 278], ["acute", "OBSERVATION_MODIFIER", 333, 338], ["exacerbations", "OBSERVATION", 339, 352], ["COPD", "OBSERVATION", 356, 360], ["bacterial", "OBSERVATION_MODIFIER", 378, 387], ["infections", "OBSERVATION", 388, 398], ["acute", "OBSERVATION_MODIFIER", 437, 442], ["exacerbations", "OBSERVATION", 443, 456], ["COPD", "OBSERVATION", 460, 464]]], ["The exact indications and patient selection remain controversial, as many previous studies did not differentiate between acute and chronic bronchitis, lacked an adequate assessment for pneumonia, or did not have a placebo control.", [["bronchitis", "DISEASE", 139, 149], ["pneumonia", "DISEASE", 185, 194], ["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["many previous studies", "TEST", 69, 90], ["acute and chronic bronchitis", "PROBLEM", 121, 149], ["pneumonia", "PROBLEM", 185, 194], ["a placebo control", "TREATMENT", 212, 229], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["bronchitis", "OBSERVATION", 139, 149], ["adequate", "OBSERVATION_MODIFIER", 161, 169], ["pneumonia", "OBSERVATION", 185, 194]]], ["The major guidelines differ slightly in their recommendations for initiation of antibiotic therapy for acute exacerbation of COPD.When should patients with acute exacerbations of COPD be treated with antibiotics?The GOLD guidelines 1 explicitly address the decision to initiate antibiotics in their most recent update, advocating for the use of antibiotics in acute exacerbations of COPD in 3 scenarios:When should patients with acute exacerbations of COPD be treated with antibiotics?1.", [["COPD", "DISEASE", 125, 129], ["COPD", "DISEASE", 179, 183], ["COPD", "DISEASE", 383, 387], ["COPD", "DISEASE", 452, 456], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 415, 423], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 415, 423], ["antibiotic therapy", "TREATMENT", 80, 98], ["acute exacerbation", "PROBLEM", 103, 121], ["COPD", "PROBLEM", 125, 129], ["acute exacerbations", "PROBLEM", 156, 175], ["COPD", "PROBLEM", 179, 183], ["antibiotics", "TREATMENT", 200, 211], ["antibiotics", "TREATMENT", 278, 289], ["antibiotics", "TREATMENT", 345, 356], ["acute exacerbations", "PROBLEM", 360, 379], ["COPD", "PROBLEM", 383, 387], ["acute exacerbations", "PROBLEM", 429, 448], ["COPD", "PROBLEM", 452, 456], ["antibiotics", "TREATMENT", 473, 484], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["exacerbation", "OBSERVATION", 109, 121], ["COPD", "OBSERVATION", 125, 129], ["COPD", "OBSERVATION", 179, 183], ["acute", "OBSERVATION_MODIFIER", 360, 365], ["exacerbations", "OBSERVATION", 366, 379], ["COPD", "OBSERVATION", 383, 387], ["acute", "OBSERVATION_MODIFIER", 429, 434], ["exacerbations", "OBSERVATION", 435, 448], ["COPD", "OBSERVATION", 452, 456]]], ["Patients presenting with all 3 cardinal symptoms of AECOPD: increased sputum purulence, increased sputum volume, and worsened dyspnea 2.", [["sputum", "ANATOMY", 70, 76], ["sputum", "ANATOMY", 98, 104], ["AECOPD", "DISEASE", 52, 58], ["sputum purulence", "DISEASE", 70, 86], ["dyspnea", "DISEASE", 126, 133], ["Patients", "ORGANISM", 0, 8], ["sputum", "ORGANISM_SUBSTANCE", 98, 104], ["Patients", "SPECIES", 0, 8], ["all 3 cardinal symptoms", "PROBLEM", 25, 48], ["AECOPD", "PROBLEM", 52, 58], ["increased sputum purulence", "PROBLEM", 60, 86], ["increased sputum volume", "PROBLEM", 88, 111], ["worsened dyspnea", "PROBLEM", 117, 133], ["AECOPD", "OBSERVATION", 52, 58], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["sputum purulence", "OBSERVATION", 70, 86], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["sputum volume", "OBSERVATION", 98, 111], ["worsened", "OBSERVATION_MODIFIER", 117, 125], ["dyspnea", "OBSERVATION", 126, 133]]], ["Patients presenting with increased sputum purulence plus either increased sputum volume or worsened dyspnea 3.", [["sputum", "ANATOMY", 35, 41], ["sputum", "ANATOMY", 74, 80], ["dyspnea", "DISEASE", 100, 107], ["Patients", "ORGANISM", 0, 8], ["sputum", "ORGANISM_SUBSTANCE", 74, 80], ["Patients", "SPECIES", 0, 8], ["increased sputum purulence", "PROBLEM", 25, 51], ["increased sputum volume", "PROBLEM", 64, 87], ["worsened dyspnea", "PROBLEM", 91, 107], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["sputum purulence", "OBSERVATION", 35, 51], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["sputum volume", "OBSERVATION", 74, 87], ["worsened", "OBSERVATION_MODIFIER", 91, 99], ["dyspnea", "OBSERVATION", 100, 107]]], ["Severe exacerbation requiring mechanical ventilation (either NIPPV or invasive endotracheal ventilation)When should patients with acute exacerbations of COPD be treated with antibiotics?The American Thoracic Society differs slightly in their recommendations by suggesting antibiotics be initiated in hospitalized patients who have a change in either sputum purulence or sputum volume.", [["endotracheal", "ANATOMY", 79, 91], ["sputum", "ANATOMY", 350, 356], ["sputum", "ANATOMY", 370, 376], ["COPD", "DISEASE", 153, 157], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 313, 321], ["sputum", "ORGANISM_SUBSTANCE", 370, 376], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 313, 321], ["Severe exacerbation", "PROBLEM", 0, 19], ["mechanical ventilation", "TREATMENT", 30, 52], ["NIPPV", "TREATMENT", 61, 66], ["invasive endotracheal ventilation", "TREATMENT", 70, 103], ["acute exacerbations", "PROBLEM", 130, 149], ["COPD", "PROBLEM", 153, 157], ["antibiotics", "TREATMENT", 174, 185], ["antibiotics", "TREATMENT", 272, 283], ["a change in either sputum purulence", "PROBLEM", 331, 366], ["sputum volume", "PROBLEM", 370, 383], ["exacerbation", "OBSERVATION", 7, 19], ["mechanical ventilation", "OBSERVATION", 30, 52], ["COPD", "OBSERVATION", 153, 157], ["Thoracic", "ANATOMY", 199, 207]]], ["9 Practically speaking, the majority of patients hospitalized with acute exacerbation of COPD will have an increase in either sputum purulence or sputum volume, and treatment with antibiotics would be indicated.When should patients with acute exacerbations of COPD be treated with antibiotics?It is important to differentiate acute exacerbations of COPD from bacterial pneumonia, because atypical bacterial infections are less frequent triggers for COPD exacerbations, and many of the common antibiotic regimens for acute exacerbations of COPD do not provide adequate coverage for these atypical pathogens.What are the benefits of antibiotics in patients with acute exacerbations of COPD?Based on the finding that the majority of acute exacerbations of COPD are triggered by infections, antibiotics have been used in the treatment of AECOPD for decades.", [["sputum", "ANATOMY", 126, 132], ["sputum", "ANATOMY", 146, 152], ["COPD", "DISEASE", 89, 93], ["COPD", "DISEASE", 260, 264], ["COPD", "DISEASE", 349, 353], ["bacterial pneumonia", "DISEASE", 359, 378], ["bacterial infections", "DISEASE", 397, 417], ["COPD", "DISEASE", 449, 453], ["COPD", "DISEASE", 539, 543], ["COPD", "DISEASE", 683, 687], ["COPD", "DISEASE", 753, 757], ["infections", "DISEASE", 775, 785], ["AECOPD", "DISEASE", 834, 840], ["patients", "ORGANISM", 40, 48], ["sputum", "ORGANISM_SUBSTANCE", 146, 152], ["patients", "ORGANISM", 223, 231], ["patients", "ORGANISM", 646, 654], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 223, 231], ["patients", "SPECIES", 646, 654], ["acute exacerbation", "PROBLEM", 67, 85], ["COPD", "PROBLEM", 89, 93], ["sputum purulence", "PROBLEM", 126, 142], ["sputum volume", "PROBLEM", 146, 159], ["treatment", "TREATMENT", 165, 174], ["antibiotics", "TREATMENT", 180, 191], ["acute exacerbations", "PROBLEM", 237, 256], ["COPD", "PROBLEM", 260, 264], ["antibiotics", "TREATMENT", 281, 292], ["acute exacerbations", "PROBLEM", 326, 345], ["COPD", "PROBLEM", 349, 353], ["bacterial pneumonia", "PROBLEM", 359, 378], ["atypical bacterial infections", "PROBLEM", 388, 417], ["COPD exacerbations", "PROBLEM", 449, 467], ["the common antibiotic regimens", "TREATMENT", 481, 511], ["acute exacerbations", "PROBLEM", 516, 535], ["COPD", "PROBLEM", 539, 543], ["these atypical pathogens", "PROBLEM", 581, 605], ["antibiotics", "TREATMENT", 631, 642], ["acute exacerbations", "PROBLEM", 660, 679], ["COPD", "PROBLEM", 683, 687], ["acute exacerbations", "PROBLEM", 730, 749], ["COPD", "PROBLEM", 753, 757], ["infections", "PROBLEM", 775, 785], ["antibiotics", "TREATMENT", 787, 798], ["AECOPD", "PROBLEM", 834, 840], ["COPD", "OBSERVATION", 89, 93], ["increase", "OBSERVATION_MODIFIER", 107, 115], ["COPD", "OBSERVATION", 260, 264], ["acute", "OBSERVATION_MODIFIER", 326, 331], ["exacerbations", "OBSERVATION", 332, 345], ["COPD", "OBSERVATION", 349, 353], ["bacterial", "OBSERVATION_MODIFIER", 359, 368], ["pneumonia", "OBSERVATION", 369, 378], ["atypical", "OBSERVATION_MODIFIER", 388, 396], ["bacterial", "OBSERVATION_MODIFIER", 397, 406], ["infections", "OBSERVATION", 407, 417], ["COPD", "OBSERVATION", 539, 543], ["atypical", "OBSERVATION_MODIFIER", 587, 595], ["pathogens", "OBSERVATION", 596, 605], ["acute", "OBSERVATION_MODIFIER", 660, 665], ["exacerbations", "OBSERVATION", 666, 679], ["COPD", "OBSERVATION", 683, 687], ["acute", "OBSERVATION_MODIFIER", 730, 735], ["exacerbations", "OBSERVATION", 736, 749], ["COPD", "OBSERVATION", 753, 757], ["infections", "OBSERVATION", 775, 785], ["AECOPD", "OBSERVATION", 834, 840]]], ["One of the earliest trials of antibiotics in AECOPD 37 showed a 23% relative increase in the rate of treatment success and a 48% decrease in the risk of deterioration in ambulatory patients treated with antibiotics.", [["AECOPD", "DISEASE", 45, 51], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["antibiotics", "TREATMENT", 30, 41], ["AECOPD", "TEST", 45, 51], ["treatment success", "TREATMENT", 101, 118], ["antibiotics", "TREATMENT", 203, 214], ["increase", "OBSERVATION_MODIFIER", 77, 85]]], ["Since this landmark article, numerous published studies have shown decreases in mortality, [38] [39] [40] duration of mechanical ventilation, 38 readmissions, 40 and treatment failure.", [["numerous published studies", "TEST", 29, 55], ["decreases in mortality", "PROBLEM", 67, 89], ["mechanical ventilation", "TREATMENT", 118, 140], ["treatment failure", "PROBLEM", 166, 183], ["decreases", "OBSERVATION_MODIFIER", 67, 76], ["mechanical ventilation", "OBSERVATION", 118, 140], ["failure", "OBSERVATION", 176, 183]]], ["40, 41 An early meta-analysis of randomized trials of antibiotics for exacerbations of COPD showed a small but significant benefit of antibiotics.", [["COPD", "DISEASE", 87, 91], ["randomized trials of antibiotics", "TREATMENT", 33, 65], ["exacerbations", "PROBLEM", 70, 83], ["COPD", "PROBLEM", 87, 91], ["antibiotics", "TREATMENT", 134, 145], ["COPD", "OBSERVATION", 87, 91], ["small", "OBSERVATION_MODIFIER", 101, 106]]], ["42 The benefit of antibiotics seems to be greatest in patients with more severe exacerbations of COPD.", [["COPD", "DISEASE", 97, 101], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["antibiotics", "TREATMENT", 18, 29], ["COPD", "PROBLEM", 97, 101], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["exacerbations", "OBSERVATION", 80, 93], ["COPD", "OBSERVATION", 97, 101]]], ["41 What are the appropriate antibiotics for the treatment of acute exacerbations of COPD?What are the benefits of antibiotics in patients with acute exacerbations of COPD?Antibiotic selection for patients with acute exacerbations of COPD requires integration of an understanding of the microbiologic pathogenesis of COPD exacerbations, patient-specific risk factors for resistant pathogens, and knowledge of the local microbiologic resistance patterns.", [["COPD", "DISEASE", 84, 88], ["COPD", "DISEASE", 166, 170], ["COPD", "DISEASE", 233, 237], ["COPD", "DISEASE", 316, 320], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 196, 204], ["patient", "ORGANISM", 336, 343], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 196, 204], ["patient", "SPECIES", 336, 343], ["the appropriate antibiotics", "TREATMENT", 12, 39], ["acute exacerbations", "PROBLEM", 61, 80], ["COPD", "PROBLEM", 84, 88], ["antibiotics", "TREATMENT", 114, 125], ["acute exacerbations", "PROBLEM", 143, 162], ["COPD", "PROBLEM", 166, 170], ["Antibiotic selection", "TREATMENT", 171, 191], ["acute exacerbations", "PROBLEM", 210, 229], ["COPD", "PROBLEM", 233, 237], ["COPD exacerbations", "PROBLEM", 316, 334], ["resistant pathogens", "PROBLEM", 370, 389], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["exacerbations", "OBSERVATION", 67, 80], ["COPD", "OBSERVATION", 84, 88], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["exacerbations", "OBSERVATION", 149, 162], ["COPD", "OBSERVATION", 166, 170], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["exacerbations", "OBSERVATION", 216, 229], ["COPD", "OBSERVATION", 233, 237], ["COPD", "OBSERVATION", 316, 320]]], ["In general, a more severe exacerbation of COPD requires broader empiric antibiotic coverage.What are the benefits of antibiotics in patients with acute exacerbations of COPD?For moderate exacerbations of COPD in patients without risk factors for P aeruginosa, monotherapy with a macrolide, respiratory fluoroquinolone, or a secondor third-generation cephalosporin are frequently recommended.", [["COPD", "DISEASE", 42, 46], ["COPD", "DISEASE", 169, 173], ["COPD", "DISEASE", 204, 208], ["macrolide", "CHEMICAL", 279, 288], ["fluoroquinolone", "CHEMICAL", 302, 317], ["cephalosporin", "CHEMICAL", 350, 363], ["macrolide", "CHEMICAL", 279, 288], ["fluoroquinolone", "CHEMICAL", 302, 317], ["cephalosporin", "CHEMICAL", 350, 363], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 212, 220], ["macrolide", "SIMPLE_CHEMICAL", 279, 288], ["cephalosporin", "SIMPLE_CHEMICAL", 350, 363], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 212, 220], ["P aeruginosa", "SPECIES", 246, 258], ["a more severe exacerbation of COPD", "PROBLEM", 12, 46], ["broader empiric antibiotic coverage", "TREATMENT", 56, 91], ["antibiotics", "TREATMENT", 117, 128], ["acute exacerbations", "PROBLEM", 146, 165], ["COPD", "PROBLEM", 169, 173], ["moderate exacerbations", "PROBLEM", 178, 200], ["COPD", "PROBLEM", 204, 208], ["risk factors", "PROBLEM", 229, 241], ["P aeruginosa", "PROBLEM", 246, 258], ["monotherapy", "TREATMENT", 260, 271], ["a macrolide", "TREATMENT", 277, 288], ["respiratory fluoroquinolone", "TREATMENT", 290, 317], ["a secondor third-generation cephalosporin", "TREATMENT", 322, 363], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["exacerbation", "OBSERVATION", 26, 38], ["COPD", "OBSERVATION", 42, 46], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["exacerbations", "OBSERVATION", 152, 165], ["COPD", "OBSERVATION", 169, 173], ["moderate", "OBSERVATION_MODIFIER", 178, 186], ["exacerbations", "OBSERVATION", 187, 200], ["COPD", "OBSERVATION", 204, 208], ["respiratory fluoroquinolone", "OBSERVATION", 290, 317]]], ["1, 43 A recent meta-analysis of randomized controlled trials comparing macrolide antibiotics with fluoroquinolone antibiotics showed no difference in the rate of treatment failure between the groups but a lower incidence of side effects with macrolide antibiotics.", [["macrolide", "CHEMICAL", 71, 80], ["fluoroquinolone", "CHEMICAL", 98, 113], ["macrolide", "CHEMICAL", 242, 251], ["macrolide", "CHEMICAL", 71, 80], ["fluoroquinolone", "CHEMICAL", 98, 113], ["macrolide", "CHEMICAL", 242, 251], ["macrolide", "SIMPLE_CHEMICAL", 71, 80], ["fluoroquinolone", "SIMPLE_CHEMICAL", 98, 113], ["macrolide", "SIMPLE_CHEMICAL", 242, 251], ["A recent meta-analysis", "TEST", 6, 28], ["randomized controlled trials", "TREATMENT", 32, 60], ["macrolide antibiotics", "TREATMENT", 71, 92], ["fluoroquinolone antibiotics", "TREATMENT", 98, 125], ["treatment failure", "PROBLEM", 162, 179], ["side effects", "PROBLEM", 224, 236], ["macrolide antibiotics", "TREATMENT", 242, 263], ["failure", "OBSERVATION", 172, 179], ["lower", "OBSERVATION_MODIFIER", 205, 210]]], ["44 In patients aged 65 years or older, those with severe COPD, 3 or more exacerbations per year, or who have received recent antibiotic therapy (within the past 90 days), the risk for resistant pathogens increases; broader coverage and sputum culture is suggested for these patients.What are the benefits of antibiotics in patients with acute exacerbations of COPD?Because of its virulence and rapid acquisition of antibiotic resistance, P aeruginosa is a particularly important pathogen in acute exacerbations of COPD.", [["COPD", "DISEASE", 57, 61], ["COPD", "DISEASE", 360, 364], ["COPD", "DISEASE", 514, 518], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 274, 282], ["patients", "ORGANISM", 323, 331], ["P aeruginosa", "ORGANISM", 438, 450], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 274, 282], ["patients", "SPECIES", 323, 331], ["P aeruginosa", "SPECIES", 438, 450], ["severe COPD", "PROBLEM", 50, 61], ["recent antibiotic therapy", "TREATMENT", 118, 143], ["resistant pathogens", "PROBLEM", 184, 203], ["broader coverage", "TREATMENT", 215, 231], ["sputum culture", "TEST", 236, 250], ["antibiotics", "TREATMENT", 308, 319], ["acute exacerbations", "PROBLEM", 337, 356], ["COPD", "PROBLEM", 360, 364], ["its virulence", "PROBLEM", 376, 389], ["antibiotic resistance", "TREATMENT", 415, 436], ["P aeruginosa", "PROBLEM", 438, 450], ["COPD", "PROBLEM", 514, 518], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["COPD", "OBSERVATION", 57, 61], ["resistant", "OBSERVATION_MODIFIER", 184, 193], ["pathogens", "OBSERVATION", 194, 203], ["acute", "OBSERVATION_MODIFIER", 337, 342], ["exacerbations", "OBSERVATION", 343, 356], ["COPD", "OBSERVATION", 360, 364], ["acute", "OBSERVATION_MODIFIER", 491, 496], ["exacerbations", "OBSERVATION", 497, 510], ["COPD", "OBSERVATION", 514, 518]]], ["32 Risk factors for P aeruginosa are detailed in Box 1.", [["P aeruginosa", "SPECIES", 20, 32], ["P aeruginosa", "PROBLEM", 20, 32]]], ["In patients presenting with one or more of these risk factors, coverage with an antibiotic with known activity against P aeruginosa, such as an antipseudomonal b-lactam, fluoroquinolone, or aminoglycoside, is indicated.", [["b-lactam", "CHEMICAL", 160, 168], ["fluoroquinolone", "CHEMICAL", 170, 185], ["aminoglycoside", "CHEMICAL", 190, 204], ["b-lactam", "CHEMICAL", 160, 168], ["fluoroquinolone", "CHEMICAL", 170, 185], ["aminoglycoside", "CHEMICAL", 190, 204], ["patients", "ORGANISM", 3, 11], ["P aeruginosa", "ORGANISM", 119, 131], ["b-lactam", "SIMPLE_CHEMICAL", 160, 168], ["fluoroquinolone", "SIMPLE_CHEMICAL", 170, 185], ["aminoglycoside", "SIMPLE_CHEMICAL", 190, 204], ["patients", "SPECIES", 3, 11], ["P aeruginosa", "SPECIES", 119, 131], ["an antibiotic", "TREATMENT", 77, 90], ["P aeruginosa", "PROBLEM", 119, 131], ["an antipseudomonal b-lactam", "TREATMENT", 141, 168], ["fluoroquinolone", "TREATMENT", 170, 185], ["aminoglycoside", "TREATMENT", 190, 204]]], ["Selection of an appropriate antibiotic should be guided by local resistance patterns and the patient's prior sputum culture sensitivities, when available.Chronic Obstructive Pulmonary Disease e177How long should antibiotics be continued for acute exacerbations of COPD?Chronic Obstructive Pulmonary Disease e177The ideal duration of antibiotic therapy for acute exacerbations of COPD is unknown.", [["sputum", "ANATOMY", 109, 115], ["Obstructive Pulmonary Disease", "DISEASE", 162, 191], ["COPD", "DISEASE", 264, 268], ["Obstructive Pulmonary Disease", "DISEASE", 277, 306], ["COPD", "DISEASE", 379, 383], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["an appropriate antibiotic", "TREATMENT", 13, 38], ["local resistance patterns", "TEST", 59, 84], ["the patient's prior sputum culture sensitivities", "TEST", 89, 137], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 154, 191], ["antibiotics", "TREATMENT", 212, 223], ["acute exacerbations", "PROBLEM", 241, 260], ["COPD", "PROBLEM", 264, 268], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 269, 306], ["antibiotic therapy", "TREATMENT", 333, 351], ["acute exacerbations", "PROBLEM", 356, 375], ["COPD", "PROBLEM", 379, 383], ["Obstructive", "OBSERVATION_MODIFIER", 162, 173], ["Pulmonary", "ANATOMY", 174, 183], ["Disease", "OBSERVATION", 184, 191], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["exacerbations", "OBSERVATION", 247, 260], ["COPD", "OBSERVATION", 264, 268], ["Obstructive", "OBSERVATION_MODIFIER", 277, 288], ["Pulmonary", "ANATOMY", 289, 298], ["Disease", "OBSERVATION", 299, 306], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["exacerbations", "OBSERVATION", 362, 375], ["COPD", "OBSERVATION", 379, 383]]], ["The GOLD guidelines recommend 5 to 10 days of antibiotic therapy.", [["antibiotic therapy", "TREATMENT", 46, 64]]], ["A recent meta-analysis comparing 5 days with 7 days of therapy showed no difference in outcome but fewer adverse events, with a shorter duration of therapy.", [["A recent meta-analysis", "TEST", 0, 22], ["therapy", "TREATMENT", 55, 62], ["fewer adverse events", "PROBLEM", 99, 119], ["a shorter duration of therapy", "TREATMENT", 126, 155], ["no", "UNCERTAINTY", 70, 72]]], ["45 In practice, the duration of antibiotic therapy is adjusted based on initial response to therapy and severity of underlying disease, with longer durations reserved for patients with delayed clinical responses or severe airflow obstruction at baseline.", [["airflow obstruction", "DISEASE", 222, 241], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["antibiotic therapy", "TREATMENT", 32, 50], ["therapy", "TREATMENT", 92, 99], ["underlying disease", "PROBLEM", 116, 134], ["delayed clinical responses", "PROBLEM", 185, 211], ["severe airflow obstruction", "PROBLEM", 215, 241], ["disease", "OBSERVATION", 127, 134], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["airflow obstruction", "OBSERVATION", 222, 241]]], ["For this reason, close follow-up after discharge from hospital is particularly important for patients with acute exacerbations of COPD.Should prophylactic antibiotics be prescribed for prevention of AECOPD?Long-term antibiotic prophylaxis for the prevention of acute exacerbations of COPD is controversial.", [["COPD", "DISEASE", 130, 134], ["AECOPD", "DISEASE", 199, 205], ["COPD", "DISEASE", 284, 288], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["acute exacerbations", "PROBLEM", 107, 126], ["COPD", "PROBLEM", 130, 134], ["prophylactic antibiotics", "TREATMENT", 142, 166], ["AECOPD", "PROBLEM", 199, 205], ["Long-term antibiotic prophylaxis", "TREATMENT", 206, 238], ["acute exacerbations", "PROBLEM", 261, 280], ["COPD", "PROBLEM", 284, 288], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["exacerbations", "OBSERVATION", 113, 126], ["COPD", "OBSERVATION", 130, 134], ["AECOPD", "OBSERVATION", 199, 205], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["exacerbations", "OBSERVATION", 267, 280], ["COPD", "OBSERVATION", 284, 288]]], ["A large meta-analysis 46 showed no reduction in acute exacerbations with long-term prophylaxis and a mean of 1 day of disability avoided per month of treatment.", [["disability", "DISEASE", 118, 128], ["A large meta-analysis", "TEST", 0, 21], ["acute exacerbations", "PROBLEM", 48, 67], ["long-term prophylaxis", "TREATMENT", 73, 94], ["treatment", "TREATMENT", 150, 159], ["large", "OBSERVATION_MODIFIER", 2, 7], ["no", "UNCERTAINTY", 32, 34], ["reduction", "OBSERVATION_MODIFIER", 35, 44], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["exacerbations", "OBSERVATION", 54, 67], ["long-term", "OBSERVATION_MODIFIER", 73, 82]]], ["Two recent trials have renewed interest in antibiotic prophylaxis, particularly in high-risk patients.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["antibiotic prophylaxis", "TREATMENT", 43, 65]]], ["47, 48 The first showed a decreased risk of exacerbation in patients treated with pulsed moxifloxacin (400 mg daily for 5 days every 8 weeks), with a greater effect in those with purulent sputum at baseline.", [["purulent sputum", "ANATOMY", 179, 194], ["moxifloxacin", "CHEMICAL", 89, 101], ["moxifloxacin", "CHEMICAL", 89, 101], ["patients", "ORGANISM", 60, 68], ["moxifloxacin", "SIMPLE_CHEMICAL", 89, 101], ["sputum", "ORGANISM_SUBSTANCE", 188, 194], ["patients", "SPECIES", 60, 68], ["exacerbation", "PROBLEM", 44, 56], ["pulsed moxifloxacin", "TREATMENT", 82, 101], ["purulent sputum", "PROBLEM", 179, 194], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["exacerbation", "OBSERVATION", 44, 56], ["greater effect", "OBSERVATION_MODIFIER", 150, 164], ["purulent", "OBSERVATION_MODIFIER", 179, 187], ["sputum", "OBSERVATION", 188, 194]]], ["47 The second demonstrated a 27% reduction in exacerbations and increased the time to first exacerbation by 3 months using a regimen of azithromycin, 250 mg daily, in patients at high risk for exacerbation.", [["azithromycin", "CHEMICAL", 136, 148], ["azithromycin", "CHEMICAL", 136, 148], ["azithromycin", "SIMPLE_CHEMICAL", 136, 148], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["a 27% reduction in exacerbations", "PROBLEM", 27, 59], ["first exacerbation", "PROBLEM", 86, 104], ["azithromycin", "TREATMENT", 136, 148], ["exacerbation", "PROBLEM", 193, 205], ["27%", "OBSERVATION_MODIFIER", 29, 32], ["reduction", "OBSERVATION_MODIFIER", 33, 42], ["exacerbations", "OBSERVATION", 46, 59], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["exacerbation", "OBSERVATION", 193, 205]]], ["However, this regimen increased the risk of hearing loss.", [["hearing loss", "DISEASE", 44, 56], ["this regimen", "TREATMENT", 9, 21], ["hearing loss", "PROBLEM", 44, 56], ["hearing loss", "OBSERVATION", 44, 56]]], ["48 Long-term prophylaxis should be considered in patients with frequent exacerbations despite optimal medical therapy, while carefully weighing the risks of increased antibiotic resistance and adverse drug reactions.Noninvasive Positive-Pressure VentilationWhat are the indications for noninvasive positive-pressure ventilation in acute exacerbations of COPD?Noninvasive Positive-Pressure VentilationNoninvasive positive-pressure ventilation (NIPPV) helps to facilitate alveolar gas exchange and has the potential to improve both ventilation and oxygenation in patients with acute respiratory failure.", [["alveolar", "ANATOMY", 470, 478], ["respiratory", "ANATOMY", 581, 592], ["adverse drug reactions", "DISEASE", 193, 215], ["COPD", "DISEASE", 354, 358], ["acute respiratory failure", "DISEASE", 575, 600], ["patients", "ORGANISM", 49, 57], ["alveolar", "MULTI-TISSUE_STRUCTURE", 470, 478], ["patients", "ORGANISM", 561, 569], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 561, 569], ["Long-term prophylaxis", "TREATMENT", 3, 24], ["frequent exacerbations", "PROBLEM", 63, 85], ["optimal medical therapy", "TREATMENT", 94, 117], ["increased antibiotic resistance", "TREATMENT", 157, 188], ["adverse drug reactions", "PROBLEM", 193, 215], ["Noninvasive Positive-Pressure VentilationWhat", "TREATMENT", 216, 261], ["noninvasive positive-pressure ventilation", "TREATMENT", 286, 327], ["acute exacerbations", "PROBLEM", 331, 350], ["COPD", "PROBLEM", 354, 358], ["Noninvasive", "TEST", 359, 370], ["Pressure Ventilation", "TREATMENT", 380, 400], ["pressure ventilation", "TREATMENT", 421, 441], ["NIPPV", "TREATMENT", 443, 448], ["alveolar gas exchange", "PROBLEM", 470, 491], ["both ventilation", "TREATMENT", 525, 541], ["acute respiratory failure", "PROBLEM", 575, 600], ["antibiotic resistance", "OBSERVATION", 167, 188], ["Positive", "OBSERVATION", 228, 236], ["Pressure VentilationWhat", "OBSERVATION", 237, 261], ["pressure ventilation", "OBSERVATION", 307, 327], ["acute", "OBSERVATION_MODIFIER", 331, 336], ["exacerbations", "OBSERVATION", 337, 350], ["COPD", "OBSERVATION", 354, 358], ["Positive", "OBSERVATION", 371, 379], ["Pressure Ventilation", "OBSERVATION", 380, 400], ["pressure ventilation", "OBSERVATION", 421, 441], ["alveolar gas", "OBSERVATION", 470, 482], ["acute", "OBSERVATION_MODIFIER", 575, 580], ["respiratory failure", "OBSERVATION", 581, 600]]], ["The indications for initiation of NIPPV in AECOPD are primarily for those patients with acute hypercarbic respiratory failure.", [["respiratory", "ANATOMY", 106, 117], ["AECOPD", "DISEASE", 43, 49], ["respiratory failure", "DISEASE", 106, 125], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["NIPPV", "TREATMENT", 34, 39], ["AECOPD", "TREATMENT", 43, 49], ["acute hypercarbic respiratory failure", "PROBLEM", 88, 125], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["hypercarbic", "OBSERVATION", 94, 105], ["respiratory failure", "OBSERVATION", 106, 125]]], ["The GOLD guidelines suggest using NIPPV in patients with either:Noninvasive Positive-Pressure VentilationRespiratory acidosis (arterial pH 7.35 and/or arterial carbon dioxide tension [PaCO 2 ] 45 mm Hg), or Severe dyspnea with signs of respiratory muscle fatigue or increased work of breathing (use of accessory respiratory muscles, paradoxic abdominal movement, or retraction of intercostal muscles) 1 The indications for NIPPV in patients with acute exacerbations of COPD and hypoxemic respiratory failure are less clear.", [["arterial", "ANATOMY", 127, 135], ["arterial", "ANATOMY", 151, 159], ["respiratory muscle", "ANATOMY", 236, 254], ["respiratory muscles", "ANATOMY", 312, 331], ["abdominal", "ANATOMY", 343, 352], ["intercostal muscles", "ANATOMY", 380, 399], ["respiratory", "ANATOMY", 488, 499], ["acidosis", "DISEASE", 117, 125], ["carbon dioxide", "CHEMICAL", 160, 174], ["dyspnea", "DISEASE", 214, 221], ["respiratory muscle fatigue", "DISEASE", 236, 262], ["COPD", "DISEASE", 469, 473], ["hypoxemic respiratory failure", "DISEASE", 478, 507], ["carbon dioxide", "CHEMICAL", 160, 174], ["PaCO 2", "CHEMICAL", 184, 190], ["Hg", "CHEMICAL", 199, 201], ["patients", "ORGANISM", 43, 51], ["arterial", "MULTI-TISSUE_STRUCTURE", 127, 135], ["arterial", "MULTI-TISSUE_STRUCTURE", 151, 159], ["muscle", "ORGAN", 248, 254], ["respiratory muscles", "ORGANISM_SUBDIVISION", 312, 331], ["abdominal", "ORGANISM_SUBDIVISION", 343, 352], ["patients", "ORGANISM", 432, 440], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 432, 440], ["NIPPV", "TREATMENT", 34, 39], ["Pressure VentilationRespiratory acidosis", "PROBLEM", 85, 125], ["arterial pH", "TEST", 127, 138], ["arterial carbon dioxide tension", "TEST", 151, 182], ["PaCO", "TEST", 184, 188], ["Severe dyspnea", "PROBLEM", 207, 221], ["respiratory muscle fatigue", "PROBLEM", 236, 262], ["increased work of breathing", "PROBLEM", 266, 293], ["accessory respiratory muscles", "PROBLEM", 302, 331], ["paradoxic abdominal movement", "PROBLEM", 333, 361], ["retraction of intercostal muscles", "PROBLEM", 366, 399], ["NIPPV", "TREATMENT", 423, 428], ["acute exacerbations", "PROBLEM", 446, 465], ["COPD", "PROBLEM", 469, 473], ["hypoxemic respiratory failure", "PROBLEM", 478, 507], ["arterial", "ANATOMY", 151, 159], ["Severe", "OBSERVATION_MODIFIER", 207, 213], ["dyspnea", "OBSERVATION", 214, 221], ["respiratory muscle", "ANATOMY", 236, 254], ["fatigue", "OBSERVATION", 255, 262], ["increased", "OBSERVATION_MODIFIER", 266, 275], ["respiratory muscles", "ANATOMY", 312, 331], ["abdominal", "ANATOMY", 343, 352], ["intercostal muscles", "ANATOMY", 380, 399], ["acute", "OBSERVATION_MODIFIER", 446, 451], ["exacerbations", "OBSERVATION", 452, 465], ["COPD", "OBSERVATION", 469, 473], ["hypoxemic", "OBSERVATION_MODIFIER", 478, 487], ["respiratory failure", "OBSERVATION", 488, 507]]], ["The 2001 International Consensus Conference in Intensive Care Medicine recommend that NIPPV be considered for patients with hypoxemic respiratory failure, but do not specifically recommend it for the subset of patients with acute exacerbations of COPD and hypoxic respiratory failure.", [["respiratory", "ANATOMY", 134, 145], ["respiratory", "ANATOMY", 264, 275], ["hypoxemic respiratory failure", "DISEASE", 124, 153], ["COPD", "DISEASE", 247, 251], ["hypoxic respiratory failure", "DISEASE", 256, 283], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 210, 218], ["NIPPV", "TREATMENT", 86, 91], ["hypoxemic respiratory failure", "PROBLEM", 124, 153], ["acute exacerbations", "PROBLEM", 224, 243], ["COPD", "PROBLEM", 247, 251], ["hypoxic respiratory failure", "PROBLEM", 256, 283], ["respiratory failure", "OBSERVATION", 134, 153], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["exacerbations", "OBSERVATION", 230, 243], ["COPD", "OBSERVATION", 247, 251], ["hypoxic", "OBSERVATION_MODIFIER", 256, 263], ["respiratory failure", "OBSERVATION", 264, 283]]], ["49What are the contraindications for NIPPV in AECOPD?The 2001 International Consensus Conference Statement of Noninvasive Positive Pressure Ventilation 49 defined contraindications to NIPPV, including:What are the contraindications for NIPPV in AECOPD?Cardiac or respiratory arrest Other acute severe organ failure (such as hemodynamic instability, severe encephalopathy, or severe upper gastrointestinal hemorrhage) Recent esophageal anastomosis, facial surgery, trauma, or deformity Upper airway obstruction Inability of the patient to protect their airway, high aspiration risk, or inability to clear oropharyngeal secretions.What are the contraindications for NIPPV in AECOPD?Many patients with severe or very severe COPD have advanced directives outlining clear limits on invasive mechanical ventilation.", [["Cardiac", "ANATOMY", 252, 259], ["respiratory", "ANATOMY", 263, 274], ["organ", "ANATOMY", 301, 306], ["gastrointestinal", "ANATOMY", 388, 404], ["esophageal", "ANATOMY", 424, 434], ["facial", "ANATOMY", 448, 454], ["airway", "ANATOMY", 491, 497], ["airway", "ANATOMY", 552, 558], ["oropharyngeal secretions", "ANATOMY", 604, 628], ["AECOPD", "DISEASE", 46, 52], ["AECOPD", "DISEASE", 245, 251], ["Cardiac or respiratory arrest", "DISEASE", 252, 281], ["organ failure", "DISEASE", 301, 314], ["hemodynamic instability", "DISEASE", 324, 347], ["encephalopathy", "DISEASE", 356, 370], ["upper gastrointestinal hemorrhage", "DISEASE", 382, 415], ["trauma", "DISEASE", 464, 470], ["deformity", "DISEASE", 475, 484], ["airway obstruction", "DISEASE", 491, 509], ["AECOPD", "DISEASE", 673, 679], ["COPD", "DISEASE", 721, 725], ["Cardiac", "ORGAN", 252, 259], ["organ", "ORGAN", 301, 306], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 382, 404], ["esophageal", "ORGAN", 424, 434], ["patient", "ORGANISM", 527, 534], ["airway", "MULTI-TISSUE_STRUCTURE", 552, 558], ["oropharyngeal secretions", "ORGANISM_SUBSTANCE", 604, 628], ["patients", "ORGANISM", 685, 693], ["patient", "SPECIES", 527, 534], ["patients", "SPECIES", 685, 693], ["NIPPV", "TREATMENT", 37, 42], ["AECOPD", "PROBLEM", 46, 52], ["Noninvasive Positive Pressure Ventilation", "TREATMENT", 110, 151], ["NIPPV", "TREATMENT", 184, 189], ["NIPPV", "TREATMENT", 236, 241], ["AECOPD", "PROBLEM", 245, 251], ["Cardiac or respiratory arrest", "PROBLEM", 252, 281], ["Other acute severe organ failure", "PROBLEM", 282, 314], ["hemodynamic instability", "PROBLEM", 324, 347], ["severe encephalopathy", "PROBLEM", 349, 370], ["severe upper gastrointestinal hemorrhage", "PROBLEM", 375, 415], ["Recent esophageal anastomosis", "TREATMENT", 417, 446], ["facial surgery", "TREATMENT", 448, 462], ["trauma", "PROBLEM", 464, 470], ["deformity", "PROBLEM", 475, 484], ["Upper airway obstruction", "PROBLEM", 485, 509], ["high aspiration risk", "PROBLEM", 560, 580], ["inability to clear oropharyngeal secretions", "PROBLEM", 585, 628], ["NIPPV", "TREATMENT", 664, 669], ["AECOPD", "PROBLEM", 673, 679], ["very severe COPD", "PROBLEM", 709, 725], ["invasive mechanical ventilation", "TREATMENT", 777, 808], ["AECOPD", "OBSERVATION", 46, 52], ["AECOPD", "OBSERVATION", 245, 251], ["respiratory arrest", "OBSERVATION", 263, 281], ["acute", "OBSERVATION_MODIFIER", 288, 293], ["severe", "OBSERVATION_MODIFIER", 294, 300], ["organ", "ANATOMY", 301, 306], ["failure", "OBSERVATION", 307, 314], ["severe", "OBSERVATION_MODIFIER", 349, 355], ["encephalopathy", "OBSERVATION", 356, 370], ["severe", "OBSERVATION_MODIFIER", 375, 381], ["upper", "ANATOMY_MODIFIER", 382, 387], ["gastrointestinal", "ANATOMY", 388, 404], ["hemorrhage", "OBSERVATION", 405, 415], ["esophageal", "ANATOMY", 424, 434], ["anastomosis", "OBSERVATION", 435, 446], ["facial", "ANATOMY", 448, 454], ["surgery", "OBSERVATION", 455, 462], ["trauma", "OBSERVATION", 464, 470], ["deformity", "OBSERVATION", 475, 484], ["Upper", "ANATOMY_MODIFIER", 485, 490], ["airway", "ANATOMY", 491, 497], ["obstruction", "OBSERVATION", 498, 509], ["airway", "ANATOMY", 552, 558], ["oropharyngeal", "ANATOMY", 604, 617], ["secretions", "OBSERVATION", 618, 628], ["AECOPD", "OBSERVATION", 673, 679], ["severe", "OBSERVATION_MODIFIER", 699, 705], ["severe", "OBSERVATION_MODIFIER", 714, 720], ["COPD", "OBSERVATION", 721, 725], ["clear limits", "OBSERVATION_MODIFIER", 761, 773], ["mechanical ventilation", "OBSERVATION", 786, 808]]], ["It is prudent to initiate a discussion of these limits, particularly as they apply to noninvasive ventilation, at the time of admission to the hospital for all patients with acute exacerbations of COPD, because of the potential benefits of NIPPV in avoiding the need for invasive mechanical ventilation.What are the main risks of NIPPV in AECOPD?The primary risk of NIPPV in AECOPD is aspiration of gastric or oropharyngeal contents.", [["gastric", "ANATOMY", 399, 406], ["oropharyngeal", "ANATOMY", 410, 423], ["COPD", "DISEASE", 197, 201], ["AECOPD", "DISEASE", 339, 345], ["AECOPD", "DISEASE", 375, 381], ["aspiration of gastric or oropharyngeal contents", "DISEASE", 385, 432], ["patients", "ORGANISM", 160, 168], ["gastric", "ORGAN", 399, 406], ["oropharyngeal", "ORGANISM_SUBDIVISION", 410, 423], ["patients", "SPECIES", 160, 168], ["noninvasive ventilation", "TREATMENT", 86, 109], ["acute exacerbations", "PROBLEM", 174, 193], ["COPD", "PROBLEM", 197, 201], ["NIPPV", "TREATMENT", 240, 245], ["invasive mechanical ventilation", "TREATMENT", 271, 302], ["NIPPV", "TREATMENT", 330, 335], ["AECOPD", "PROBLEM", 339, 345], ["NIPPV", "TREATMENT", 366, 371], ["AECOPD", "PROBLEM", 375, 381], ["aspiration of gastric or oropharyngeal contents", "PROBLEM", 385, 432], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["exacerbations", "OBSERVATION", 180, 193], ["COPD", "OBSERVATION", 197, 201], ["mechanical ventilation", "OBSERVATION", 280, 302], ["NIPPV", "OBSERVATION", 330, 335], ["AECOPD", "OBSERVATION", 339, 345], ["NIPPV", "OBSERVATION", 366, 371], ["AECOPD", "OBSERVATION", 375, 381], ["aspiration", "OBSERVATION", 385, 395], ["gastric", "ANATOMY", 399, 406], ["oropharyngeal", "ANATOMY", 410, 423], ["contents", "OBSERVATION", 424, 432]]], ["Unlike invasive mechanical ventilation, NIPPV has no mechanism to prevent aspiration of gastric contents.", [["gastric", "ANATOMY", 88, 95], ["gastric", "ORGAN", 88, 95], ["invasive mechanical ventilation", "TREATMENT", 7, 38], ["NIPPV", "TREATMENT", 40, 45], ["aspiration of gastric contents", "PROBLEM", 74, 104], ["invasive", "OBSERVATION_MODIFIER", 7, 15], ["mechanical ventilation", "OBSERVATION", 16, 38], ["aspiration", "OBSERVATION", 74, 84], ["gastric", "ANATOMY", 88, 95], ["contents", "OBSERVATION", 96, 104]]], ["In addition, the positive airway pressure creates a pressure gradient, which can facilitate passage of oropharyngeal or gastric contents into the lower airway.What are the main risks of NIPPV in AECOPD?Other complications of NIPPV include:What are the main risks of NIPPV in AECOPD?Facial irritation Gastric distension Sinusitis Conjunctival irritation (from an improper mask seal) Patient discomfort 50What are the main benefits of NIPPV in AECOPD?Numerous prospective randomized trials have demonstrated the benefits of NIPPV in acute exacerbations of COPD 51-53 :What are the main benefits of NIPPV in AECOPD?Reduces the need for invasive mechanical ventilation by up to 80% to 85% [53] [54] [55] Chronic Obstructive Pulmonary Disease e179 Improves respiratory mechanics 56 Reduces both in-hospital and 30-day mortality A large meta-analysis 57 showed a reduction in in-hospital mortality, less need for endotracheal intubation, and less treatment failure compared with standard medical care.", [["airway", "ANATOMY", 26, 32], ["oropharyngeal", "ANATOMY", 103, 116], ["gastric", "ANATOMY", 120, 127], ["lower airway", "ANATOMY", 146, 158], ["Facial", "ANATOMY", 282, 288], ["Gastric", "ANATOMY", 300, 307], ["Conjunctival", "ANATOMY", 329, 341], ["endotracheal", "ANATOMY", 907, 919], ["AECOPD", "DISEASE", 195, 201], ["AECOPD", "DISEASE", 275, 281], ["Facial irritation", "DISEASE", 282, 299], ["Conjunctival irritation", "DISEASE", 329, 352], ["AECOPD", "DISEASE", 442, 448], ["COPD", "DISEASE", 554, 558], ["AECOPD", "DISEASE", 605, 611], ["Obstructive Pulmonary Disease", "DISEASE", 708, 737], ["airway", "MULTI-TISSUE_STRUCTURE", 26, 32], ["oropharyngeal", "ORGANISM_SUBDIVISION", 103, 116], ["gastric", "ORGAN", 120, 127], ["lower airway", "ORGANISM_SUBDIVISION", 146, 158], ["Patient", "SPECIES", 382, 389], ["the positive airway pressure", "TEST", 13, 41], ["a pressure gradient", "PROBLEM", 50, 69], ["passage of oropharyngeal or gastric contents into the lower airway", "PROBLEM", 92, 158], ["NIPPV", "TREATMENT", 186, 191], ["AECOPD", "PROBLEM", 195, 201], ["NIPPV", "TREATMENT", 225, 230], ["NIPPV", "TREATMENT", 266, 271], ["AECOPD", "PROBLEM", 275, 281], ["Facial irritation", "PROBLEM", 282, 299], ["Gastric distension", "PROBLEM", 300, 318], ["Sinusitis", "PROBLEM", 319, 328], ["Conjunctival irritation", "PROBLEM", 329, 352], ["an improper mask seal", "TREATMENT", 359, 380], ["Patient discomfort", "PROBLEM", 382, 400], ["NIPPV", "TREATMENT", 433, 438], ["AECOPD", "PROBLEM", 442, 448], ["Numerous prospective randomized trials", "TREATMENT", 449, 487], ["NIPPV", "TREATMENT", 522, 527], ["acute exacerbations", "PROBLEM", 531, 550], ["COPD", "PROBLEM", 554, 558], ["NIPPV", "TREATMENT", 596, 601], ["AECOPD", "PROBLEM", 605, 611], ["invasive mechanical ventilation", "TREATMENT", 633, 664], ["Chronic Obstructive Pulmonary Disease e", "PROBLEM", 700, 739], ["respiratory mechanics", "TEST", 752, 773], ["A large meta-analysis", "TEST", 823, 844], ["endotracheal intubation", "TREATMENT", 907, 930], ["less treatment failure", "PROBLEM", 936, 958], ["standard medical care", "TREATMENT", 973, 994], ["positive airway pressure", "OBSERVATION", 17, 41], ["pressure gradient", "OBSERVATION", 52, 69], ["gastric", "ANATOMY", 120, 127], ["contents", "OBSERVATION", 128, 136], ["lower", "ANATOMY_MODIFIER", 146, 151], ["airway", "ANATOMY", 152, 158], ["NIPPV", "OBSERVATION", 186, 191], ["AECOPD", "OBSERVATION", 195, 201], ["NIPPV", "OBSERVATION", 225, 230], ["NIPPV", "OBSERVATION", 266, 271], ["AECOPD", "OBSERVATION", 275, 281], ["irritation", "OBSERVATION_MODIFIER", 289, 299], ["Gastric", "ANATOMY", 300, 307], ["distension", "OBSERVATION_MODIFIER", 308, 318], ["Sinusitis", "OBSERVATION", 319, 328], ["Conjunctival irritation", "OBSERVATION", 329, 352], ["mask seal", "OBSERVATION", 371, 380], ["AECOPD", "OBSERVATION", 442, 448], ["acute", "OBSERVATION_MODIFIER", 531, 536], ["exacerbations", "OBSERVATION", 537, 550], ["COPD", "OBSERVATION", 554, 558], ["AECOPD", "OBSERVATION", 605, 611], ["Chronic", "OBSERVATION_MODIFIER", 700, 707], ["Obstructive", "OBSERVATION_MODIFIER", 708, 719], ["Pulmonary", "ANATOMY", 720, 729], ["Disease", "OBSERVATION", 730, 737], ["reduction", "OBSERVATION_MODIFIER", 857, 866], ["endotracheal intubation", "OBSERVATION", 907, 930]]], ["The benefits of NIPPV are much less clear in patients with mild to moderate COPD exacerbations.", [["COPD", "DISEASE", 76, 80], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["NIPPV", "TREATMENT", 16, 21], ["mild to moderate COPD exacerbations", "PROBLEM", 59, 94], ["NIPPV", "OBSERVATION", 16, 21], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["COPD", "OBSERVATION", 76, 80]]], ["58 What mode of NIPPV should be selected for patients with acute exacerbations of COPD?What are the main benefits of NIPPV in AECOPD?Clinicians have several choices of mode when initiating NIPPV in patients with acute exacerbation of COPD.", [["COPD", "DISEASE", 82, 86], ["AECOPD", "DISEASE", 126, 132], ["COPD", "DISEASE", 234, 238], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 198, 206], ["NIPPV", "TREATMENT", 16, 21], ["acute exacerbations", "PROBLEM", 59, 78], ["COPD", "PROBLEM", 82, 86], ["NIPPV", "TREATMENT", 117, 122], ["AECOPD", "PROBLEM", 126, 132], ["NIPPV", "TREATMENT", 189, 194], ["acute exacerbation", "PROBLEM", 212, 230], ["COPD", "PROBLEM", 234, 238], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["exacerbations", "OBSERVATION", 65, 78], ["COPD", "OBSERVATION", 82, 86], ["AECOPD", "OBSERVATION", 126, 132], ["acute", "OBSERVATION_MODIFIER", 212, 217], ["exacerbation", "OBSERVATION", 218, 230], ["COPD", "OBSERVATION", 234, 238]]], ["Assist control, pressure support ventilation, and proportional assist ventilation have all been shown to improve respiratory physiology and decrease respiratory distress in patients with acute exacerbations of COPD.", [["respiratory", "ANATOMY", 113, 124], ["respiratory", "ANATOMY", 149, 160], ["respiratory distress", "DISEASE", 149, 169], ["COPD", "DISEASE", 210, 214], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["Assist control", "TREATMENT", 0, 14], ["pressure support ventilation", "TREATMENT", 16, 44], ["proportional assist ventilation", "TREATMENT", 50, 81], ["respiratory physiology", "PROBLEM", 113, 135], ["decrease respiratory distress", "PROBLEM", 140, 169], ["acute exacerbations", "PROBLEM", 187, 206], ["COPD", "PROBLEM", 210, 214], ["decrease", "OBSERVATION_MODIFIER", 140, 148], ["respiratory distress", "OBSERVATION", 149, 169], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["exacerbations", "OBSERVATION", 193, 206], ["COPD", "OBSERVATION", 210, 214]]], ["59, 60 Bilevel positive airway pressure provides a higher inspiratory pressure coupled with a lower expiratory pressure, and is generally well tolerated by patients.", [["airway", "ANATOMY", 24, 30], ["airway", "MULTI-TISSUE_STRUCTURE", 24, 30], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["Bilevel positive airway pressure", "TEST", 7, 39], ["a higher inspiratory pressure", "TREATMENT", 49, 78], ["a lower expiratory pressure", "TREATMENT", 92, 119], ["airway pressure", "OBSERVATION", 24, 39], ["inspiratory pressure", "OBSERVATION", 58, 78], ["lower", "OBSERVATION_MODIFIER", 94, 99], ["expiratory pressure", "OBSERVATION", 100, 119]]], ["Very little evidence supports one mode of NIPPV over another.How should patients initiated on NIPPV for acute exacerbations of COPD be monitored?After initiation of NIPPV, patients should be monitored closely for signs of clinical improvement.", [["COPD", "DISEASE", 127, 131], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 172, 180], ["NIPPV", "TREATMENT", 42, 47], ["NIPPV", "TREATMENT", 94, 99], ["acute exacerbations", "PROBLEM", 104, 123], ["COPD", "PROBLEM", 127, 131], ["NIPPV", "TREATMENT", 165, 170], ["COPD", "OBSERVATION", 127, 131]]], ["A repeat arterial blood gas analysis should be obtained within 2 hours of initiation, as improvement of pH and PaCO 2 after 2 hours predicts success of NIPPV.", [["arterial blood", "ANATOMY", 9, 23], ["PaCO 2", "CHEMICAL", 111, 117], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 9, 23], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 111, 117], ["A repeat arterial blood gas analysis", "TEST", 0, 36], ["pH", "TEST", 104, 106], ["PaCO", "TEST", 111, 115], ["NIPPV", "TREATMENT", 152, 157]]], ["61, 62 In certain patients, NIPPV is poorly tolerated or can worsen respiratory distress, and such patients must be identified early to facilitate an expeditious transition to alternative modes of ventilation.What are the common cardiac comorbidities in patients with AECOPD?Patients with COPD have a high incidence of cardiovascular disease.", [["respiratory", "ANATOMY", 68, 79], ["cardiac", "ANATOMY", 229, 236], ["cardiovascular", "ANATOMY", 319, 333], ["respiratory distress", "DISEASE", 68, 88], ["cardiac comorbidities", "DISEASE", 229, 250], ["AECOPD", "DISEASE", 268, 274], ["COPD", "DISEASE", 289, 293], ["cardiovascular disease", "DISEASE", 319, 341], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 99, 107], ["cardiac", "ORGAN", 229, 236], ["patients", "ORGANISM", 254, 262], ["Patients", "ORGANISM", 275, 283], ["cardiovascular", "ANATOMICAL_SYSTEM", 319, 333], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 254, 262], ["Patients", "SPECIES", 275, 283], ["NIPPV", "TREATMENT", 28, 33], ["respiratory distress", "PROBLEM", 68, 88], ["alternative modes of ventilation", "TREATMENT", 176, 208], ["the common cardiac comorbidities", "PROBLEM", 218, 250], ["AECOPD", "PROBLEM", 268, 274], ["COPD", "PROBLEM", 289, 293], ["cardiovascular disease", "PROBLEM", 319, 341], ["cardiac", "ANATOMY", 229, 236], ["comorbidities", "OBSERVATION", 237, 250], ["AECOPD", "OBSERVATION", 268, 274], ["COPD", "OBSERVATION", 289, 293], ["high", "OBSERVATION_MODIFIER", 301, 305], ["cardiovascular", "ANATOMY", 319, 333], ["disease", "OBSERVATION", 334, 341]]], ["Coronary artery disease is common in this population, probably related to the shared risk factor of tobacco smoking; one study of a population of patients with COPD found cardiovascular disease was a more common cause than lung disease of hospitalization and death.", [["Coronary artery", "ANATOMY", 0, 15], ["cardiovascular", "ANATOMY", 171, 185], ["lung", "ANATOMY", 223, 227], ["Coronary artery disease", "DISEASE", 0, 23], ["COPD", "DISEASE", 160, 164], ["cardiovascular disease", "DISEASE", 171, 193], ["lung disease", "DISEASE", 223, 235], ["death", "DISEASE", 259, 264], ["Coronary artery", "MULTI-TISSUE_STRUCTURE", 0, 15], ["tobacco", "ORGANISM", 100, 107], ["patients", "ORGANISM", 146, 154], ["cardiovascular", "ANATOMICAL_SYSTEM", 171, 185], ["lung", "ORGAN", 223, 227], ["patients", "SPECIES", 146, 154], ["tobacco", "SPECIES", 100, 107], ["Coronary artery disease", "PROBLEM", 0, 23], ["COPD", "PROBLEM", 160, 164], ["cardiovascular disease", "PROBLEM", 171, 193], ["lung disease of hospitalization", "PROBLEM", 223, 254], ["death", "PROBLEM", 259, 264], ["artery", "ANATOMY", 9, 15], ["disease", "OBSERVATION", 16, 23], ["COPD", "OBSERVATION", 160, 164], ["cardiovascular", "ANATOMY", 171, 185], ["disease", "OBSERVATION", 186, 193], ["lung", "ANATOMY", 223, 227], ["disease", "OBSERVATION", 228, 235]]], ["63 Supraventricular arrhythmias (including atrial fibrillation and multifocal atrial tachycardia) are also common in patients with AECOPD, possibly related to the hypercarbia, hypoxemia, and hemodynamic changes that occur in this condition, or as a side effect of medications used its the treatment, such as methylxanthine medications (eg, theophylline) and glucocorticoids.", [["Supraventricular", "ANATOMY", 3, 19], ["atrial", "ANATOMY", 43, 49], ["atrial", "ANATOMY", 78, 84], ["Supraventricular arrhythmias", "DISEASE", 3, 31], ["atrial fibrillation", "DISEASE", 43, 62], ["atrial tachycardia", "DISEASE", 78, 96], ["AECOPD", "DISEASE", 131, 137], ["hypercarbia", "DISEASE", 163, 174], ["hypoxemia", "DISEASE", 176, 185], ["methylxanthine", "CHEMICAL", 308, 322], ["theophylline", "CHEMICAL", 340, 352], ["glucocorticoids", "CHEMICAL", 358, 373], ["methylxanthine", "CHEMICAL", 308, 322], ["theophylline", "CHEMICAL", 340, 352], ["atrial", "MULTI-TISSUE_STRUCTURE", 43, 49], ["atrial", "ORGAN", 78, 84], ["patients", "ORGANISM", 117, 125], ["methylxanthine", "SIMPLE_CHEMICAL", 308, 322], ["theophylline", "SIMPLE_CHEMICAL", 340, 352], ["glucocorticoids", "SIMPLE_CHEMICAL", 358, 373], ["patients", "SPECIES", 117, 125], ["Supraventricular arrhythmias", "PROBLEM", 3, 31], ["atrial fibrillation", "PROBLEM", 43, 62], ["multifocal atrial tachycardia", "PROBLEM", 67, 96], ["AECOPD", "PROBLEM", 131, 137], ["the hypercarbia", "PROBLEM", 159, 174], ["hypoxemia", "PROBLEM", 176, 185], ["hemodynamic changes", "PROBLEM", 191, 210], ["medications", "TREATMENT", 264, 275], ["the treatment", "TREATMENT", 285, 298], ["methylxanthine medications (eg", "TREATMENT", 308, 338], ["theophylline)", "TREATMENT", 340, 353], ["glucocorticoids", "TREATMENT", 358, 373], ["Supraventricular arrhythmias", "OBSERVATION", 3, 31], ["atrial", "ANATOMY", 43, 49], ["fibrillation", "OBSERVATION", 50, 62], ["multifocal", "OBSERVATION_MODIFIER", 67, 77], ["atrial tachycardia", "OBSERVATION", 78, 96], ["AECOPD", "OBSERVATION", 131, 137], ["possibly related to", "UNCERTAINTY", 139, 158], ["hypercarbia", "OBSERVATION", 163, 174], ["hypoxemia", "OBSERVATION", 176, 185], ["hemodynamic changes", "OBSERVATION", 191, 210]]], ["64, 65 Because of these associations, hospitalists often must simultaneously manage AECOPD and acute cardiovascular diseases.What are the key treatment considerations when managing concomitant cardiovascular disease in patients with acute exacerbations of COPD?When managing AECOPD in the hospital, the hospitalist must be aware of cardiovascular comorbidities, including underlying coronary artery disease, acute cardiac ischemia, and atrial arrhythmias.", [["cardiovascular", "ANATOMY", 101, 115], ["cardiovascular", "ANATOMY", 193, 207], ["cardiovascular", "ANATOMY", 332, 346], ["coronary artery", "ANATOMY", 383, 398], ["cardiac", "ANATOMY", 414, 421], ["atrial", "ANATOMY", 436, 442], ["AECOPD", "DISEASE", 84, 90], ["acute cardiovascular diseases", "DISEASE", 95, 124], ["cardiovascular disease", "DISEASE", 193, 215], ["COPD", "DISEASE", 256, 260], ["AECOPD", "DISEASE", 275, 281], ["cardiovascular comorbidities", "DISEASE", 332, 360], ["coronary artery disease", "DISEASE", 383, 406], ["cardiac ischemia", "DISEASE", 414, 430], ["atrial arrhythmias", "DISEASE", 436, 454], ["cardiovascular", "ANATOMICAL_SYSTEM", 101, 115], ["cardiovascular", "ANATOMICAL_SYSTEM", 193, 207], ["patients", "ORGANISM", 219, 227], ["cardiovascular", "ANATOMICAL_SYSTEM", 332, 346], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 383, 398], ["cardiac", "ORGAN", 414, 421], ["atrial", "MULTI-TISSUE_STRUCTURE", 436, 442], ["patients", "SPECIES", 219, 227], ["AECOPD", "PROBLEM", 84, 90], ["acute cardiovascular diseases", "PROBLEM", 95, 124], ["concomitant cardiovascular disease", "PROBLEM", 181, 215], ["acute exacerbations", "PROBLEM", 233, 252], ["COPD", "PROBLEM", 256, 260], ["AECOPD", "PROBLEM", 275, 281], ["cardiovascular comorbidities", "PROBLEM", 332, 360], ["underlying coronary artery disease", "PROBLEM", 372, 406], ["acute cardiac ischemia", "PROBLEM", 408, 430], ["atrial arrhythmias", "PROBLEM", 436, 454], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["cardiovascular diseases", "OBSERVATION", 101, 124], ["cardiovascular", "ANATOMY", 193, 207], ["disease", "OBSERVATION", 208, 215], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["exacerbations", "OBSERVATION", 239, 252], ["COPD", "OBSERVATION", 256, 260], ["coronary artery", "ANATOMY", 383, 398], ["disease", "OBSERVATION", 399, 406], ["acute", "OBSERVATION_MODIFIER", 408, 413], ["cardiac", "ANATOMY", 414, 421], ["ischemia", "OBSERVATION", 422, 430], ["atrial", "ANATOMY", 436, 442], ["arrhythmias", "OBSERVATION", 443, 454]]], ["When acute heart and lung disease occur together, some special considerations arise.", [["heart", "ANATOMY", 11, 16], ["lung", "ANATOMY", 21, 25], ["acute heart and lung disease", "DISEASE", 5, 33], ["heart", "ORGAN", 11, 16], ["lung", "ORGAN", 21, 25], ["acute heart and lung disease", "PROBLEM", 5, 33], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["heart", "ANATOMY", 11, 16], ["lung", "ANATOMY", 21, 25], ["disease", "OBSERVATION", 26, 33]]], ["First, the urgency of controlling the patient's lung disease increases in the setting of concomitant cardiovascular disease.", [["lung", "ANATOMY", 48, 52], ["cardiovascular", "ANATOMY", 101, 115], ["lung disease", "DISEASE", 48, 60], ["cardiovascular disease", "DISEASE", 101, 123], ["patient", "ORGANISM", 38, 45], ["lung", "ORGAN", 48, 52], ["cardiovascular", "ANATOMICAL_SYSTEM", 101, 115], ["patient", "SPECIES", 38, 45], ["the patient's lung disease", "PROBLEM", 34, 60], ["concomitant cardiovascular disease", "PROBLEM", 89, 123], ["lung", "ANATOMY", 48, 52], ["disease", "OBSERVATION", 53, 60], ["concomitant", "OBSERVATION_MODIFIER", 89, 100], ["cardiovascular disease", "OBSERVATION", 101, 123]]], ["Second, the medications used for treatment may need to be altered when treating acute cardiac and pulmonary problems simultaneously.What are the key treatment considerations when managing concomitant cardiovascular disease in patients with acute exacerbations of COPD?In the case of coronary artery disease, attention to hypoxemia is critical in maximizing myocardial oxygen delivery.", [["cardiac", "ANATOMY", 86, 93], ["pulmonary", "ANATOMY", 98, 107], ["cardiovascular", "ANATOMY", 200, 214], ["coronary artery", "ANATOMY", 283, 298], ["myocardial", "ANATOMY", 357, 367], ["acute cardiac and pulmonary problems", "DISEASE", 80, 116], ["cardiovascular disease", "DISEASE", 200, 222], ["COPD", "DISEASE", 263, 267], ["coronary artery disease", "DISEASE", 283, 306], ["hypoxemia", "DISEASE", 321, 330], ["oxygen", "CHEMICAL", 368, 374], ["oxygen", "CHEMICAL", 368, 374], ["cardiac", "ORGAN", 86, 93], ["pulmonary", "ORGAN", 98, 107], ["cardiovascular", "ANATOMICAL_SYSTEM", 200, 214], ["patients", "ORGANISM", 226, 234], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 283, 298], ["myocardial", "MULTI-TISSUE_STRUCTURE", 357, 367], ["oxygen", "SIMPLE_CHEMICAL", 368, 374], ["patients", "SPECIES", 226, 234], ["the medications", "TREATMENT", 8, 23], ["treatment", "TREATMENT", 33, 42], ["acute cardiac and pulmonary problems", "PROBLEM", 80, 116], ["concomitant cardiovascular disease", "PROBLEM", 188, 222], ["acute exacerbations", "PROBLEM", 240, 259], ["COPD", "PROBLEM", 263, 267], ["coronary artery disease", "PROBLEM", 283, 306], ["hypoxemia", "PROBLEM", 321, 330], ["maximizing myocardial oxygen delivery", "TREATMENT", 346, 383], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["cardiac", "ANATOMY", 86, 93], ["pulmonary", "ANATOMY", 98, 107], ["problems", "OBSERVATION", 108, 116], ["cardiovascular", "ANATOMY", 200, 214], ["disease", "OBSERVATION", 215, 222], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["exacerbations", "OBSERVATION", 246, 259], ["COPD", "OBSERVATION", 263, 267], ["coronary artery", "ANATOMY", 283, 298], ["disease", "OBSERVATION", 299, 306], ["hypoxemia", "OBSERVATION", 321, 330], ["oxygen delivery", "OBSERVATION", 368, 383]]], ["Moreover, in the case of atrial arrhythmias, the reversal of hypoxemia and acidosis caused by the underlying lung disease may eliminate the arrhythmia altogether.What are the key treatment considerations when managing concomitant cardiovascular disease in patients with acute exacerbations of COPD?However, the treatment of atrial fibrillation or cardiac ischemia and the simultaneous treatment of AECOPD sometimes require the use of medications that have opposite effects, especially in the case of adrenergic and antiadrenergic medications.", [["atrial", "ANATOMY", 25, 31], ["lung", "ANATOMY", 109, 113], ["cardiovascular", "ANATOMY", 230, 244], ["atrial", "ANATOMY", 324, 330], ["cardiac", "ANATOMY", 347, 354], ["atrial arrhythmias", "DISEASE", 25, 43], ["hypoxemia", "DISEASE", 61, 70], ["acidosis", "DISEASE", 75, 83], ["lung disease", "DISEASE", 109, 121], ["arrhythmia", "DISEASE", 140, 150], ["cardiovascular disease", "DISEASE", 230, 252], ["COPD", "DISEASE", 293, 297], ["atrial fibrillation", "DISEASE", 324, 343], ["cardiac ischemia", "DISEASE", 347, 363], ["AECOPD", "DISEASE", 398, 404], ["atrial", "MULTI-TISSUE_STRUCTURE", 25, 31], ["lung", "ORGAN", 109, 113], ["cardiovascular", "ANATOMICAL_SYSTEM", 230, 244], ["patients", "ORGANISM", 256, 264], ["atrial", "MULTI-TISSUE_STRUCTURE", 324, 330], ["cardiac", "ORGAN", 347, 354], ["adrenergic", "SIMPLE_CHEMICAL", 500, 510], ["antiadrenergic", "SIMPLE_CHEMICAL", 515, 529], ["patients", "SPECIES", 256, 264], ["atrial arrhythmias", "PROBLEM", 25, 43], ["hypoxemia", "PROBLEM", 61, 70], ["acidosis", "PROBLEM", 75, 83], ["the underlying lung disease", "PROBLEM", 94, 121], ["the arrhythmia", "PROBLEM", 136, 150], ["concomitant cardiovascular disease", "PROBLEM", 218, 252], ["acute exacerbations", "PROBLEM", 270, 289], ["COPD", "PROBLEM", 293, 297], ["atrial fibrillation", "PROBLEM", 324, 343], ["cardiac ischemia", "PROBLEM", 347, 363], ["the simultaneous treatment", "TREATMENT", 368, 394], ["AECOPD", "PROBLEM", 398, 404], ["medications", "TREATMENT", 434, 445], ["adrenergic and antiadrenergic medications", "TREATMENT", 500, 541], ["atrial", "ANATOMY", 25, 31], ["arrhythmias", "OBSERVATION", 32, 43], ["hypoxemia", "OBSERVATION", 61, 70], ["acidosis", "OBSERVATION", 75, 83], ["lung", "ANATOMY", 109, 113], ["disease", "OBSERVATION", 114, 121], ["cardiovascular", "ANATOMY", 230, 244], ["disease", "OBSERVATION", 245, 252], ["acute", "OBSERVATION_MODIFIER", 270, 275], ["exacerbations", "OBSERVATION", 276, 289], ["COPD", "OBSERVATION", 293, 297], ["atrial", "ANATOMY", 324, 330], ["fibrillation", "OBSERVATION", 331, 343], ["cardiac", "ANATOMY", 347, 354], ["ischemia", "OBSERVATION", 355, 363], ["AECOPD", "OBSERVATION", 398, 404]]], ["Specifically, b-blockers are often used to control the heart rate in atrial fibrillation or myocardial O 2 demand in acute cardiac ischemia, whereas b-agonists are typically used to combat bronchospasm in AECOPD.", [["heart", "ANATOMY", 55, 60], ["atrial", "ANATOMY", 69, 75], ["myocardial", "ANATOMY", 92, 102], ["cardiac", "ANATOMY", 123, 130], ["atrial fibrillation", "DISEASE", 69, 88], ["cardiac ischemia", "DISEASE", 123, 139], ["bronchospasm", "DISEASE", 189, 201], ["AECOPD", "DISEASE", 205, 211], ["O 2", "CHEMICAL", 103, 106], ["heart", "ORGAN", 55, 60], ["atrial", "MULTI-TISSUE_STRUCTURE", 69, 75], ["myocardial", "MULTI-TISSUE_STRUCTURE", 92, 102], ["cardiac", "ORGAN", 123, 130], ["b-blockers", "TREATMENT", 14, 24], ["the heart rate", "TEST", 51, 65], ["atrial fibrillation", "PROBLEM", 69, 88], ["myocardial O 2 demand", "PROBLEM", 92, 113], ["acute cardiac ischemia", "PROBLEM", 117, 139], ["bronchospasm", "PROBLEM", 189, 201], ["AECOPD", "PROBLEM", 205, 211], ["heart", "ANATOMY", 55, 60], ["atrial", "ANATOMY", 69, 75], ["fibrillation", "OBSERVATION", 76, 88], ["myocardial", "ANATOMY", 92, 102], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["cardiac", "ANATOMY", 123, 130], ["ischemia", "OBSERVATION", 131, 139], ["AECOPD", "OBSERVATION", 205, 211]]], ["Therefore, a hospitalist may encounter situations whereby both a b-agonist and a b-antagonist might be indicated, although seemingly contradictory.What are the key treatment considerations when managing concomitant cardiovascular disease in patients with acute exacerbations of COPD?In theory, the effects of b-agonists might be undesirable in the setting of cardiac disease.", [["cardiovascular", "ANATOMY", 215, 229], ["cardiac", "ANATOMY", 359, 366], ["cardiovascular disease", "DISEASE", 215, 237], ["COPD", "DISEASE", 278, 282], ["cardiac disease", "DISEASE", 359, 374], ["cardiovascular", "ANATOMICAL_SYSTEM", 215, 229], ["patients", "ORGANISM", 241, 249], ["b-agonists", "SIMPLE_CHEMICAL", 309, 319], ["cardiac", "ORGAN", 359, 366], ["patients", "SPECIES", 241, 249], ["concomitant cardiovascular disease", "PROBLEM", 203, 237], ["acute exacerbations", "PROBLEM", 255, 274], ["COPD", "PROBLEM", 278, 282], ["b-agonists", "PROBLEM", 309, 319], ["cardiac disease", "PROBLEM", 359, 374], ["cardiovascular", "ANATOMY", 215, 229], ["disease", "OBSERVATION", 230, 237], ["acute", "OBSERVATION_MODIFIER", 255, 260], ["exacerbations", "OBSERVATION", 261, 274], ["COPD", "OBSERVATION", 278, 282], ["cardiac", "ANATOMY", 359, 366], ["disease", "OBSERVATION", 367, 374]]], ["Despite their relative selectivity for b2 receptors, b2-agonists do cause tachycardia, especially when used at high doses.", [["tachycardia", "DISEASE", 74, 85], ["b2 receptors", "GENE_OR_GENE_PRODUCT", 39, 51], ["b2-agonists", "GENE_OR_GENE_PRODUCT", 53, 64], ["b2 receptors", "PROTEIN", 39, 51], ["b2", "PROTEIN", 53, 55], ["b2 receptors", "TREATMENT", 39, 51], ["b2-agonists", "TREATMENT", 53, 64], ["tachycardia", "PROBLEM", 74, 85]]], ["66 However, a significant association with arrhythmias other than sinus tachycardia has not been clearly demonstrated.", [["sinus", "ANATOMY", 66, 71], ["arrhythmias", "DISEASE", 43, 54], ["sinus tachycardia", "DISEASE", 66, 83], ["sinus", "MULTI-TISSUE_STRUCTURE", 66, 71], ["arrhythmias", "PROBLEM", 43, 54], ["sinus tachycardia", "PROBLEM", 66, 83]]], ["Clinicians have to balance the risks of tachycardia against the benefits of b-agonist treatment in the acute setting, and there is little evidence to guide the decision.", [["tachycardia", "DISEASE", 40, 51], ["tachycardia", "PROBLEM", 40, 51], ["b-agonist treatment", "TREATMENT", 76, 95]]], ["It may be prudent to use non-b-agonist bronchodilators (eg, anticholinergics) preferentially in situations where tachycardia and cardiac ischemia are major concerns.", [["cardiac", "ANATOMY", 129, 136], ["tachycardia", "DISEASE", 113, 124], ["cardiac ischemia", "DISEASE", 129, 145], ["cardiac", "ORGAN", 129, 136], ["non-b-agonist bronchodilators", "TREATMENT", 25, 54], ["anticholinergics", "TREATMENT", 60, 76], ["tachycardia", "PROBLEM", 113, 124], ["cardiac ischemia", "PROBLEM", 129, 145], ["cardiac", "ANATOMY", 129, 136], ["ischemia", "OBSERVATION", 137, 145]]], ["The 2006 American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of atrial fibrillation recommend that b-agonists be avoided in patients with bronchospastic illness if they develop atrial fibrillation.", [["atrial", "ANATOMY", 110, 116], ["atrial", "ANATOMY", 223, 229], ["atrial fibrillation", "DISEASE", 110, 129], ["bronchospastic illness", "DISEASE", 184, 206], ["atrial fibrillation", "DISEASE", 223, 242], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["ACC/AHA)", "TREATMENT", 68, 76], ["the management", "TREATMENT", 92, 106], ["atrial fibrillation", "PROBLEM", 110, 129], ["b-agonists", "TREATMENT", 145, 155], ["bronchospastic illness", "PROBLEM", 184, 206], ["atrial fibrillation", "PROBLEM", 223, 242], ["Heart", "ANATOMY", 49, 54], ["atrial", "ANATOMY", 110, 116], ["fibrillation", "OBSERVATION", 117, 129], ["atrial", "ANATOMY", 223, 229], ["fibrillation", "OBSERVATION", 230, 242]]], ["67 However, there is insufficient evidence of harm from b-agonist therapy in this setting to preclude its use, if it is thought to be essential to a patient's care.Can b-blockers be safely used in patients with AECOPD?Nonselective b-blockers do cause significant bronchoconstriction, but this pulmonary effect is not seen in b1-selective b-blockers.", [["pulmonary", "ANATOMY", 293, 302], ["AECOPD", "DISEASE", 211, 217], ["b-agonist", "SIMPLE_CHEMICAL", 56, 65], ["patient", "ORGANISM", 149, 156], ["b-blockers", "SIMPLE_CHEMICAL", 168, 178], ["patients", "ORGANISM", 197, 205], ["b-blockers", "SIMPLE_CHEMICAL", 231, 241], ["pulmonary", "ORGAN", 293, 302], ["b1-selective b-blockers", "SIMPLE_CHEMICAL", 325, 348], ["patient", "SPECIES", 149, 156], ["patients", "SPECIES", 197, 205], ["b-agonist therapy", "TREATMENT", 56, 73], ["a patient's care", "TREATMENT", 147, 163], ["b-blockers", "TREATMENT", 168, 178], ["AECOPD", "PROBLEM", 211, 217], ["Nonselective b-blockers", "TREATMENT", 218, 241], ["significant bronchoconstriction", "PROBLEM", 251, 282], ["this pulmonary effect", "PROBLEM", 288, 309], ["b1-selective b-blockers", "TREATMENT", 325, 348], ["insufficient evidence of", "UNCERTAINTY", 21, 45], ["harm", "OBSERVATION", 46, 50], ["AECOPD", "OBSERVATION", 211, 217], ["significant", "OBSERVATION_MODIFIER", 251, 262], ["bronchoconstriction", "OBSERVATION", 263, 282], ["pulmonary", "ANATOMY", 293, 302]]], ["68 One meta-analysis examined 22 trials in which \"cardioselective\" (b1-selective) b-blockers were prescribed to patients with COPD, 69 and examined effects on spirometric measurements and symptoms, and the effect of bronchodilator medications when patients were given b-blockers.", [["COPD", "DISEASE", 126, 130], ["b1-selective) b-blockers", "SIMPLE_CHEMICAL", 68, 92], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 248, 256], ["b1-selective) b-blockers", "TREATMENT", 68, 92], ["COPD", "PROBLEM", 126, 130], ["spirometric measurements", "TEST", 159, 183], ["symptoms", "PROBLEM", 188, 196], ["bronchodilator medications", "TREATMENT", 216, 242], ["b-blockers", "TREATMENT", 268, 278]]], ["The study concluded that there is no effect on any of the studied parameters, and that b-blocker medications appear to be entirely safe in in patients with COPD.", [["COPD", "DISEASE", 156, 160], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["The study", "TEST", 0, 9], ["the studied parameters", "TEST", 54, 76], ["b-blocker medications", "TREATMENT", 87, 108], ["COPD", "PROBLEM", 156, 160], ["no", "UNCERTAINTY", 34, 36], ["COPD", "OBSERVATION", 156, 160]]], ["Of note, the patients in these studies all had COPD, and some had severe disease.", [["COPD", "DISEASE", 47, 51], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["these studies", "TEST", 25, 38], ["COPD", "PROBLEM", 47, 51], ["severe disease", "PROBLEM", 66, 80], ["COPD", "OBSERVATION", 47, 51], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["disease", "OBSERVATION", 73, 80]]], ["However, none of the studies targeted patients with AECOPD.Can b-blockers be safely used in patients with AECOPD?This meta-analysis offers strong evidence that the pulmonary effects of b1-selective b-blockers are minimal, and that the common practice of withholding these medications from patients with stable COPD is unwarranted.Can b-blockers be safely used in patients with AECOPD?In addition, 2 large observational studies have suggested that b-blockers may even be beneficial for patients with COPD.", [["pulmonary", "ANATOMY", 164, 173], ["AECOPD", "DISEASE", 52, 58], ["AECOPD", "DISEASE", 106, 112], ["COPD", "DISEASE", 310, 314], ["AECOPD", "DISEASE", 377, 383], ["COPD", "DISEASE", 499, 503], ["patients", "ORGANISM", 38, 46], ["b-blockers", "SIMPLE_CHEMICAL", 63, 73], ["patients", "ORGANISM", 92, 100], ["pulmonary", "ORGAN", 164, 173], ["b1-selective b-blockers", "SIMPLE_CHEMICAL", 185, 208], ["patients", "ORGANISM", 289, 297], ["b-blockers", "SIMPLE_CHEMICAL", 334, 344], ["patients", "ORGANISM", 363, 371], ["patients", "ORGANISM", 485, 493], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 289, 297], ["patients", "SPECIES", 363, 371], ["patients", "SPECIES", 485, 493], ["the studies", "TEST", 17, 28], ["AECOPD", "PROBLEM", 52, 58], ["b-blockers", "TREATMENT", 63, 73], ["AECOPD", "PROBLEM", 106, 112], ["This meta-analysis", "TEST", 113, 131], ["the pulmonary effects", "PROBLEM", 160, 181], ["b1-selective b-blockers", "TREATMENT", 185, 208], ["these medications", "TREATMENT", 266, 283], ["stable COPD", "PROBLEM", 303, 314], ["b-blockers", "TREATMENT", 334, 344], ["AECOPD", "PROBLEM", 377, 383], ["2 large observational studies", "TEST", 397, 426], ["b-blockers", "TREATMENT", 447, 457], ["COPD", "PROBLEM", 499, 503], ["AECOPD", "OBSERVATION", 52, 58], ["AECOPD", "OBSERVATION", 106, 112], ["pulmonary", "ANATOMY", 164, 173], ["minimal", "OBSERVATION_MODIFIER", 213, 220], ["stable", "OBSERVATION_MODIFIER", 303, 309], ["COPD", "OBSERVATION", 310, 314], ["AECOPD", "OBSERVATION", 377, 383], ["COPD", "OBSERVATION", 499, 503]]], ["70, 71 The first of these examined a large population of COPD patients, and demonstrated a lower risk of death and acute exacerbation of COPD associated with the use of b-blockers.", [["COPD", "DISEASE", 57, 61], ["death", "DISEASE", 105, 110], ["COPD", "DISEASE", 137, 141], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["COPD", "PROBLEM", 57, 61], ["death", "PROBLEM", 105, 110], ["acute exacerbation", "PROBLEM", 115, 133], ["COPD", "PROBLEM", 137, 141], ["b-blockers", "TREATMENT", 169, 179], ["large", "OBSERVATION_MODIFIER", 37, 42], ["population", "OBSERVATION_MODIFIER", 43, 53], ["COPD", "OBSERVATION", 57, 61], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["exacerbation", "OBSERVATION", 121, 133], ["COPD", "OBSERVATION", 137, 141]]], ["The second study examined COPD patients during a hospitalization for a COPD exacerbation, and demonstrated a lower risk of death associated with the use of b-blockers during that hospitalization.", [["COPD", "DISEASE", 26, 30], ["COPD", "DISEASE", 71, 75], ["death", "DISEASE", 123, 128], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["The second study", "TEST", 0, 16], ["COPD", "PROBLEM", 26, 30], ["a COPD exacerbation", "PROBLEM", 69, 88], ["death", "PROBLEM", 123, 128], ["b-blockers", "TREATMENT", 156, 166], ["COPD", "OBSERVATION", 26, 30], ["COPD", "OBSERVATION", 71, 75]]], ["Although these studies challenge the conventional wisdom that b-blockers are to be Chronic Obstructive Pulmonary Disease e181 avoided in COPD, they should be interpreted with caution.", [["Chronic Obstructive Pulmonary Disease", "DISEASE", 83, 120], ["COPD", "DISEASE", 137, 141], ["these studies", "TEST", 9, 22], ["b-blockers", "TREATMENT", 62, 72], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 83, 120], ["COPD", "PROBLEM", 137, 141], ["Chronic", "OBSERVATION_MODIFIER", 83, 90], ["Obstructive", "OBSERVATION_MODIFIER", 91, 102], ["Pulmonary", "ANATOMY", 103, 112], ["Disease", "OBSERVATION", 113, 120], ["COPD", "OBSERVATION", 137, 141]]], ["These observational studies are almost certainly tainted by selection bias (eg, with patients who exhibit the most severe bronchoconstriction being the least likely to be treated with a b-blocker).", [["bronchoconstriction", "DISEASE", 122, 141], ["patients", "ORGANISM", 85, 93], ["b-blocker", "SIMPLE_CHEMICAL", 186, 195], ["patients", "SPECIES", 85, 93], ["These observational studies", "TEST", 0, 27], ["the most severe bronchoconstriction", "PROBLEM", 106, 141], ["a b-blocker", "TREATMENT", 184, 195]]], ["Although both of these studies used statistical methods to correct for this bias, these methods are imperfect, and any conclusions based on them must acknowledge this methodologic limitation.Can b-blockers be safely used in patients with AECOPD?The available studies do not clearly delineate how an acutely ill patient with active bronchoconstriction might react to the initiation of a b-blocker medication.", [["AECOPD", "DISEASE", 238, 244], ["acutely ill", "DISEASE", 299, 310], ["b-blockers", "SIMPLE_CHEMICAL", 195, 205], ["patients", "ORGANISM", 224, 232], ["patient", "ORGANISM", 311, 318], ["patients", "SPECIES", 224, 232], ["patient", "SPECIES", 311, 318], ["these studies", "TEST", 17, 30], ["this bias", "PROBLEM", 71, 80], ["b-blockers", "TREATMENT", 195, 205], ["AECOPD", "PROBLEM", 238, 244], ["The available studies", "TEST", 245, 266], ["active bronchoconstriction", "PROBLEM", 324, 350], ["a b-blocker medication", "TREATMENT", 384, 406], ["AECOPD", "OBSERVATION", 238, 244]]], ["It may therefore be prudent to use alternative medications (eg, nondihydropyridine calcium-channel blockers or digoxin) to control heart rate in the setting of acute bronchoconstriction, if there is no strong indication for a b-blocker medication.", [["heart", "ANATOMY", 131, 136], ["calcium", "CHEMICAL", 83, 90], ["digoxin", "CHEMICAL", 111, 118], ["nondihydropyridine", "CHEMICAL", 64, 82], ["calcium", "CHEMICAL", 83, 90], ["digoxin", "CHEMICAL", 111, 118], ["nondihydropyridine calcium-channel blockers", "SIMPLE_CHEMICAL", 64, 107], ["digoxin", "SIMPLE_CHEMICAL", 111, 118], ["heart", "ORGAN", 131, 136], ["alternative medications", "TREATMENT", 35, 58], ["eg", "TREATMENT", 60, 62], ["nondihydropyridine calcium", "TREATMENT", 64, 90], ["channel blockers", "TREATMENT", 91, 107], ["digoxin", "TREATMENT", 111, 118], ["heart rate", "TEST", 131, 141], ["acute bronchoconstriction", "PROBLEM", 160, 185], ["a b-blocker medication", "TREATMENT", 224, 246], ["heart", "ANATOMY", 131, 136], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["bronchoconstriction", "OBSERVATION", 166, 185]]], ["The ACC/ AHA 2006 guidelines for the management of atrial fibrillation recommend avoiding b-blockers in the treatment of patients with atrial fibrillation who also have bronchospastic lung disease.", [["atrial", "ANATOMY", 51, 57], ["atrial", "ANATOMY", 135, 141], ["lung", "ANATOMY", 184, 188], ["atrial fibrillation", "DISEASE", 51, 70], ["atrial fibrillation", "DISEASE", 135, 154], ["bronchospastic lung disease", "DISEASE", 169, 196], ["atrial", "MULTI-TISSUE_STRUCTURE", 51, 57], ["patients", "ORGANISM", 121, 129], ["lung", "ORGAN", 184, 188], ["patients", "SPECIES", 121, 129], ["the management", "TREATMENT", 33, 47], ["atrial fibrillation", "PROBLEM", 51, 70], ["b-blockers", "TREATMENT", 90, 100], ["the treatment", "TREATMENT", 104, 117], ["atrial fibrillation", "PROBLEM", 135, 154], ["bronchospastic lung disease", "PROBLEM", 169, 196], ["atrial", "ANATOMY", 51, 57], ["fibrillation", "OBSERVATION", 58, 70], ["atrial", "ANATOMY", 135, 141], ["fibrillation", "OBSERVATION", 142, 154], ["bronchospastic", "OBSERVATION_MODIFIER", 169, 183], ["lung", "ANATOMY", 184, 188], ["disease", "OBSERVATION", 189, 196]]], ["67 However, if there is a strong indication for a b-blocker medication (eg, cardiac ischemia), or if alternative medications are not providing the desired effect, it is appropriate to prescribe b1-selective b-blockers, even in the face of acute bronchoconstriction.Can b-blockers be safely used in patients with AECOPD?Methylxanthine medications (eg, theophylline, aminophylline) should also be avoided in patients with atrial arrhythmias, as they are known precipitants of these arrhythmias.Is multifocal atrial tachycardia associated with COPD?Multifocal atrial tachycardia (MAT) is an arrhythmia that appears to be secondary to abnormal automatic or triggered atrial activity.", [["cardiac", "ANATOMY", 76, 83], ["atrial", "ANATOMY", 420, 426], ["atrial", "ANATOMY", 506, 512], ["atrial", "ANATOMY", 557, 563], ["atrial", "ANATOMY", 663, 669], ["cardiac ischemia", "DISEASE", 76, 92], ["AECOPD", "DISEASE", 312, 318], ["Methylxanthine", "CHEMICAL", 319, 333], ["theophylline", "CHEMICAL", 351, 363], ["aminophylline", "CHEMICAL", 365, 378], ["atrial arrhythmias", "DISEASE", 420, 438], ["arrhythmias", "DISEASE", 480, 491], ["atrial tachycardia", "DISEASE", 506, 524], ["COPD", "DISEASE", 541, 545], ["atrial tachycardia", "DISEASE", 557, 575], ["arrhythmia", "DISEASE", 588, 598], ["Methylxanthine", "CHEMICAL", 319, 333], ["theophylline", "CHEMICAL", 351, 363], ["aminophylline", "CHEMICAL", 365, 378], ["cardiac", "ORGAN", 76, 83], ["b1-selective b-blockers", "SIMPLE_CHEMICAL", 194, 217], ["b-blockers", "SIMPLE_CHEMICAL", 269, 279], ["patients", "ORGANISM", 298, 306], ["Methylxanthine", "SIMPLE_CHEMICAL", 319, 333], ["theophylline", "SIMPLE_CHEMICAL", 351, 363], ["aminophylline", "SIMPLE_CHEMICAL", 365, 378], ["patients", "ORGANISM", 406, 414], ["atrial", "MULTI-TISSUE_STRUCTURE", 420, 426], ["atrial", "MULTI-TISSUE_STRUCTURE", 506, 512], ["atrial", "MULTI-TISSUE_STRUCTURE", 557, 563], ["atrial", "MULTI-TISSUE_STRUCTURE", 663, 669], ["patients", "SPECIES", 298, 306], ["patients", "SPECIES", 406, 414], ["a b-blocker medication", "TREATMENT", 48, 70], ["cardiac ischemia", "PROBLEM", 76, 92], ["alternative medications", "TREATMENT", 101, 124], ["b1-selective b-blockers", "TREATMENT", 194, 217], ["acute bronchoconstriction", "PROBLEM", 239, 264], ["b-blockers", "TREATMENT", 269, 279], ["AECOPD", "PROBLEM", 312, 318], ["Methylxanthine medications", "TREATMENT", 319, 345], ["theophylline", "TREATMENT", 351, 363], ["aminophylline)", "TREATMENT", 365, 379], ["atrial arrhythmias", "PROBLEM", 420, 438], ["these arrhythmias", "PROBLEM", 474, 491], ["multifocal atrial tachycardia", "PROBLEM", 495, 524], ["COPD", "PROBLEM", 541, 545], ["Multifocal atrial tachycardia", "PROBLEM", 546, 575], ["an arrhythmia", "PROBLEM", 585, 598], ["abnormal automatic or triggered atrial activity", "PROBLEM", 631, 678], ["cardiac", "ANATOMY", 76, 83], ["ischemia", "OBSERVATION", 84, 92], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["bronchoconstriction", "OBSERVATION", 245, 264], ["AECOPD", "OBSERVATION", 312, 318], ["atrial", "ANATOMY", 420, 426], ["arrhythmias", "OBSERVATION", 427, 438], ["multifocal", "OBSERVATION_MODIFIER", 495, 505], ["atrial", "ANATOMY", 506, 512], ["tachycardia", "OBSERVATION", 513, 524], ["COPD", "OBSERVATION", 541, 545], ["atrial", "ANATOMY", 557, 563], ["tachycardia", "OBSERVATION", 564, 575], ["arrhythmia", "OBSERVATION", 588, 598], ["appears to be", "UNCERTAINTY", 604, 617], ["abnormal", "OBSERVATION_MODIFIER", 631, 639], ["automatic", "OBSERVATION", 640, 649], ["atrial activity", "OBSERVATION", 663, 678]]], ["The rhythm is recognized when 3 or more distinct p-wave morphologies can be observed on an electrocardiogram demonstrating a ventricular rate of greater than 100 beats per minute.", [["ventricular", "ANATOMY", 125, 136], ["ventricular", "MULTI-TISSUE_STRUCTURE", 125, 136], ["an electrocardiogram", "TEST", 88, 108], ["a ventricular rate", "TEST", 123, 141]]], ["72, 73 MAT is much less common than atrial fibrillation, but is more closely associated with COPD.", [["atrial", "ANATOMY", 36, 42], ["atrial fibrillation", "DISEASE", 36, 55], ["COPD", "DISEASE", 93, 97], ["atrial fibrillation", "PROBLEM", 36, 55], ["COPD", "PROBLEM", 93, 97], ["atrial", "ANATOMY", 36, 42], ["fibrillation", "OBSERVATION", 43, 55], ["COPD", "OBSERVATION", 93, 97]]], ["72, 73 Most patients with MAT have significant underlying lung disease, and nearly 20% of patients with acute respiratory failure will demonstrate this arrhythmia.", [["lung", "ANATOMY", 58, 62], ["respiratory", "ANATOMY", 110, 121], ["lung disease", "DISEASE", 58, 70], ["acute respiratory failure", "DISEASE", 104, 129], ["arrhythmia", "DISEASE", 152, 162], ["patients", "ORGANISM", 12, 20], ["lung", "ORGAN", 58, 62], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 90, 98], ["significant underlying lung disease", "PROBLEM", 35, 70], ["acute respiratory failure", "PROBLEM", 104, 129], ["this arrhythmia", "PROBLEM", 147, 162], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["lung", "ANATOMY", 58, 62], ["disease", "OBSERVATION", 63, 70], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory failure", "OBSERVATION", 110, 129]]], ["The hypoxemia, hypercarbia, and hemodynamic changes related to AECOPD, and treatment with methyxanthines, all may contribute to the development of this rhythm.", [["hypoxemia", "DISEASE", 4, 13], ["hypercarbia", "DISEASE", 15, 26], ["AECOPD", "DISEASE", 63, 69], ["methyxanthines", "CHEMICAL", 90, 104], ["methyxanthines", "CHEMICAL", 90, 104], ["methyxanthines", "SIMPLE_CHEMICAL", 90, 104], ["The hypoxemia", "PROBLEM", 0, 13], ["hypercarbia", "PROBLEM", 15, 26], ["hemodynamic changes", "PROBLEM", 32, 51], ["AECOPD", "PROBLEM", 63, 69], ["treatment", "TREATMENT", 75, 84], ["methyxanthines", "TREATMENT", 90, 104], ["hypoxemia", "OBSERVATION", 4, 13], ["hypercarbia", "OBSERVATION", 15, 26], ["hemodynamic changes", "OBSERVATION", 32, 51], ["AECOPD", "OBSERVATION", 63, 69]]], ["However, MAT is also associated with a variety of other clinical conditions, including heart disease, hypokalemia, and hypomagnesemia.How should multifocal atrial tachycardia be treated?MAT is typically a transient rhythm, and often resolves with treatment of the underlying disease.", [["heart", "ANATOMY", 87, 92], ["atrial", "ANATOMY", 156, 162], ["heart disease", "DISEASE", 87, 100], ["hypokalemia", "DISEASE", 102, 113], ["hypomagnesemia", "DISEASE", 119, 133], ["atrial tachycardia", "DISEASE", 156, 174], ["heart", "ORGAN", 87, 92], ["atrial", "ORGAN", 156, 162], ["MAT", "PROTEIN", 9, 12], ["other clinical conditions", "PROBLEM", 50, 75], ["heart disease", "PROBLEM", 87, 100], ["hypokalemia", "PROBLEM", 102, 113], ["hypomagnesemia", "PROBLEM", 119, 133], ["multifocal atrial tachycardia", "PROBLEM", 145, 174], ["a transient rhythm", "PROBLEM", 203, 221], ["treatment", "TREATMENT", 247, 256], ["the underlying disease", "PROBLEM", 260, 282], ["heart", "ANATOMY", 87, 92], ["disease", "OBSERVATION", 93, 100], ["hypokalemia", "OBSERVATION", 102, 113], ["hypomagnesemia", "OBSERVATION", 119, 133], ["multifocal", "OBSERVATION_MODIFIER", 145, 155], ["atrial", "ANATOMY", 156, 162], ["tachycardia", "OBSERVATION", 163, 174], ["transient rhythm", "OBSERVATION", 205, 221], ["disease", "OBSERVATION", 275, 282]]], ["Patients with MAT in the setting of AECOPD should therefore be treated aggressively for their lung disease; methyxanthine medications should be avoided, and hypokalemia and hypomagnesemia should be corrected.", [["lung", "ANATOMY", 94, 98], ["AECOPD", "DISEASE", 36, 42], ["lung disease", "DISEASE", 94, 106], ["methyxanthine", "CHEMICAL", 108, 121], ["hypokalemia", "DISEASE", 157, 168], ["hypomagnesemia", "DISEASE", 173, 187], ["methyxanthine", "CHEMICAL", 108, 121], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 94, 98], ["methyxanthine", "SIMPLE_CHEMICAL", 108, 121], ["Patients", "SPECIES", 0, 8], ["AECOPD", "PROBLEM", 36, 42], ["their lung disease", "PROBLEM", 88, 106], ["methyxanthine medications", "TREATMENT", 108, 133], ["hypokalemia", "PROBLEM", 157, 168], ["hypomagnesemia", "PROBLEM", 173, 187], ["AECOPD", "OBSERVATION", 36, 42], ["lung", "ANATOMY", 94, 98], ["disease", "OBSERVATION", 99, 106]]], ["In small studies, the intravenous administration of magnesium often slowed or terminated the rhythm, even in patients with normal serum concentrations of magnesium, so this might be considered as an early intervention in those patients without contraindications.", [["intravenous", "ANATOMY", 22, 33], ["serum", "ANATOMY", 130, 135], ["magnesium", "CHEMICAL", 52, 61], ["magnesium", "CHEMICAL", 154, 163], ["magnesium", "CHEMICAL", 52, 61], ["magnesium", "CHEMICAL", 154, 163], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 33], ["magnesium", "SIMPLE_CHEMICAL", 52, 61], ["patients", "ORGANISM", 109, 117], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["magnesium", "SIMPLE_CHEMICAL", 154, 163], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 227, 235], ["small studies", "TEST", 3, 16], ["the intravenous administration of magnesium", "TREATMENT", 18, 61], ["magnesium", "TREATMENT", 154, 163], ["an early intervention", "TREATMENT", 196, 217], ["small", "OBSERVATION_MODIFIER", 3, 8]]], ["74, 75 If MAT is persistent or problematic, pharmacologic treatment can also be prescribed, with the goal of slowing and/or terminating the rhythm.", [["pharmacologic treatment", "TREATMENT", 44, 67], ["slowing and/or terminating the rhythm", "PROBLEM", 109, 146], ["persistent", "OBSERVATION_MODIFIER", 17, 27]]], ["Both verapamil and metoprolol are effective in achieving each of these goals, with a small comparative trial suggesting that metoprolol may be the more effective of the two.", [["verapamil", "CHEMICAL", 5, 14], ["metoprolol", "CHEMICAL", 19, 29], ["metoprolol", "CHEMICAL", 125, 135], ["verapamil", "CHEMICAL", 5, 14], ["metoprolol", "CHEMICAL", 19, 29], ["metoprolol", "CHEMICAL", 125, 135], ["verapamil", "SIMPLE_CHEMICAL", 5, 14], ["metoprolol", "SIMPLE_CHEMICAL", 19, 29], ["metoprolol", "SIMPLE_CHEMICAL", 125, 135], ["Both verapamil", "TREATMENT", 0, 14], ["metoprolol", "TREATMENT", 19, 29], ["metoprolol", "TREATMENT", 125, 135]]], ["76 The use of b-blocking medications in patients with AECOPD and bronchospasm is discussed above.", [["AECOPD", "DISEASE", 54, 60], ["bronchospasm", "DISEASE", 65, 77], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["b-blocking medications", "TREATMENT", 14, 36], ["AECOPD", "PROBLEM", 54, 60], ["bronchospasm", "PROBLEM", 65, 77], ["AECOPD", "OBSERVATION", 54, 60], ["bronchospasm", "OBSERVATION", 65, 77]]], ["Of note, cardioversion has not been shown to effectively treat this arrhythmia, but atrioventricular nodal ablation has been used to control the rhythm in refractory cases.How should multifocal atrial tachycardia be treated?Harte et al e182Which preventive interventions should be addressed when a patient is hospitalized with AECOPD?In addition to venous thromboembolism prophylaxis, smoking cessation should be emphasized, and appropriate vaccinations should be provided.Smoking CessationSmoking cessation is probably the most important preventive health intervention that can be delivered for a smoking patient.", [["atrioventricular nodal", "ANATOMY", 84, 106], ["atrial", "ANATOMY", 194, 200], ["venous", "ANATOMY", 349, 355], ["arrhythmia", "DISEASE", 68, 78], ["atrial tachycardia", "DISEASE", 194, 212], ["AECOPD", "DISEASE", 327, 333], ["venous thromboembolism", "DISEASE", 349, 371], ["atrioventricular nodal", "MULTI-TISSUE_STRUCTURE", 84, 106], ["atrial", "ORGAN", 194, 200], ["patient", "ORGANISM", 298, 305], ["venous", "MULTI-TISSUE_STRUCTURE", 349, 355], ["patient", "ORGANISM", 606, 613], ["patient", "SPECIES", 298, 305], ["patient", "SPECIES", 606, 613], ["cardioversion", "TREATMENT", 9, 22], ["this arrhythmia", "PROBLEM", 63, 78], ["atrioventricular nodal ablation", "TREATMENT", 84, 115], ["refractory cases", "PROBLEM", 155, 171], ["multifocal atrial tachycardia", "PROBLEM", 183, 212], ["Harte et al e182Which preventive interventions", "TREATMENT", 224, 270], ["AECOPD", "PROBLEM", 327, 333], ["venous thromboembolism prophylaxis", "TREATMENT", 349, 383], ["smoking cessation", "TREATMENT", 385, 402], ["appropriate vaccinations", "TREATMENT", 429, 453], ["nodal ablation", "OBSERVATION", 101, 115], ["refractory", "OBSERVATION_MODIFIER", 155, 165], ["multifocal", "OBSERVATION_MODIFIER", 183, 193], ["atrial", "ANATOMY", 194, 200], ["tachycardia", "OBSERVATION", 201, 212], ["AECOPD", "OBSERVATION", 327, 333], ["venous", "ANATOMY", 349, 355], ["thromboembolism", "OBSERVATION", 356, 371]]], ["Although tobacco abuse and dependence is a chronic disease, it is widely believed that recurrent, brief counseling interventions will increase the likelihood of cessation.", [["tobacco abuse", "DISEASE", 9, 22], ["tobacco", "ORGANISM", 9, 16], ["tobacco", "SPECIES", 9, 16], ["a chronic disease", "PROBLEM", 41, 58], ["brief counseling interventions", "TREATMENT", 98, 128], ["tobacco abuse", "OBSERVATION", 9, 22], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["disease", "OBSERVATION", 51, 58]]], ["77 Hospitalization creates an unusual set of circumstances whereby the patient is temporarily not allowed to smoke, and is in direct contact with health care workers who can provide education and support.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78]]], ["In addition, many hospitalized patients are treated with nicotine replacement therapy to curb the symptoms of nicotine withdrawal.", [["nicotine", "CHEMICAL", 57, 65], ["nicotine", "CHEMICAL", 110, 118], ["nicotine", "CHEMICAL", 57, 65], ["nicotine", "CHEMICAL", 110, 118], ["patients", "ORGANISM", 31, 39], ["nicotine", "SIMPLE_CHEMICAL", 57, 65], ["nicotine", "SIMPLE_CHEMICAL", 110, 118], ["patients", "SPECIES", 31, 39], ["nicotine replacement therapy", "TREATMENT", 57, 85], ["the symptoms", "PROBLEM", 94, 106], ["nicotine withdrawal", "PROBLEM", 110, 129], ["nicotine withdrawal", "OBSERVATION", 110, 129]]], ["Therefore, hospitalization is a perfect opportunity to encourage smoking cessation.", [["smoking", "CHEMICAL", 65, 72]]], ["A systematic review of studies of smoking cessation in hospitalized patients from 2008 demonstrated that counseling interventions in the hospital did result in improved cessation rates at 6 and 12 months (OR 1.65, 95% CI 1.44-1.9), but only if the intervention continued (as phone or face-toface contacts) for more than a month after discharge.", [["smoking", "CHEMICAL", 34, 41], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["smoking cessation", "TREATMENT", 34, 51], ["counseling interventions", "TREATMENT", 105, 129], ["CI", "TEST", 218, 220]]], ["This review also found that nicotine replacement therapy, when added to counseling, resulted in a trend toward improved cessation rates (OR 1.47, 95% CI 0.92-2.35).Smoking CessationTherefore, hospitalists should recommend smoking cessation to all smokers who are hospitalized.Smoking CessationIt is also reasonable to use nicotine replacement therapies in the hospital to treat nicotine withdrawal symptoms, and to continue as such after discharge, if the patient expresses an intention to quit.", [["nicotine", "CHEMICAL", 28, 36], ["nicotine", "CHEMICAL", 322, 330], ["nicotine", "CHEMICAL", 378, 386], ["nicotine", "CHEMICAL", 28, 36], ["nicotine", "CHEMICAL", 322, 330], ["nicotine", "CHEMICAL", 378, 386], ["nicotine", "SIMPLE_CHEMICAL", 28, 36], ["nicotine", "SIMPLE_CHEMICAL", 322, 330], ["patient", "ORGANISM", 456, 463], ["patient", "SPECIES", 456, 463], ["nicotine replacement therapy", "TREATMENT", 28, 56], ["CI", "TEST", 150, 152], ["nicotine replacement therapies", "TREATMENT", 322, 352], ["nicotine withdrawal symptoms", "PROBLEM", 378, 406], ["nicotine replacement", "OBSERVATION", 28, 48]]], ["If inpatient smoking-cessation consultation services are available, hospitalists should also use these services to benefit the patient.VaccinationsThe United States Center for Disease Control and Prevention recommends an annual influenza vaccination and a pneumococcal vaccination for patients with COPD.", [["COPD", "DISEASE", 299, 303], ["patient", "ORGANISM", 127, 134], ["patients", "ORGANISM", 285, 293], ["patient", "SPECIES", 127, 134], ["patients", "SPECIES", 285, 293], ["pneumococcal", "SPECIES", 256, 268], ["Disease Control", "TREATMENT", 176, 191], ["an annual influenza vaccination", "TREATMENT", 218, 249], ["a pneumococcal vaccination", "TREATMENT", 254, 280], ["COPD", "PROBLEM", 299, 303], ["COPD", "OBSERVATION", 299, 303]]], ["79 In this patient population, influenza vaccination results in a fewer COPD exacerbations, 80 and may also lead to decreased hospitalizations and death.", [["influenza", "DISEASE", 31, 40], ["COPD", "DISEASE", 72, 76], ["death", "DISEASE", 147, 152], ["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["influenza vaccination", "TREATMENT", 31, 52], ["a fewer COPD exacerbations", "PROBLEM", 64, 90], ["decreased hospitalizations", "PROBLEM", 116, 142], ["death", "PROBLEM", 147, 152]]], ["81 Pneumococcal vaccination has not been shown to reduce these complications, 82 but does appear to reduce invasive pneumococcal disease in a general population of patients.", [["pneumococcal disease", "DISEASE", 116, 136], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["pneumococcal", "SPECIES", 116, 128], ["Pneumococcal vaccination", "TREATMENT", 3, 27], ["these complications", "PROBLEM", 57, 76], ["invasive pneumococcal disease", "PROBLEM", 107, 136], ["invasive", "OBSERVATION_MODIFIER", 107, 115], ["pneumococcal", "OBSERVATION", 116, 128]]], ["81 Efforts to improve vaccination rates to these organisms has led to the development of \"standing-order vaccine programs,\" which allow for hospitals and other facilities to provide these vaccinations to appropriate patients, without an individual physician order.", [["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["vaccination rates", "TREATMENT", 22, 39], ["\"standing-order vaccine programs", "TREATMENT", 89, 121], ["these vaccinations", "TREATMENT", 182, 200]]], ["These programs have resulted in improvements in vaccination rates, and hospitalized patients now commonly receive vaccination to these organisms (although this is often accomplished without direct input from the hospitalist).", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["vaccination rates", "TREATMENT", 48, 65], ["vaccination", "TREATMENT", 114, 125], ["these organisms", "PROBLEM", 129, 144]]], ["81 For hospitalists practicing in hospitals without standing-order programs, it is reasonable to recommend these vaccinations at the time of hospital discharge for these patients.", [["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["these vaccinations", "TREATMENT", 107, 125]]], ["When discharging a patient after hospitalization for an AECOPD, hospitalists should consider the need for close follow-up, long-term oxygen therapy, and pulmonary rehabilitation.VaccinationsWhen should a follow-up appointment be scheduled after hospitalization for an AECOPD?VaccinationsClose outpatient follow-up after discharge is recommended for this population of patients.", [["pulmonary", "ANATOMY", 153, 162], ["AECOPD", "DISEASE", 56, 62], ["oxygen", "CHEMICAL", 133, 139], ["AECOPD", "DISEASE", 268, 274], ["oxygen", "CHEMICAL", 133, 139], ["patient", "ORGANISM", 19, 26], ["oxygen", "SIMPLE_CHEMICAL", 133, 139], ["pulmonary", "ORGAN", 153, 162], ["patients", "ORGANISM", 368, 376], ["patient", "SPECIES", 19, 26], ["patients", "SPECIES", 368, 376], ["long-term oxygen therapy", "TREATMENT", 123, 147], ["pulmonary rehabilitation", "TREATMENT", 153, 177], ["an AECOPD", "PROBLEM", 265, 274], ["AECOPD", "OBSERVATION", 56, 62], ["pulmonary", "ANATOMY", 153, 162], ["AECOPD", "OBSERVATION", 268, 274]]], ["Approximately 20% of patients hospitalized with an AECOPD are readmitted within 30 days.", [["AECOPD", "DISEASE", 51, 57], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["an AECOPD", "PROBLEM", 48, 57], ["AECOPD", "OBSERVATION", 51, 57]]], ["6 Although the best means of reducing readmissions in this population remain uncertain, one large, retrospective cohort study demonstrated that the rate of readmissions was lower in those patients who attended a follow-up visit with either their primary care physician or their pulmonologist within 30 days of discharge.", [["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["reducing readmissions", "PROBLEM", 29, 50], ["retrospective cohort study", "TEST", 99, 125], ["large", "OBSERVATION_MODIFIER", 92, 97]]], ["83 A causal link between follow-up appointments and readmissions cannot be deduced from this study, but it has certainly raised awareness of the potential benefits of timely follow-up appointments in these patients.", [["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["this study", "TEST", 88, 98]]], ["The optimal timing of follow-up after an AECOPD is not clear, but the GOLD guidelines suggest that it be scheduled for 4 to 6 weeks after discharge.", [["AECOPD", "DISEASE", 41, 47], ["an AECOPD", "PROBLEM", 38, 47], ["AECOPD", "OBSERVATION", 41, 47]]], ["1Which patients should be discharged with continuous oxygen therapy after hospitalization for an AECOPD?Patients who continue to require oxygen therapy to maintain adequate oxygenation at the time of discharge should be discharged with continuous oxygen therapy.", [["oxygen", "CHEMICAL", 53, 59], ["AECOPD", "DISEASE", 97, 103], ["oxygen", "CHEMICAL", 137, 143], ["oxygen", "CHEMICAL", 247, 253], ["oxygen", "CHEMICAL", 53, 59], ["oxygen", "CHEMICAL", 137, 143], ["oxygen", "CHEMICAL", 247, 253], ["patients", "ORGANISM", 7, 15], ["oxygen", "SIMPLE_CHEMICAL", 53, 59], ["Patients", "ORGANISM", 104, 112], ["oxygen", "SIMPLE_CHEMICAL", 137, 143], ["oxygen", "SIMPLE_CHEMICAL", 247, 253], ["patients", "SPECIES", 7, 15], ["Patients", "SPECIES", 104, 112], ["continuous oxygen therapy", "TREATMENT", 42, 67], ["an AECOPD", "PROBLEM", 94, 103], ["oxygen therapy", "TREATMENT", 137, 151], ["continuous oxygen therapy", "TREATMENT", 236, 261], ["AECOPD", "OBSERVATION", 97, 103]]], ["Long-term oxygen therapy has been shown to reduce mortality and hospitalizations in patients with severe hypoxemia.", [["oxygen", "CHEMICAL", 10, 16], ["hypoxemia", "DISEASE", 105, 114], ["oxygen", "CHEMICAL", 10, 16], ["oxygen", "SIMPLE_CHEMICAL", 10, 16], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Long-term oxygen therapy", "TREATMENT", 0, 24], ["severe hypoxemia", "PROBLEM", 98, 114], ["-term", "OBSERVATION_MODIFIER", 4, 9], ["oxygen therapy", "OBSERVATION", 10, 24], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["hypoxemia", "OBSERVATION", 105, 114]]], ["84 Guidelines from the American Thoracic Society and the European Respiratory Society recommend that patients with hypoxemia be treated with long-term oxygen therapy (Fig. 2) .", [["hypoxemia", "DISEASE", 115, 124], ["oxygen", "CHEMICAL", 151, 157], ["oxygen", "CHEMICAL", 151, 157], ["patients", "ORGANISM", 101, 109], ["oxygen", "SIMPLE_CHEMICAL", 151, 157], ["patients", "SPECIES", 101, 109], ["hypoxemia", "PROBLEM", 115, 124], ["long-term oxygen therapy", "TREATMENT", 141, 165], ["Thoracic", "ANATOMY", 32, 40], ["Society", "OBSERVATION", 41, 48]]], ["9 Patients with an AECOPD often meet the criteria for long-term oxygen therapy at the time of hospital discharge, and hospitalists should prescribe oxygen in these cases.", [["AECOPD", "DISEASE", 19, 25], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 148, 154], ["Patients", "ORGANISM", 2, 10], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["Patients", "SPECIES", 2, 10], ["an AECOPD", "PROBLEM", 16, 25], ["long-term oxygen therapy", "TREATMENT", 54, 78], ["oxygen", "TREATMENT", 148, 154], ["AECOPD", "OBSERVATION", 19, 25]]], ["However, some of these patients who are discharged with home oxygen therapy after an AECOPD will have improved oxygenation as they recover from the acute illness, and will be able to eventually discontinue oxygen therapy.", [["oxygen", "CHEMICAL", 61, 67], ["AECOPD", "DISEASE", 85, 91], ["oxygen", "CHEMICAL", 206, 212], ["oxygen", "CHEMICAL", 61, 67], ["oxygen", "CHEMICAL", 206, 212], ["patients", "ORGANISM", 23, 31], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["oxygen", "SIMPLE_CHEMICAL", 206, 212], ["patients", "SPECIES", 23, 31], ["home oxygen therapy", "TREATMENT", 56, 75], ["an AECOPD", "PROBLEM", 82, 91], ["the acute illness", "PROBLEM", 144, 161], ["oxygen therapy", "TREATMENT", 206, 220], ["AECOPD", "OBSERVATION", 85, 91], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["illness", "OBSERVATION", 154, 161]]], ["Reassessment of a patient's oxygen status is one important goal of the follow-up appointment already discussed.", [["oxygen", "CHEMICAL", 28, 34], ["oxygen", "CHEMICAL", 28, 34], ["patient", "ORGANISM", 18, 25], ["oxygen", "SIMPLE_CHEMICAL", 28, 34], ["patient", "SPECIES", 18, 25], ["a patient's oxygen status", "PROBLEM", 16, 41]]], ["It is also worth noting that patients who use long-term oxygen therapy chronically (ie, they are using it at the time of admission) should generally continue that therapy after discharge, even if they appear not to meet criteria for it at the time of discharge.", [["oxygen", "CHEMICAL", 56, 62], ["oxygen", "CHEMICAL", 56, 62], ["patients", "ORGANISM", 29, 37], ["oxygen", "SIMPLE_CHEMICAL", 56, 62], ["patients", "SPECIES", 29, 37], ["long-term oxygen therapy", "TREATMENT", 46, 70]]], ["It is thought that long-term oxygen therapy may have a reparative effect over time in patients with chronic hypoxemia that leads to augmented oxygenation, which may be undone by discontinuing the oxygen therapy.", [["oxygen", "CHEMICAL", 29, 35], ["hypoxemia", "DISEASE", 108, 117], ["oxygen", "CHEMICAL", 196, 202], ["oxygen", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 196, 202], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["patients", "ORGANISM", 86, 94], ["oxygen", "SIMPLE_CHEMICAL", 196, 202], ["patients", "SPECIES", 86, 94], ["long-term oxygen therapy", "TREATMENT", 19, 43], ["chronic hypoxemia", "PROBLEM", 100, 117], ["the oxygen therapy", "TREATMENT", 192, 210], ["long-term", "OBSERVATION_MODIFIER", 19, 28], ["oxygen therapy", "OBSERVATION", 29, 43], ["reparative", "OBSERVATION_MODIFIER", 55, 65], ["chronic", "OBSERVATION_MODIFIER", 100, 107], ["hypoxemia", "OBSERVATION", 108, 117], ["oxygenation", "OBSERVATION_MODIFIER", 142, 153], ["oxygen therapy", "OBSERVATION", 196, 210]]], ["9 Should hospitalists refer patients to pulmonary rehabilitation programs after hospitalizations for AECOPD?Which patients should be discharged with continuous oxygen therapy after hospitalization for an AECOPD?Pulmonary rehabilitation is an established part of the treatment of COPD.", [["pulmonary", "ANATOMY", 40, 49], ["Pulmonary", "ANATOMY", 211, 220], ["AECOPD", "DISEASE", 101, 107], ["oxygen", "CHEMICAL", 160, 166], ["AECOPD", "DISEASE", 204, 210], ["COPD", "DISEASE", 279, 283], ["oxygen", "CHEMICAL", 160, 166], ["patients", "ORGANISM", 28, 36], ["pulmonary", "ORGAN", 40, 49], ["patients", "ORGANISM", 114, 122], ["oxygen", "SIMPLE_CHEMICAL", 160, 166], ["Pulmonary", "ORGAN", 211, 220], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 114, 122], ["pulmonary rehabilitation programs", "TREATMENT", 40, 73], ["AECOPD", "PROBLEM", 101, 107], ["continuous oxygen therapy", "TREATMENT", 149, 174], ["an AECOPD", "PROBLEM", 201, 210], ["Pulmonary rehabilitation", "TREATMENT", 211, 235], ["COPD", "PROBLEM", 279, 283], ["pulmonary", "ANATOMY", 40, 49], ["AECOPD", "OBSERVATION", 204, 210], ["rehabilitation", "OBSERVATION", 221, 235], ["COPD", "OBSERVATION", 279, 283]]], ["These programs include multiple interventions (which might include strength and endurance training, breathing exercises, smoking cessation, education, psychosocial interventions, and so forth), but a core part of this treatment involves training the muscles of ambulation.", [["muscles", "ANATOMY", 250, 257], ["muscles", "ORGANISM_SUBDIVISION", 250, 257], ["multiple interventions", "TREATMENT", 23, 45], ["strength and endurance training", "TREATMENT", 67, 98], ["breathing exercises", "TREATMENT", 100, 119], ["smoking cessation", "TREATMENT", 121, 138], ["psychosocial interventions", "TREATMENT", 151, 177], ["this treatment", "TREATMENT", 213, 227], ["muscles", "ANATOMY", 250, 257]]], ["These programs decrease dyspnea, improve quality of life, and decrease hospitalization in COPD patients.", [["dyspnea", "DISEASE", 24, 31], ["COPD", "DISEASE", 90, 94], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["dyspnea", "PROBLEM", 24, 31], ["COPD patients", "PROBLEM", 90, 103], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["dyspnea", "OBSERVATION", 24, 31]]], ["85 Several studies have looked at the value of pulmonary rehabilitation, specifically in the context of an AECOPD.", [["pulmonary", "ANATOMY", 47, 56], ["AECOPD", "DISEASE", 107, 113], ["pulmonary", "ORGAN", 47, 56], ["Several studies", "TEST", 3, 18], ["pulmonary rehabilitation", "TREATMENT", 47, 71], ["an AECOPD", "PROBLEM", 104, 113], ["pulmonary", "ANATOMY", 47, 56], ["rehabilitation", "OBSERVATION", 57, 71], ["AECOPD", "OBSERVATION", 107, 113]]], ["A Cochrane Collaboration meta-analysis of 9 studies of pulmonary rehabilitation after AECOPD (not all requiring hospitalization) demonstrated significant reduction in rates of hospitalization and death in those patients randomized to early pulmonary rehabilitation.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary", "ANATOMY", 240, 249], ["AECOPD", "DISEASE", 86, 92], ["death", "DISEASE", 196, 201], ["pulmonary", "ORGAN", 55, 64], ["patients", "ORGANISM", 211, 219], ["pulmonary", "ORGAN", 240, 249], ["patients", "SPECIES", 211, 219], ["pulmonary rehabilitation", "TREATMENT", 55, 79], ["AECOPD", "PROBLEM", 86, 92], ["death", "PROBLEM", 196, 201], ["early pulmonary rehabilitation", "TREATMENT", 234, 264], ["pulmonary", "ANATOMY", 55, 64], ["AECOPD", "OBSERVATION", 86, 92], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["reduction", "OBSERVATION_MODIFIER", 154, 163], ["pulmonary", "ANATOMY", 240, 249], ["rehabilitation", "OBSERVATION", 250, 264]]], ["Some quality-of-life measures were also improved in this group.", [["improved", "OBSERVATION_MODIFIER", 40, 48]]], ["86 Most of these studies started the rehabilitation within 10 days of discharge for those patients who were hospitalized, and the mean FEV 1 was less than 40% predicted in most studies (range, 32%-52% predicted).", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["these studies", "TEST", 11, 24], ["the rehabilitation", "TREATMENT", 33, 51], ["the mean FEV", "TEST", 126, 138]]], ["Individually the studies in this meta-analysis were small and of modest methodologic quality, but taken together the findings are compelling.Which patients should be discharged with continuous oxygen therapy after hospitalization for an AECOPD?Hospitalists should consider early referral to pulmonary rehabilitation programs when arranging post-hospital care for their patients after an AECOPD.", [["pulmonary", "ANATOMY", 291, 300], ["oxygen", "CHEMICAL", 193, 199], ["AECOPD", "DISEASE", 237, 243], ["AECOPD", "DISEASE", 387, 393], ["oxygen", "CHEMICAL", 193, 199], ["patients", "ORGANISM", 147, 155], ["oxygen", "SIMPLE_CHEMICAL", 193, 199], ["pulmonary", "ORGAN", 291, 300], ["patients", "ORGANISM", 369, 377], ["patients", "SPECIES", 147, 155], ["patients", "SPECIES", 369, 377], ["the studies", "TEST", 13, 24], ["this meta-analysis", "TEST", 28, 46], ["continuous oxygen therapy", "TREATMENT", 182, 207], ["an AECOPD", "PROBLEM", 234, 243], ["pulmonary rehabilitation programs", "TREATMENT", 291, 324], ["an AECOPD", "PROBLEM", 384, 393], ["small", "OBSERVATION_MODIFIER", 52, 57], ["AECOPD", "OBSERVATION", 237, 243], ["pulmonary", "ANATOMY", 291, 300], ["AECOPD", "OBSERVATION", 387, 393]]]], "d428c833299e8f39140505fbff407a5ff5bbdc32": [["IntroductionNumbers of wild boar (Sus scrofa) within Europe has been growing continuously since 1980s.", [["wild boar", "ORGANISM", 23, 32], ["Sus scrofa", "ORGANISM", 34, 44], ["boar", "SPECIES", 28, 32], ["Sus scrofa", "SPECIES", 34, 44], ["Sus scrofa", "SPECIES", 34, 44], ["wild boar", "OBSERVATION", 23, 32], ["growing", "OBSERVATION_MODIFIER", 69, 76]]], ["Insufficient hunting together with other various causes have been identified as factors contributing to the population increase.", [["other various causes", "PROBLEM", 35, 55], ["hunting", "OBSERVATION", 13, 20]]], ["Nowadays, wild boar is one of the most widely distributed mammals in Europe (Massei et al., 2015) and its hunting bag on many localities exceeds 1 ind/ km 2 .", [["wild boar", "ORGANISM", 10, 19], ["boar", "SPECIES", 15, 19]]], ["High density of wild boar increased damage on field crops and also risk of transmission of pathogens in their populations.", [["boar", "ORGANISM", 21, 25], ["wild boar increased damage", "PROBLEM", 16, 42], ["field crops", "TREATMENT", 46, 57], ["pathogens", "PROBLEM", 91, 100], ["density", "OBSERVATION_MODIFIER", 5, 12], ["wild boar", "OBSERVATION", 16, 25], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["damage", "OBSERVATION_MODIFIER", 36, 42], ["pathogens", "OBSERVATION", 91, 100]]], ["Moreover, spreading of human habitation to suburban areas, increased use of lands for agricultural purposes, and deforestation have all enhanced chances of contact between wild boars and humans or domestic animals.", [["human", "ORGANISM", 23, 28], ["boars", "ORGANISM", 177, 182], ["humans", "ORGANISM", 187, 193], ["human", "SPECIES", 23, 28], ["humans", "SPECIES", 187, 193], ["human", "SPECIES", 23, 28], ["humans", "SPECIES", 187, 193], ["human habitation", "TREATMENT", 23, 39], ["agricultural purposes", "TREATMENT", 86, 107], ["deforestation", "TREATMENT", 113, 126], ["increased", "OBSERVATION_MODIFIER", 59, 68]]], ["Together with recreational hunting and consumption of wild boar meat, that facts form an ideal environment for the transmission of pathogens between wild boars and both humans and domestic animals (Meng et al., 2009 ).", [["meat", "ANATOMY", 64, 68], ["boar", "ORGANISM", 59, 63], ["meat", "ORGANISM_SUBDIVISION", 64, 68], ["boars", "ORGANISM", 154, 159], ["humans", "ORGANISM", 169, 175], ["boar", "SPECIES", 59, 63], ["boars", "SPECIES", 154, 159], ["humans", "SPECIES", 169, 175], ["boar", "SPECIES", 59, 63], ["humans", "SPECIES", 169, 175], ["pathogens", "PROBLEM", 131, 140], ["recreational hunting", "OBSERVATION", 14, 34]]], ["On the contrary, wild boars could become infected from foraged waste of human or domestic animal origin due to their typical behaviour.", [["boars", "ORGANISM", 22, 27], ["human", "ORGANISM", 72, 77], ["boars", "SPECIES", 22, 27], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["infected", "OBSERVATION", 41, 49]]], ["Wild boar is an omnivore foraging for food mainly close to the soil surface or by grubbing and digging 15 cm deep (\u0160krkal et al., 2015) .", [["soil surface", "ANATOMY", 63, 75], ["boar", "ORGANISM", 5, 9], ["boar", "SPECIES", 5, 9], ["Wild boar", "SPECIES", 0, 9]]], ["Moreover, pigs have the ability to discriminate between food sites of different relative value and to remember their respective locations.", [["pigs", "ORGANISM", 10, 14], ["pigs", "SPECIES", 10, 14], ["pigs", "SPECIES", 10, 14]]], ["Food foraging, reproduction, and other social factors may affect the aggregation of animal (Podg\u00f3rski et al., 2014) presenting a determining role in epidemiology of diseases.IntroductionWild boars have been recognized as a source of viral infectious diseases for domestic pigs.", [["viral infectious diseases", "DISEASE", 233, 258], ["pigs", "ORGANISM", 272, 276], ["pigs", "SPECIES", 272, 276], ["pigs", "SPECIES", 272, 276], ["diseases", "PROBLEM", 165, 173], ["viral infectious diseases", "PROBLEM", 233, 258], ["domestic pigs", "TREATMENT", 263, 276], ["foraging", "OBSERVATION_MODIFIER", 5, 13], ["diseases", "OBSERVATION", 165, 173]]], ["The presence of antibodies against viral pathogens or viral nucleic acids of viral pathogens representing a serious economic threat was confirmed in several epidemiological studies; it refers particularly to African swine fever virus (ASFV) (Wo zniakowski et al., 2015) , classical swine fever virus (CSFV) (recently reviewed by Moenning, 2015) , and Aujeszky's disease virus (ADV) (Meier et al., 2015) .", [["nucleic acids", "CHEMICAL", 60, 73], ["swine fever", "DISEASE", 216, 227], ["swine fever", "DISEASE", 282, 293], ["Aujeszky's disease", "DISEASE", 351, 369], ["African swine fever virus", "ORGANISM", 208, 233], ["ASFV", "ORGANISM", 235, 239], ["classical swine fever virus", "ORGANISM", 272, 299], ["CSFV", "ORGANISM", 301, 305], ["Aujeszky's disease virus", "ORGANISM", 351, 375], ["antibodies", "PROTEIN", 16, 26], ["African swine fever virus", "SPECIES", 208, 233], ["swine fever virus", "SPECIES", 282, 299], ["CSFV", "SPECIES", 301, 305], ["Aujeszky", "SPECIES", 351, 359], ["African swine fever virus", "SPECIES", 208, 233], ["ASFV", "SPECIES", 235, 239], ["classical swine fever virus", "SPECIES", 272, 299], ["CSFV", "SPECIES", 301, 305], ["Aujeszky's disease virus", "SPECIES", 351, 375], ["ADV", "SPECIES", 377, 380], ["antibodies", "PROBLEM", 16, 26], ["viral pathogens", "PROBLEM", 35, 50], ["viral nucleic acids", "PROBLEM", 54, 73], ["viral pathogens", "PROBLEM", 77, 92], ["a serious economic threat", "PROBLEM", 106, 131], ["African swine fever virus", "PROBLEM", 208, 233], ["classical swine fever virus", "PROBLEM", 272, 299], ["Aujeszky's disease virus", "PROBLEM", 351, 375], ["serious", "OBSERVATION_MODIFIER", 108, 115]]], ["However, not so much is known about other prevalent viral diseases of swine such as porcine circovirus type 2 (PCV-2), porcine reproductive and respiratory syndrome virus (PRRSV), influenza A virus (IAV), porcine parvovirus (PPV) (Gonz\u00e1les-Barrio et al., 2015; Sliz et al., 2015; Touloudi et al., 2015) .", [["viral diseases", "DISEASE", 52, 66], ["porcine reproductive and respiratory syndrome virus", "DISEASE", 119, 170], ["influenza A virus", "DISEASE", 180, 197], ["porcine parvovirus", "DISEASE", 205, 223], ["swine", "ORGANISM", 70, 75], ["porcine circovirus type 2", "ORGANISM", 84, 109], ["PCV-2", "ORGANISM", 111, 116], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 119, 170], ["PRRSV", "ORGANISM", 172, 177], ["influenza A virus", "ORGANISM", 180, 197], ["IAV", "ORGANISM", 199, 202], ["porcine parvovirus", "ORGANISM", 205, 223], ["swine", "SPECIES", 70, 75], ["porcine circovirus type", "SPECIES", 84, 107], ["PCV-2", "SPECIES", 111, 116], ["porcine", "SPECIES", 119, 126], ["syndrome virus", "SPECIES", 156, 170], ["PRRSV", "SPECIES", 172, 177], ["influenza A virus", "SPECIES", 180, 197], ["porcine parvovirus", "SPECIES", 205, 223], ["swine", "SPECIES", 70, 75], ["porcine circovirus type 2 (PCV-2", "SPECIES", 84, 116], ["respiratory syndrome virus", "SPECIES", 144, 170], ["PRRSV", "SPECIES", 172, 177], ["influenza A virus", "SPECIES", 180, 197], ["IAV", "SPECIES", 199, 202], ["porcine parvovirus", "SPECIES", 205, 223], ["other prevalent viral diseases of swine", "PROBLEM", 36, 75], ["porcine circovirus type 2", "PROBLEM", 84, 109], ["PCV", "TEST", 111, 114], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 119, 170], ["PRRSV", "PROBLEM", 172, 177], ["influenza A virus (IAV)", "TREATMENT", 180, 203], ["porcine parvovirus (PPV", "TREATMENT", 205, 228], ["respiratory syndrome", "OBSERVATION", 144, 164]]], ["Unexpectedly, specific antibodies against Schmallenberg virus (SBV) were detected in wild boars (Mouchantat et al., 2015) .", [["antibodies against", "GENE_OR_GENE_PRODUCT", 23, 41], ["Schmallenberg virus", "ORGANISM", 42, 61], ["SBV", "ORGANISM", 63, 66], ["boars", "ORGANISM", 90, 95], ["Schmallenberg virus", "SPECIES", 42, 61], ["Schmallenberg virus", "SPECIES", 42, 61], ["SBV", "SPECIES", 63, 66], ["specific antibodies", "TEST", 14, 33], ["Schmallenberg virus", "PROBLEM", 42, 61]]], ["Despite of the fact that enteric viruses are significant pathogens of domestic pigs, they have been studied only sporadically in wild boar.", [["enteric viruses", "DISEASE", 25, 40], ["enteric viruses", "ORGANISM", 25, 40], ["pigs", "ORGANISM", 79, 83], ["boar", "ORGANISM", 134, 138], ["pigs", "SPECIES", 79, 83], ["boar", "SPECIES", 134, 138], ["pigs", "SPECIES", 79, 83], ["enteric viruses", "PROBLEM", 25, 40], ["enteric", "OBSERVATION_MODIFIER", 25, 32], ["viruses", "OBSERVATION", 33, 40], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["pathogens", "OBSERVATION_MODIFIER", 57, 66], ["domestic pigs", "OBSERVATION", 70, 83]]], ["Enteric viruses are transmitted by faecal-oral route, shed in extremely high numbers in the faeces of infected individuals, generally less susceptible to inactivation caused by environmental conditions, and can be easily transported in the environment (Fong and Lipp, 2005) .", [["oral", "ANATOMY", 42, 46], ["faeces", "ANATOMY", 92, 98], ["Enteric viruses", "DISEASE", 0, 15], ["faecal", "ORGANISM_SUBDIVISION", 35, 41], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["faeces", "ORGANISM_SUBDIVISION", 92, 98], ["Enteric viruses", "PROBLEM", 0, 15], ["infected individuals", "PROBLEM", 102, 122], ["viruses", "OBSERVATION", 8, 15], ["high numbers", "OBSERVATION_MODIFIER", 72, 84], ["infected", "OBSERVATION", 102, 110]]], ["Antibodies against transmissible gastroenteritis virus (TGEV) have been detected extremely rarely (H\u00e4lli et al., 2012; McGregor et al., 2015) .", [["transmissible gastroenteritis virus", "DISEASE", 19, 54], ["transmissible gastroenteritis virus", "ORGANISM", 19, 54], ["TGEV", "ORGANISM", 56, 60], ["transmissible gastroenteritis virus", "SPECIES", 19, 54], ["transmissible gastroenteritis virus", "SPECIES", 19, 54], ["TGEV", "SPECIES", 56, 60], ["Antibodies", "TEST", 0, 10], ["transmissible gastroenteritis virus", "PROBLEM", 19, 54]]], ["Viral nucleic acids of porcine enteric picornaviruses, comprising teschoviruses, sapeloviruses, and enteroviruses G have been detected in stool samples (Prod elalov\u00e1, 2012; Cano-Gom\u00e9z et al., 2013) .", [["stool samples", "ANATOMY", 138, 151], ["nucleic acids", "CHEMICAL", 6, 19], ["enteric picornaviruses", "DISEASE", 31, 53], ["porcine enteric picornaviruses", "ORGANISM", 23, 53], ["teschoviruses", "GENE_OR_GENE_PRODUCT", 66, 79], ["sapeloviruses", "GENE_OR_GENE_PRODUCT", 81, 94], ["enteroviruses G", "GENE_OR_GENE_PRODUCT", 100, 115], ["stool samples", "ORGANISM_SUBSTANCE", 138, 151], ["porcine", "SPECIES", 23, 30], ["Viral nucleic acids", "TEST", 0, 19], ["porcine enteric picornaviruses", "PROBLEM", 23, 53], ["teschoviruses", "PROBLEM", 66, 79], ["sapeloviruses", "PROBLEM", 81, 94], ["enteroviruses G", "PROBLEM", 100, 115], ["stool samples", "TEST", 138, 151], ["nucleic acids", "OBSERVATION", 6, 19], ["porcine enteric picornaviruses", "OBSERVATION", 23, 53], ["enteroviruses", "OBSERVATION", 100, 113]]], ["Moreover, wild boars represent an important source of zoonotic hepatitis E virus (Schlosser et al., 2015) .", [["zoonotic hepatitis E", "DISEASE", 54, 74], ["boars", "ORGANISM", 15, 20], ["hepatitis E virus", "ORGANISM", 63, 80], ["hepatitis E virus", "SPECIES", 63, 80], ["hepatitis E virus", "SPECIES", 63, 80], ["zoonotic hepatitis E virus", "PROBLEM", 54, 80]]], ["The prevalence of rotaviruses in wild boars is almost unknown.", [["rotaviruses", "DISEASE", 18, 29], ["rotaviruses", "ORGANISM", 18, 29], ["boars", "ORGANISM", 38, 43], ["rotaviruses", "PROBLEM", 18, 29], ["rotaviruses", "OBSERVATION", 18, 29]]], ["The only study which detected rotavirus A (RVA) in wild boars was carried out in Japan.", [["rotavirus A", "ORGANISM", 30, 41], ["boars", "ORGANISM", 56, 61], ["rotavirus A", "SPECIES", 30, 41], ["The only study", "TEST", 0, 14], ["rotavirus A (RVA) in wild boars", "PROBLEM", 30, 61]]], ["Okadera et al. (2013) detected RVA in four animals from 90 tested faecal samples.IntroductionAim of the study was to survey population of wild boar in the Czech Republic for the presence of enteric RNA-viruses including RVA, RVC, PRRSV, and members of family Coronaviridae and Picornaviridae, and to assess the role of wild boars as natural reservoirs of those important pathogens which can be transmitted to domestic pigs and in case of rotaviruses also to humans.Field sample collection and total RNA preparationFaecal samples or intestinal contents from wild boar (n = 203, 91 males and 112 females) were collected from animals culled between October 2014 and January 2015 and come from four regions representing almost half of the Czech Republic area (South Moravian, Central and South Bohemian, and Vysocina Regions).", [["faecal samples", "ANATOMY", 66, 80], ["sample", "ANATOMY", 471, 477], ["samples", "ANATOMY", 521, 528], ["intestinal", "ANATOMY", 532, 542], ["faecal samples", "ORGANISM_SUBSTANCE", 66, 80], ["boar", "ORGANISM", 143, 147], ["RVC", "GENE_OR_GENE_PRODUCT", 225, 228], ["PRRSV", "ORGANISM", 230, 235], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 259, 272], ["wild boars", "ORGANISM", 319, 329], ["pigs", "ORGANISM", 418, 422], ["rotaviruses", "ORGANISM", 438, 449], ["humans", "ORGANISM", 458, 464], ["intestinal", "ORGAN", 532, 542], ["boar", "ORGANISM", 562, 566], ["PRRSV", "SPECIES", 230, 235], ["pigs", "SPECIES", 418, 422], ["humans", "SPECIES", 458, 464], ["boar", "SPECIES", 562, 566], ["RVC", "SPECIES", 225, 228], ["PRRSV", "SPECIES", 230, 235], ["pigs", "SPECIES", 418, 422], ["humans", "SPECIES", 458, 464], ["RVA", "PROBLEM", 31, 34], ["faecal samples", "TEST", 66, 80], ["the study", "TEST", 100, 109], ["enteric RNA-viruses", "PROBLEM", 190, 209], ["RVA", "PROBLEM", 220, 223], ["RVC", "PROBLEM", 225, 228], ["PRRSV", "PROBLEM", 230, 235], ["Coronaviridae", "TREATMENT", 259, 272], ["Picornaviridae", "TREATMENT", 277, 291], ["wild boars", "TREATMENT", 319, 329], ["natural reservoirs", "TREATMENT", 333, 351], ["rotaviruses", "PROBLEM", 438, 449], ["Field sample collection", "TEST", 465, 488], ["total RNA preparationFaecal samples", "TEST", 493, 528], ["intestinal contents", "PROBLEM", 532, 551], ["Central and South Bohemian", "TREATMENT", 772, 798], ["enteric RNA", "ANATOMY", 190, 201], ["viruses", "OBSERVATION", 202, 209], ["RVC", "ANATOMY", 225, 228], ["rotaviruses", "OBSERVATION", 438, 449], ["intestinal", "ANATOMY", 532, 542], ["Central", "ANATOMY_MODIFIER", 772, 779]]], ["The age of culled animals was determined by mandibular tooth eruption and wear and ranged between 2 and 90 months with the average age of 12.9 months and median age of 9 months.", [["mandibular tooth", "ANATOMY", 44, 60], ["tooth eruption", "DISEASE", 55, 69], ["animals", "ORGANISM", 18, 25], ["mandibular tooth", "MULTI-TISSUE_STRUCTURE", 44, 60], ["mandibular tooth eruption", "PROBLEM", 44, 69], ["mandibular tooth", "ANATOMY", 44, 60], ["eruption", "OBSERVATION", 61, 69]]], ["The sites of sample collection are specified on the map of the Czech Republic (Supplementary data -see the map in the online version at DOI: 10.1016/j.vetmic.2016.08.003).Field sample collection and total RNA preparationIn the day of collection the 10% faecal suspensions in phosphate buffered saline (PBS) were prepared and homogenized with added glass beads (diameter 2 mm) for 10 min at 2100 rpm in a vortex and then clarified in a table centrifuge for 1 min at 12,000 rpm.", [["sample", "ANATOMY", 13, 19], ["sample", "ANATOMY", 177, 183], ["phosphate", "CHEMICAL", 275, 284], ["DOI", "CHEMICAL", 136, 139], ["phosphate", "CHEMICAL", 275, 284], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 275, 300], ["sample collection", "PROBLEM", 13, 30], ["Supplementary data", "TEST", 79, 97], ["the map", "TEST", 103, 110], ["Field sample collection", "TEST", 171, 194], ["total RNA preparation", "TREATMENT", 199, 220], ["the 10% faecal suspensions", "TREATMENT", 245, 271], ["phosphate buffered saline (PBS", "TREATMENT", 275, 305], ["added glass beads", "TREATMENT", 342, 359], ["sample", "OBSERVATION_MODIFIER", 13, 19], ["collection", "OBSERVATION", 20, 30], ["glass beads", "OBSERVATION", 348, 359]]], ["If not processed immediately, the supernatants were stored at \u00c080 C.Field sample collection and total RNA preparationTotal RNA was extracted from 100 ml of the supernatant using 1 ml of TRI Reagent (Sigma, St. Louis, USA) according to the manufacturer's instructions.", [["supernatants", "ANATOMY", 34, 46], ["sample", "ANATOMY", 74, 80], ["supernatant", "ANATOMY", 160, 171], ["TRI", "CHEMICAL", 186, 189], ["RNA preparationTotal RNA", "RNA", 102, 126], ["Field sample collection", "TEST", 68, 91], ["total RNA preparationTotal RNA", "TREATMENT", 96, 126], ["TRI Reagent", "TREATMENT", 186, 197]]], ["Extracted RNA was dissolved in 100 ml of RNase-free dH 2 O, divided into aliquots and stored at \u00c080 C until further analysis.Reverse transcription and polymerase chain reactionRandom primed reverse transcription (RT) was carried out with the use of Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany) following the manufacturer's instructions.", [["RNase", "GENE_OR_GENE_PRODUCT", 41, 46], ["dH 2 O", "SIMPLE_CHEMICAL", 52, 58], ["RNase", "PROTEIN", 41, 46], ["Extracted RNA", "PROBLEM", 0, 13], ["RNase", "TEST", 41, 46], ["further analysis", "TEST", 108, 124], ["Reverse transcription", "TREATMENT", 125, 146], ["polymerase chain reaction", "PROBLEM", 151, 176], ["RNA", "OBSERVATION_MODIFIER", 10, 13]]], ["PCR for detection of specific RNA-viruses was accomplished with Fast Start Taq DNA Polymerase (Roche, Germany) and with gene specific primers.", [["DNA", "CELLULAR_COMPONENT", 79, 82], ["Fast Start Taq DNA Polymerase", "PROTEIN", 64, 93], ["PCR", "TEST", 0, 3], ["specific RNA-viruses", "PROBLEM", 21, 41], ["gene specific primers", "TREATMENT", 120, 141], ["viruses", "OBSERVATION", 34, 41]]], ["The presence of viral RNA of following enteric pathogens was surveyed: RVA, RVC, members of family Coronaviridae (specifically TGEV, PEDV, porcine respiratory coronavirus \u00c0 PRCV, and porcine hemagglutination encephalomyelitis virus \u00c0 PHEV), PRRSV, enterovirus G (EV-G), teschovirus A (PTV), sapelovirus A (PSV).", [["hemagglutination encephalomyelitis", "DISEASE", 191, 225], ["TGEV", "ORGANISM", 127, 131], ["PEDV", "GENE_OR_GENE_PRODUCT", 133, 137], ["porcine respiratory coronavirus \u00c0 PRCV", "ORGANISM", 139, 177], ["porcine hemagglutination encephalomyelitis virus \u00c0 PHEV", "ORGANISM", 183, 238], ["PRRSV", "ORGANISM", 241, 246], ["enterovirus G", "ORGANISM", 248, 261], ["EV-G", "ORGANISM", 263, 267], ["teschovirus A", "ORGANISM", 270, 283], ["PTV", "CANCER", 285, 288], ["sapelovirus A", "GENE_OR_GENE_PRODUCT", 291, 304], ["PSV", "MULTI-TISSUE_STRUCTURE", 306, 309], ["viral RNA", "RNA", 16, 25], ["porcine respiratory coronavirus", "SPECIES", 139, 170], ["porcine", "SPECIES", 183, 190], ["hemagglutination encephalomyelitis virus", "SPECIES", 191, 231], ["PRRSV", "SPECIES", 241, 246], ["TGEV", "SPECIES", 127, 131], ["PEDV", "SPECIES", 133, 137], ["porcine respiratory coronavirus", "SPECIES", 139, 170], ["PRCV", "SPECIES", 173, 177], ["porcine hemagglutination encephalomyelitis virus", "SPECIES", 183, 231], ["PHEV", "SPECIES", 234, 238], ["PRRSV", "SPECIES", 241, 246], ["enterovirus G (EV-G", "SPECIES", 248, 267], ["PSV", "SPECIES", 306, 309], ["viral RNA", "PROBLEM", 16, 25], ["RVA", "PROBLEM", 71, 74], ["Coronaviridae", "TREATMENT", 99, 112], ["TGEV", "PROBLEM", 127, 131], ["PEDV", "PROBLEM", 133, 137], ["porcine respiratory coronavirus", "PROBLEM", 139, 170], ["PRCV", "TEST", 173, 177], ["porcine hemagglutination encephalomyelitis virus", "PROBLEM", 183, 231], ["PHEV", "TEST", 234, 238], ["PRRSV", "PROBLEM", 241, 246], ["enterovirus G", "TEST", 248, 261], ["EV", "TEST", 263, 265], ["teschovirus", "TEST", 270, 281], ["PTV", "TEST", 285, 288], ["viral RNA", "OBSERVATION", 16, 25], ["RVC", "ANATOMY", 76, 79]]], ["Detection of PTV and PSV was carried out with the use of one primer pair; the two virus species were distinguished according to the PCR product length (PTV -161 bp, PSV -180 bp) and verified with sequencing (Eurofins MWG Operon, Germany).", [["PTV", "CANCER", 13, 16], ["PTV", "DNA", 13, 16], ["PSV", "PROTEIN", 21, 24], ["PCR product length", "DNA", 132, 150], ["PTV", "DNA", 152, 155], ["PSV", "DNA", 165, 168], ["PTV", "TEST", 13, 16], ["PSV", "TREATMENT", 21, 24], ["one primer pair", "TREATMENT", 57, 72], ["the two virus species", "PROBLEM", 74, 95], ["PTV", "TEST", 152, 155], ["bp", "TEST", 161, 163], ["PSV", "TEST", 165, 168], ["bp", "TEST", 174, 176], ["sequencing", "TEST", 196, 206]]], ["Detection of members of Coronaviridae family was accomplished with the use of universal primers detecting four viral species (TGEV, PEDV, PRCV, and PHEV).", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 24, 37], ["TGEV", "ORGANISM", 126, 130], ["PEDV", "GENE_OR_GENE_PRODUCT", 132, 136], ["PRCV", "GENE_OR_GENE_PRODUCT", 138, 142], ["PHEV", "GENE_OR_GENE_PRODUCT", 148, 152], ["Coronaviridae family", "PROTEIN", 24, 44], ["PEDV", "PROTEIN", 132, 136], ["PRCV", "PROTEIN", 138, 142], ["PHEV", "PROTEIN", 148, 152], ["TGEV", "SPECIES", 126, 130], ["PEDV", "SPECIES", 132, 136], ["PRCV", "SPECIES", 138, 142], ["PHEV", "SPECIES", 148, 152], ["universal primers", "TREATMENT", 78, 95], ["four viral species", "PROBLEM", 106, 124], ["PEDV", "PROBLEM", 132, 136]]], ["The specificity of detection primers was verified on the specific pathogens deposited in the Collection of Animal Pathogenic Microorganisms (CAPM, Veterinary Research Institute, Brno) and in the case of RVC on own field isolates of porcine strains (Moutel\u00edkov\u00e1 et al., 2014) .", [["Pathogenic Microorganisms", "DISEASE", 114, 139], ["RVC", "CANCER", 203, 206], ["porcine", "ORGANISM", 232, 239], ["porcine", "SPECIES", 232, 239], ["detection primers", "TEST", 19, 36], ["the specific pathogens", "PROBLEM", 53, 75], ["Animal Pathogenic Microorganisms", "PROBLEM", 107, 139], ["RVC", "PROBLEM", 203, 206], ["porcine strains", "PROBLEM", 232, 247], ["Pathogenic Microorganisms", "OBSERVATION", 114, 139], ["RVC", "ANATOMY", 203, 206], ["porcine strains", "OBSERVATION", 232, 247]]], ["To increase the sensitivity of the reactions, the second round of PCR was carried out with a seminested pair of primers (in RVC and Coronaviridae detection) or with the same set of primers as in the first round.", [["the reactions", "PROBLEM", 31, 44], ["PCR", "TEST", 66, 69], ["a seminested pair of primers", "TREATMENT", 91, 119], ["RVC", "ANATOMY", 124, 127]]], ["Limit of detection (LOD) of the RT-PCR assay with re-amplification was specified for RVA assay by 10-fold serial dilution of porcine RVA strain with known original concentration which was determined by transmission electron microscope virus quantitation using latex particles (Malenovska, 2013) .", [["porcine", "ORGANISM", 125, 132], ["porcine", "SPECIES", 125, 132], ["porcine RVA strain", "SPECIES", 125, 143], ["the RT-PCR assay", "TEST", 28, 44], ["RVA assay", "TEST", 85, 94], ["porcine RVA strain", "TREATMENT", 125, 143], ["RT", "ANATOMY", 32, 34]]], ["The minimal concentration of RVA still detected was 1.2 \u00c2 10 3 virus particles/1 g of faeces.", [["faeces", "ANATOMY", 86, 92], ["faeces", "ORGANISM_SUBSTANCE", 86, 92], ["RVA", "TEST", 29, 32], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25], ["RVA", "OBSERVATION_MODIFIER", 29, 32]]], ["Used primers, sizes of the expected amplicons and references are listed in Supplementary Table S1 (see Supplementary material Table S1 in the online version at DOI: doi:10.1016/j.vetmic.2016.08.003).", [["DOI", "CHEMICAL", 160, 163], ["primers", "TREATMENT", 5, 12], ["sizes", "OBSERVATION_MODIFIER", 14, 19]]], ["The PCR products were examined by electrophoreses in a 2% agarose gel, stained with Midori Green stain (Nippon Genetics Europe, Germany) and visualized by ultraviolet transillumination.", [["agarose", "SIMPLE_CHEMICAL", 58, 65], ["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16], ["a 2% agarose gel", "TREATMENT", 53, 69], ["ultraviolet transillumination", "TEST", 155, 184], ["ultraviolet transillumination", "OBSERVATION", 155, 184]]], ["Selected PCR products of used diagnostic assays were submitted to sequencing and obtained sequences were analysed with the use of BLAST on-line tool to confirm their classification into respective viral species.Phylogenetic analysis of RVA-positive samplesTo further characterize RVA-positive samples we attempted to determine the genotypes of the VP7, VP4, and VP6 segments.", [["samples", "ANATOMY", 249, 256], ["samples", "ANATOMY", 293, 300], ["VP7", "GENE_OR_GENE_PRODUCT", 348, 351], ["VP4", "GENE_OR_GENE_PRODUCT", 353, 356], ["VP6", "GENE_OR_GENE_PRODUCT", 362, 365], ["PCR products", "DNA", 9, 21], ["VP7, VP4, and VP6 segments", "DNA", 348, 374], ["Selected PCR products", "TEST", 0, 21], ["diagnostic assays", "TEST", 30, 47], ["BLAST on-line tool", "TEST", 130, 148], ["Phylogenetic analysis", "TEST", 211, 232], ["RVA", "PROBLEM", 236, 239], ["positive samples", "PROBLEM", 240, 256], ["RVA", "TEST", 280, 283], ["the VP7", "TEST", 344, 351], ["viral species", "OBSERVATION", 197, 210], ["VP7", "ANATOMY_MODIFIER", 348, 351], ["VP4", "ANATOMY_MODIFIER", 353, 356], ["VP6 segments", "ANATOMY_MODIFIER", 362, 374]]], ["The primers used for the whole (VP7, VP6) or partial (VP4) ORF preparation are described in the Supplementary Table S2 (see Supplementary material Table S2 in the online version at DOI: http://dx.doi.org/10.1016/j.vetmic.2016.08.003).", [["DOI", "CHEMICAL", 181, 184], ["VP7", "GENE_OR_GENE_PRODUCT", 32, 35], ["VP6", "GENE_OR_GENE_PRODUCT", 37, 40], ["VP7", "DNA", 32, 35], ["VP6", "DNA", 37, 40], ["VP4", "DNA", 54, 57], ["The primers", "TREATMENT", 0, 11], ["the whole (VP7, VP6", "TREATMENT", 21, 40], ["partial (VP4) ORF preparation", "TREATMENT", 45, 74]]], ["The obtained sequences were phylogenetically analysed with the MEGA version 6 (Tamura et al., 2013) .", [["The obtained sequences", "TEST", 0, 22], ["the MEGA version", "TEST", 59, 75]]], ["To assess the reliability of constructed phylogenetic trees, the bootstrap test with 1000 of replicates was used.", [["the bootstrap test", "TEST", 61, 79]]], ["The bootstrap value >75% indicates satisfactory topology of phylogenetic tree branches; the bootstrap value of 95-100% is very good.", [["tree branches", "MULTI-TISSUE_STRUCTURE", 73, 86], ["The bootstrap value", "TEST", 0, 19], ["the bootstrap value", "TEST", 88, 107], ["phylogenetic tree", "OBSERVATION", 60, 77], ["branches", "OBSERVATION_MODIFIER", 78, 86]]], ["To classify the RVA sequence into the corresponding genotype, the percentage of nucleotide sequence similarity between the Czech RVA strains and RVA sequences deposited in the GenBank was calculated using the p-distances method.", [["nucleotide", "CHEMICAL", 80, 90], ["nucleotide", "CHEMICAL", 80, 90], ["RVA sequence", "DNA", 16, 28], ["Czech RVA strains", "DNA", 123, 140], ["RVA sequences", "DNA", 145, 158], ["Czech RVA", "SPECIES", 123, 132], ["the RVA sequence", "TEST", 12, 28], ["nucleotide sequence", "TEST", 80, 99], ["the Czech RVA strains", "PROBLEM", 119, 140], ["RVA sequences", "TEST", 145, 158], ["the p-distances method", "TREATMENT", 205, 227], ["GenBank", "ANATOMY", 176, 183]]], ["The VP7, VP4, and VP6 genotypes of RVA strains were determined with the use of previously published cut-off values (Matthijnssens et al., 2008) .", [["VP7", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP4", "GENE_OR_GENE_PRODUCT", 9, 12], ["VP6", "GENE_OR_GENE_PRODUCT", 18, 21], ["VP7, VP4, and VP6 genotypes", "DNA", 4, 31], ["The VP7", "TEST", 0, 7], ["VP4", "TEST", 9, 12], ["RVA strains", "PROBLEM", 35, 46], ["RVA strains", "OBSERVATION", 35, 46]]], ["The assigned genotypes were verified with RotaC online tool (Maes et al., 2009) in accord with the Rotavirus Classification Working Group (RCWG) guidelines.Detection of viral pathogens in faeces of wild boarsIn total, 203 faeces samples from wild boars were surveyed for RNA-viruses.", [["faeces samples", "ANATOMY", 222, 236], ["Rotavirus", "DISEASE", 99, 108], ["faeces", "ORGANISM_SUBDIVISION", 188, 194], ["faeces", "ORGANISM", 222, 228], ["boars", "ORGANISM", 247, 252], ["boars", "SPECIES", 247, 252], ["viral pathogens", "PROBLEM", 169, 184], ["faeces samples", "TEST", 222, 236], ["wild boars", "TREATMENT", 242, 252], ["RNA-viruses", "PROBLEM", 271, 282], ["viral pathogens", "OBSERVATION", 169, 184]]], ["The screening revealed presence of RVA, RVC, and members of family Picornaviridae.", [["RVC", "CANCER", 40, 43], ["The screening", "TEST", 0, 13], ["RVA", "PROBLEM", 35, 38], ["family Picornaviridae", "TREATMENT", 60, 81], ["RVA", "OBSERVATION", 35, 38], ["RVC", "ANATOMY", 40, 43]]], ["Single infections with enteral viruses as well as mixed infections with two or three viruses were also evaluated.", [["infections", "DISEASE", 7, 17], ["enteral viruses", "DISEASE", 23, 38], ["infections", "DISEASE", 56, 66], ["Single infections", "PROBLEM", 0, 17], ["enteral viruses", "PROBLEM", 23, 38], ["mixed infections", "PROBLEM", 50, 66], ["three viruses", "PROBLEM", 79, 92], ["infections", "OBSERVATION", 7, 17], ["enteral viruses", "OBSERVATION", 23, 38], ["mixed", "OBSERVATION_MODIFIER", 50, 55], ["infections", "OBSERVATION", 56, 66], ["viruses", "OBSERVATION", 85, 92]]], ["No members of family Coronaviridae (TGEV, PEDV, PRCV, and PHEV) or PRRSV were found.", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 21, 34], ["TGEV", "ORGANISM", 36, 40], ["PEDV", "GENE_OR_GENE_PRODUCT", 42, 46], ["PRCV", "GENE_OR_GENE_PRODUCT", 48, 52], ["PHEV", "GENE_OR_GENE_PRODUCT", 58, 62], ["PRRSV", "ORGANISM", 67, 72], ["family Coronaviridae", "PROTEIN", 14, 34], ["PEDV", "PROTEIN", 42, 46], ["PRCV", "PROTEIN", 48, 52], ["PHEV", "PROTEIN", 58, 62], ["TGEV", "SPECIES", 36, 40], ["PRRSV", "SPECIES", 67, 72], ["TGEV", "SPECIES", 36, 40], ["PEDV", "SPECIES", 42, 46], ["PRCV", "SPECIES", 48, 52], ["PHEV", "SPECIES", 58, 62], ["PRRSV", "SPECIES", 67, 72], ["Coronaviridae", "TREATMENT", 21, 34], ["PEDV", "PROBLEM", 42, 46], ["PRCV", "TREATMENT", 48, 52], ["PHEV", "TREATMENT", 58, 62], ["PRRSV", "PROBLEM", 67, 72]]], ["The distribution of detected viruses on different sites of collection may be seen on the map of the Czech Republic (Supplementary data).", [["detected viruses", "PROBLEM", 20, 36], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["viruses", "OBSERVATION", 29, 36], ["collection", "OBSERVATION", 59, 69]]], ["The acquired sequences were compared with RVA sequences available in the GenBank and the phylogenetic trees based on the nucleotide sequences of VP7, VP4 (VP8* region), and VP6 genes were constructed (Figs.", [["VP7", "GENE_OR_GENE_PRODUCT", 145, 148], ["VP4", "GENE_OR_GENE_PRODUCT", 150, 153], ["VP8* region", "GENE_OR_GENE_PRODUCT", 155, 166], ["VP6", "GENE_OR_GENE_PRODUCT", 173, 176], ["RVA sequences", "DNA", 42, 55], ["VP7", "DNA", 145, 148], ["VP4", "DNA", 150, 153], ["VP8* region", "DNA", 155, 166], ["VP6 genes", "DNA", 173, 182], ["The acquired sequences", "TEST", 0, 22], ["RVA sequences", "TEST", 42, 55], ["the nucleotide sequences", "TEST", 117, 141], ["VP7", "TEST", 145, 148], ["VP4", "TEST", 150, 153]]], ["Although some of the Czech wild boar RVA strains shared the same genotypes (e.g. P211/2014, P218/2014, and P245/2014 were I5 genotype the in the segment coding VP6, or P70/2015 and P211/2014 were G4 genotype in the segment coding VP7), the cross similarities of their sequences on nucleotide level were quite low for most of the analysed gene segments (68.1-81.6% for VP7, 57.5-83.3% for VP4, and 83.4-93.5% for VP6).Detection of RVCs in wild boarsRVC was detected in 12.8% (n = 26) of the faecal samples.", [["RVCs", "ANATOMY", 430, 434], ["faecal samples", "ANATOMY", 490, 504], ["nucleotide", "CHEMICAL", 281, 291], ["nucleotide", "CHEMICAL", 281, 291], ["Czech wild boar RVA strains", "ORGANISM", 21, 48], ["VP6", "GENE_OR_GENE_PRODUCT", 160, 163], ["VP7", "GENE_OR_GENE_PRODUCT", 230, 233], ["VP7", "GENE_OR_GENE_PRODUCT", 368, 371], ["VP4", "GENE_OR_GENE_PRODUCT", 388, 391], ["VP6", "GENE_OR_GENE_PRODUCT", 412, 415], ["RVCs", "GENE_OR_GENE_PRODUCT", 430, 434], ["boarsRVC", "CANCER", 443, 451], ["VP6", "DNA", 160, 163], ["P70/2015", "DNA", 168, 176], ["P211/2014", "DNA", 181, 190], ["VP7", "DNA", 230, 233], ["VP7", "PROTEIN", 368, 371], ["VP4", "PROTEIN", 388, 391], ["VP6", "PROTEIN", 412, 415], ["Czech wild boar RVA", "SPECIES", 21, 40], ["P218/2014", "TEST", 92, 101], ["P245/2014", "TEST", 107, 116], ["VP6", "TEST", 160, 163], ["G4 genotype in the segment coding VP7", "PROBLEM", 196, 233], ["nucleotide level", "TEST", 281, 297], ["VP7", "TEST", 368, 371], ["VP4", "TEST", 388, 391], ["VP6", "TEST", 412, 415], ["RVCs", "TEST", 430, 434], ["wild boarsRVC", "TEST", 438, 451], ["the faecal samples", "TEST", 486, 504], ["segment", "ANATOMY_MODIFIER", 145, 152], ["segment", "ANATOMY_MODIFIER", 215, 222], ["faecal", "ANATOMY", 490, 496]]], ["Two thirds of RVC-positive samples (n = 18) contained RVC as a single detected pathogen.", [["RVC", "ANATOMY", 14, 17], ["samples", "ANATOMY", 27, 34], ["RVC", "ANATOMY", 54, 57], ["RVC", "GENE_OR_GENE_PRODUCT", 14, 17], ["RVC", "CANCER", 54, 57], ["RVC", "TEST", 14, 17], ["positive samples", "PROBLEM", 18, 34], ["RVC", "PROBLEM", 54, 57], ["a single detected pathogen", "PROBLEM", 61, 87], ["RVC", "ANATOMY", 14, 17], ["positive", "OBSERVATION", 18, 26], ["RVC", "ANATOMY", 54, 57], ["pathogen", "OBSERVATION", 79, 87]]], ["In the rest of RVC-positive samples one or more other pathogens were detected (RVA, PSV, PTV).", [["samples", "ANATOMY", 28, 35], ["RVC", "GENE_OR_GENE_PRODUCT", 15, 18], ["positive samples", "PROBLEM", 19, 35], ["more other pathogens", "PROBLEM", 43, 63], ["RVA", "TEST", 79, 82], ["PSV", "TEST", 84, 87], ["PTV", "TEST", 89, 92], ["RVC", "ANATOMY", 15, 18], ["positive", "OBSERVATION", 19, 27]]], ["The percentage of RVC-positive samples was higher in the group of animals younger than 6 months of age (15.6%) than among older animals (11.5%) but the difference was not statistically significant (p < 0.05, Fisher's exact test, GraphPad Prism 5).", [["RVC", "ANATOMY", 18, 21], ["samples", "ANATOMY", 31, 38], ["RVC", "GENE_OR_GENE_PRODUCT", 18, 21], ["RVC", "PROTEIN", 18, 21], ["RVC", "TEST", 18, 21], ["positive samples", "PROBLEM", 22, 38], ["Fisher's exact test", "TEST", 208, 227], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["RVC", "OBSERVATION", 18, 21], ["positive", "OBSERVATION_MODIFIER", 22, 30], ["higher", "OBSERVATION_MODIFIER", 43, 49]]], ["Sixteen randomly selected RVCpositive PCR products (326 bp) were submitted to sequencing.", [["RVCpositive PCR products", "DNA", 26, 50], ["Sixteen randomly selected RVCpositive PCR products", "TREATMENT", 0, 50], ["bp", "TEST", 56, 58]]], ["The similarity of analysed sequences detected in the Czech wild boars and sequences of VP6 segment of porcine RVC strains deposited in the GenBank ranged between 87 and 98% on nucleotide level (data on request).Detection of members of family Picornaviridae in wild boarsThe most prevalent virus detected during our study in wild boars was PTV which was detected in 20.2% (n = 41) of all tested samples including coinfections with other viruses.", [["samples", "ANATOMY", 394, 401], ["nucleotide", "CHEMICAL", 176, 186], ["coinfections", "DISEASE", 412, 424], ["nucleotide", "CHEMICAL", 176, 186], ["Czech wild boars", "ORGANISM", 53, 69], ["VP6", "GENE_OR_GENE_PRODUCT", 87, 90], ["porcine RVC strains", "ORGANISM", 102, 121], ["Picornaviridae", "GENE_OR_GENE_PRODUCT", 242, 256], ["boars", "ORGANISM", 265, 270], ["boars", "ORGANISM", 329, 334], ["PTV", "CANCER", 339, 342], ["samples", "CANCER", 394, 401], ["VP6 segment", "DNA", 87, 98], ["porcine", "SPECIES", 102, 109], ["analysed sequences", "TEST", 18, 36], ["porcine RVC strains", "PROBLEM", 102, 121], ["the GenBank", "TEST", 135, 146], ["nucleotide level", "TEST", 176, 192], ["Picornaviridae", "TREATMENT", 242, 256], ["The most prevalent virus", "PROBLEM", 270, 294], ["our study", "TEST", 311, 320], ["PTV", "TEST", 339, 342], ["all tested samples", "TEST", 383, 401], ["coinfections", "PROBLEM", 412, 424], ["other viruses", "PROBLEM", 430, 443], ["porcine RVC", "OBSERVATION", 102, 113], ["most prevalent", "OBSERVATION_MODIFIER", 274, 288], ["virus", "OBSERVATION", 289, 294], ["viruses", "OBSERVATION", 436, 443]]], ["PSV was less prevalent with 8.9% (n = 18) of positive samples.", [["samples", "ANATOMY", 54, 61], ["PSV", "TEST", 0, 3], ["positive samples", "PROBLEM", 45, 61]]], ["Infections with PTV were found evenly in both age groups of animals while PSV was more often detected in the group of animals above 6 months of age (10.1% of samples were PSV-positive) than in the group of younger animals (6.3% of samples PSV-positive) but the difference was not found statistically significant (p < 0.05, Fisher's exact test, GraphPad Prism 5).", [["samples", "ANATOMY", 158, 165], ["samples", "ANATOMY", 231, 238], ["Infections", "DISEASE", 0, 10], ["PTV", "CANCER", 16, 19], ["samples", "CANCER", 158, 165], ["samples", "CANCER", 231, 238], ["Infections with PTV", "PROBLEM", 0, 19], ["PSV", "TREATMENT", 74, 77], ["samples", "TEST", 158, 165], ["PSV", "TEST", 171, 174], ["samples PSV", "TEST", 231, 242], ["Fisher's exact test", "TEST", 323, 342]]], ["EV-G was detected only in 2.5% (n = 5) of all tested samples (including mixed infections).", [["samples", "ANATOMY", 53, 60], ["infections", "DISEASE", 78, 88], ["EV-G", "GENE_OR_GENE_PRODUCT", 0, 4], ["EV-G", "TEST", 0, 4], ["all tested samples", "TEST", 42, 60], ["mixed infections", "PROBLEM", 72, 88], ["mixed", "OBSERVATION_MODIFIER", 72, 77], ["infections", "OBSERVATION", 78, 88]]], ["All PCR products of PTV-, PSV-, and EV-G-positive samples were sequenced and nucleotide sequences compared to sequences available in the GenBank.", [["samples", "ANATOMY", 50, 57], ["PTV", "CANCER", 20, 23], ["PSV", "GENE_OR_GENE_PRODUCT", 26, 29], ["PCR products", "DNA", 4, 16], ["PTV", "TEST", 20, 23], ["PSV", "TEST", 26, 29], ["EV", "TEST", 36, 38], ["nucleotide sequences", "TEST", 77, 97]]], ["The similarities of picornavirus sequences detected in the Czech wild boars and the sequences in the GenBank were 97-100% for PTV and EV-G, and 97-99% for PSV (data on request).DiscussionThis study investigated the prevalence of eleven enteric viral infections in 203 wild boars culled during the 2014/2015 hunting season in the Czech Republic.", [["viral infections", "DISEASE", 244, 260], ["picornavirus", "ORGANISM", 20, 32], ["PTV", "CANCER", 126, 129], ["EV-G", "GENE_OR_GENE_PRODUCT", 134, 138], ["boars", "ORGANISM", 273, 278], ["picornavirus sequences", "DNA", 20, 42], ["PSV", "PROTEIN", 155, 158], ["boars", "SPECIES", 273, 278], ["Czech wild boars", "SPECIES", 59, 75], ["picornavirus sequences", "TEST", 20, 42], ["the sequences", "TEST", 80, 93], ["the GenBank", "TEST", 97, 108], ["PTV", "TEST", 126, 129], ["EV", "TEST", 134, 136], ["PSV", "TREATMENT", 155, 158], ["This study", "TEST", 187, 197], ["eleven enteric viral infections", "PROBLEM", 229, 260], ["picornavirus", "OBSERVATION", 20, 32], ["GenBank", "ANATOMY", 101, 108], ["enteric", "OBSERVATION_MODIFIER", 236, 243], ["viral infections", "OBSERVATION", 244, 260]]], ["Previously described RT-PCR primers were used to detect RVA, RVC, PRRSV and members of families Coronaviridae (TGEV, PEDV, PRCV, and PHEV) and Picornaviridae (PTV, PSV, and EV-G).DiscussionPorcine rotaviruses (both RVA and RVC) are considered to be major pathogens causing diarrhoea in pigs.", [["diarrhoea", "DISEASE", 273, 282], ["RVC", "GENE_OR_GENE_PRODUCT", 61, 64], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 96, 109], ["TGEV", "ORGANISM", 111, 115], ["PEDV", "GENE_OR_GENE_PRODUCT", 117, 121], ["PRCV", "GENE_OR_GENE_PRODUCT", 123, 127], ["PHEV", "GENE_OR_GENE_PRODUCT", 133, 137], ["PTV", "CANCER", 159, 162], ["EV-G", "GENE_OR_GENE_PRODUCT", 173, 177], ["DiscussionPorcine rotaviruses", "ORGANISM", 179, 208], ["RVC", "CANCER", 223, 226], ["pigs", "ORGANISM", 286, 290], ["RT-PCR primers", "DNA", 21, 35], ["RVA", "PROTEIN", 56, 59], ["RVC", "PROTEIN", 61, 64], ["PRCV", "PROTEIN", 123, 127], ["PHEV", "PROTEIN", 133, 137], ["PTV", "PROTEIN", 159, 162], ["PSV", "PROTEIN", 164, 167], ["TGEV", "SPECIES", 111, 115], ["pigs", "SPECIES", 286, 290], ["RVC", "SPECIES", 61, 64], ["PRRSV", "SPECIES", 66, 71], ["TGEV", "SPECIES", 111, 115], ["PEDV", "SPECIES", 117, 121], ["PRCV", "SPECIES", 123, 127], ["PHEV", "SPECIES", 133, 137], ["pigs", "SPECIES", 286, 290], ["RT-PCR primers", "TREATMENT", 21, 35], ["RVA", "PROBLEM", 56, 59], ["RVC", "PROBLEM", 61, 64], ["families Coronaviridae", "TREATMENT", 87, 109], ["TGEV", "TREATMENT", 111, 115], ["PEDV", "TREATMENT", 117, 121], ["PRCV", "TREATMENT", 123, 127], ["PHEV", "TREATMENT", 133, 137], ["Picornaviridae", "TREATMENT", 143, 157], ["PTV", "TREATMENT", 159, 162], ["PSV", "TREATMENT", 164, 167], ["DiscussionPorcine rotaviruses", "PROBLEM", 179, 208], ["RVA and RVC", "TREATMENT", 215, 226], ["major pathogens", "PROBLEM", 249, 264], ["diarrhoea", "PROBLEM", 273, 282], ["RVC", "ANATOMY", 61, 64], ["RVC", "ANATOMY", 223, 226], ["diarrhoea", "OBSERVATION", 273, 282]]], ["Transmission of RVC from animal reservoir to human host was reported only once in Brazil (Gabbay et al., 2008) and owing to high degree of conservation (>93% of nucleotide sequence identity) of all segments of human RVC isolates (except for the VP3 gene) (Ghosh and Kobayashi, 2011) it may be presumed that zoonotic transmission of RVC strains is a rare event.", [["RVC", "CHEMICAL", 16, 19], ["nucleotide", "CHEMICAL", 161, 171], ["RVC", "DISEASE", 332, 335], ["nucleotide", "CHEMICAL", 161, 171], ["RVC", "GENE_OR_GENE_PRODUCT", 16, 19], ["human", "ORGANISM", 45, 50], ["human", "ORGANISM", 210, 215], ["RVC", "GENE_OR_GENE_PRODUCT", 216, 219], ["VP3", "GENE_OR_GENE_PRODUCT", 245, 248], ["RVC strains", "ORGANISM", 332, 343], ["VP3 gene", "DNA", 245, 253], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 210, 215], ["nucleotide sequence identity", "TEST", 161, 189], ["RVC strains", "PROBLEM", 332, 343], ["RVC", "ANATOMY", 16, 19], ["human RVC", "ANATOMY", 210, 219], ["may be presumed", "UNCERTAINTY", 286, 301]]], ["However, zoonotic potential of RVA strains has been proven repeatedly (Zeller et al., 2012; Papp et al., 2013) .", [["RVA strains", "PROBLEM", 31, 42]]], ["So far, there is no available information concerning RVC prevalence in wild boars and only very limited knowledge about RVA detected in wild boars in Japan (Okadera et al., 2013) .", [["RVC", "ANATOMY", 53, 56], ["RVC", "CANCER", 53, 56], ["no", "UNCERTAINTY", 17, 19]]], ["The detected RVC prevalence in our study was 12.8% (26/203) including coinfections with other enteral viruses.", [["RVC", "ANATOMY", 13, 16], ["coinfections", "DISEASE", 70, 82], ["enteral viruses", "DISEASE", 94, 109], ["RVC", "CANCER", 13, 16], ["our study", "TEST", 31, 40], ["coinfections", "PROBLEM", 70, 82], ["other enteral viruses", "PROBLEM", 88, 109], ["RVC", "OBSERVATION_MODIFIER", 13, 16], ["enteral viruses", "OBSERVATION", 94, 109]]], ["Similar prevalence of RVC was detected in domestic pigs in the Czech Republic (25.6%) (Moutel\u00edkov\u00e1 et al., 2014) , in South Korea (26.2%) (Jeong et al., 2009) or in Italy (31.3%) (Martella et al., 2007) .", [["RVC", "ANATOMY", 22, 25], ["RVC", "DISEASE", 22, 25], ["RVC", "CANCER", 22, 25], ["pigs", "ORGANISM", 51, 55], ["pigs", "SPECIES", 51, 55], ["RVC", "PROBLEM", 22, 25], ["RVC", "OBSERVATION", 22, 25], ["domestic pigs", "OBSERVATION", 42, 55]]], ["Although the RVC infection can cause severe gastroenteritis in pigs of all ages, it may also have subclinical course (Amimo et al., 2013) .", [["RVC infection", "DISEASE", 13, 26], ["gastroenteritis", "DISEASE", 44, 59], ["RVC", "CANCER", 13, 16], ["pigs", "ORGANISM", 63, 67], ["pigs", "SPECIES", 63, 67], ["pigs", "SPECIES", 63, 67], ["the RVC infection", "PROBLEM", 9, 26], ["severe gastroenteritis", "PROBLEM", 37, 59], ["RVC", "ANATOMY", 13, 16], ["infection", "OBSERVATION", 17, 26], ["can cause", "UNCERTAINTY", 27, 36], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["gastroenteritis", "OBSERVATION", 44, 59]]], ["The samples collected during our study came from animals without any apparent clinical signs of a disease and the faeces processed were of normal consistence.", [["samples", "ANATOMY", 4, 11], ["faeces", "ANATOMY", 114, 120], ["faeces", "ORGANISM", 114, 120], ["The samples", "TEST", 0, 11], ["our study", "TEST", 29, 38], ["a disease", "PROBLEM", 96, 105], ["the faeces", "TEST", 110, 120], ["disease", "OBSERVATION", 98, 105]]], ["RVA was in the Czech wild boars detected in 2.5% (5/203) of tested samples which is in agreement with results of Okadera et al. (2013) .", [["samples", "ANATOMY", 67, 74], ["Czech wild boars", "SPECIES", 15, 31], ["RVA", "PROBLEM", 0, 3]]], ["They found RVA in 4.4% of tested faecal samples from wild boars in Japan.", [["faecal samples", "ANATOMY", 33, 47], ["faecal samples", "ORGANISM_SUBSTANCE", 33, 47], ["RVA", "PROBLEM", 11, 14], ["tested faecal samples", "TEST", 26, 47], ["RVA", "OBSERVATION", 11, 14]]], ["The possibility of RVA transmission between wild boars and domestic pigs in Japan was supported by very close phylogenetic relationship between their VP7 and VP4 nucleotide sequences.", [["nucleotide", "CHEMICAL", 162, 172], ["boars", "ORGANISM", 49, 54], ["domestic pigs", "ORGANISM", 59, 72], ["VP7", "GENE_OR_GENE_PRODUCT", 150, 153], ["VP4", "GENE_OR_GENE_PRODUCT", 158, 161], ["VP7 and VP4 nucleotide sequences", "DNA", 150, 182], ["pigs", "SPECIES", 68, 72], ["RVA transmission", "PROBLEM", 19, 35], ["wild boars", "TREATMENT", 44, 54], ["domestic pigs", "TREATMENT", 59, 72], ["their VP7 and VP4 nucleotide sequences", "TEST", 144, 182], ["possibility of", "UNCERTAINTY", 4, 18], ["RVA", "OBSERVATION", 19, 22]]], ["The RVApositive strain P70/2015 detected during our survey showed the highest similarities of all studied genomic segments to human RVA strains which were described elsewhere as porcine-human reassortments (Mullick et al., 2013; Zhou et al., 2015) .", [["human", "ORGANISM", 126, 131], ["porcine", "ORGANISM", 178, 185], ["human", "ORGANISM", 186, 191], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 186, 191], ["The RVApositive strain P70", "TEST", 0, 26], ["our survey", "TEST", 48, 58], ["human RVA strains", "PROBLEM", 126, 143]]], ["It is of great interest that the P[25] genotype of VP4 segment was found so far only very rarely in several RVA strains isolated from humans.", [["VP4", "GENE_OR_GENE_PRODUCT", 51, 54], ["humans", "ORGANISM", 134, 140], ["P[25] genotype", "DNA", 33, 47], ["VP4 segment", "DNA", 51, 62], ["humans", "SPECIES", 134, 140], ["humans", "SPECIES", 134, 140], ["the P[25] genotype of VP4 segment", "PROBLEM", 29, 62], ["several RVA strains", "PROBLEM", 100, 119]]], ["This genotype is thought to be of porcine origin but so far no porcine (or other animal) sample was described to bear this scarce VP4 genotype (Matthijnssens et al., 2010) .", [["sample", "ANATOMY", 89, 95], ["porcine", "ORGANISM", 34, 41], ["porcine", "ORGANISM", 63, 70], ["VP4", "GENE_OR_GENE_PRODUCT", 130, 133], ["porcine (or other animal) sample", "PROBLEM", 63, 95], ["thought to be", "UNCERTAINTY", 17, 30]]], ["This is the first time the possible animal progenitor strain reservoir of P[25] genotype was Fig. 1 .", [["progenitor strain", "ANATOMY", 43, 60], ["animal progenitor strain reservoir", "TREATMENT", 36, 70]]], ["Phylogenetic tree based on the complete CDS (981 bp) of the VP7 gene (G-genotypes).", [["VP7", "GENE_OR_GENE_PRODUCT", 60, 63], ["CDS", "DNA", 40, 43], ["VP7 gene", "DNA", 60, 68], ["Phylogenetic tree", "PROBLEM", 0, 17], ["the complete CDS", "TEST", 27, 43], ["bp", "TEST", 49, 51], ["the VP7 gene", "TEST", 56, 68], ["tree", "OBSERVATION_MODIFIER", 13, 17]]], ["The Czech RVA strains described in this study are marked with a black dot ( region, nucleotide 16-854 of the Gottfried strain KR052749) gene (P-genotypes).", [["nucleotide", "CHEMICAL", 84, 94], ["nucleotide", "CHEMICAL", 84, 94], ["KR052749", "GENE_OR_GENE_PRODUCT", 126, 134], ["nucleotide 16-854 of the Gottfried strain KR052749) gene", "DNA", 84, 140], ["P", "DNA", 142, 143], ["The Czech RVA strains", "PROBLEM", 0, 21], ["this study", "TEST", 35, 45], ["a black dot ( region", "PROBLEM", 62, 82], ["nucleotide", "TEST", 84, 94], ["marked", "OBSERVATION_MODIFIER", 50, 56]]], ["The Czech RVA strains described in this study are marked with a black dot ().", [["The Czech RVA strains", "PROBLEM", 0, 21], ["this study", "TEST", 35, 45], ["marked", "OBSERVATION_MODIFIER", 50, 56]]], ["The tree was generated by the neighbor-joining method using MEGA version 6.", [["MEGA version", "TREATMENT", 60, 72], ["tree", "ANATOMY_MODIFIER", 4, 8]]], ["Bootstrap values (1000 replicates) below 70% were hidden.", [["Bootstrap values", "TEST", 0, 16]]], ["The cut-off value of 85% is indicated with a dashed line.Table 2The highest nucleotide (nt) identities of VP7, VP4 (VP8* region), and VP6 genes of the Czech RVA strains detected in wild boars and other available RVA sequences specified with the use of the p-distances method of MEGA version 6.StrainGene segment studies carried out in Slovenia, Finland, and Canada did not find any anti-PRRSV antibodies (Vengust et al., 2006; H\u00e4lli et al., 2012; McGregor et al., 2015) .", [["nucleotide", "CHEMICAL", 76, 86], ["nucleotide", "CHEMICAL", 76, 86], ["VP7", "GENE_OR_GENE_PRODUCT", 106, 109], ["VP4", "GENE_OR_GENE_PRODUCT", 111, 114], ["VP8* region", "GENE_OR_GENE_PRODUCT", 116, 127], ["VP6", "GENE_OR_GENE_PRODUCT", 134, 137], ["Czech RVA strains", "ORGANISM", 151, 168], ["VP7, VP4 (VP8* region", "DNA", 106, 127], ["VP6 genes", "DNA", 134, 143], ["RVA sequences", "DNA", 212, 225], ["anti-PRRSV antibodies", "PROTEIN", 382, 403], ["Czech RVA", "SPECIES", 151, 160], ["anti-PRRSV", "SPECIES", 382, 392], ["The cut-off value", "TEST", 0, 17], ["a dashed line", "TREATMENT", 43, 56], ["VP7", "TEST", 106, 109], ["VP4", "TEST", 111, 114], ["the Czech RVA strains", "PROBLEM", 147, 168], ["the p-distances method of MEGA version", "TREATMENT", 252, 290], ["StrainGene segment studies", "TEST", 293, 319]]], ["So far, the evidence of PRRS virus presence in wild boar was confirmed in Germany (Reiner et al., 2009) or recently in Slovakia .", [["PRRS virus", "ORGANISM", 24, 34], ["boar", "ORGANISM", 52, 56], ["boar", "SPECIES", 52, 56], ["PRRS virus", "SPECIES", 24, 34], ["boar", "SPECIES", 52, 56], ["PRRS virus presence", "PROBLEM", 24, 43], ["evidence of", "UNCERTAINTY", 12, 23], ["PRRS virus", "OBSERVATION", 24, 34]]], ["In those studies, tissues of lungs, tonsils or spleen were used for PRRSV detection, which are the places of virus replication.", [["tissues", "ANATOMY", 18, 25], ["lungs", "ANATOMY", 29, 34], ["tonsils", "ANATOMY", 36, 43], ["spleen", "ANATOMY", 47, 53], ["tissues", "TISSUE", 18, 25], ["lungs", "ORGAN", 29, 34], ["tonsils", "ORGAN", 36, 43], ["spleen", "ORGAN", 47, 53], ["PRRSV", "ORGANISM", 68, 73], ["PRRSV", "SPECIES", 68, 73], ["those studies", "TEST", 3, 16], ["PRRSV detection", "TEST", 68, 83], ["virus replication", "TREATMENT", 109, 126], ["lungs", "ANATOMY", 29, 34], ["tonsils", "ANATOMY", 36, 43], ["spleen", "ANATOMY", 47, 53], ["virus replication", "OBSERVATION", 109, 126]]], ["Our study did not confirm presence of PRRSV nucleic acid in wild boar faeces although the shedding of virus in faeces of domestic pigs was previously documented (Ram\u00edrez et al., 2008) .ConclusionIn summary, our survey shows that RVA and RVC are circulating in the population of wild boar in the Czech Republic.", [["faeces", "ANATOMY", 70, 76], ["RVC", "ANATOMY", 237, 240], ["nucleic acid", "CHEMICAL", 44, 56], ["RVC", "CHEMICAL", 237, 240], ["PRRSV", "ORGANISM", 38, 43], ["boar faeces", "ORGANISM", 65, 76], ["faeces", "ORGANISM_SUBDIVISION", 111, 117], ["pigs", "ORGANISM", 130, 134], ["RVC", "CANCER", 237, 240], ["boar", "ORGANISM", 283, 287], ["boar", "SPECIES", 65, 69], ["pigs", "SPECIES", 130, 134], ["PRRSV", "SPECIES", 38, 43], ["boar", "SPECIES", 65, 69], ["pigs", "SPECIES", 130, 134], ["Our study", "TEST", 0, 9], ["PRRSV nucleic acid in wild boar faeces", "PROBLEM", 38, 76], ["the shedding of virus", "PROBLEM", 86, 107], ["our survey", "TEST", 207, 217], ["RVA", "PROBLEM", 229, 232], ["RVC", "PROBLEM", 237, 240], ["nucleic acid", "OBSERVATION", 44, 56], ["virus", "OBSERVATION", 102, 107], ["RVA", "OBSERVATION", 229, 232], ["RVC", "ANATOMY", 237, 240], ["wild boar", "OBSERVATION", 278, 287]]], ["To the best of our knowledge, this is the first time the prevalence of RVC was assessed in wild boars.", [["RVC", "ANATOMY", 71, 74], ["RVC", "DISEASE", 71, 74], ["RVC", "CANCER", 71, 74], ["boars", "ORGANISM", 96, 101], ["RVC", "PROBLEM", 71, 74]]], ["RVA strains isolated from wild boars were genetically described and close relationship with human and domestic pig RVA strains was found so the transmission of RVA between wild boars and humans or between domestic pigs and humans and subsequently between domestic pigs and wild boars is highly probable.", [["boars", "ORGANISM", 31, 36], ["human", "ORGANISM", 92, 97], ["domestic", "ORGANISM", 102, 110], ["pig RVA strains", "ORGANISM", 111, 126], ["boars", "ORGANISM", 177, 182], ["humans", "ORGANISM", 187, 193], ["pigs", "ORGANISM", 214, 218], ["humans", "ORGANISM", 223, 229], ["pigs", "ORGANISM", 264, 268], ["boars", "SPECIES", 31, 36], ["human", "SPECIES", 92, 97], ["pig", "SPECIES", 111, 114], ["boars", "SPECIES", 177, 182], ["humans", "SPECIES", 187, 193], ["pigs", "SPECIES", 214, 218], ["humans", "SPECIES", 223, 229], ["pigs", "SPECIES", 264, 268], ["human", "SPECIES", 92, 97], ["pig", "SPECIES", 111, 114], ["humans", "SPECIES", 187, 193], ["pigs", "SPECIES", 214, 218], ["humans", "SPECIES", 223, 229], ["pigs", "SPECIES", 264, 268], ["RVA strains", "PROBLEM", 0, 11], ["human and domestic pig RVA strains", "TREATMENT", 92, 126], ["RVA", "PROBLEM", 160, 163], ["domestic pigs and wild boars", "TREATMENT", 255, 283], ["highly probable", "UNCERTAINTY", 287, 302]]], ["Furthermore, high prevalence of PTV in Czech wild boars was confirmed, PSV and EV-G were found less frequently.", [["PTV", "CANCER", 32, 35], ["EV-G", "GENE_OR_GENE_PRODUCT", 79, 83], ["Czech wild boars", "SPECIES", 39, 55], ["PTV in Czech wild boars", "TREATMENT", 32, 55], ["PSV", "TREATMENT", 71, 74], ["EV-G", "TREATMENT", 79, 83], ["high", "OBSERVATION_MODIFIER", 13, 17]]], ["During our study no PRRSV or members of family Coronaviridae were detected.", [["PRRSV", "ORGANISM", 20, 25], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 47, 60], ["PRRSV", "SPECIES", 20, 25], ["our study", "TEST", 7, 16], ["PRRSV", "PROBLEM", 20, 25], ["family Coronaviridae", "TREATMENT", 40, 60]]], ["Our findings indicate that wild boars might contribute to the genetic variability of RVA and also serve as an important reservoir of other enteric viruses including RVC, PTV, PSV, and EV-G.", [["boars", "ORGANISM", 32, 37], ["RVC", "CANCER", 165, 168], ["PTV", "MULTI-TISSUE_STRUCTURE", 170, 173], ["RVC", "SPECIES", 165, 168], ["EV-G.", "SPECIES", 184, 189], ["RVA", "PROBLEM", 85, 88], ["PTV", "TEST", 170, 173], ["PSV", "TREATMENT", 175, 178], ["viruses", "OBSERVATION", 147, 154]]]], "PMC7120285": [["IntroductionThe severe acute respiratory syndrome [SARS] first appeared in southern China [Guangdong Province] in November 2002, as an atypical community pneumonia [1].", [["acute respiratory syndrome", "DISEASE", 23, 49], ["SARS", "DISEASE", 51, 55], ["pneumonia", "DISEASE", 154, 163], ["The severe acute respiratory syndrome", "PROBLEM", 12, 49], ["SARS", "PROBLEM", 51, 55], ["an atypical community pneumonia", "PROBLEM", 132, 163], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome", "OBSERVATION", 29, 49], ["atypical", "OBSERVATION_MODIFIER", 135, 143], ["community", "OBSERVATION_MODIFIER", 144, 153], ["pneumonia", "OBSERVATION", 154, 163]]], ["Within a year, the World Health Organization [WHO] reported 8096 cases with 774 deaths [9.6% fatality] in >30 countries from five continents, and the outbreak was declared a pandemic infection [1].", [["deaths", "DISEASE", 80, 86], ["infection", "DISEASE", 183, 192], ["a pandemic infection", "PROBLEM", 172, 192]]], ["In the elderly and subjects with significant comorbid illness, the mortality rate was up to 50%.", [["comorbid illness", "DISEASE", 45, 61], ["significant comorbid illness", "PROBLEM", 33, 61], ["the mortality rate", "TEST", 63, 81], ["significant", "OBSERVATION_MODIFIER", 33, 44]]], ["Investigations revealed that SARS was due to a novel coronavirus [SARS-CoV] which was circulating among wild game animals in wet markets of southern China.", [["SARS", "DISEASE", 29, 33], ["coronavirus", "ORGANISM", 53, 64], ["SARS-CoV", "ORGANISM", 66, 74], ["SARS-CoV", "SPECIES", 66, 74], ["Investigations", "TEST", 0, 14], ["SARS", "PROBLEM", 29, 33], ["a novel coronavirus", "PROBLEM", 45, 64], ["SARS", "PROBLEM", 66, 70]]], ["The palm civet, a wild feline, was considered the amplification host that transmitted the virus to humans from occupational contact and handling by consumers during the preparation for consumption as a delicacy [2, 3].", [["palm", "ORGANISM_SUBDIVISION", 4, 8], ["feline", "ORGANISM", 23, 29], ["humans", "ORGANISM", 99, 105], ["feline", "SPECIES", 23, 29], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105]]], ["SARS-CoV mainly spread from human to human by respiratory droplets or by contact of mucosae with contaminated fomites.", [["respiratory droplets", "ANATOMY", 46, 66], ["mucosae", "ANATOMY", 84, 91], ["fomites", "ANATOMY", 110, 117], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 28, 33], ["human", "ORGANISM", 37, 42], ["mucosae", "MULTI-TISSUE_STRUCTURE", 84, 91], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 37, 42], ["SARS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 37, 42], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["mucosae", "ANATOMY", 84, 91]]], ["Spread of SARS-CoV from mainland China to Hong Kong and other countries was from interpersonal transmission in healthcare facilities, homes, workplaces, and public transports [1].IntroductionThe Middle East respiratory syndrome [MERS] coronavirus [ MERS-CoV] was first isolated from a patient with fatal pneumonia in September 2012, in Jeddah, Saudi Arabia [4].", [["SARS", "DISEASE", 10, 14], ["Middle East respiratory syndrome", "DISEASE", 195, 227], ["pneumonia", "DISEASE", 304, 313], ["SARS-CoV", "ORGANISM", 10, 18], ["Middle East respiratory syndrome", "ORGANISM", 195, 227], ["MERS] coronavirus", "ORGANISM", 229, 246], ["MERS-CoV", "ORGANISM", 249, 257], ["patient", "ORGANISM", 285, 292], ["patient", "SPECIES", 285, 292], ["SARS-CoV", "SPECIES", 10, 18], ["Middle East respiratory syndrome [MERS] coronavirus", "SPECIES", 195, 246], ["MERS-CoV", "SPECIES", 249, 257], ["SARS", "PROBLEM", 10, 14], ["The Middle East respiratory syndrome", "PROBLEM", 191, 227], ["MERS", "PROBLEM", 229, 233], ["coronavirus", "PROBLEM", 235, 246], ["fatal pneumonia", "PROBLEM", 298, 313], ["SARS", "OBSERVATION", 10, 14], ["Middle", "ANATOMY_MODIFIER", 195, 201], ["respiratory syndrome", "OBSERVATION", 207, 227], ["fatal", "OBSERVATION_MODIFIER", 298, 303], ["pneumonia", "OBSERVATION", 304, 313]]], ["From September 2012 through July 2014, WHO reported at least 834 laboratory-confirmed cases of MERS with 288 deaths [34.5% fatality]; and known cases were directly or indirectly linked to countries in the Arabian Peninsula [5].", [["MERS", "DISEASE", 95, 99], ["deaths", "DISEASE", 109, 115]]], ["However, an outbreak of MERS was subsequently reported from South Korea in June 2015.", [["MERS", "DISEASE", 24, 28], ["MERS", "CANCER", 24, 28], ["an outbreak of MERS", "PROBLEM", 9, 28], ["outbreak", "OBSERVATION_MODIFIER", 12, 20]]], ["The illness occurred in an older man who returned from traveling to Saudi Arabia, and within a month 17 secondary cases occurred in South Korea which was connected to the index case [6].", [["illness", "DISEASE", 4, 11], ["man", "ORGANISM", 33, 36], ["man", "SPECIES", 33, 36], ["illness", "OBSERVATION", 4, 11]]], ["Within 2 months the local outbreak resulted in a total of 186 confirmed cases of MERS in South Korea, except for one case exported to China.", [["MERS", "DISEASE", 81, 85]]], ["There were 36 deaths attributed to MERS-CoV infection with a mortality rate of 19.4% [6].VirologyCoronavirusesare the largest RNA viruses and they are enveloped with positive-strand genomes of 26\u201332 kb, and they are distributed globally in a wide range of animals and humans [7].", [["deaths", "DISEASE", 14, 20], ["MERS-CoV infection", "DISEASE", 35, 53], ["MERS-CoV", "ORGANISM", 35, 43], ["humans", "ORGANISM", 268, 274], ["positive-strand genomes", "DNA", 166, 189], ["humans", "SPECIES", 268, 274], ["MERS-CoV", "SPECIES", 35, 43], ["humans", "SPECIES", 268, 274], ["36 deaths", "PROBLEM", 11, 20], ["MERS", "PROBLEM", 35, 39], ["CoV infection", "PROBLEM", 40, 53], ["a mortality rate", "TEST", 59, 75], ["largest", "OBSERVATION_MODIFIER", 118, 125], ["RNA viruses", "OBSERVATION", 126, 137], ["distributed", "OBSERVATION_MODIFIER", 216, 227], ["globally", "OBSERVATION_MODIFIER", 228, 236], ["wide", "OBSERVATION_MODIFIER", 242, 246]]], ["The coronaviruses are classified in four genera based on phylogenetic analysis: alpha-coronaviruses, beta-coronaviruses, gamma-coronaviruses, and delta-coronaviruses [7].", [["coronaviruses", "ORGANISM", 4, 17], ["alpha-coronaviruses", "ORGANISM", 80, 99], ["beta-coronaviruses", "ORGANISM", 101, 119], ["gamma-coronaviruses", "ORGANISM", 121, 140], ["phylogenetic analysis", "TEST", 57, 78], ["alpha-coronaviruses", "PROBLEM", 80, 99], ["beta-coronaviruses", "PROBLEM", 101, 119], ["gamma", "TEST", 121, 126], ["coronaviruses", "PROBLEM", 127, 140], ["coronaviruses", "OBSERVATION", 4, 17]]], ["Some strains of coronaviruses, HCoV-OC43 [a beta-coronavirus] and HCoV-229E [an alpha-coronavirus], are causative agents of the common cold and rarely severe respiratory disease [8, 9].", [["respiratory", "ANATOMY", 158, 169], ["respiratory disease", "DISEASE", 158, 177], ["coronaviruses", "ORGANISM", 16, 29], ["HCoV-OC43", "ORGANISM", 31, 40], ["beta-coronavirus", "ORGANISM", 44, 60], ["HCoV-229E", "ORGANISM", 66, 75], ["alpha-coronavirus", "ORGANISM", 80, 97], ["HCoV-OC43", "SPECIES", 31, 40], ["beta-coronavirus", "SPECIES", 44, 60], ["HCoV-229E [an alpha-coronavirus", "SPECIES", 66, 97], ["Some strains of coronaviruses", "PROBLEM", 0, 29], ["HCoV", "TEST", 31, 35], ["a beta-coronavirus", "TEST", 42, 60], ["HCoV", "TEST", 66, 70], ["an alpha-coronavirus", "PROBLEM", 77, 97], ["the common cold", "PROBLEM", 124, 139], ["rarely severe respiratory disease", "PROBLEM", 144, 177], ["common cold", "ANATOMY", 128, 139], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["respiratory disease", "OBSERVATION", 158, 177]]], ["Other newly discovered human coronaviruses, HCoV-NL634 and HCoV-HKU1, are occasionally associated with severe lower respiratory tract infection in infants and immunocompromised patients [10, 11].", [["lower respiratory tract", "ANATOMY", 110, 133], ["lower respiratory tract infection", "DISEASE", 110, 143], ["human", "ORGANISM", 23, 28], ["coronaviruses", "ORGANISM", 29, 42], ["HCoV-NL634", "ORGANISM", 44, 54], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 59, 68], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 110, 133], ["infants", "ORGANISM", 147, 154], ["patients", "ORGANISM", 177, 185], ["human", "SPECIES", 23, 28], ["infants", "SPECIES", 147, 154], ["patients", "SPECIES", 177, 185], ["human coronaviruses", "SPECIES", 23, 42], ["HCoV", "SPECIES", 44, 48], ["human coronaviruses", "TEST", 23, 42], ["HCoV", "TEST", 44, 48], ["HCoV", "TEST", 59, 63], ["severe lower respiratory tract infection", "PROBLEM", 103, 143], ["human coronaviruses", "OBSERVATION", 23, 42], ["occasionally associated with", "UNCERTAINTY", 74, 102], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory tract", "ANATOMY", 116, 133], ["infection", "OBSERVATION", 134, 143]]], ["SARS-CoV is a lineage B beta-coronavirus and MERS-CoV is a novel beta-coronavirus of lineage C, and both these viruses appear to have crossed the species barrier from bats to humans [12, 13].", [["SARS", "DISEASE", 0, 4], ["MERS-CoV", "ORGANISM", 45, 53], ["lineage C", "CELL", 85, 94], ["humans", "ORGANISM", 175, 181], ["humans", "SPECIES", 175, 181], ["B beta-coronavirus", "SPECIES", 22, 40], ["MERS-CoV", "SPECIES", 45, 53], ["humans", "SPECIES", 175, 181], ["a lineage B beta-coronavirus", "PROBLEM", 12, 40], ["lineage C", "PROBLEM", 85, 94], ["viruses", "OBSERVATION", 111, 118]]], ["Bats are reservoirs for many mammalian coronaviruses [13\u201315].", [["Bats", "CELL", 0, 4], ["mammalian coronaviruses", "ORGANISM", 29, 52], ["many mammalian coronaviruses", "PROBLEM", 24, 52]]], ["Various SARS-like coronaviruses have been found in bats from China, Asia, and Europe, but none were considered as direct progenitor of SARS-CoV.", [["SARS-like coronaviruses", "DISEASE", 8, 31], ["SARS", "DISEASE", 135, 139], ["SARS-like coronaviruses", "ORGANISM", 8, 31], ["progenitor", "CELL", 121, 131], ["SARS-CoV", "ORGANISM", 135, 143], ["SARS-CoV", "SPECIES", 135, 143], ["Various SARS-like coronaviruses", "PROBLEM", 0, 31], ["SARS", "OBSERVATION", 8, 12]]], ["Recently, however, investigators from China reported whole genome sequences of two novel bat coronaviruses from Chinese horseshoe bats closely related to SARS-CoV [16].", [["SARS", "DISEASE", 154, 158], ["bat coronaviruses", "ORGANISM", 89, 106], ["horseshoe bats", "ORGANISM", 120, 134], ["SARS-CoV", "ORGANISM", 154, 162], ["bat coronaviruses", "SPECIES", 89, 106], ["Chinese horseshoe bats", "SPECIES", 112, 134], ["SARS-CoV", "SPECIES", 154, 162], ["two novel bat coronaviruses", "PROBLEM", 79, 106], ["Chinese horseshoe bats", "PROBLEM", 112, 134]]], ["The receptor-binding domain of the spike protein was very similar to that of SARS-CoV, and one of the isolates [bat SL-CoV-w1V1] uses the angiotensin-converting enzyme 2 [ACE2] from humans, civets, and Chinese horseshoe bats for cell entry [16].", [["cell", "ANATOMY", 229, 233], ["SARS", "DISEASE", 77, 81], ["angiotensin", "CHEMICAL", 138, 149], ["SARS-CoV", "ORGANISM", 77, 85], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 138, 169], ["ACE2", "GENE_OR_GENE_PRODUCT", 171, 175], ["humans", "ORGANISM", 182, 188], ["cell", "CELL", 229, 233], ["receptor-binding domain", "PROTEIN", 4, 27], ["spike protein", "PROTEIN", 35, 48], ["angiotensin-converting enzyme 2", "PROTEIN", 138, 169], ["ACE2", "PROTEIN", 171, 175], ["humans", "SPECIES", 182, 188], ["SARS-CoV", "SPECIES", 77, 85], ["humans", "SPECIES", 182, 188], ["Chinese horseshoe bats", "SPECIES", 202, 224], ["the spike protein", "TEST", 31, 48], ["SARS", "PROBLEM", 77, 81], ["CoV", "TEST", 82, 85], ["the isolates", "TEST", 98, 110], ["bat SL", "TEST", 112, 118], ["CoV", "TEST", 119, 122], ["the angiotensin", "TREATMENT", 134, 149], ["converting enzyme", "TREATMENT", 150, 167], ["civets", "TREATMENT", 190, 196], ["Chinese horseshoe bats", "TREATMENT", 202, 224]]], ["SARS-CoV was previously shown to use human ACE2 molecule as its entry receptor, an outstanding feature of its cross-species transmissibility [17].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["human", "ORGANISM", 37, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["human ACE2 molecule", "PROTEIN", 37, 56], ["entry receptor", "PROTEIN", 64, 78], ["human", "SPECIES", 37, 42], ["SARS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 37, 42], ["SARS", "PROBLEM", 0, 4], ["human ACE2 molecule", "TREATMENT", 37, 56]]], ["Thus, the bat SL-CoV-WIVI may be the ancestor virus that precedes the evolution of SARS-CoV in humans.VirologyThe respiratory epithelial cells of humans are the main targets of SARS-CoV, but the virus can also be found in immune cells in the circulation [lymphocytes and macrophages] and in various organs [18].", [["respiratory epithelial cells", "ANATOMY", 114, 142], ["immune cells", "ANATOMY", 222, 234], ["lymphocytes", "ANATOMY", 255, 266], ["macrophages", "ANATOMY", 271, 282], ["organs", "ANATOMY", 299, 305], ["SARS", "DISEASE", 83, 87], ["SARS", "DISEASE", 177, 181], ["bat SL-CoV", "ORGANISM", 10, 20], ["WIVI", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV", "ORGANISM", 83, 91], ["humans", "ORGANISM", 95, 101], ["respiratory epithelial cells", "CELL", 114, 142], ["humans", "ORGANISM", 146, 152], ["SARS-CoV", "ORGANISM", 177, 185], ["immune cells", "CELL", 222, 234], ["lymphocytes", "CELL", 255, 266], ["macrophages", "CELL", 271, 282], ["organs", "ORGAN", 299, 305], ["respiratory epithelial cells", "CELL_TYPE", 114, 142], ["immune cells", "CELL_TYPE", 222, 234], ["lymphocytes", "CELL_TYPE", 255, 266], ["macrophages", "CELL_TYPE", 271, 282], ["humans", "SPECIES", 95, 101], ["humans", "SPECIES", 146, 152], ["SARS-CoV", "SPECIES", 83, 91], ["humans", "SPECIES", 95, 101], ["humans", "SPECIES", 146, 152], ["SARS-CoV", "SPECIES", 177, 185], ["the bat SL", "TEST", 6, 16], ["the ancestor virus", "PROBLEM", 33, 51], ["SARS", "PROBLEM", 83, 87], ["CoV in humans", "PROBLEM", 88, 101], ["SARS-CoV", "PROBLEM", 177, 185], ["the virus", "PROBLEM", 191, 200], ["immune cells", "PROBLEM", 222, 234], ["macrophages", "PROBLEM", 271, 282], ["respiratory epithelial cells", "OBSERVATION", 114, 142], ["main", "OBSERVATION_MODIFIER", 161, 165], ["immune cells", "OBSERVATION", 222, 234], ["circulation", "ANATOMY", 242, 253], ["lymphocytes", "ANATOMY", 255, 266]]], ["MERS-CoV, on the other hand, uses human and bat dipeptidyl peptidase-4 [DPP4] as receptor for cell entry [19].", [["cell", "ANATOMY", 94, 98], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 34, 39], ["dipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 48, 70], ["DPP4", "GENE_OR_GENE_PRODUCT", 72, 76], ["cell", "CELL", 94, 98], ["MERS-CoV", "PROTEIN", 0, 8], ["human and bat dipeptidyl peptidase-4", "PROTEIN", 34, 70], ["DPP4", "PROTEIN", 72, 76], ["human", "SPECIES", 34, 39], ["MERS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 34, 39], ["human and bat dipeptidyl peptidase", "TREATMENT", 34, 68], ["DPP4] as receptor", "TREATMENT", 72, 89], ["CoV", "OBSERVATION", 5, 8]]], ["Replication and RNA protein synthesis by MERS-CoV can occur in human airway epithelial cells, lung fibroblasts, microvascular endothelium, and alveolar type II pneumocytes [20].", [["airway epithelial cells", "ANATOMY", 69, 92], ["lung fibroblasts", "ANATOMY", 94, 110], ["microvascular endothelium", "ANATOMY", 112, 137], ["alveolar type II pneumocytes", "ANATOMY", 143, 171], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["human", "ORGANISM", 63, 68], ["airway epithelial cells", "CELL", 69, 92], ["lung fibroblasts", "CELL", 94, 110], ["microvascular endothelium", "TISSUE", 112, 137], ["alveolar type II pneumocytes", "CELL", 143, 171], ["MERS", "PROTEIN", 41, 45], ["human airway epithelial cells", "CELL_TYPE", 63, 92], ["lung fibroblasts", "CELL_TYPE", 94, 110], ["alveolar type II pneumocytes", "CELL_TYPE", 143, 171], ["human", "SPECIES", 63, 68], ["MERS-CoV", "SPECIES", 41, 49], ["human", "SPECIES", 63, 68], ["Replication", "TREATMENT", 0, 11], ["RNA protein synthesis", "TEST", 16, 37], ["human airway epithelial cells", "PROBLEM", 63, 92], ["lung fibroblasts", "PROBLEM", 94, 110], ["microvascular endothelium", "PROBLEM", 112, 137], ["alveolar type II pneumocytes", "PROBLEM", 143, 171], ["airway", "ANATOMY", 69, 75], ["epithelial cells", "OBSERVATION", 76, 92], ["lung", "ANATOMY", 94, 98], ["fibroblasts", "OBSERVATION", 99, 110], ["microvascular endothelium", "ANATOMY", 112, 137], ["alveolar", "ANATOMY_MODIFIER", 143, 151]]], ["Hence MERS-CoV has a broader tissue tropism than the SARS-CoV.", [["tissue", "ANATOMY", 29, 35], ["SARS", "DISEASE", 53, 57], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["tissue", "TISSUE", 29, 35], ["SARS-CoV", "ORGANISM", 53, 61], ["MERS-CoV", "SPECIES", 6, 14], ["SARS-CoV", "SPECIES", 53, 61], ["a broader tissue tropism", "PROBLEM", 19, 43]]], ["The mechanism of the SARS-CoV and MERS-CoV interspecies transmission appears to be mediated by the S protein, by mediating receptor recognition and membrane fusion, a key factorin host specificity [21].PathogenesisIt has been postulated that the primary mechanismof SARS is immune suppression resulting from damage to the immune cells of the spleen, lymph nodes, and lymphoid tissue with severe lymphopenia [18].", [["membrane", "ANATOMY", 148, 156], ["immune cells", "ANATOMY", 322, 334], ["spleen", "ANATOMY", 342, 348], ["lymph nodes", "ANATOMY", 350, 361], ["lymphoid tissue", "ANATOMY", 367, 382], ["SARS", "DISEASE", 21, 25], ["SARS", "DISEASE", 266, 270], ["lymphopenia", "DISEASE", 395, 406], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 21, 29], ["MERS-CoV", "ORGANISM", 34, 42], ["membrane", "CELLULAR_COMPONENT", 148, 156], ["immune cells", "CELL", 322, 334], ["spleen", "ORGAN", 342, 348], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 350, 361], ["lymphoid tissue", "TISSUE", 367, 382], ["S protein", "PROTEIN", 99, 108], ["immune cells", "CELL_TYPE", 322, 334], ["SARS-CoV", "SPECIES", 21, 29], ["MERS-CoV", "SPECIES", 34, 42], ["the SARS", "PROBLEM", 17, 25], ["CoV", "PROBLEM", 26, 29], ["CoV interspecies transmission", "PROBLEM", 39, 68], ["the S protein", "TEST", 95, 108], ["membrane fusion", "TREATMENT", 148, 163], ["Pathogenesis", "PROBLEM", 202, 214], ["the primary mechanismof SARS", "PROBLEM", 242, 270], ["immune suppression", "PROBLEM", 274, 292], ["lymph nodes", "PROBLEM", 350, 361], ["lymphoid tissue", "PROBLEM", 367, 382], ["severe lymphopenia", "PROBLEM", 388, 406], ["membrane fusion", "OBSERVATION", 148, 163], ["immune cells", "OBSERVATION", 322, 334], ["spleen", "ANATOMY", 342, 348], ["lymph nodes", "OBSERVATION", 350, 361], ["lymphoid tissue", "OBSERVATION", 367, 382], ["severe", "OBSERVATION_MODIFIER", 388, 394], ["lymphopenia", "OBSERVATION", 395, 406]]], ["Furthermore, Gu et al. [18] estimated that the extent of immune cell damage is a better predictor of outcome than the damage to the lungs.", [["immune cell", "ANATOMY", 57, 68], ["lungs", "ANATOMY", 132, 137], ["immune cell", "CELL", 57, 68], ["lungs", "ORGAN", 132, 137], ["immune cell damage", "PROBLEM", 57, 75], ["the damage to the lungs", "PROBLEM", 114, 137], ["immune cell damage", "OBSERVATION", 57, 75], ["lungs", "ANATOMY", 132, 137]]], ["Other investigators judge the lung injury and subsequent acute respiratory distress syndrome [ARDS] and pulmonary fibrosis as the primary events leading to adverse outcome and death.", [["lung", "ANATOMY", 30, 34], ["respiratory", "ANATOMY", 63, 74], ["pulmonary", "ANATOMY", 104, 113], ["lung injury", "DISEASE", 30, 41], ["acute respiratory distress syndrome", "DISEASE", 57, 92], ["ARDS", "DISEASE", 94, 98], ["pulmonary fibrosis", "DISEASE", 104, 122], ["death", "DISEASE", 176, 181], ["lung", "ORGAN", 30, 34], ["pulmonary", "ORGAN", 104, 113], ["the lung injury", "PROBLEM", 26, 41], ["subsequent acute respiratory distress syndrome", "PROBLEM", 46, 92], ["ARDS", "PROBLEM", 94, 98], ["pulmonary fibrosis", "PROBLEM", 104, 122], ["the primary events", "PROBLEM", 126, 144], ["adverse outcome", "PROBLEM", 156, 171], ["death", "PROBLEM", 176, 181], ["lung", "ANATOMY", 30, 34], ["injury", "OBSERVATION", 35, 41], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory distress", "OBSERVATION", 63, 83], ["ARDS", "OBSERVATION", 94, 98], ["pulmonary", "ANATOMY", 104, 113], ["fibrosis", "OBSERVATION", 114, 122]]], ["Using multiple modes of investigation, modeling with gene sets, proteomic analysis, and histopathology correlation, these investigators conclude that the urokinase and the extracellular fibrinolytic pathways are the primary mechanisms involved in lung damage and overall SARS-CoV infection pathogenesis [22].", [["extracellular", "ANATOMY", 172, 185], ["lung", "ANATOMY", 247, 251], ["lung damage", "DISEASE", 247, 258], ["SARS-CoV infection", "DISEASE", 271, 289], ["urokinase", "GENE_OR_GENE_PRODUCT", 154, 163], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 172, 185], ["lung", "ORGAN", 247, 251], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 271, 279], ["urokinase", "PROTEIN", 154, 163], ["SARS-CoV", "SPECIES", 271, 279], ["investigation", "TEST", 24, 37], ["proteomic analysis", "TEST", 64, 82], ["histopathology correlation", "TEST", 88, 114], ["the urokinase", "TREATMENT", 150, 163], ["the extracellular fibrinolytic pathways", "PROBLEM", 168, 207], ["lung damage", "PROBLEM", 247, 258], ["overall SARS", "PROBLEM", 263, 275], ["CoV infection pathogenesis", "PROBLEM", 276, 302], ["lung", "ANATOMY", 247, 251], ["damage", "OBSERVATION", 252, 258]]], ["Events driven by these pathways result in imbalance between the host coagulationand fibrinolysin pathways, ultimately leading to diffuse alveolar and acute lung damage.", [["alveolar", "ANATOMY", 137, 145], ["lung", "ANATOMY", 156, 160], ["acute lung damage", "DISEASE", 150, 167], ["fibrinolysin", "GENE_OR_GENE_PRODUCT", 84, 96], ["alveolar", "MULTI-TISSUE_STRUCTURE", 137, 145], ["lung", "ORGAN", 156, 160], ["diffuse alveolar and acute lung damage", "PROBLEM", 129, 167], ["diffuse", "OBSERVATION_MODIFIER", 129, 136], ["alveolar", "ANATOMY_MODIFIER", 137, 145], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["lung", "ANATOMY", 156, 160], ["damage", "OBSERVATION", 161, 167]]], ["It is likely, however, that both mechanisms are involved in the pathogenesis of SARS.PathogenesisMERS-CoV infection has been associated with severe pneumonia and multiorgan dysfunction with higher mortality rate than SARS.", [["multiorgan", "ANATOMY", 162, 172], ["SARS", "DISEASE", 80, 84], ["infection", "DISEASE", 106, 115], ["pneumonia", "DISEASE", 148, 157], ["multiorgan dysfunction", "DISEASE", 162, 184], ["SARS", "DISEASE", 217, 221], ["multiorgan", "ORGAN", 162, 172], ["SARS", "PROBLEM", 80, 84], ["PathogenesisMERS", "PROBLEM", 85, 101], ["CoV infection", "PROBLEM", 102, 115], ["severe pneumonia", "PROBLEM", 141, 157], ["multiorgan dysfunction", "PROBLEM", 162, 184], ["higher mortality rate than SARS", "PROBLEM", 190, 221], ["is likely", "UNCERTAINTY", 3, 12], ["CoV", "OBSERVATION_MODIFIER", 102, 105], ["infection", "OBSERVATION", 106, 115], ["associated with", "UNCERTAINTY", 125, 140], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["pneumonia", "OBSERVATION", 148, 157], ["multiorgan dysfunction", "OBSERVATION", 162, 184], ["higher", "OBSERVATION_MODIFIER", 190, 196]]], ["A recent study compared the viral replication, cytokine/chemokine response, and antigen presentation in MERS-CoV-infected human monocyte-derived macrophages [MDMs] and SARS-CoV-infected MDMs [23].", [["monocyte", "ANATOMY", 128, 136], ["macrophages", "ANATOMY", 145, 156], ["MDMs", "ANATOMY", 158, 162], ["MDMs", "ANATOMY", 186, 190], ["SARS-CoV-infected", "DISEASE", 168, 185], ["MERS-CoV", "ORGANISM", 104, 112], ["human", "ORGANISM", 122, 127], ["monocyte-derived macrophages", "CELL", 128, 156], ["MDMs", "CELL", 158, 162], ["SARS-CoV", "ORGANISM", 168, 176], ["MDMs", "CELL", 186, 190], ["cytokine", "PROTEIN", 47, 55], ["chemokine", "PROTEIN", 56, 65], ["MERS-CoV-infected human monocyte-derived macrophages", "CELL_LINE", 104, 156], ["MDMs", "CELL_TYPE", 158, 162], ["MDMs", "CELL_TYPE", 186, 190], ["human", "SPECIES", 122, 127], ["MERS-CoV", "SPECIES", 104, 112], ["human", "SPECIES", 122, 127], ["SARS-CoV", "SPECIES", 168, 176], ["A recent study", "TEST", 0, 14], ["the viral replication", "TREATMENT", 24, 45], ["cytokine/chemokine response", "TEST", 47, 74], ["antigen presentation", "TEST", 80, 100], ["MERS", "TEST", 104, 108], ["CoV", "TEST", 109, 112], ["infected human monocyte", "TEST", 113, 136], ["MDMs", "PROBLEM", 158, 162], ["SARS", "PROBLEM", 168, 172], ["infected MDMs", "PROBLEM", 177, 190], ["human monocyte", "OBSERVATION_MODIFIER", 122, 136]]], ["Only MERS-CoV and not SARS-CoV could replicate in human macrophages, but both viruses could not stimulate the expression of antiviral cytokines, interferon-alpha [IFN-\u03b1], and IFN-\u03b2.", [["macrophages", "ANATOMY", 56, 67], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 5, 13], ["SARS-CoV", "ORGANISM", 22, 30], ["human", "ORGANISM", 50, 55], ["macrophages", "CELL", 56, 67], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 145, 161], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 163, 168], ["human macrophages", "CELL_TYPE", 50, 67], ["antiviral cytokines", "PROTEIN", 124, 143], ["interferon-alpha", "PROTEIN", 145, 161], ["IFN", "PROTEIN", 163, 166], ["IFN", "PROTEIN", 175, 178], ["human", "SPECIES", 50, 55], ["MERS-CoV", "SPECIES", 5, 13], ["SARS-CoV", "SPECIES", 22, 30], ["human", "SPECIES", 50, 55], ["CoV", "PROBLEM", 10, 13], ["SARS", "PROBLEM", 22, 26], ["CoV", "PROBLEM", 27, 30], ["both viruses", "PROBLEM", 73, 85], ["antiviral cytokines", "TREATMENT", 124, 143], ["interferon", "TREATMENT", 145, 155], ["IFN", "TREATMENT", 175, 178]]], ["Comparable levels of tumor necrosis factor [TNF]-\u03b1 and interleukin [IL]-6 could be induced by both viruses.", [["tumor", "DISEASE", 21, 26], ["necrosis", "DISEASE", 27, 35], ["tumor necrosis factor [TNF]-\u03b1", "GENE_OR_GENE_PRODUCT", 21, 50], ["interleukin [IL]-6", "GENE_OR_GENE_PRODUCT", 55, 73], ["tumor necrosis factor [TNF]-\u03b1", "PROTEIN", 21, 50], ["interleukin [IL]-6", "PROTEIN", 55, 73], ["tumor necrosis factor", "PROBLEM", 21, 42], ["TNF", "TEST", 44, 47], ["interleukin [IL]", "TREATMENT", 55, 71], ["tumor", "OBSERVATION", 21, 26], ["necrosis", "OBSERVATION_MODIFIER", 27, 35], ["viruses", "OBSERVATION", 99, 106]]], ["However, MERS-CoV induced significantly higher levels of IL-12, IFN-\u00a5, and several chemokines than SARS-CoV [23].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["IL-12", "GENE_OR_GENE_PRODUCT", 57, 62], ["IFN-\u00a5", "GENE_OR_GENE_PRODUCT", 64, 69], ["SARS-CoV", "ORGANISM", 99, 107], ["IL-12", "PROTEIN", 57, 62], ["IFN", "PROTEIN", 64, 67], ["\u00a5", "PROTEIN", 68, 69], ["chemokines", "PROTEIN", 83, 93], ["MERS-CoV", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 99, 107], ["IL", "TEST", 57, 59], ["IFN", "TEST", 64, 67]]], ["In addition, the expression of major histocompatibility complex [HLA] class 1 and costimulatory molecules were greater in MERS-CoV-infected MDMs than SARS-CoV-infected cells.", [["MDMs", "ANATOMY", 140, 144], ["cells", "ANATOMY", 168, 173], ["SARS-CoV-infected", "DISEASE", 150, 167], ["HLA] class 1", "GENE_OR_GENE_PRODUCT", 65, 77], ["MERS-CoV", "ORGANISM", 122, 130], ["MDMs", "CELL", 140, 144], ["SARS-CoV", "ORGANISM", 150, 158], ["cells", "CELL", 168, 173], ["major histocompatibility complex [HLA] class 1 and costimulatory molecules", "PROTEIN", 31, 105], ["MDMs", "CELL_TYPE", 140, 144], ["SARS-CoV-infected cells", "CELL_LINE", 150, 173], ["MERS-CoV", "SPECIES", 122, 130], ["SARS-CoV", "SPECIES", 150, 158], ["costimulatory molecules", "TEST", 82, 105], ["infected MDMs", "PROBLEM", 131, 144], ["SARS", "PROBLEM", 150, 154], ["infected cells", "PROBLEM", 159, 173], ["greater", "OBSERVATION_MODIFIER", 111, 118], ["infected cells", "OBSERVATION", 159, 173]]], ["The establishment of productive infection in macrophages and dendritic cells results in impaired antigen-presenting pathway, and greater aberrant induction of cytokines/chemokines by MERS-CoV could explain the higher severity of infection and greater mortality than SARS-CoV infection [23].", [["macrophages", "ANATOMY", 45, 56], ["dendritic cells", "ANATOMY", 61, 76], ["infection", "DISEASE", 32, 41], ["infection", "DISEASE", 229, 238], ["SARS-CoV infection", "DISEASE", 266, 284], ["macrophages", "CELL", 45, 56], ["dendritic cells", "CELL", 61, 76], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 183, 191], ["SARS-CoV", "ORGANISM", 266, 274], ["macrophages", "CELL_TYPE", 45, 56], ["dendritic cells", "CELL_TYPE", 61, 76], ["cytokines", "PROTEIN", 159, 168], ["chemokines", "PROTEIN", 169, 179], ["MERS-CoV", "SPECIES", 183, 191], ["SARS-CoV", "SPECIES", 266, 274], ["productive infection in macrophages", "PROBLEM", 21, 56], ["dendritic cells", "PROBLEM", 61, 76], ["impaired antigen", "PROBLEM", 88, 104], ["cytokines/chemokines", "TREATMENT", 159, 179], ["CoV", "PROBLEM", 188, 191], ["the higher severity of infection", "PROBLEM", 206, 238], ["SARS", "PROBLEM", 266, 270], ["CoV infection", "PROBLEM", 271, 284], ["productive", "OBSERVATION_MODIFIER", 21, 31], ["infection", "OBSERVATION", 32, 41], ["dendritic cells", "OBSERVATION", 61, 76], ["higher severity", "OBSERVATION_MODIFIER", 210, 225], ["infection", "OBSERVATION", 229, 238], ["greater", "OBSERVATION_MODIFIER", 243, 250]]], ["Furthermore, it has recently been shown that MERS-CoVhas the capacity to infect T lymphocytes and induce apoptosis of these cells by activation of the extrinsic and intrinsic apoptosis pathways [24].", [["T lymphocytes", "ANATOMY", 80, 93], ["cells", "ANATOMY", 124, 129], ["MERS-CoVhas", "GENE_OR_GENE_PRODUCT", 45, 56], ["T lymphocytes", "CELL", 80, 93], ["cells", "CELL", 124, 129], ["MERS", "PROTEIN", 45, 49], ["T lymphocytes", "CELL_TYPE", 80, 93], ["MERS", "PROBLEM", 45, 49], ["the capacity", "PROBLEM", 57, 69], ["T lymphocytes", "PROBLEM", 80, 93], ["apoptosis of these cells", "PROBLEM", 105, 129], ["intrinsic apoptosis", "OBSERVATION", 165, 184]]], ["MERS-CoV-derived proteins inhibit IFN-\u03b1/IFN-\u03b2 expression [25], resulting in lower IFN levels in the respiratory tract [26], and lower expression of type 1 IFN in fatal cases [27].", [["respiratory tract", "ANATOMY", 100, 117], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 34, 39], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 40, 45], ["IFN", "GENE_OR_GENE_PRODUCT", 82, 85], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 148, 158], ["MERS-CoV-derived proteins", "PROTEIN", 0, 25], ["IFN", "PROTEIN", 34, 37], ["IFN", "PROTEIN", 40, 43], ["\u03b2", "PROTEIN", 44, 45], ["IFN", "PROTEIN", 82, 85], ["IFN", "PROTEIN", 155, 158], ["MERS", "TEST", 0, 4], ["IFN", "TEST", 34, 37], ["IFN", "PROBLEM", 40, 43], ["lower IFN levels in the respiratory tract", "PROBLEM", 76, 117], ["type 1 IFN in fatal cases", "PROBLEM", 148, 173], ["lower", "ANATOMY_MODIFIER", 76, 81], ["respiratory tract", "ANATOMY", 100, 117], ["lower expression", "OBSERVATION_MODIFIER", 128, 144]]], ["Persistent expression of proinflammatory cytokines, neutrophil activation, and chemotactic response can result in damage to surrounding uninfected lung tissues [27].", [["neutrophil", "ANATOMY", 52, 62], ["lung tissues", "ANATOMY", 147, 159], ["neutrophil", "CELL", 52, 62], ["lung tissues", "TISSUE", 147, 159], ["proinflammatory cytokines", "PROTEIN", 25, 50], ["proinflammatory cytokines", "PROBLEM", 25, 50], ["neutrophil activation", "PROBLEM", 52, 73], ["chemotactic response", "PROBLEM", 79, 99], ["damage to surrounding uninfected lung tissues", "PROBLEM", 114, 159], ["proinflammatory cytokines", "OBSERVATION", 25, 50], ["neutrophil activation", "OBSERVATION", 52, 73], ["lung", "ANATOMY", 147, 151]]], ["Furthermore, MERS-CoV can impair activation of the adaptive immunity through multiple mechanisms: downregulation of antigen-presenting pathways to inhibit activation of T-cells [28], infection of CD4+ and CD8+ T-cells of peripheral blood lymphoid organs [tonsils and spleen], and extensive apoptosis of T-cells can result in impaired T- and B-cell function as the helper T-cells are also affected.PathogenesisThe spike [S] and nucleocapsid [N] proteins are the major immunogenic components of the coronaviruses and are produced in large quantities during infection.", [["T-cells", "ANATOMY", 169, 176], ["CD4+", "ANATOMY", 196, 200], ["CD8+ T-cells", "ANATOMY", 205, 217], ["peripheral blood lymphoid organs", "ANATOMY", 221, 253], ["tonsils", "ANATOMY", 255, 262], ["spleen", "ANATOMY", 267, 273], ["T-cells", "ANATOMY", 303, 310], ["B-cell", "ANATOMY", 341, 347], ["helper T-cells", "ANATOMY", 364, 378], ["infection", "DISEASE", 183, 192], ["infection", "DISEASE", 555, 564], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["T-cells", "CELL", 169, 176], ["CD4", "GENE_OR_GENE_PRODUCT", 196, 199], ["CD8", "GENE_OR_GENE_PRODUCT", 205, 208], ["peripheral blood lymphoid organs", "TISSUE", 221, 253], ["tonsils", "ORGAN", 255, 262], ["spleen", "ORGAN", 267, 273], ["T-cells", "CELL", 303, 310], ["T", "CELL", 334, 335], ["B-cell", "CELL", 341, 347], ["T-cells", "CELL", 371, 378], ["coronaviruses", "ORGANISM", 497, 510], ["T-cells", "CELL_TYPE", 169, 176], ["CD4+ and CD8+ T-cells", "CELL_TYPE", 196, 217], ["T-cells", "CELL_TYPE", 303, 310], ["helper T-cells", "CELL_TYPE", 364, 378], ["spike [S] and nucleocapsid [N] proteins", "PROTEIN", 413, 452], ["MERS-CoV", "SPECIES", 13, 21], ["downregulation of antigen", "PROBLEM", 98, 123], ["infection", "PROBLEM", 183, 192], ["CD4", "TEST", 196, 199], ["CD8", "TEST", 205, 208], ["peripheral blood lymphoid organs [tonsils and spleen", "PROBLEM", 221, 273], ["extensive apoptosis of T-cells", "PROBLEM", 280, 310], ["The spike", "PROBLEM", 409, 418], ["nucleocapsid [N] proteins", "PROBLEM", 427, 452], ["the coronaviruses", "PROBLEM", 493, 510], ["infection", "PROBLEM", 555, 564], ["peripheral", "ANATOMY_MODIFIER", 221, 231], ["blood", "ANATOMY", 232, 237], ["lymphoid organs", "OBSERVATION", 238, 253], ["tonsils", "ANATOMY", 255, 262], ["spleen", "ANATOMY", 267, 273], ["extensive", "OBSERVATION_MODIFIER", 280, 289], ["apoptosis", "OBSERVATION_MODIFIER", 290, 299], ["coronaviruses", "OBSERVATION", 497, 510], ["large", "OBSERVATION_MODIFIER", 531, 536], ["quantities", "OBSERVATION_MODIFIER", 537, 547], ["infection", "OBSERVATION", 555, 564]]], ["Antibodies against the S and N proteins have diagnostic and therapeutic potentials [28\u201330].", [["S and N proteins", "PROTEIN", 23, 39], ["Antibodies", "TEST", 0, 10], ["the S and N proteins", "PROBLEM", 19, 39]]], ["The S protein appears to be the main determinant of protective immunity and cross-species transmission in SARS-CoV and other emerging animal coronaviruses [31].", [["SARS-CoV", "DISEASE", 106, 114], ["S protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["SARS-CoV", "ORGANISM", 106, 114], ["S protein", "PROTEIN", 4, 13], ["SARS-CoV", "SPECIES", 106, 114], ["The S protein", "TEST", 0, 13], ["protective immunity", "TREATMENT", 52, 71], ["SARS", "PROBLEM", 106, 110], ["CoV", "PROBLEM", 111, 114], ["appears to be", "UNCERTAINTY", 14, 27]]], ["In mice antibodies against S protein protect against SARS-CoV challenge but antibodies against N proteinproduced limited protection [32].TransmissionThe initial cases of SARSin 2003 and the Guangdong outbreak of 2004 were related to game animals contact in wet markets, or handling for consumption [3].", [["SARS", "DISEASE", 53, 57], ["mice", "ORGANISM", 3, 7], ["antibodies against S protein", "GENE_OR_GENE_PRODUCT", 8, 36], ["SARS-CoV", "ORGANISM", 53, 61], ["mice antibodies", "PROTEIN", 3, 18], ["S protein", "PROTEIN", 27, 36], ["antibodies", "PROTEIN", 76, 86], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["SARS-CoV", "SPECIES", 53, 61], ["mice antibodies", "TREATMENT", 3, 18], ["S protein protect", "TREATMENT", 27, 44], ["SARS", "PROBLEM", 53, 57], ["CoV challenge", "TREATMENT", 58, 71], ["antibodies", "TEST", 76, 86]]], ["However, secondary cases [the majority] were from exposure to infected droplets or contaminated fomites from other infected patients.", [["fomites", "ANATOMY", 96, 103], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["infected droplets", "PROBLEM", 62, 79], ["contaminated fomites", "PROBLEM", 83, 103], ["infected", "OBSERVATION_MODIFIER", 62, 70], ["droplets", "OBSERVATION", 71, 79], ["infected", "OBSERVATION_MODIFIER", 115, 123]]], ["Airborne transmission of SARS-CoV was considered rare or unlikely, but may have occurred in one community outbreak from generationof negative pressure by exhaust fans with dissemination of contaminated aerosols from sewage drains [33].", [["SARS", "DISEASE", 25, 29], ["SARS-CoV", "ORGANISM", 25, 33], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["CoV", "PROBLEM", 30, 33], ["contaminated aerosols", "PROBLEM", 189, 210], ["sewage drains", "TREATMENT", 216, 229], ["pressure", "OBSERVATION_MODIFIER", 142, 150]]], ["Nosocomial transmission of SARS-CoV, which was a major source of the outbreaks in Hong Kong and Toronto, was enhanced with the use of nebulizers, suction, intubation, bronchoscopy, or cardiopulmonary resuscitation, from generation of high amount of infectious droplets [1].", [["cardiopulmonary", "ANATOMY", 184, 199], ["SARS-CoV", "DISEASE", 27, 35], ["SARS-CoV", "ORGANISM", 27, 35], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31], ["CoV", "PROBLEM", 32, 35], ["nebulizers", "TREATMENT", 134, 144], ["suction", "TREATMENT", 146, 153], ["intubation", "TREATMENT", 155, 165], ["bronchoscopy", "TREATMENT", 167, 179], ["cardiopulmonary resuscitation", "TREATMENT", 184, 213], ["infectious droplets", "PROBLEM", 249, 268], ["infectious droplets", "OBSERVATION", 249, 268]]], ["It was estimated during the height of the SARS pandemic that each single case resulted in an average of 2\u20134 secondary cases, but some patients were superspreaders of the virus and could infect larger number of people [1].TransmissionMERS-CoV infection outbreak epidemiology strongly suggested zoonotic transmission through an intermediate animal host.", [["SARS", "DISEASE", 42, 46], ["infection", "DISEASE", 242, 251], ["patients", "ORGANISM", 134, 142], ["people", "ORGANISM", 210, 216], ["patients", "SPECIES", 134, 142], ["people", "SPECIES", 210, 216], ["the virus", "PROBLEM", 166, 175], ["TransmissionMERS", "TEST", 221, 237], ["CoV infection", "PROBLEM", 238, 251], ["CoV", "OBSERVATION_MODIFIER", 238, 241], ["infection", "OBSERVATION", 242, 251]]], ["Genomic analysis of the virus indicated that the MERS-CoV arose from a bat coronavirus [34, 35].", [["MERS-CoV", "ORGANISM", 49, 57], ["bat coronavirus", "ORGANISM", 71, 86], ["MERS-CoV", "DNA", 49, 57], ["bat coronavirus", "SPECIES", 71, 86], ["MERS-CoV", "SPECIES", 49, 57], ["bat coronavirus", "SPECIES", 71, 86], ["Genomic analysis", "TEST", 0, 16], ["the virus", "PROBLEM", 20, 29], ["a bat coronavirus", "PROBLEM", 69, 86]]], ["This is supported by the presence of a small fragment of genomic sequences identical to the MERS-CoV Essen isolate [KC875821] in an Egyptian tomb bat [ ] found in Saudi Arabia [36].", [["MERS-CoV", "ORGANISM", 92, 100], ["tomb bat", "ORGANISM", 141, 149], ["genomic sequences", "DNA", 57, 74], ["MERS-CoV", "SPECIES", 92, 100], ["a small fragment of genomic sequences", "PROBLEM", 37, 74], ["small", "OBSERVATION_MODIFIER", 39, 44], ["fragment", "OBSERVATION", 45, 53]]], ["There is increasing evidence that camels are the intermediate hosts responsible for cross-species transmission to humans.", [["camels", "ORGANISM_SUBDIVISION", 34, 40], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["humans", "SPECIES", 114, 120], ["increasing", "OBSERVATION_MODIFIER", 9, 19]]], ["Cross-reactive antibodies to MERS-CoV have been found in dromedary camels in Oman, Canary Islands, and Egypt [37, 38].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 29, 37], ["Cross-reactive antibodies", "PROTEIN", 0, 25], ["MERS-CoV", "PROTEIN", 29, 37], ["MERS-CoV", "SPECIES", 29, 37], ["CoV", "PROBLEM", 34, 37]]], ["Further studies have also confirmed the presence of MERS-CoV RNA by real-time reverse transcriptase polymerase chain reactor [RT-PCR] assay and partial genome sequencing of viral RNA in 3 of 14 nasal samples collected from 14 camels in Qatar and two subjects from the same farm [39].", [["nasal samples", "ANATOMY", 194, 207], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 52, 60], ["nasal samples", "CANCER", 194, 207], ["MERS-CoV RNA", "RNA", 52, 64], ["viral RNA", "RNA", 173, 182], ["MERS-CoV", "SPECIES", 52, 60], ["Further studies", "TEST", 0, 15], ["MERS", "PROBLEM", 52, 56], ["CoV RNA", "TEST", 57, 64], ["chain reactor", "TEST", 111, 124], ["RT-PCR", "TEST", 126, 132], ["assay", "TEST", 134, 139], ["viral RNA", "PROBLEM", 173, 182], ["nasal samples", "TEST", 194, 207], ["viral RNA", "OBSERVATION", 173, 182]]], ["In addition, a fatal case of human MERS-CoV infection was transmitted through contact with an infected camel with rhinorrhea, and the full genome sequence of the isolates from the patient and the camel was identical [40].", [["MERS-CoV infection", "DISEASE", 35, 53], ["rhinorrhea", "DISEASE", 114, 124], ["human", "ORGANISM", 29, 34], ["MERS-CoV", "ORGANISM", 35, 43], ["camel", "ORGANISM", 103, 108], ["patient", "ORGANISM", 180, 187], ["camel", "ORGANISM", 196, 201], ["human", "SPECIES", 29, 34], ["camel", "SPECIES", 103, 108], ["patient", "SPECIES", 180, 187], ["human MERS-CoV", "SPECIES", 29, 43], ["camel", "SPECIES", 103, 108], ["human MERS", "PROBLEM", 29, 39], ["CoV infection", "PROBLEM", 40, 53], ["rhinorrhea", "PROBLEM", 114, 124], ["infection", "OBSERVATION", 44, 53]]], ["It has been recently reported that a high proportion of dromedaries at a slaughterhouse shed nasal MERS-CoV, with a high-risk of human exposure and potential of driving the epidemic [41].TransmissionSimilar to the epidemiology of SARS, most cases of MERS occurred from human-to-human transmission from respiratory droplets, contamination of mucosae with infected fomites, and direct contact in various settings.", [["respiratory droplets", "ANATOMY", 302, 322], ["mucosae", "ANATOMY", 341, 348], ["fomites", "ANATOMY", 363, 370], ["dromedaries", "DISEASE", 56, 67], ["SARS", "DISEASE", 230, 234], ["MERS", "DISEASE", 250, 254], ["nasal", "ORGANISM_SUBDIVISION", 93, 98], ["MERS-CoV", "ORGANISM", 99, 107], ["human", "ORGANISM", 129, 134], ["human", "ORGANISM", 269, 274], ["human", "ORGANISM", 278, 283], ["mucosae", "MULTI-TISSUE_STRUCTURE", 341, 348], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 278, 283], ["MERS-CoV", "SPECIES", 99, 107], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 278, 283], ["SARS", "PROBLEM", 230, 234], ["MERS", "PROBLEM", 250, 254], ["respiratory droplets", "PROBLEM", 302, 322], ["contamination of mucosae", "PROBLEM", 324, 348], ["infected fomites", "PROBLEM", 354, 370], ["respiratory droplets", "OBSERVATION", 302, 322], ["mucosae", "ANATOMY", 341, 348]]], ["There is no direct evidence of airborne transmission of infectious aerosols.", [["airborne transmission of infectious aerosols", "PROBLEM", 31, 75], ["no direct evidence of", "UNCERTAINTY", 9, 30], ["airborne transmission", "OBSERVATION", 31, 52], ["infectious", "OBSERVATION", 56, 66]]], ["Household contact clusters were associated with 26 index patients infected with MERS-CoV in 2013 in Saudi Arabia.", [["patients", "ORGANISM", 57, 65], ["MERS-CoV", "ORGANISM", 80, 88], ["patients", "SPECIES", 57, 65], ["MERS-CoV", "SPECIES", 80, 88]]], ["Investigations for secondary transmission to 280 household contacts, using serology and RT-PCR from throat swabs, identified secondary transmission in 6 of 26 clusters [23%], but only 12 secondary infected persons for a transmission rate of only 5% [42].", [["throat swabs", "ANATOMY", 100, 112], ["persons", "ORGANISM", 206, 213], ["persons", "SPECIES", 206, 213], ["serology", "TEST", 75, 83], ["RT-PCR", "TEST", 88, 94], ["throat swabs", "TEST", 100, 112], ["a transmission rate", "TEST", 218, 237], ["throat", "ANATOMY", 100, 106]]], ["However, most cases of MERS in the Arabian Peninsula resulted from transmission were associated with direct or indirect contact with healthcare facilities, from patients with unrecognized infection to other patients, visitors, and healthcare personnel [39].", [["MERS", "DISEASE", 23, 27], ["infection", "DISEASE", 188, 197], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 207, 215], ["unrecognized infection", "PROBLEM", 175, 197], ["infection", "OBSERVATION", 188, 197]]], ["In the largest single outbreak in Jeddah, Saudi Arabia, in 2014, the majority of patients with MERS-CoV infection had contact with healthcare facility, other patients, or both [44].", [["MERS-CoV infection", "DISEASE", 95, 113], ["patients", "ORGANISM", 81, 89], ["MERS-CoV", "ORGANISM", 95, 103], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 158, 166], ["MERS-CoV", "SPECIES", 95, 103], ["CoV infection", "PROBLEM", 100, 113], ["largest", "OBSERVATION_MODIFIER", 7, 14], ["single", "OBSERVATION_MODIFIER", 15, 21], ["outbreak", "OBSERVATION_MODIFIER", 22, 30], ["infection", "OBSERVATION", 104, 113]]], ["There were 255 laboratory-confirmed MERS-CoV infection of which 64 subjects [25.1%] were asymptomatic and 93 of the ill patients died, with an overall mortality of 36.5%.", [["MERS-CoV infection", "DISEASE", 36, 54], ["MERS-CoV", "ORGANISM", 36, 44], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["MERS-CoV", "SPECIES", 36, 44], ["MERS", "PROBLEM", 36, 40], ["CoV infection", "PROBLEM", 41, 54], ["asymptomatic", "PROBLEM", 89, 101]]], ["However, many of \u201casymptomatic\u201d subjects could recall symptoms consistent with a mild respiratory infection or illness.", [["respiratory", "ANATOMY", 86, 97], ["respiratory infection", "DISEASE", 86, 107], ["illness", "DISEASE", 111, 118], ["symptoms", "PROBLEM", 54, 62], ["a mild respiratory infection", "PROBLEM", 79, 107], ["illness", "PROBLEM", 111, 118], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["respiratory", "ANATOMY", 86, 97], ["infection", "OBSERVATION", 98, 107]]], ["Over 90% of the symptomatic patients [excluding healthcare personnel] had contact with healthcare facility, persons with confirmed MERS, or someone with severe respiratory illness in the preceding 14 days before onset of their illness [44].TransmissionThe largest outbreak of MERS outside of the Middle East occurred in South Korea in 2015, with 186 confirmed cases and 36 [19%] deaths.", [["respiratory", "ANATOMY", 160, 171], ["respiratory illness", "DISEASE", 160, 179], ["illness", "DISEASE", 227, 234], ["deaths", "DISEASE", 379, 385], ["patients", "ORGANISM", 28, 36], ["persons", "ORGANISM", 108, 115], ["patients", "SPECIES", 28, 36], ["persons", "SPECIES", 108, 115], ["severe respiratory illness", "PROBLEM", 153, 179], ["largest", "OBSERVATION_MODIFIER", 256, 263], ["outbreak", "OBSERVATION_MODIFIER", 264, 272], ["Middle", "ANATOMY_MODIFIER", 296, 302]]], ["Investigation in isolation wards found extensive viable MERS-CoV contamination of the air and surrounding materials in MERS units, raising concern of the adequacy of current infection control procedures [45].TransmissionThe interhuman transmissibility of MERS-CoV has been estimated by using Bayesian analysis to calculate the basic reproduction number [Ro].", [["infection", "DISEASE", 174, 183], ["MERS-CoV", "ORGANISM", 255, 263], ["MERS-CoV", "SPECIES", 255, 263], ["extensive viable MERS", "PROBLEM", 39, 60], ["current infection control procedures", "TREATMENT", 166, 202], ["CoV", "PROBLEM", 260, 263], ["Bayesian analysis", "TEST", 292, 309], ["extensive", "OBSERVATION_MODIFIER", 39, 48], ["viable", "OBSERVATION_MODIFIER", 49, 55], ["MERS", "OBSERVATION", 56, 60], ["air", "ANATOMY", 86, 89], ["infection", "OBSERVATION", 174, 183]]], ["The estimated Ro for MERS-CoV was 0.60\u20130.69 [95% confidence interval (CI) 0.42\u20130.92], whereas prepandemic SARS-CoV Ro was 0.80, CI 0.54\u20131.13 [46].", [["SARS", "DISEASE", 106, 110], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 21, 29], ["MERS-CoV", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 106, 114], ["MERS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["CI", "TEST", 70, 72], ["prepandemic SARS", "TEST", 94, 110], ["CoV Ro", "TEST", 111, 117], ["CI", "TEST", 128, 130]]], ["When Ro is above 1.0, a pandemic potential exists; hence MERS-CoV was not considered of pandemic potential.", [["Ro", "CHEMICAL", 5, 7], ["MERS-CoV", "ORGANISM", 57, 65], ["MERS-CoV", "SPECIES", 57, 65]]], ["The cycles of transmissionof SARS-CoV and MERS-CoV are demonstrated in Fig. 4.1a, b.", [["SARS", "DISEASE", 29, 33], ["CoV", "ORGANISM", 34, 37], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["SARS-CoV", "SPECIES", 29, 37], ["MERS-CoV", "SPECIES", 42, 50], ["transmissionof SARS", "TEST", 14, 33], ["CoV", "TEST", 34, 37]]]], "PMC7120969": [["Turning Chemical Warfare into Cancer TherapyCancer and efforts to treat cancer are described in Ancient Egyptian documents dating back to 1600B.C. The first successful cancer treatments were arsenic-based therapies for leukemias, with the first reported application to cancer in the nineteenth century [1].", [["Cancer", "ANATOMY", 30, 36], ["cancer", "ANATOMY", 72, 78], ["cancer", "ANATOMY", 168, 174], ["leukemias", "ANATOMY", 219, 228], ["cancer", "ANATOMY", 269, 275], ["Cancer", "DISEASE", 30, 36], ["cancer", "DISEASE", 72, 78], ["cancer", "DISEASE", 168, 174], ["arsenic", "CHEMICAL", 191, 198], ["leukemias", "DISEASE", 219, 228], ["cancer", "DISEASE", 269, 275], ["arsenic", "CHEMICAL", 191, 198], ["Cancer", "CANCER", 30, 36], ["cancer", "CANCER", 72, 78], ["cancer", "CANCER", 168, 174], ["arsenic", "SIMPLE_CHEMICAL", 191, 198], ["leukemias", "CANCER", 219, 228], ["cancer", "CANCER", 269, 275], ["Cancer TherapyCancer", "TREATMENT", 30, 50], ["cancer", "PROBLEM", 72, 78], ["The first successful cancer treatments", "TREATMENT", 147, 185], ["arsenic-based therapies", "TREATMENT", 191, 214], ["leukemias", "PROBLEM", 219, 228], ["Cancer", "OBSERVATION", 30, 36], ["successful", "OBSERVATION_MODIFIER", 157, 167], ["cancer", "OBSERVATION", 168, 174], ["cancer", "OBSERVATION", 269, 275]]], ["However, nitrogen mustards are often accredited as the first modern chemotherapy.", [["nitrogen mustards", "CHEMICAL", 9, 26], ["nitrogen", "CHEMICAL", 9, 17], ["nitrogen mustards", "SIMPLE_CHEMICAL", 9, 26], ["nitrogen mustards", "TREATMENT", 9, 26], ["the first modern chemotherapy", "TREATMENT", 51, 80], ["nitrogen mustards", "OBSERVATION", 9, 26]]], ["Originally intended as a chemical warfare agent in World War I, nitrogen mustard was stockpiled by several countries.", [["nitrogen mustard", "CHEMICAL", 64, 80], ["nitrogen", "CHEMICAL", 64, 72], ["nitrogen mustard", "SIMPLE_CHEMICAL", 64, 80], ["nitrogen mustard", "TREATMENT", 64, 80]]], ["During World War II, Axis bombers sunk a ship containing large quantities of nitrogen mustard and killed numerous Allied sailors.", [["nitrogen mustard", "CHEMICAL", 77, 93], ["nitrogen", "CHEMICAL", 77, 85], ["nitrogen mustard", "TREATMENT", 77, 93], ["large", "OBSERVATION_MODIFIER", 57, 62], ["nitrogen mustard", "OBSERVATION", 77, 93]]], ["Autopsies revealed that most of the victims\u2019 white blood cells were depleted, suggesting that the nitrogen mustard destroyed these cells or inhibited cell division of these cells.", [["white blood cells", "ANATOMY", 45, 62], ["cells", "ANATOMY", 131, 136], ["cell", "ANATOMY", 150, 154], ["cells", "ANATOMY", 173, 178], ["nitrogen mustard", "CHEMICAL", 98, 114], ["nitrogen", "CHEMICAL", 98, 106], ["white blood cells", "CELL", 45, 62], ["nitrogen mustard", "SIMPLE_CHEMICAL", 98, 114], ["cells", "CELL", 131, 136], ["cell", "CELL", 150, 154], ["cells", "CELL", 173, 178], ["white blood cells", "CELL_TYPE", 45, 62], ["Autopsies", "TEST", 0, 9], ["white blood cells", "TEST", 45, 62], ["the nitrogen mustard", "PROBLEM", 94, 114], ["these cells", "PROBLEM", 125, 136], ["inhibited cell", "OBSERVATION", 140, 154]]], ["This observation birthed the hypothesis that nitrogen mustards might prevent the rapid division of cancer cells, one of the few properties of cancer understood at that time.", [["cancer cells", "ANATOMY", 99, 111], ["cancer", "ANATOMY", 142, 148], ["nitrogen mustards", "CHEMICAL", 45, 62], ["cancer", "DISEASE", 99, 105], ["cancer", "DISEASE", 142, 148], ["nitrogen", "CHEMICAL", 45, 53], ["nitrogen mustards", "SIMPLE_CHEMICAL", 45, 62], ["cancer cells", "CELL", 99, 111], ["cancer", "CANCER", 142, 148], ["cancer cells", "CELL_TYPE", 99, 111], ["nitrogen mustards", "TREATMENT", 45, 62], ["cancer cells", "PROBLEM", 99, 111], ["cancer", "PROBLEM", 142, 148], ["cancer cells", "OBSERVATION", 99, 111], ["cancer", "OBSERVATION", 142, 148]]], ["Today, the hallmarks of cancer as recently redefined by Hanahan and Weinberg [2] include several complex and connected cellular properties that allow for this phenotype: resistance to cell death, sustained angiogenesis, limitless ability to replicate, self-sufficiency in growth factor signaling, unresponsiveness to anti-growth factor signaling, genomic instability and mutation, deregulating cellular energetics, evading immune-mediated destruction, oncogenic inflammation, and invasiveness and metastasis [3].", [["cancer", "ANATOMY", 24, 30], ["cellular", "ANATOMY", 119, 127], ["cell", "ANATOMY", 184, 188], ["cellular", "ANATOMY", 394, 402], ["cancer", "DISEASE", 24, 30], ["death", "DISEASE", 189, 194], ["inflammation", "DISEASE", 462, 474], ["cancer", "CANCER", 24, 30], ["cellular", "CELL", 119, 127], ["cell", "CELL", 184, 188], ["anti-growth factor", "GENE_OR_GENE_PRODUCT", 317, 335], ["cellular", "CELL", 394, 402], ["growth factor", "PROTEIN", 272, 285], ["anti-growth factor", "PROTEIN", 317, 335], ["cancer", "PROBLEM", 24, 30], ["several complex and connected cellular properties", "PROBLEM", 89, 138], ["cell death", "PROBLEM", 184, 194], ["sustained angiogenesis", "PROBLEM", 196, 218], ["self-sufficiency in growth factor signaling", "PROBLEM", 252, 295], ["unresponsiveness", "PROBLEM", 297, 313], ["anti-growth factor signaling", "PROBLEM", 317, 345], ["genomic instability", "PROBLEM", 347, 366], ["mutation", "PROBLEM", 371, 379], ["deregulating cellular energetics", "PROBLEM", 381, 413], ["immune-mediated destruction", "PROBLEM", 423, 450], ["oncogenic inflammation", "PROBLEM", 452, 474], ["invasiveness", "PROBLEM", 480, 492], ["metastasis", "PROBLEM", 497, 507], ["cancer", "OBSERVATION", 24, 30], ["destruction", "OBSERVATION", 439, 450], ["oncogenic", "OBSERVATION_MODIFIER", 452, 461], ["inflammation", "OBSERVATION", 462, 474], ["invasiveness", "OBSERVATION_MODIFIER", 480, 492], ["metastasis", "OBSERVATION", 497, 507]]], ["The identification and understanding of these hallmarks is a direct result of our molecular understanding of cancer that has surfaced relatively recently.", [["cancer", "ANATOMY", 109, 115], ["cancer", "DISEASE", 109, 115], ["cancer", "CANCER", 109, 115], ["cancer", "PROBLEM", 109, 115], ["cancer", "OBSERVATION", 109, 115]]], ["Each of these hallmarks is determined by a host of molecules which together represent distinct therapeutic opportunities to target molecules that give rise to these defining properties of cancer (Fig. 38.1).", [["cancer", "ANATOMY", 188, 194], ["cancer", "DISEASE", 188, 194], ["cancer", "CANCER", 188, 194], ["cancer", "PROBLEM", 188, 194], ["hallmarks", "OBSERVATION", 14, 23], ["distinct", "OBSERVATION_MODIFIER", 86, 94], ["therapeutic", "OBSERVATION_MODIFIER", 95, 106], ["cancer", "OBSERVATION", 188, 194]]]], "cdec1c36256baca0ccd0c1be6c62892f320ca74a": [["IntroductionDespite the drastic containment measures implemented in many countries across the world, SARS-CoV-2 outbreak (also known as , started in the city of Wuhan (Hubei province of China) in December 2019, is spreading all over the world [1, 2] .", [["SARS-CoV-2 outbreak", "DISEASE", 101, 120], ["SARS-CoV", "SPECIES", 101, 109], ["the drastic containment measures", "TREATMENT", 20, 52], ["drastic", "OBSERVATION_MODIFIER", 24, 31], ["containment", "OBSERVATION_MODIFIER", 32, 43]]], ["In this landscape, due to the sudden and rapid explosion of the infection and to the lack of new effective therapies, clinicians are investigating the effect of drugs used for other viral diseases.", [["infection", "DISEASE", 64, 73], ["viral diseases", "DISEASE", 182, 196], ["the sudden", "PROBLEM", 26, 36], ["the infection", "PROBLEM", 60, 73], ["new effective therapies", "TREATMENT", 93, 116], ["drugs", "TREATMENT", 161, 166], ["other viral diseases", "PROBLEM", 176, 196], ["rapid", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 64, 73], ["viral diseases", "OBSERVATION", 182, 196]]], ["Recently, Alberici et al. reported the therapeutic management of the SARS-CoV-2 infection in a population of renal patients in the city of Brescia, in Italy (Brescia COVID Task Force) based on the disease activity [3, 4] .IntroductionCurrently, nephrologists are using the available drugs with particular attention to the renal impairment degree, interactions with other medications and, regarding dialysis patients, to the dialytic clearance.", [["renal", "ANATOMY", 109, 114], ["renal", "ANATOMY", 322, 327], ["SARS-CoV-2 infection", "DISEASE", 69, 89], ["renal impairment", "DISEASE", 322, 338], ["SARS-CoV-2", "ORGANISM", 69, 79], ["renal", "ORGAN", 109, 114], ["patients", "ORGANISM", 115, 123], ["renal", "ORGAN", 322, 327], ["patients", "ORGANISM", 407, 415], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 407, 415], ["SARS-CoV-2", "SPECIES", 69, 79], ["the therapeutic management", "TREATMENT", 35, 61], ["the SARS", "PROBLEM", 65, 73], ["CoV", "PROBLEM", 74, 77], ["2 infection", "PROBLEM", 78, 89], ["the disease activity", "PROBLEM", 193, 213], ["the available drugs", "TREATMENT", 269, 288], ["the renal impairment degree", "PROBLEM", 318, 345], ["other medications", "TREATMENT", 365, 382], ["dialysis", "TREATMENT", 398, 406], ["the dialytic clearance", "TEST", 420, 442], ["infection", "OBSERVATION", 80, 89], ["renal", "ANATOMY", 109, 114], ["patients", "OBSERVATION", 115, 123], ["Brescia", "ANATOMY", 139, 146], ["renal", "ANATOMY", 322, 327], ["impairment", "OBSERVATION", 328, 338]]], ["The novel SARS-CoV-2 coronavirus is a RNA obligate intracellular virus and its replication depends on synthetic processes of the host cell.", [["intracellular", "ANATOMY", 51, 64], ["cell", "ANATOMY", 134, 138], ["SARS-CoV-2 coronavirus", "ORGANISM", 10, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["host cell", "CELL", 129, 138], ["host cell", "CELL_TYPE", 129, 138], ["CoV-2 coronavirus", "SPECIES", 15, 32], ["SARS-CoV-2 coronavirus", "SPECIES", 10, 32], ["The novel SARS", "TEST", 0, 14], ["CoV", "TEST", 15, 18], ["a RNA obligate intracellular virus", "PROBLEM", 36, 70], ["intracellular virus", "OBSERVATION", 51, 70], ["host cell", "OBSERVATION", 129, 138]]], ["To date, none of the drugs currently used have shown therapeutics effects.", [["the drugs", "TREATMENT", 17, 26]]], ["As a rule, to be effective, selective antiviral agents should block viral entry into the cell and should be active inside the host cell, whereas nonselective viral inhibitors may interfere with human cell function and promote the side effects.IntroductionThe clinical onset of SARS-CoV-2 infection is variable from mild self-limited influenza-like symptoms to severe acute respiratory syndrome with possible association of multi-organ failure (MOF) secondary to cytokine storm and sometimes of haemophagocitic syndrome [3, 4] .", [["cell", "ANATOMY", 89, 93], ["cell", "ANATOMY", 131, 135], ["cell", "ANATOMY", 200, 204], ["multi-organ", "ANATOMY", 423, 434], ["SARS-CoV-2 infection", "DISEASE", 277, 297], ["influenza-like symptoms", "DISEASE", 333, 356], ["acute respiratory syndrome", "DISEASE", 367, 393], ["multi-organ failure", "DISEASE", 423, 442], ["MOF", "DISEASE", 444, 447], ["haemophagocitic syndrome", "DISEASE", 494, 518], ["cell", "CELL", 89, 93], ["cell", "CELL", 131, 135], ["human", "ORGANISM", 194, 199], ["cell", "CELL", 200, 204], ["SARS-CoV-2", "ORGANISM", 277, 287], ["multi-organ", "ORGAN", 423, 434], ["host cell", "CELL_TYPE", 126, 135], ["cytokine", "PROTEIN", 462, 470], ["human", "SPECIES", 194, 199], ["CoV-", "SPECIES", 282, 286], ["human", "SPECIES", 194, 199], ["SARS-CoV-2", "SPECIES", 277, 287], ["selective antiviral agents", "TREATMENT", 28, 54], ["nonselective viral inhibitors", "TREATMENT", 145, 174], ["human cell function", "TREATMENT", 194, 213], ["SARS", "PROBLEM", 277, 281], ["CoV", "PROBLEM", 282, 285], ["2 infection", "PROBLEM", 286, 297], ["mild self-limited influenza", "PROBLEM", 315, 342], ["symptoms", "PROBLEM", 348, 356], ["severe acute respiratory syndrome", "PROBLEM", 360, 393], ["multi-organ failure", "PROBLEM", 423, 442], ["MOF)", "PROBLEM", 444, 448], ["cytokine storm", "PROBLEM", 462, 476], ["haemophagocitic syndrome", "PROBLEM", 494, 518], ["host cell", "OBSERVATION", 126, 135], ["mild", "OBSERVATION_MODIFIER", 315, 319], ["severe", "OBSERVATION_MODIFIER", 360, 366], ["acute", "OBSERVATION_MODIFIER", 367, 372], ["respiratory syndrome", "OBSERVATION", 373, 393], ["multi-organ", "ANATOMY", 423, 434], ["failure", "OBSERVATION", 435, 442], ["cytokine storm", "OBSERVATION", 462, 476], ["haemophagocitic syndrome", "OBSERVATION", 494, 518]]], ["It is noteworthy that in renal patients, the latter conditions represent a real challenge in terms of care and survival.", [["renal", "ANATOMY", 25, 30], ["renal", "CANCER", 25, 30], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["the latter conditions", "PROBLEM", 41, 62], ["survival", "TREATMENT", 111, 119], ["renal", "ANATOMY", 25, 30]]], ["The diagnosis of COVID-19 has to be confirmed by the reverse transcription polymerase chain reaction (RT-PCR) or gene sequencing for respiratory tract samples or by serologic test.", [["respiratory tract samples", "ANATOMY", 133, 158], ["COVID-19", "CHEMICAL", 17, 25], ["COVID-19", "DNA", 17, 25], ["COVID", "TEST", 17, 22], ["the reverse transcription polymerase chain reaction", "PROBLEM", 49, 100], ["RT-PCR", "TEST", 102, 108], ["gene sequencing", "TEST", 113, 128], ["respiratory tract samples", "TEST", 133, 158], ["serologic test", "TEST", 165, 179], ["respiratory tract", "ANATOMY", 133, 150]]], ["Moreover, chest computed tomography (CT) represents an indispensable tool for screening and diagnosing COVID-19 patients.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["chest computed tomography (CT", "TEST", 10, 39], ["screening", "TEST", 78, 87], ["diagnosing COVID", "TEST", 92, 108], ["chest", "ANATOMY", 10, 15]]], ["CT chest imaging in the early stages, from mild to severe cases, shows interstitial changes that developed into multiple ground glass opacification with or without consolidative abnormalities.", [["interstitial", "ANATOMY", 71, 83], ["CT chest imaging", "TEST", 0, 16], ["mild to severe cases", "PROBLEM", 43, 63], ["interstitial changes", "PROBLEM", 71, 91], ["multiple ground glass opacification", "PROBLEM", 112, 147], ["consolidative abnormalities", "PROBLEM", 164, 191], ["chest", "ANATOMY", 3, 8], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["interstitial", "OBSERVATION", 71, 83], ["multiple", "OBSERVATION_MODIFIER", 112, 120], ["ground glass opacification", "OBSERVATION", 121, 147], ["without", "UNCERTAINTY", 156, 163], ["consolidative", "OBSERVATION_MODIFIER", 164, 177], ["abnormalities", "OBSERVATION", 178, 191]]], ["Pleural effusions and mediastinal lymphnode enlargement should be detected in severe cases.", [["Pleural effusions", "ANATOMY", 0, 17], ["mediastinal lymphnode", "ANATOMY", 22, 43], ["Pleural effusions", "DISEASE", 0, 17], ["mediastinal lymphnode enlargement", "DISEASE", 22, 55], ["Pleural effusions", "CANCER", 0, 17], ["mediastinal lymphnode", "CANCER", 22, 43], ["Pleural effusions", "PROBLEM", 0, 17], ["mediastinal lymphnode enlargement", "PROBLEM", 22, 55], ["effusions", "OBSERVATION", 8, 17], ["mediastinal", "ANATOMY", 22, 33], ["lymphnode", "OBSERVATION", 34, 43], ["severe", "OBSERVATION_MODIFIER", 78, 84]]], ["Findings are often peripheral, bilateral and involving the lower lobes.", [["lower lobes", "ANATOMY", 59, 70], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 59, 70], ["peripheral", "ANATOMY_MODIFIER", 19, 29], ["bilateral", "ANATOMY_MODIFIER", 31, 40], ["lower lobes", "ANATOMY", 59, 70]]], ["Also chest X-ray can be considered a reliable diagnostic tool, especially in the emergency setting [2, [5] [6] [7] .", [["chest X-ray", "TEST", 5, 16], ["chest", "ANATOMY", 5, 10]]], ["Actually, the therapeutic management of SARS-CoV-2 infection has many fields of action.", [["SARS", "DISEASE", 40, 44], ["infection", "DISEASE", 51, 60], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV-2", "SPECIES", 40, 50], ["the therapeutic management", "TREATMENT", 10, 36], ["SARS", "PROBLEM", 40, 44], ["CoV", "PROBLEM", 45, 48], ["2 infection", "PROBLEM", 49, 60]]], ["On one side to block the viral replication, on the other side to treat the interstitial pneumonia and MOF which cause the most severe clinical setting.", [["interstitial", "ANATOMY", 75, 87], ["interstitial pneumonia", "DISEASE", 75, 97], ["MOF", "DISEASE", 102, 105], ["the viral replication", "TREATMENT", 21, 42], ["the interstitial pneumonia", "PROBLEM", 71, 97], ["MOF", "PROBLEM", 102, 105], ["viral replication", "OBSERVATION", 25, 42], ["interstitial", "ANATOMY_MODIFIER", 75, 87], ["pneumonia", "OBSERVATION", 88, 97], ["most severe", "OBSERVATION_MODIFIER", 122, 133]]], ["Currently, the antiviral drugs available are: hydroxychloroquine (HCL), chloroquine (CL), azithromycin, lopinavir/ritonavir, darunavir/cobicistat, remdesivir, and favipavir.", [["hydroxychloroquine", "CHEMICAL", 46, 64], ["HCL", "CHEMICAL", 66, 69], ["chloroquine", "CHEMICAL", 72, 83], ["CL", "CHEMICAL", 85, 87], ["azithromycin", "CHEMICAL", 90, 102], ["lopinavir/ritonavir", "CHEMICAL", 104, 123], ["darunavir", "CHEMICAL", 125, 134], ["cobicistat", "CHEMICAL", 135, 145], ["remdesivir", "CHEMICAL", 147, 157], ["favipavir", "CHEMICAL", 163, 172], ["hydroxychloroquine", "CHEMICAL", 46, 64], ["HCL", "CHEMICAL", 66, 69], ["chloroquine", "CHEMICAL", 72, 83], ["azithromycin", "CHEMICAL", 90, 102], ["lopinavir", "CHEMICAL", 104, 113], ["ritonavir", "CHEMICAL", 114, 123], ["darunavir", "CHEMICAL", 125, 134], ["cobicistat", "CHEMICAL", 135, 145], ["remdesivir", "CHEMICAL", 147, 157], ["favipavir", "CHEMICAL", 163, 172], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 46, 64], ["HCL", "SIMPLE_CHEMICAL", 66, 69], ["chloroquine", "SIMPLE_CHEMICAL", 72, 83], ["CL", "SIMPLE_CHEMICAL", 85, 87], ["azithromycin", "SIMPLE_CHEMICAL", 90, 102], ["lopinavir", "SIMPLE_CHEMICAL", 104, 113], ["ritonavir", "SIMPLE_CHEMICAL", 114, 123], ["darunavir", "SIMPLE_CHEMICAL", 125, 134], ["cobicistat", "SIMPLE_CHEMICAL", 135, 145], ["remdesivir", "SIMPLE_CHEMICAL", 147, 157], ["favipavir", "SIMPLE_CHEMICAL", 163, 172], ["the antiviral drugs", "TREATMENT", 11, 30], ["hydroxychloroquine (HCL)", "TREATMENT", 46, 70], ["chloroquine (CL)", "TREATMENT", 72, 88], ["azithromycin", "TREATMENT", 90, 102], ["lopinavir", "TREATMENT", 104, 113], ["ritonavir", "TREATMENT", 114, 123], ["darunavir", "TREATMENT", 125, 134], ["cobicistat", "TREATMENT", 135, 145], ["remdesivir", "TREATMENT", 147, 157], ["favipavir", "TREATMENT", 163, 172]]], ["The other drugs, in particular those necessary to contrast the MOF and haemophagocytic syndrome are corticosteroids and monoclonal antibodies; also dialysis therapy with special filters should be used.", [["MOF", "DISEASE", 63, 66], ["haemophagocytic syndrome", "DISEASE", 71, 95], ["corticosteroids", "SIMPLE_CHEMICAL", 100, 115], ["monoclonal antibodies", "PROTEIN", 120, 141], ["The other drugs", "TREATMENT", 0, 15], ["the MOF", "PROBLEM", 59, 66], ["haemophagocytic syndrome", "PROBLEM", 71, 95], ["corticosteroids", "TREATMENT", 100, 115], ["monoclonal antibodies", "TREATMENT", 120, 141], ["dialysis therapy", "TREATMENT", 148, 164], ["special filters", "TREATMENT", 170, 185], ["haemophagocytic syndrome", "OBSERVATION", 71, 95]]], ["Given the lack of specific therapy about the ongoing SARS-CoV-2 infection, we conducted a brief review to summarize the mechanism of action and the potentially side effects of the treatment currently available, focusing on the effects of the drugs on renal disease at different stages in terms of therapeutic management and survival.Hydroxychloroquine and chloroquineHydroxychloroquine (HCL) and chloroquine (CL) are the cornerstone therapies of sensitive falciparum malaria and the second-line treatment of many rheumatologic diseases.", [["renal", "ANATOMY", 251, 256], ["SARS-CoV-2 infection", "DISEASE", 53, 73], ["renal disease", "DISEASE", 251, 264], ["Hydroxychloroquine", "CHEMICAL", 333, 351], ["chloroquine", "CHEMICAL", 356, 367], ["Hydroxychloroquine", "CHEMICAL", 367, 385], ["HCL", "CHEMICAL", 387, 390], ["chloroquine", "CHEMICAL", 396, 407], ["CL", "CHEMICAL", 409, 411], ["falciparum malaria", "DISEASE", 456, 474], ["rheumatologic diseases", "DISEASE", 513, 535], ["Hydroxychloroquine", "CHEMICAL", 333, 351], ["chloroquine", "CHEMICAL", 356, 367], ["Hydroxychloroquine", "CHEMICAL", 367, 385], ["HCL", "CHEMICAL", 387, 390], ["chloroquine", "CHEMICAL", 396, 407], ["SARS-CoV-2", "ORGANISM", 53, 63], ["renal", "ORGAN", 251, 256], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 333, 351], ["chloroquineHydroxychloroquine", "SIMPLE_CHEMICAL", 356, 385], ["HCL", "SIMPLE_CHEMICAL", 387, 390], ["chloroquine", "SIMPLE_CHEMICAL", 396, 407], ["CL", "MULTI-TISSUE_STRUCTURE", 409, 411], ["specific therapy", "TREATMENT", 18, 34], ["the ongoing SARS", "PROBLEM", 41, 57], ["CoV-2 infection", "PROBLEM", 58, 73], ["the treatment", "TREATMENT", 176, 189], ["the drugs", "TREATMENT", 238, 247], ["renal disease", "PROBLEM", 251, 264], ["therapeutic management", "TREATMENT", 297, 319], ["survival", "TREATMENT", 324, 332], ["Hydroxychloroquine", "TREATMENT", 333, 351], ["chloroquineHydroxychloroquine (HCL)", "TREATMENT", 356, 391], ["chloroquine (CL)", "TREATMENT", 396, 412], ["the cornerstone therapies", "TREATMENT", 417, 442], ["sensitive falciparum malaria", "PROBLEM", 446, 474], ["the second-line treatment", "TREATMENT", 479, 504], ["many rheumatologic diseases", "PROBLEM", 508, 535], ["renal", "ANATOMY", 251, 256], ["disease", "OBSERVATION", 257, 264], ["many", "OBSERVATION_MODIFIER", 508, 512], ["rheumatologic diseases", "OBSERVATION", 513, 535]]], ["Both drugs are currently under investigation for use in the SARS-CoV-2 outbreaks.", [["SARS", "DISEASE", 60, 64], ["SARS-CoV-2", "ORGANISM", 60, 70], ["SARS-CoV", "SPECIES", 60, 68]]], ["CL and HCL were described as potent in vitro inhibitors for other coronaviruses, including SARS-CoV-1, so they are used in the treatment of SARS-CoV-2 [8, 9] .", [["HCL", "ANATOMY", 7, 10], ["HCL", "CHEMICAL", 7, 10], ["SARS", "DISEASE", 140, 144], ["CL", "MULTI-TISSUE_STRUCTURE", 0, 2], ["HCL", "CANCER", 7, 10], ["coronaviruses", "ORGANISM", 66, 79], ["SARS-CoV-1", "ORGANISM", 91, 101], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV-1", "SPECIES", 91, 101], ["SARS-CoV", "SPECIES", 140, 148], ["HCL", "TREATMENT", 7, 10], ["vitro inhibitors", "TREATMENT", 39, 55], ["other coronaviruses", "PROBLEM", 60, 79], ["SARS", "PROBLEM", 91, 95], ["SARS", "PROBLEM", 140, 144], ["CoV", "TEST", 145, 148]]], ["It has been demonstrated that SARS-CoV-2 links the angiotensin-converting enzyme 2 expressed in the lung.", [["lung", "ANATOMY", 100, 104], ["angiotensin", "CHEMICAL", 51, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 51, 82], ["lung", "ORGAN", 100, 104], ["angiotensin-converting enzyme 2", "PROTEIN", 51, 82], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["the angiotensin", "TREATMENT", 47, 62], ["converting enzyme", "TEST", 63, 80], ["lung", "ANATOMY", 100, 104]]], ["CL/HCL could also reduce the expression of sialic acids that may be required for binding SARS-CoV-2.", [["HCL", "ANATOMY", 3, 6], ["HCL", "CHEMICAL", 3, 6], ["sialic acids", "CHEMICAL", 43, 55], ["sialic acids", "CHEMICAL", 43, 55], ["sialic acids", "SIMPLE_CHEMICAL", 43, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["CL/HCL", "TREATMENT", 0, 6], ["sialic acids", "TREATMENT", 43, 55], ["binding SARS", "TEST", 81, 93], ["CoV", "TEST", 94, 97]]], ["Moreover, CL/HCL increase endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.", [["CL/HCL", "ANATOMY", 10, 16], ["endosomal", "ANATOMY", 26, 35], ["cell", "ANATOMY", 58, 62], ["cellular", "ANATOMY", 120, 128], ["HCL", "CHEMICAL", 13, 16], ["SARS", "DISEASE", 142, 146], ["endosomal", "CELLULAR_COMPONENT", 26, 35], ["cell", "CELL", 58, 62], ["cellular", "CELL", 120, 128], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 142, 150], ["cellular receptors", "PROTEIN", 120, 138], ["SARS-CoV", "SPECIES", 142, 150], ["CL/HCL", "TREATMENT", 10, 16], ["endosomal pH", "PROBLEM", 26, 38], ["virus/cell fusion", "TREATMENT", 52, 69], ["CoV", "PROBLEM", 147, 150], ["cell fusion", "OBSERVATION", 58, 69]]], ["Finally, CL/HCL interfere with the virion assembly through the blockage of cytokine storm reducing the pro-inflammatory mediators production and, consequently, the systemic inflammatory response syndrome (SIRS).", [["CL/HCL", "ANATOMY", 9, 15], ["virion", "ANATOMY", 35, 41], ["HCL", "CHEMICAL", 12, 15], ["SIRS", "DISEASE", 205, 209], ["HCL", "CANCER", 12, 15], ["virion", "CELLULAR_COMPONENT", 35, 41], ["cytokine", "PROTEIN", 75, 83], ["pro-inflammatory mediators", "PROTEIN", 103, 129], ["CL/HCL", "TREATMENT", 9, 15], ["the virion", "TREATMENT", 31, 41], ["cytokine storm", "TREATMENT", 75, 89], ["the systemic inflammatory response syndrome", "PROBLEM", 160, 203], ["cytokine storm", "OBSERVATION", 75, 89], ["pro-inflammatory mediators", "OBSERVATION", 103, 129], ["systemic", "OBSERVATION_MODIFIER", 164, 172], ["inflammatory response syndrome", "OBSERVATION", 173, 203]]], ["In a Chinese study [9] , patients diagnosed as mild, moderate, and severe cases of pneumonia received chloroquine 500 mg twice per day for 10 days, improving clinical outcomes.", [["pneumonia", "DISEASE", 83, 92], ["chloroquine", "CHEMICAL", 102, 113], ["chloroquine", "CHEMICAL", 102, 113], ["patients", "ORGANISM", 25, 33], ["chloroquine", "SIMPLE_CHEMICAL", 102, 113], ["patients", "SPECIES", 25, 33], ["a Chinese study", "TEST", 3, 18], ["pneumonia", "PROBLEM", 83, 92], ["chloroquine", "TREATMENT", 102, 113], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["moderate", "OBSERVATION_MODIFIER", 53, 61], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["pneumonia", "OBSERVATION", 83, 92]]], ["Moreover, HCL plus azithromycin (AZT) are significantly associated with SARS-CoV-2 viral load reduction [8, [10] [11] [12] [13] [14] [15] [16] [17] although the association leads to the more common side effect of QTc interval prolongation.Hydroxychloroquine and chloroquineRecently, concerns have been raised about the toxicity of CL and HCL in patients with SARS-CoV-2 infection.", [["HCL", "CHEMICAL", 10, 13], ["azithromycin", "CHEMICAL", 19, 31], ["AZT", "CHEMICAL", 33, 36], ["Hydroxychloroquine", "CHEMICAL", 239, 257], ["toxicity", "DISEASE", 319, 327], ["HCL", "CHEMICAL", 338, 341], ["SARS-CoV-2 infection", "DISEASE", 359, 379], ["HCL", "CHEMICAL", 10, 13], ["azithromycin", "CHEMICAL", 19, 31], ["AZT", "CHEMICAL", 33, 36], ["Hydroxychloroquine", "CHEMICAL", 239, 257], ["HCL", "SIMPLE_CHEMICAL", 10, 13], ["azithromycin", "SIMPLE_CHEMICAL", 19, 31], ["AZT", "SIMPLE_CHEMICAL", 33, 36], ["CoV-2", "ORGANISM", 77, 82], ["[10] [11] [12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 108, 147], ["QTc", "SIMPLE_CHEMICAL", 213, 216], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 239, 257], ["CL", "MULTI-TISSUE_STRUCTURE", 331, 333], ["HCL", "CANCER", 338, 341], ["patients", "ORGANISM", 345, 353], ["SARS-CoV-2", "ORGANISM", 359, 369], ["patients", "SPECIES", 345, 353], ["SARS-CoV-2", "SPECIES", 359, 369], ["HCL", "TREATMENT", 10, 13], ["azithromycin (AZT)", "TREATMENT", 19, 37], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80], ["viral load reduction", "TEST", 83, 103], ["QTc interval prolongation", "PROBLEM", 213, 238], ["Hydroxychloroquine", "TREATMENT", 239, 257], ["chloroquineRecently", "TREATMENT", 262, 281], ["the toxicity of CL", "PROBLEM", 315, 333], ["HCL", "TREATMENT", 338, 341], ["SARS", "PROBLEM", 359, 363], ["CoV", "PROBLEM", 364, 367], ["2 infection", "PROBLEM", 368, 379], ["more common", "OBSERVATION_MODIFIER", 186, 197], ["prolongation", "OBSERVATION_MODIFIER", 226, 238], ["infection", "OBSERVATION", 370, 379]]], ["In a multinational study, 96,032 COVID patients were enrolled.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["a multinational study", "TEST", 3, 24]]], ["A group of 14,888 treated patients (1868 received chloroquine, 3783 received CL plus a macrolide, 3016 received HCL, and 6221 received HCL plus macrolide) was compared with 81,144 patients in the control group.", [["chloroquine", "CHEMICAL", 50, 61], ["CL", "CHEMICAL", 77, 79], ["macrolide", "CHEMICAL", 87, 96], ["HCL", "CHEMICAL", 112, 115], ["HCL", "CHEMICAL", 135, 138], ["macrolide", "CHEMICAL", 144, 153], ["chloroquine", "CHEMICAL", 50, 61], ["macrolide", "CHEMICAL", 87, 96], ["macrolide", "CHEMICAL", 144, 153], ["patients", "ORGANISM", 26, 34], ["chloroquine", "SIMPLE_CHEMICAL", 50, 61], ["HCL", "CANCER", 112, 115], ["macrolide", "SIMPLE_CHEMICAL", 144, 153], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 180, 188], ["chloroquine", "TREATMENT", 50, 61], ["a macrolide", "TREATMENT", 85, 96], ["HCL", "TREATMENT", 112, 115], ["HCL", "TREATMENT", 135, 138], ["macrolide", "TREATMENT", 144, 153]]], ["A multivariate analysis showed that the treatments with HCL and Cl with or without a macrolide, were independently associated with an increased risk of in-hospital mortality.Hydroxychloroquine and chloroquineFurthermore, the HCL regimens were independently associated with an increased risk of ventricular arrhythmia if compared with the control group [18] .Hydroxychloroquine and chloroquineIn addition, Borba et al. have compared two dosage regimens of CL (450 mg two times per day on day one then 450 mg once daily for 5 days and 600 mg two times per day for 10 days) and the study was finished early due to ventricular tachycardia and QTc prolongation especially in the high dose arm [19] .", [["ventricular", "ANATOMY", 294, 305], ["ventricular", "ANATOMY", 611, 622], ["HCL", "CHEMICAL", 56, 59], ["Cl", "CHEMICAL", 64, 66], ["macrolide", "CHEMICAL", 85, 94], ["Hydroxychloroquine", "CHEMICAL", 174, 192], ["chloroquineFurthermore", "CHEMICAL", 197, 219], ["HCL", "CHEMICAL", 225, 228], ["ventricular arrhythmia", "DISEASE", 294, 316], ["Hydroxychloroquine", "CHEMICAL", 358, 376], ["chloroquineIn", "CHEMICAL", 381, 394], ["CL", "CHEMICAL", 455, 457], ["ventricular tachycardia", "DISEASE", 611, 634], ["QTc prolongation", "DISEASE", 639, 655], ["HCL", "CHEMICAL", 56, 59], ["Cl", "CHEMICAL", 64, 66], ["macrolide", "CHEMICAL", 85, 94], ["Hydroxychloroquine", "CHEMICAL", 174, 192], ["chloroquineFurthermore", "CHEMICAL", 197, 219], ["Hydroxychloroquine", "CHEMICAL", 358, 376], ["chloroquineIn", "CHEMICAL", 381, 394], ["HCL", "SIMPLE_CHEMICAL", 56, 59], ["Cl", "SIMPLE_CHEMICAL", 64, 66], ["macrolide", "SIMPLE_CHEMICAL", 85, 94], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 174, 192], ["chloroquineFurthermore", "SIMPLE_CHEMICAL", 197, 219], ["ventricular", "ORGAN", 294, 305], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 358, 376], ["chloroquineIn", "SIMPLE_CHEMICAL", 381, 394], ["CL", "SIMPLE_CHEMICAL", 455, 457], ["ventricular", "MULTI-TISSUE_STRUCTURE", 611, 622], ["A multivariate analysis", "TEST", 0, 23], ["HCL", "TREATMENT", 56, 59], ["a macrolide", "TREATMENT", 83, 94], ["Hydroxychloroquine", "TREATMENT", 174, 192], ["chloroquineFurthermore", "TREATMENT", 197, 219], ["the HCL regimens", "TREATMENT", 221, 237], ["ventricular arrhythmia", "PROBLEM", 294, 316], ["Hydroxychloroquine", "TREATMENT", 358, 376], ["chloroquineIn addition", "TREATMENT", 381, 403], ["Borba et al", "TREATMENT", 405, 416], ["CL", "TREATMENT", 455, 457], ["the study", "TEST", 575, 584], ["ventricular tachycardia", "PROBLEM", 611, 634], ["QTc prolongation", "PROBLEM", 639, 655], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["ventricular", "ANATOMY", 294, 305], ["arrhythmia", "OBSERVATION", 306, 316], ["ventricular", "ANATOMY", 611, 622], ["tachycardia", "OBSERVATION", 623, 634]]], ["Based on the above studies, it is crucial to emphasize the importance of performing a tailor-made dosage of drugs through a continual monitoring of renal function which often worsens during SARS-CoV-2 infection, with risk of accumulation and significant increase in toxicity.Hydroxychloroquine and chloroquineIdeal dose and duration of SARS-CoV-2 treatment are unknown.", [["renal", "ANATOMY", 148, 153], ["infection", "DISEASE", 201, 210], ["toxicity", "DISEASE", 266, 274], ["Hydroxychloroquine", "CHEMICAL", 275, 293], ["chloroquineIdeal", "CHEMICAL", 298, 314], ["Hydroxychloroquine", "CHEMICAL", 275, 293], ["chloroquineIdeal", "CHEMICAL", 298, 314], ["renal", "ORGAN", 148, 153], ["CoV-2", "ORGANISM", 195, 200], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 275, 293], ["chloroquineIdeal", "SIMPLE_CHEMICAL", 298, 314], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 336, 346], ["the above studies", "TEST", 9, 26], ["drugs", "TREATMENT", 108, 113], ["a continual monitoring of renal function", "TEST", 122, 162], ["SARS", "PROBLEM", 190, 194], ["CoV-2 infection", "PROBLEM", 195, 210], ["accumulation", "PROBLEM", 225, 237], ["significant increase in toxicity", "PROBLEM", 242, 274], ["Hydroxychloroquine", "TREATMENT", 275, 293], ["chloroquineIdeal dose", "TREATMENT", 298, 319], ["SARS", "TREATMENT", 336, 340], ["CoV-2 treatment", "TREATMENT", 341, 356], ["renal", "ANATOMY", 148, 153], ["infection", "OBSERVATION", 201, 210], ["significant", "OBSERVATION_MODIFIER", 242, 253], ["increase", "OBSERVATION_MODIFIER", 254, 262]]], ["More data are available for HCL sulfate dose recommended in general population than CL: 200 mg, two times per day (BID) or three times per day (TID) for 10 days.", [["HCL sulfate", "CHEMICAL", 28, 39], ["HCL sulfate", "CHEMICAL", 28, 39], ["HCL sulfate", "SIMPLE_CHEMICAL", 28, 39], ["CL", "MULTI-TISSUE_STRUCTURE", 84, 86], ["HCL sulfate dose", "TREATMENT", 28, 44]]], ["The adjusted doses of HCL required for renal patients are based on the glomerular filtration rate (GFR).", [["renal", "ANATOMY", 39, 44], ["glomerular", "ANATOMY", 71, 81], ["HCL", "CHEMICAL", 22, 25], ["HCL", "SIMPLE_CHEMICAL", 22, 25], ["patients", "ORGANISM", 45, 53], ["glomerular", "TISSUE", 71, 81], ["patients", "SPECIES", 45, 53], ["The adjusted doses of HCL", "TREATMENT", 0, 25], ["renal patients", "TREATMENT", 39, 53], ["the glomerular filtration rate", "TEST", 67, 97], ["GFR", "TEST", 99, 102], ["renal", "ANATOMY", 39, 44]]], ["For GFR between 15 and 30 ml/min the suggested dose is 200 mg/die once a day (OD).", [["GFR", "TEST", 4, 7]]], ["For GFR < 15 ml/min the suggested dose is 200 mg every other day (alternate days).", [["GFR", "TEST", 4, 7]]], ["CL is administered 500 mg BID for 10 days.", [["BID", "CHEMICAL", 26, 29], ["CL", "MULTI-TISSUE_STRUCTURE", 0, 2], ["BID", "SIMPLE_CHEMICAL", 26, 29]]], ["The adjusted doses of CL required for renal patients are: if GFR < 10 ml/min, in hemodialysis (HD) and peritoneal dialysis (PD) 50% of dose should be administered.", [["renal", "ANATOMY", 38, 43], ["peritoneal", "ANATOMY", 103, 113], ["PD", "DISEASE", 124, 126], ["CL", "MULTI-TISSUE_STRUCTURE", 22, 24], ["patients", "ORGANISM", 44, 52], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 103, 113], ["patients", "SPECIES", 44, 52], ["The adjusted doses of CL", "TREATMENT", 0, 24], ["GFR", "TEST", 61, 64], ["hemodialysis", "TREATMENT", 81, 93], ["HD", "TREATMENT", 95, 97], ["peritoneal dialysis (PD)", "TREATMENT", 103, 127], ["renal", "ANATOMY", 38, 43], ["peritoneal", "ANATOMY", 103, 113]]], ["In continuous renal replacement therapy (CRRT), no dosage adjustment is required.Hydroxychloroquine and chloroquineStandard dose, renal dose, and side effects of HCL, CL and of all the other drugs described below are summarized in Table 1 .", [["renal", "ANATOMY", 14, 19], ["renal", "ANATOMY", 130, 135], ["Hydroxychloroquine", "CHEMICAL", 81, 99], ["chloroquineStandard", "CHEMICAL", 104, 123], ["HCL", "CHEMICAL", 162, 165], ["Hydroxychloroquine", "CHEMICAL", 81, 99], ["chloroquineStandard", "CHEMICAL", 104, 123], ["renal", "ORGAN", 14, 19], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 81, 99], ["chloroquineStandard", "SIMPLE_CHEMICAL", 104, 123], ["renal", "ORGAN", 130, 135], ["HCL", "SIMPLE_CHEMICAL", 162, 165], ["CL", "MULTI-TISSUE_STRUCTURE", 167, 169], ["continuous renal replacement therapy", "TREATMENT", 3, 39], ["CRRT", "TREATMENT", 41, 45], ["dosage adjustment", "TREATMENT", 51, 68], ["Hydroxychloroquine", "TREATMENT", 81, 99], ["chloroquineStandard dose", "TREATMENT", 104, 128], ["renal dose", "TREATMENT", 130, 140], ["HCL", "TREATMENT", 162, 165], ["CL", "TREATMENT", 167, 169], ["all the other drugs", "TREATMENT", 177, 196], ["renal", "ANATOMY", 14, 19], ["replacement", "OBSERVATION", 20, 31], ["renal", "ANATOMY", 130, 135]]], ["Side effects are reported in Table 2 .AzithromycinAZT is a bacteriostatic antibiotic of macrolides class with a broad spectrum of activity against Gram-positive and atypical bacteria.", [["AzithromycinAZT", "CHEMICAL", 38, 53], ["macrolides", "CHEMICAL", 88, 98], ["AzithromycinAZT", "CHEMICAL", 38, 53], ["macrolides", "CHEMICAL", 88, 98], ["AzithromycinAZT", "SIMPLE_CHEMICAL", 38, 53], ["Gram-", "GENE_OR_GENE_PRODUCT", 147, 152], ["Side effects", "PROBLEM", 0, 12], ["AzithromycinAZT", "TREATMENT", 38, 53], ["a bacteriostatic antibiotic of macrolides class", "TREATMENT", 57, 104], ["Gram-positive and atypical bacteria", "PROBLEM", 147, 182], ["atypical", "OBSERVATION_MODIFIER", 165, 173], ["bacteria", "OBSERVATION", 174, 182]]], ["The immune-modulatory and antiinflammatory effects of AZT take place by the downregulation of the inflammatory response, the reduction in cytokine production, and the induction of immunoglobulin antibodies production.", [["AZT", "CHEMICAL", 54, 57], ["AZT", "CHEMICAL", 54, 57], ["AZT", "SIMPLE_CHEMICAL", 54, 57], ["immunoglobulin antibodies", "GENE_OR_GENE_PRODUCT", 180, 205], ["cytokine", "PROTEIN", 138, 146], ["immunoglobulin antibodies", "PROTEIN", 180, 205], ["AZT", "TREATMENT", 54, 57], ["the inflammatory response", "PROBLEM", 94, 119], ["the reduction in cytokine production", "PROBLEM", 121, 157], ["immunoglobulin antibodies production", "PROBLEM", 180, 216], ["antiinflammatory", "OBSERVATION_MODIFIER", 26, 42], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["reduction", "OBSERVATION_MODIFIER", 125, 134], ["cytokine production", "OBSERVATION", 138, 157]]], ["Moreover, AZT is active in vitro against Zika and Ebola viruses [20, 21] .", [["AZT", "CHEMICAL", 10, 13], ["Ebola viruses", "DISEASE", 50, 63], ["AZT", "CHEMICAL", 10, 13], ["AZT", "SIMPLE_CHEMICAL", 10, 13], ["Zika", "GENE_OR_GENE_PRODUCT", 41, 45], ["Ebola viruses", "ORGANISM", 50, 63], ["Ebola viruses", "SPECIES", 50, 63], ["AZT", "TREATMENT", 10, 13], ["Zika", "PROBLEM", 41, 45], ["Ebola viruses", "PROBLEM", 50, 63], ["active", "OBSERVATION_MODIFIER", 17, 23]]], ["Given these properties, AZT and other macrolides have been studied for their potential use as target therapy for viral respiratory infections including MERS (Middle East respiratory syndrome) and SARS (severe acute respiratory syndrome).", [["respiratory", "ANATOMY", 119, 130], ["AZT", "CHEMICAL", 24, 27], ["macrolides", "CHEMICAL", 38, 48], ["viral respiratory infections", "DISEASE", 113, 141], ["Middle East respiratory syndrome", "DISEASE", 158, 190], ["SARS", "DISEASE", 196, 200], ["acute respiratory syndrome", "DISEASE", 209, 235], ["AZT", "CHEMICAL", 24, 27], ["macrolides", "CHEMICAL", 38, 48], ["AZT", "SIMPLE_CHEMICAL", 24, 27], ["macrolides", "SIMPLE_CHEMICAL", 38, 48], ["AZT", "TREATMENT", 24, 27], ["other macrolides", "TREATMENT", 32, 48], ["target therapy", "TREATMENT", 94, 108], ["viral respiratory infections", "PROBLEM", 113, 141], ["MERS", "PROBLEM", 152, 156], ["Middle East respiratory syndrome", "PROBLEM", 158, 190], ["SARS (severe acute respiratory syndrome", "PROBLEM", 196, 235], ["respiratory infections", "OBSERVATION", 119, 141], ["severe", "OBSERVATION_MODIFIER", 202, 208], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["respiratory syndrome", "OBSERVATION", 215, 235]]], ["In a recent publication, the authors suggested that macrolide therapy had no significant association with MERS COV RNA clearance and was not associated with a significant change in 90-days patient mortality [22] .", [["macrolide", "CHEMICAL", 52, 61], ["macrolide", "CHEMICAL", 52, 61], ["macrolide", "SIMPLE_CHEMICAL", 52, 61], ["patient", "ORGANISM", 189, 196], ["patient", "SPECIES", 189, 196], ["macrolide therapy", "TREATMENT", 52, 69]]], ["Furthermore, another study conducted in a small population suggested that the use of HCL in combination with AZT was associated with significant viral load reduction in SARS-CoV-2 infected patients, although the risk of QT prolongation induced by the association of the two drugs should be considered.", [["HCL", "CHEMICAL", 85, 88], ["AZT", "CHEMICAL", 109, 112], ["SARS-CoV-2 infected", "DISEASE", 169, 188], ["QT prolongation", "DISEASE", 220, 235], ["HCL", "CHEMICAL", 85, 88], ["AZT", "CHEMICAL", 109, 112], ["HCL", "SIMPLE_CHEMICAL", 85, 88], ["AZT", "SIMPLE_CHEMICAL", 109, 112], ["SARS-CoV-2", "ORGANISM", 169, 179], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 169, 177], ["another study", "TEST", 13, 26], ["HCL", "TREATMENT", 85, 88], ["AZT", "TREATMENT", 109, 112], ["significant viral load reduction", "PROBLEM", 133, 165], ["SARS", "PROBLEM", 169, 173], ["QT prolongation", "PROBLEM", 220, 235], ["the two drugs", "TREATMENT", 266, 279], ["significant", "OBSERVATION_MODIFIER", 133, 144], ["viral load", "OBSERVATION", 145, 155]]], ["As for each treatment, the cost benefits of the risk should be individually evaluated [10] .", [["each treatment", "TREATMENT", 7, 21]]], ["In April 2020, two clinical trials began to verify the efficacy of AZT therapy in SARS-CoV-2.", [["AZT", "CHEMICAL", 67, 70], ["SARS", "DISEASE", 82, 86], ["AZT", "CHEMICAL", 67, 70], ["AZT", "SIMPLE_CHEMICAL", 67, 70], ["SARS-CoV", "SPECIES", 82, 90], ["AZT therapy", "TREATMENT", 67, 78], ["CoV", "TEST", 87, 90]]], ["Currently there is no clear evidence of the efficacy of AZT treatment in SARS-CoV-2 pneumonia [23, 24] .", [["AZT", "CHEMICAL", 56, 59], ["SARS-CoV-2 pneumonia", "DISEASE", 73, 93], ["AZT", "CHEMICAL", 56, 59], ["AZT", "SIMPLE_CHEMICAL", 56, 59], ["SARS-CoV-2", "ORGANISM", 73, 83], ["SARS-CoV", "SPECIES", 73, 81], ["AZT treatment", "TREATMENT", 56, 69], ["SARS", "PROBLEM", 73, 77], ["CoV", "TEST", 78, 81], ["pneumonia", "PROBLEM", 84, 93], ["no clear evidence of", "UNCERTAINTY", 19, 39], ["AZT", "OBSERVATION", 56, 59], ["pneumonia", "OBSERVATION", 84, 93]]], ["The WHO guidelines and Surviving Sepsis Campaign Guidelines (March 2020) recommended empiric antimicrobial therapy only for prevention or treatment of superinfections [25] .", [["Sepsis", "DISEASE", 33, 39], ["superinfections", "DISEASE", 151, 166], ["Surviving Sepsis Campaign Guidelines", "TREATMENT", 23, 59], ["empiric antimicrobial therapy", "TREATMENT", 85, 114], ["superinfections", "PROBLEM", 151, 166], ["superinfections", "OBSERVATION", 151, 166]]], ["The dose recommended for patients with mild to severe symptoms is 500 mg OD for three days.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["mild to severe symptoms", "PROBLEM", 39, 62]]], ["In patient with severe CKD (GFR < 10 ml/min), dose adjustment is required (50% of dose).Lopinavir/ritonavirThe co-formulation lopinavir/ritonavir is one of the main treatment for HIV infections.", [["CKD", "DISEASE", 23, 26], ["Lopinavir", "CHEMICAL", 88, 97], ["ritonavir", "CHEMICAL", 98, 107], ["lopinavir/ritonavir", "CHEMICAL", 126, 145], ["HIV infections", "DISEASE", 179, 193], ["Lopinavir", "CHEMICAL", 88, 97], ["ritonavir", "CHEMICAL", 98, 107], ["lopinavir", "CHEMICAL", 126, 135], ["ritonavir", "CHEMICAL", 136, 145], ["patient", "ORGANISM", 3, 10], ["Lopinavir", "SIMPLE_CHEMICAL", 88, 97], ["ritonavir", "SIMPLE_CHEMICAL", 98, 107], ["lopinavir", "SIMPLE_CHEMICAL", 126, 135], ["ritonavir", "SIMPLE_CHEMICAL", 136, 145], ["HIV", "ORGANISM", 179, 182], ["patient", "SPECIES", 3, 10], ["HIV", "SPECIES", 179, 182], ["HIV", "SPECIES", 179, 182], ["severe CKD", "PROBLEM", 16, 26], ["GFR", "TEST", 28, 31], ["Lopinavir", "TREATMENT", 88, 97], ["ritonavir", "TREATMENT", 98, 107], ["The co-formulation lopinavir", "TREATMENT", 107, 135], ["ritonavir", "TREATMENT", 136, 145], ["the main treatment", "TREATMENT", 156, 174], ["HIV infections", "PROBLEM", 179, 193], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["CKD", "OBSERVATION", 23, 26], ["infections", "OBSERVATION", 183, 193]]], ["Lopinavir is a HIV protease inhibitor, whereas ritonavir inhibits the CYP3A-mediated metabolism of lopinavir providing to increase plasma level of lopinavir.", [["plasma", "ANATOMY", 131, 137], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 47, 56], ["lopinavir", "CHEMICAL", 99, 108], ["lopinavir", "CHEMICAL", 147, 156], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 47, 56], ["lopinavir", "CHEMICAL", 99, 108], ["lopinavir", "CHEMICAL", 147, 156], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 47, 56], ["CYP3A", "GENE_OR_GENE_PRODUCT", 70, 75], ["lopinavir", "SIMPLE_CHEMICAL", 99, 108], ["plasma", "ORGANISM_SUBSTANCE", 131, 137], ["lopinavir", "SIMPLE_CHEMICAL", 147, 156], ["CYP3A", "PROTEIN", 70, 75], ["HIV", "SPECIES", 15, 18], ["Lopinavir", "TREATMENT", 0, 9], ["a HIV protease inhibitor", "TREATMENT", 13, 37], ["ritonavir", "TREATMENT", 47, 56], ["the CYP3A", "TEST", 66, 75], ["lopinavir", "TREATMENT", 99, 108], ["lopinavir", "TREATMENT", 147, 156]]], ["Furthermore, lopinavir is mainly metabolized and eliminated by the liver [26] .", [["liver", "ANATOMY", 67, 72], ["lopinavir", "CHEMICAL", 13, 22], ["lopinavir", "CHEMICAL", 13, 22], ["lopinavir", "SIMPLE_CHEMICAL", 13, 22], ["liver", "ORGAN", 67, 72], ["lopinavir", "TREATMENT", 13, 22], ["lopinavir", "OBSERVATION", 13, 22], ["liver", "ANATOMY", 67, 72]]], ["Many studies, carried out during the past epidemic respiratory syndromes (SARS and MERS), suggested a reduction in viral load, steroid usage and, consequently, in nosocomial infections, in patients treated with lopinavir/ritonavir, showing a clinical improvement [27, 28] .", [["respiratory syndromes", "DISEASE", 51, 72], ["SARS", "DISEASE", 74, 78], ["steroid", "CHEMICAL", 127, 134], ["nosocomial infections", "DISEASE", 163, 184], ["lopinavir/ritonavir", "CHEMICAL", 211, 230], ["steroid", "CHEMICAL", 127, 134], ["lopinavir", "CHEMICAL", 211, 220], ["ritonavir", "CHEMICAL", 221, 230], ["steroid", "SIMPLE_CHEMICAL", 127, 134], ["patients", "ORGANISM", 189, 197], ["lopinavir", "SIMPLE_CHEMICAL", 211, 220], ["ritonavir", "SIMPLE_CHEMICAL", 221, 230], ["patients", "SPECIES", 189, 197], ["Many studies", "TEST", 0, 12], ["epidemic respiratory syndromes", "PROBLEM", 42, 72], ["SARS", "PROBLEM", 74, 78], ["a reduction in viral load", "PROBLEM", 100, 125], ["steroid usage", "TREATMENT", 127, 140], ["nosocomial infections", "PROBLEM", 163, 184], ["lopinavir", "TREATMENT", 211, 220], ["ritonavir", "TREATMENT", 221, 230], ["respiratory syndromes", "OBSERVATION", 51, 72], ["reduction", "OBSERVATION_MODIFIER", 102, 111], ["viral load", "OBSERVATION", 115, 125], ["nosocomial", "OBSERVATION_MODIFIER", 163, 173], ["infections", "OBSERVATION", 174, 184]]], ["A randomized clinical trial, handled by a Chinese group, suggested that in hospitalized adult patients with severe infection, no benefit was observed with lopinavir/ritonavir beyond standard care in terms of time to clinical improvement, reduction of mortality and safety (side effects and discontinuation of treatment) [29, 30] .", [["infection", "DISEASE", 115, 124], ["lopinavir/ritonavir", "CHEMICAL", 155, 174], ["lopinavir", "CHEMICAL", 155, 164], ["ritonavir", "CHEMICAL", 165, 174], ["patients", "ORGANISM", 94, 102], ["lopinavir", "SIMPLE_CHEMICAL", 155, 164], ["ritonavir", "SIMPLE_CHEMICAL", 165, 174], ["patients", "SPECIES", 94, 102], ["severe infection", "PROBLEM", 108, 124], ["lopinavir", "TREATMENT", 155, 164], ["ritonavir", "TREATMENT", 165, 174], ["discontinuation of treatment", "TREATMENT", 290, 318], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["infection", "OBSERVATION", 115, 124]]], ["The recommended doses of lopinavir/ritonavir are 400/100 mg BID for 5-10 days [31] [32] [33] .", [["lopinavir/ritonavir", "CHEMICAL", 25, 44], ["lopinavir", "CHEMICAL", 25, 34], ["ritonavir", "CHEMICAL", 35, 44], ["BID", "CHEMICAL", 60, 63], ["lopinavir", "SIMPLE_CHEMICAL", 25, 34], ["ritonavir", "SIMPLE_CHEMICAL", 35, 44], ["BID", "SIMPLE_CHEMICAL", 60, 63], ["lopinavir", "TREATMENT", 25, 34], ["ritonavir", "TREATMENT", 35, 44]]], ["This therapeutic schemes has been suggested in symptomatic elderly patients with underlying diseases or patient with acute respiratory distress syndrome (ARDS) when Remdesivir is not available (mild/high-risk groups) starting from the early stage.", [["respiratory", "ANATOMY", 123, 134], ["acute respiratory distress syndrome", "DISEASE", 117, 152], ["ARDS", "DISEASE", 154, 158], ["Remdesivir", "CHEMICAL", 165, 175], ["patients", "ORGANISM", 67, 75], ["patient", "ORGANISM", 104, 111], ["patients", "SPECIES", 67, 75], ["patient", "SPECIES", 104, 111], ["This therapeutic schemes", "TREATMENT", 0, 24], ["underlying diseases", "PROBLEM", 81, 100], ["acute respiratory distress syndrome", "PROBLEM", 117, 152], ["ARDS", "PROBLEM", 154, 158], ["Remdesivir", "TREATMENT", 165, 175], ["mild/high-risk groups", "PROBLEM", 194, 215], ["symptomatic", "OBSERVATION_MODIFIER", 47, 58], ["diseases", "OBSERVATION", 92, 100], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["respiratory distress", "OBSERVATION", 123, 143]]], ["Lopinavir pharmacokinetics have not been studied in patients with renal disease; however, since the renal clearance of drug is negligible, a decrease in total body clearance is not expected in patients with renal disease.", [["renal", "ANATOMY", 66, 71], ["renal", "ANATOMY", 100, 105], ["body", "ANATOMY", 159, 163], ["renal", "ANATOMY", 207, 212], ["Lopinavir", "CHEMICAL", 0, 9], ["renal disease", "DISEASE", 66, 79], ["renal disease", "DISEASE", 207, 220], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["patients", "ORGANISM", 52, 60], ["renal", "ORGAN", 66, 71], ["renal", "ORGAN", 100, 105], ["body", "ORGANISM_SUBDIVISION", 159, 163], ["patients", "ORGANISM", 193, 201], ["renal", "ORGAN", 207, 212], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 193, 201], ["Lopinavir pharmacokinetics", "TREATMENT", 0, 26], ["renal disease", "PROBLEM", 66, 79], ["a decrease in total body clearance", "PROBLEM", 139, 173], ["renal disease", "PROBLEM", 207, 220], ["renal", "ANATOMY", 66, 71], ["disease", "OBSERVATION", 72, 79], ["renal", "ANATOMY", 100, 105], ["clearance", "OBSERVATION", 106, 115], ["negligible", "OBSERVATION_MODIFIER", 127, 137], ["decrease", "OBSERVATION_MODIFIER", 141, 149], ["total body", "OBSERVATION_MODIFIER", 153, 163], ["not expected", "UNCERTAINTY", 177, 189], ["renal", "ANATOMY", 207, 212], ["disease", "OBSERVATION", 213, 220]]], ["In HD, PD and CRRT, no dosage adjustment is required.Darunavir/cobicistatDarunavir (DRV) is a HIV protease inhibitor that blocks the cut of Gag-Pol proteins encoded by HIV in the cells infected by the virus preventing the development of mature infective viral particles.", [["cells", "ANATOMY", 179, 184], ["PD", "DISEASE", 7, 9], ["Darunavir", "CHEMICAL", 53, 62], ["cobicistatDarunavir", "CHEMICAL", 63, 82], ["DRV", "CHEMICAL", 84, 87], ["Darunavir", "CHEMICAL", 53, 62], ["cobicistatDarunavir", "CHEMICAL", 63, 82], ["DRV", "CHEMICAL", 84, 87], ["Darunavir", "SIMPLE_CHEMICAL", 53, 62], ["cobicistatDarunavir", "SIMPLE_CHEMICAL", 63, 82], ["DRV", "SIMPLE_CHEMICAL", 84, 87], ["Pol", "GENE_OR_GENE_PRODUCT", 144, 147], ["HIV", "ORGANISM", 168, 171], ["cells", "CELL", 179, 184], ["Gag", "PROTEIN", 140, 143], ["Pol proteins", "PROTEIN", 144, 156], ["HIV", "SPECIES", 168, 171], ["HIV", "SPECIES", 94, 97], ["HIV", "SPECIES", 168, 171], ["HD", "TREATMENT", 3, 5], ["PD", "TREATMENT", 7, 9], ["CRRT", "TREATMENT", 14, 18], ["dosage adjustment", "TREATMENT", 23, 40], ["Darunavir", "TREATMENT", 53, 62], ["cobicistatDarunavir (DRV)", "TREATMENT", 63, 88], ["a HIV protease inhibitor", "TREATMENT", 92, 116], ["Gag-Pol proteins", "TREATMENT", 140, 156], ["HIV", "PROBLEM", 168, 171], ["the virus", "PROBLEM", 197, 206], ["mature infective viral particles", "PROBLEM", 237, 269], ["mature", "OBSERVATION_MODIFIER", 237, 243], ["infective viral particles", "OBSERVATION", 244, 269]]], ["It was initially used in combination with ritonavir [34] and then boosted with cobicistat [35] .", [["ritonavir", "CHEMICAL", 42, 51], ["cobicistat", "CHEMICAL", 79, 89], ["ritonavir", "CHEMICAL", 42, 51], ["cobicistat", "CHEMICAL", 79, 89], ["ritonavir", "SIMPLE_CHEMICAL", 42, 51], ["cobicistat", "SIMPLE_CHEMICAL", 79, 89], ["ritonavir", "TREATMENT", 42, 51]]], ["Cobicistat is a booster for the improvement of pharmacokinetics and pharmacodynamics of DRV by cytochrome P450 (CYP3A) inhibition [36] .", [["Cobicistat", "CHEMICAL", 0, 10], ["DRV", "CHEMICAL", 88, 91], ["Cobicistat", "CHEMICAL", 0, 10], ["Cobicistat", "SIMPLE_CHEMICAL", 0, 10], ["DRV", "SIMPLE_CHEMICAL", 88, 91], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 95, 110], ["CYP3A", "GENE_OR_GENE_PRODUCT", 112, 117], ["cytochrome P450", "PROTEIN", 95, 110], ["CYP3A", "PROTEIN", 112, 117], ["a booster", "TREATMENT", 14, 23], ["pharmacokinetics and pharmacodynamics of DRV by cytochrome P450 (CYP3A) inhibition", "TREATMENT", 47, 129]]], ["Darunavir/cobicistat (DRV/c) is approved by the United States Food and Drug Administration (FDA) only for use with a boosting agent, and in combination with other anti-retrovirals, for the treatment of HIV-1 infection.", [["Darunavir", "CHEMICAL", 0, 9], ["cobicistat", "CHEMICAL", 10, 20], ["DRV", "CHEMICAL", 22, 25], ["HIV-1 infection", "DISEASE", 202, 217], ["Darunavir", "CHEMICAL", 0, 9], ["cobicistat", "CHEMICAL", 10, 20], ["Darunavir", "SIMPLE_CHEMICAL", 0, 9], ["cobicistat", "SIMPLE_CHEMICAL", 10, 20], ["HIV-1", "ORGANISM", 202, 207], ["HIV-1", "SPECIES", 202, 207], ["HIV-1", "SPECIES", 202, 207], ["Darunavir", "TREATMENT", 0, 9], ["cobicistat (DRV/c)", "TREATMENT", 10, 28], ["a boosting agent", "TREATMENT", 115, 131], ["other anti-retrovirals", "TREATMENT", 157, 179], ["HIV", "PROBLEM", 202, 205], ["1 infection", "PROBLEM", 206, 217], ["infection", "OBSERVATION", 208, 217]]], ["Janssen Pharmaceutical Companies, a subsidiary of Johnson&Johnson, yielded its brand DRV/c used for HIV treatment for the use in activities research for SARS-CoV-2 treatment.", [["SARS", "DISEASE", 153, 157], ["HIV", "ORGANISM", 100, 103], ["CoV-2", "ORGANISM", 158, 163], ["HIV", "SPECIES", 100, 103], ["HIV treatment", "TREATMENT", 100, 113], ["SARS", "PROBLEM", 153, 157], ["CoV-2 treatment", "TREATMENT", 158, 173]]], ["Anecdotal reports suggested that darunavir has potential antiviral activity against SARS-CoV-2 virus.", [["darunavir", "CHEMICAL", 33, 42], ["darunavir", "CHEMICAL", 33, 42], ["darunavir", "SIMPLE_CHEMICAL", 33, 42], ["SARS-CoV-2 virus", "ORGANISM", 84, 100], ["CoV-2 virus", "SPECIES", 89, 100], ["SARS-CoV-2 virus", "SPECIES", 84, 100], ["darunavir", "TREATMENT", 33, 42], ["SARS", "PROBLEM", 84, 88], ["CoV-2 virus", "PROBLEM", 89, 100], ["darunavir", "OBSERVATION", 33, 42], ["antiviral activity", "OBSERVATION", 57, 75]]], ["Janssen have found low interactions between DRV and the active site of SARS-CoV-2 protease.", [["DRV", "GENE_OR_GENE_PRODUCT", 44, 47], ["SARS-CoV-2 protease", "GENE_OR_GENE_PRODUCT", 71, 90], ["DRV", "PROTEIN", 44, 47], ["SARS-CoV-2 protease", "PROTEIN", 71, 90], ["low interactions between DRV", "PROBLEM", 19, 47], ["SARS", "PROBLEM", 71, 75], ["low interactions", "OBSERVATION_MODIFIER", 19, 35], ["active", "OBSERVATION_MODIFIER", 56, 62], ["SARS", "OBSERVATION", 71, 75]]], ["Actually, the use of DRV as treatment for SARS-CoV-2 is not supported by in vitro or clinical studies [37, 38] .", [["DRV", "CHEMICAL", 21, 24], ["SARS", "DISEASE", 42, 46], ["DRV", "CHEMICAL", 21, 24], ["DRV", "SIMPLE_CHEMICAL", 21, 24], ["DRV", "TREATMENT", 21, 24], ["treatment", "TREATMENT", 28, 37], ["SARS", "PROBLEM", 42, 46], ["clinical studies", "TEST", 85, 101]]], ["DRV/c is metabolized by the liver.", [["liver", "ANATOMY", 28, 33], ["DRV/c", "GENE_OR_GENE_PRODUCT", 0, 5], ["liver", "ORGAN", 28, 33], ["DRV/c", "PROTEIN", 0, 5], ["c", "OBSERVATION", 4, 5], ["liver", "ANATOMY", 28, 33]]], ["Caution, without any dose adaptation, is suggested in case of slight and mild liver dysfunction, whereas the use of DRV/c is not recommended in case of severe liver dysfunction.", [["liver", "ANATOMY", 78, 83], ["liver", "ANATOMY", 159, 164], ["liver dysfunction", "DISEASE", 78, 95], ["liver dysfunction", "DISEASE", 159, 176], ["liver", "ORGAN", 78, 83], ["DRV/c", "GENE_OR_GENE_PRODUCT", 116, 121], ["liver", "ORGAN", 159, 164], ["slight and mild liver dysfunction", "PROBLEM", 62, 95], ["DRV/c", "TREATMENT", 116, 121], ["severe liver dysfunction", "PROBLEM", 152, 176], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["liver", "ANATOMY", 78, 83], ["dysfunction", "OBSERVATION", 84, 95], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["liver", "ANATOMY", 159, 164], ["dysfunction", "OBSERVATION", 165, 176]]], ["Actually, the therapeutic scheme for the treatment of SARS-CoV-2 infection is off-label.", [["SARS", "DISEASE", 54, 58], ["infection", "DISEASE", 65, 74], ["SARS-CoV-2", "ORGANISM", 54, 64], ["SARS-CoV-2", "SPECIES", 54, 64], ["the therapeutic scheme", "TREATMENT", 10, 32], ["the treatment", "TREATMENT", 37, 50], ["SARS", "PROBLEM", 54, 58], ["CoV", "PROBLEM", 59, 62], ["2 infection", "PROBLEM", 63, 74], ["infection", "OBSERVATION", 65, 74]]], ["The drug doses suggested is 800/150 mg OD for 5-7 days.", [["OD", "CHEMICAL", 39, 41], ["The drug doses", "TREATMENT", 0, 14]]], ["DRV/c has the same mechanism of action of lopinavir/ritonavir; therefore, it is reasonable to consider the use of DRV/c as an alternative treatment for SARS-CoV-2 infection disease when lopinavir/ritonavir is not available [39] .", [["lopinavir/ritonavir", "CHEMICAL", 42, 61], ["SARS-CoV-2 infection", "DISEASE", 152, 172], ["lopinavir/ritonavir", "CHEMICAL", 186, 205], ["lopinavir", "CHEMICAL", 42, 51], ["ritonavir", "CHEMICAL", 52, 61], ["lopinavir", "CHEMICAL", 186, 195], ["ritonavir", "CHEMICAL", 196, 205], ["DRV/c", "GENE_OR_GENE_PRODUCT", 0, 5], ["lopinavir", "SIMPLE_CHEMICAL", 42, 51], ["ritonavir", "SIMPLE_CHEMICAL", 52, 61], ["SARS-CoV-2", "ORGANISM", 152, 162], ["lopinavir", "SIMPLE_CHEMICAL", 186, 195], ["ritonavir", "SIMPLE_CHEMICAL", 196, 205], ["DRV/c", "PROTEIN", 0, 5], ["SARS-CoV", "SPECIES", 152, 160], ["lopinavir", "TREATMENT", 42, 51], ["ritonavir", "TREATMENT", 52, 61], ["DRV/c", "TREATMENT", 114, 119], ["an alternative treatment", "TREATMENT", 123, 147], ["SARS", "PROBLEM", 152, 156], ["CoV-2 infection disease", "PROBLEM", 157, 180], ["lopinavir/ritonavir", "TREATMENT", 186, 205]]], ["DRV is poorly eliminated by the kidney [40]; changing in dosage is not requested in patient with renal disease.", [["kidney", "ANATOMY", 32, 38], ["renal", "ANATOMY", 97, 102], ["renal disease", "DISEASE", 97, 110], ["kidney", "ORGAN", 32, 38], ["patient", "ORGANISM", 84, 91], ["renal", "ORGAN", 97, 102], ["patient", "SPECIES", 84, 91], ["DRV", "TREATMENT", 0, 3], ["renal disease", "PROBLEM", 97, 110], ["poorly", "OBSERVATION_MODIFIER", 7, 13], ["eliminated", "OBSERVATION", 14, 24], ["kidney", "ANATOMY", 32, 38], ["renal", "ANATOMY", 97, 102], ["disease", "OBSERVATION", 103, 110]]], ["Instead, considering that cobicistat should reduce the renal clearance, its use is contraindicated in patient with GFR < 70 ml/min.", [["renal", "ANATOMY", 55, 60], ["cobicistat", "CHEMICAL", 26, 36], ["cobicistat", "CHEMICAL", 26, 36], ["cobicistat", "SIMPLE_CHEMICAL", 26, 36], ["renal", "ORGAN", 55, 60], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["cobicistat", "TREATMENT", 26, 36], ["the renal clearance", "TREATMENT", 51, 70], ["GFR", "TEST", 115, 118], ["renal", "ANATOMY", 55, 60]]], ["Finally, no evidence or clinical study is available regarding the dialysis clearance [35] .RemdesivirRemdesivir (RDV) is a novel antiviral drug, recently used for the Ebola treatment.", [["RemdesivirRemdesivir", "CHEMICAL", 91, 111], ["RDV", "CHEMICAL", 113, 116], ["Ebola", "DISEASE", 167, 172], ["RemdesivirRemdesivir", "CHEMICAL", 91, 111], ["RDV", "CHEMICAL", 113, 116], ["RemdesivirRemdesivir", "SIMPLE_CHEMICAL", 91, 111], ["RDV", "SIMPLE_CHEMICAL", 113, 116], ["Ebola", "ORGANISM", 167, 172], ["RDV", "SPECIES", 113, 116], ["clinical study", "TEST", 24, 38], ["the dialysis clearance", "TEST", 62, 84], ["RemdesivirRemdesivir (RDV)", "TREATMENT", 91, 117], ["a novel antiviral drug", "TREATMENT", 121, 143], ["the Ebola treatment", "TREATMENT", 163, 182], ["no evidence", "UNCERTAINTY", 9, 20]]], ["RDV is an adenosine nucleotide analogue with a broad spectrum of antiviral activity.", [["RDV", "CHEMICAL", 0, 3], ["adenosine", "CHEMICAL", 10, 19], ["RDV", "CHEMICAL", 0, 3], ["adenosine nucleotide", "CHEMICAL", 10, 30], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["adenosine", "SIMPLE_CHEMICAL", 10, 19], ["RDV", "SPECIES", 0, 3], ["an adenosine nucleotide analogue", "TREATMENT", 7, 39], ["antiviral activity", "TREATMENT", 65, 83], ["antiviral activity", "OBSERVATION", 65, 83]]], ["It works as RNAdependent RNA polymerase (RpRd) inhibitor.", [["RNAdependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 12, 39], ["RpRd", "GENE_OR_GENE_PRODUCT", 41, 45], ["RNAdependent RNA polymerase", "PROTEIN", 12, 39], ["RpRd", "PROTEIN", 41, 45], ["RNAdependent RNA polymerase (RpRd) inhibitor", "TREATMENT", 12, 56]]], ["RDV creates a tightly bind with RpRd, showing a high level of binding affinity comparable to these of native nucleotides.", [["RDV", "CHEMICAL", 0, 3], ["nucleotides", "CHEMICAL", 109, 120], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["RpRd", "GENE_OR_GENE_PRODUCT", 32, 36], ["RDV", "PROTEIN", 0, 3], ["RpRd", "PROTEIN", 32, 36], ["a high level of binding affinity", "PROBLEM", 46, 78], ["native nucleotides", "OBSERVATION", 102, 120]]], ["RDV inhibits viral replication through premature termination of RNA, blocking the transcription and consequently the viral replication [41] .", [["RDV", "CHEMICAL", 0, 3], ["RDV", "CHEMICAL", 0, 3], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["RDV", "PROTEIN", 0, 3], ["RDV", "SPECIES", 0, 3], ["RDV", "PROBLEM", 0, 3], ["viral replication", "TREATMENT", 13, 30], ["premature termination of RNA", "PROBLEM", 39, 67], ["blocking the transcription", "TREATMENT", 69, 95], ["the viral replication", "TREATMENT", 113, 134], ["viral replication", "OBSERVATION", 13, 30]]], ["RDV has been studied in clinical trials and it is still under investigation for the Ebola treatment in humans, MERS, and SARS-CoV viruses [42, 43] .", [["RDV", "CHEMICAL", 0, 3], ["Ebola", "DISEASE", 84, 89], ["SARS-CoV viruses", "DISEASE", 121, 137], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["Ebola", "ORGANISM", 84, 89], ["humans", "ORGANISM", 103, 109], ["SARS-CoV viruses", "ORGANISM", 121, 137], ["humans", "SPECIES", 103, 109], ["RDV", "SPECIES", 0, 3], ["humans", "SPECIES", 103, 109], ["SARS-CoV viruses", "SPECIES", 121, 137], ["the Ebola treatment", "TREATMENT", 80, 99]]], ["It is currently under investigation for SARS-CoV-2 treatment.", [["CoV-2", "ORGANISM", 45, 50], ["SARS", "PROBLEM", 40, 44], ["CoV-2 treatment", "TREATMENT", 45, 60]]], ["Indeed, clinical trials are currently in progress to verify the efficacy and safety of RDV use in hospitalized adult patients with mild or severe SARS-CoV-2 disease [44, 45] .", [["RDV", "CHEMICAL", 87, 90], ["SARS-CoV-2 disease", "DISEASE", 146, 164], ["RDV", "CHEMICAL", 87, 90], ["RDV", "SIMPLE_CHEMICAL", 87, 90], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["RDV", "SPECIES", 87, 90], ["mild or severe SARS", "PROBLEM", 131, 150], ["CoV-2 disease", "PROBLEM", 151, 164], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["SARS", "OBSERVATION", 146, 150]]], ["Successful results have been reached in one case of SARS-CoV-2-infected patients treated with intravenous RDV [46] .", [["intravenous", "ANATOMY", 94, 105], ["SARS-CoV-2-infected", "DISEASE", 52, 71], ["RDV", "CHEMICAL", 106, 109], ["RDV", "CHEMICAL", 106, 109], ["SARS-CoV-2", "ORGANISM", 52, 62], ["patients", "ORGANISM", 72, 80], ["CoV-", "SPECIES", 57, 61], ["patients", "SPECIES", 72, 80], ["SARS", "PROBLEM", 52, 56], ["CoV", "TEST", 57, 60], ["intravenous RDV", "TREATMENT", 94, 109]]], ["RDV is a prodrug, predominantly metabolized by hepatic enzymes with hydrolase activity.", [["hepatic", "ANATOMY", 47, 54], ["RDV", "CHEMICAL", 0, 3], ["RDV", "CHEMICAL", 0, 3], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["hepatic", "ORGAN", 47, 54], ["hepatic enzymes", "PROTEIN", 47, 62], ["hydrolase", "PROTEIN", 68, 77], ["RDV", "SPECIES", 0, 3], ["hepatic enzymes", "TEST", 47, 62], ["hydrolase activity", "TREATMENT", 68, 86], ["hepatic", "ANATOMY", 47, 54], ["hydrolase activity", "OBSERVATION", 68, 86]]], ["Based on rapid distribution, metabolism and clearance, the drug has scarce clinically significant interactions and does not prolong the QTc interval [47] .", [["rapid", "OBSERVATION_MODIFIER", 9, 14], ["distribution", "OBSERVATION_MODIFIER", 15, 27]]], ["There are three different therapeutic schemes proposed by the ongoing trials; all of them share the same dosage but differ in the duration of the treatment based on the clinical stage of the disease (mild or severe).", [["the treatment", "TREATMENT", 142, 155], ["the disease (mild or severe)", "PROBLEM", 187, 215], ["three", "OBSERVATION_MODIFIER", 10, 15], ["different", "OBSERVATION_MODIFIER", 16, 25], ["therapeutic", "OBSERVATION_MODIFIER", 26, 37], ["disease", "OBSERVATION", 191, 198], ["mild", "OBSERVATION_MODIFIER", 200, 204], ["severe", "OBSERVATION_MODIFIER", 208, 214]]], ["The recommended dose of RDV is 200 mg intravenous (IV) on day 1, 100 mg IV daily for 5 up to 10 days.", [["RDV", "CHEMICAL", 24, 27], ["RDV", "CHEMICAL", 24, 27], ["RDV", "SIMPLE_CHEMICAL", 24, 27], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 49], ["RDV", "TREATMENT", 24, 27]]], ["The use of RDV has not been approved by FDA (Food and Drug Administration) and EMA (European Medicines Agency) even if its compassionate use is recommended in patients with severe SARS-CoV-2 infection who are not eligible for inclusion criteria in clinical trials and in absence of alternative therapeutic options [48] .", [["RDV", "CHEMICAL", 11, 14], ["SARS-CoV-2 infection", "DISEASE", 180, 200], ["RDV", "CHEMICAL", 11, 14], ["RDV", "SIMPLE_CHEMICAL", 11, 14], ["patients", "ORGANISM", 159, 167], ["CoV-2", "ORGANISM", 185, 190], ["patients", "SPECIES", 159, 167], ["RDV", "TREATMENT", 11, 14], ["EMA (European Medicines", "TREATMENT", 79, 102], ["severe SARS", "PROBLEM", 173, 184], ["CoV-2 infection", "PROBLEM", 185, 200]]], ["In a recent randomized, double-blinded, placebo-controlled, multicenter trial, the efficacy of the RDV in adults hospitalized SARS-CoV-2 patients with pulmonary involvement has been demonstrated.", [["pulmonary", "ANATOMY", 151, 160], ["RDV", "CHEMICAL", 99, 102], ["SARS", "DISEASE", 126, 130], ["SARS-CoV-2", "ORGANISM", 126, 136], ["patients", "ORGANISM", 137, 145], ["pulmonary", "ORGAN", 151, 160], ["patients", "SPECIES", 137, 145], ["placebo", "TREATMENT", 40, 47], ["multicenter trial", "TREATMENT", 60, 77], ["pulmonary involvement", "PROBLEM", 151, 172], ["pulmonary", "ANATOMY", 151, 160], ["involvement", "OBSERVATION", 161, 172]]], ["RDV has received the authorization for the treatment of suspected or laboratory-confirmed SARS-CoV-2 adults and children hospitalized patients with severe disease (low blood oxygen levels, needing oxygen therapy, needing mechanical ventilation), due to shortening the time to recovery [49] .", [["blood", "ANATOMY", 168, 173], ["RDV", "CHEMICAL", 0, 3], ["SARS", "DISEASE", 90, 94], ["oxygen", "CHEMICAL", 174, 180], ["oxygen", "CHEMICAL", 197, 203], ["oxygen", "CHEMICAL", 174, 180], ["oxygen", "CHEMICAL", 197, 203], ["SARS-CoV-2", "ORGANISM", 90, 100], ["adults", "ORGANISM", 101, 107], ["children", "ORGANISM", 112, 120], ["patients", "ORGANISM", 134, 142], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["oxygen", "SIMPLE_CHEMICAL", 174, 180], ["oxygen", "SIMPLE_CHEMICAL", 197, 203], ["children", "SPECIES", 112, 120], ["patients", "SPECIES", 134, 142], ["RDV", "SPECIES", 0, 3], ["the treatment", "TREATMENT", 39, 52], ["SARS", "PROBLEM", 90, 94], ["severe disease", "PROBLEM", 148, 162], ["low blood oxygen levels", "PROBLEM", 164, 187], ["oxygen therapy", "TREATMENT", 197, 211], ["mechanical ventilation", "TREATMENT", 221, 243], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["disease", "OBSERVATION", 155, 162]]], ["Instead, the renal recommended doses are: if eGFR \u2265 30 ml/min no dosage adjustment necessary, if eGFR \u2264 30 ml/min avoid use, in renal replacement therapies avoid use.FavipavirThe antiviral 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (T-705, favipiravir) Favipavir (FP) is a RNA-dependent RNA polymerase (RdRp) inhibitor.", [["renal", "ANATOMY", 13, 18], ["renal", "ANATOMY", 128, 133], ["FavipavirThe", "CHEMICAL", 166, 178], ["6-fluoro-3-hydroxy-2-pyrazinecarboxamide", "CHEMICAL", 189, 229], ["T-705", "CHEMICAL", 231, 236], ["favipiravir", "CHEMICAL", 238, 249], ["Favipavir", "CHEMICAL", 251, 260], ["FP", "CHEMICAL", 262, 264], ["FavipavirThe", "CHEMICAL", 166, 178], ["6-fluoro-3-hydroxy-2-pyrazinecarboxamide", "CHEMICAL", 189, 229], ["T-705", "CHEMICAL", 231, 236], ["favipiravir", "CHEMICAL", 238, 249], ["Favipavir", "CHEMICAL", 251, 260], ["renal", "ORGAN", 13, 18], ["renal", "ORGAN", 128, 133], ["FavipavirThe", "SIMPLE_CHEMICAL", 166, 178], ["6-fluoro-3-hydroxy-2-pyrazinecarboxamide", "SIMPLE_CHEMICAL", 189, 229], ["T-705", "SIMPLE_CHEMICAL", 231, 236], ["favipiravir", "SIMPLE_CHEMICAL", 238, 249], ["Favipavir", "SIMPLE_CHEMICAL", 251, 260], ["FP", "SIMPLE_CHEMICAL", 262, 264], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 271, 299], ["RNA-dependent RNA polymerase", "PROTEIN", 271, 299], ["RdRp", "PROTEIN", 301, 305], ["eGFR", "TEST", 45, 49], ["eGFR", "TEST", 97, 101], ["renal replacement therapies", "TREATMENT", 128, 155], ["FavipavirThe antiviral", "TREATMENT", 166, 188], ["fluoro", "TREATMENT", 191, 197], ["hydroxy", "TREATMENT", 200, 207], ["pyrazinecarboxamide (T", "TREATMENT", 210, 232], ["favipiravir) Favipavir (FP)", "TREATMENT", 238, 265], ["a RNA-dependent RNA polymerase (RdRp) inhibitor", "TREATMENT", 269, 316], ["renal", "ANATOMY", 13, 18], ["renal", "ANATOMY", 128, 133], ["replacement", "OBSERVATION", 134, 145]]], ["Its use was approved only in Japan for the treatment of influenza infection and it is distributed only upon request by the Minister of Health, Labor and Welfare of Japan to avoid irrational prescriptions [50] In addition to its anti-influenza activity, FP blocks the replication of other RNA viruses [51] .", [["influenza infection", "DISEASE", 56, 75], ["FP", "CHEMICAL", 253, 255], ["FP", "SIMPLE_CHEMICAL", 253, 255], ["influenza infection", "PROBLEM", 56, 75], ["irrational prescriptions", "TREATMENT", 179, 203], ["its anti-influenza activity", "TREATMENT", 224, 251], ["FP blocks", "TREATMENT", 253, 262], ["other RNA viruses", "PROBLEM", 282, 299], ["influenza", "OBSERVATION", 56, 65]]], ["FP has been used for the treatment of human infection with life-threatening Ebola virus and severe fever with thrombocytopenia syndrome [52] .", [["FP", "CHEMICAL", 0, 2], ["infection", "DISEASE", 44, 53], ["Ebola virus", "DISEASE", 76, 87], ["fever", "DISEASE", 99, 104], ["thrombocytopenia", "DISEASE", 110, 126], ["FP", "SIMPLE_CHEMICAL", 0, 2], ["human", "ORGANISM", 38, 43], ["Ebola virus", "ORGANISM", 76, 87], ["human", "SPECIES", 38, 43], ["Ebola virus", "SPECIES", 76, 87], ["human", "SPECIES", 38, 43], ["Ebola virus", "SPECIES", 76, 87], ["FP", "TEST", 0, 2], ["human infection", "PROBLEM", 38, 53], ["life-threatening Ebola virus", "PROBLEM", 59, 87], ["severe fever", "PROBLEM", 92, 104], ["thrombocytopenia syndrome", "PROBLEM", 110, 135], ["infection", "OBSERVATION", 44, 53], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["fever", "OBSERVATION", 99, 104], ["thrombocytopenia", "OBSERVATION", 110, 126]]], ["Moreover, the FP activity against multiple RNA viruses has been demonstrated [53] .", [["the FP activity", "TEST", 10, 25], ["multiple RNA viruses", "PROBLEM", 34, 54]]], ["Due to its inhibition of RNA polymerase, FP may have potential antiviral activity on SARS-CoV-2 infection [54] .", [["FP", "CHEMICAL", 41, 43], ["SARS-CoV-2 infection", "DISEASE", 85, 105], ["FP", "SIMPLE_CHEMICAL", 41, 43], ["SARS-CoV-2", "ORGANISM", 85, 95], ["RNA polymerase", "PROTEIN", 25, 39], ["CoV-2", "SPECIES", 90, 95], ["SARS-CoV-2", "SPECIES", 85, 95], ["its inhibition of RNA polymerase", "PROBLEM", 7, 39], ["antiviral activity", "PROBLEM", 63, 81], ["SARS", "PROBLEM", 85, 89], ["CoV-2 infection", "PROBLEM", 90, 105], ["antiviral activity", "OBSERVATION", 63, 81]]], ["The preliminary results of a clinical Chinese trial suggested that FP should have stronger antiviral action than lopinavir/ritonavir [55] .", [["FP", "CHEMICAL", 67, 69], ["lopinavir/ritonavir", "CHEMICAL", 113, 132], ["lopinavir", "CHEMICAL", 113, 122], ["ritonavir", "CHEMICAL", 123, 132], ["FP", "SIMPLE_CHEMICAL", 67, 69], ["lopinavir", "SIMPLE_CHEMICAL", 113, 122], ["ritonavir", "SIMPLE_CHEMICAL", 123, 132], ["antiviral action", "TREATMENT", 91, 107], ["lopinavir/ritonavir", "TREATMENT", 113, 132]]], ["FP was approved in China for SARS-CoV-2 treatment since February 15, 2020 [56] .", [["FP", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 29, 33], ["FP", "SIMPLE_CHEMICAL", 0, 2], ["SARS", "PROBLEM", 29, 33], ["CoV-2 treatment", "TREATMENT", 34, 49]]], ["Dosage and treatment duration for SARS-CoV-2 infection are unavailable.", [["SARS-CoV-2 infection", "DISEASE", 34, 54], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV-2", "SPECIES", 34, 44], ["Dosage", "TREATMENT", 0, 6], ["treatment duration", "TREATMENT", 11, 29], ["SARS", "PROBLEM", 34, 38], ["CoV", "PROBLEM", 39, 42], ["2 infection", "PROBLEM", 43, 54], ["infection", "OBSERVATION", 45, 54]]], ["The approved FP dose in Japan is 1600 mg TID on day 1 followed by 600 mg TID for 4 days.", [["FP", "CHEMICAL", 13, 15], ["TID", "CHEMICAL", 41, 44], ["TID", "CHEMICAL", 73, 76], ["TID", "CHEMICAL", 41, 44], ["TID", "CHEMICAL", 73, 76], ["FP", "SIMPLE_CHEMICAL", 13, 15], ["The approved FP dose", "TREATMENT", 0, 20]]], ["The viral replication period is 6 days or longer for seasonal influenza.", [["influenza", "DISEASE", 62, 71], ["The viral replication period", "TREATMENT", 0, 28], ["seasonal influenza", "PROBLEM", 53, 71], ["viral replication", "OBSERVATION", 4, 21], ["influenza", "OBSERVATION", 62, 71]]], ["When drug administration is stopped during the virus replication period or when resistant strains appear, virus replication and fever relapse.", [["fever", "DISEASE", 128, 133], ["drug administration", "TREATMENT", 5, 24], ["the virus replication period", "TREATMENT", 43, 71], ["resistant strains", "PROBLEM", 80, 97], ["virus replication", "PROBLEM", 106, 123], ["fever relapse", "PROBLEM", 128, 141]]], ["Thus, 10 days of administration should be required for severe influenza or novel influenza [57] .", [["influenza", "DISEASE", 62, 71], ["influenza", "DISEASE", 81, 90], ["administration", "TREATMENT", 17, 31], ["severe influenza", "PROBLEM", 55, 71], ["novel influenza", "PROBLEM", 75, 90]]], ["However, no published clinical studies are available about the efficacy and safety of the drug in the treatment of SARS-CoV-2 disease.CorticosteroidsCorticosteroids (CST) are immunomodulatory agents that modulate the host response by the secretion of various interleukins (IL-1, IL-6, IL-8, IL-11, IL-12, IFN-\u03b3 e TNF\u03b1) and the expression of their receptors.", [["SARS-CoV-2 disease", "DISEASE", 115, 133], ["SARS-CoV-2", "ORGANISM", 115, 125], ["Corticosteroids", "SIMPLE_CHEMICAL", 134, 149], ["Corticosteroids", "SIMPLE_CHEMICAL", 149, 164], ["CST", "SIMPLE_CHEMICAL", 166, 169], ["interleukins", "GENE_OR_GENE_PRODUCT", 259, 271], ["IL-1", "GENE_OR_GENE_PRODUCT", 273, 277], ["IL-6", "GENE_OR_GENE_PRODUCT", 279, 283], ["IL-8", "GENE_OR_GENE_PRODUCT", 285, 289], ["IL-11", "GENE_OR_GENE_PRODUCT", 291, 296], ["IL-12", "GENE_OR_GENE_PRODUCT", 298, 303], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 305, 310], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 313, 317], ["interleukins", "PROTEIN", 259, 271], ["IFN", "PROTEIN", 305, 308], ["TNF\u03b1", "PROTEIN", 313, 317], ["SARS-CoV", "SPECIES", 115, 123], ["published clinical studies", "TEST", 12, 38], ["the drug", "TREATMENT", 86, 94], ["SARS", "PROBLEM", 115, 119], ["CoV-2 disease", "PROBLEM", 120, 133], ["CorticosteroidsCorticosteroids (CST)", "TREATMENT", 134, 170], ["immunomodulatory agents", "TREATMENT", 175, 198], ["various interleukins", "TEST", 251, 271], ["IL", "TEST", 273, 275], ["IL", "TEST", 279, 281], ["IL", "TEST", 285, 287], ["IL", "TEST", 291, 293], ["IL", "TEST", 298, 300], ["IFN", "TREATMENT", 305, 308], ["host response", "OBSERVATION", 217, 230]]], ["Some corticosteroids attenuate the CD28 co-stimulatory pathway through the inhibition of na\u00efve T-cell proliferation and differentiation, a key mechanism in the pathogenesis of ARDS in SARS-CoV-2-associated pneumoniae.", [["T-cell", "ANATOMY", 95, 101], ["ARDS", "DISEASE", 176, 180], ["corticosteroids", "CHEMICAL", 5, 20], ["corticosteroids", "SIMPLE_CHEMICAL", 5, 20], ["CD28", "GENE_OR_GENE_PRODUCT", 35, 39], ["T-cell", "CELL", 95, 101], ["SARS-CoV-2-associated pneumoniae", "ORGANISM", 184, 216], ["CD28", "PROTEIN", 35, 39], ["SARS-CoV", "SPECIES", 184, 192], ["Some corticosteroids", "TREATMENT", 0, 20], ["na\u00efve T-cell proliferation", "TREATMENT", 89, 115], ["ARDS", "PROBLEM", 176, 180], ["SARS", "PROBLEM", 184, 188], ["CoV", "TEST", 189, 192], ["pneumoniae", "PROBLEM", 206, 216], ["corticosteroids", "OBSERVATION", 5, 20], ["cell proliferation", "OBSERVATION", 97, 115], ["ARDS", "OBSERVATION", 176, 180], ["pneumoniae", "OBSERVATION", 206, 216]]], ["CTS have been largely used in the treatment of past coronavirus infection (SARS, MERS).", [["CTS", "DISEASE", 0, 3], ["coronavirus infection", "DISEASE", 52, 73], ["SARS", "DISEASE", 75, 79], ["coronavirus", "ORGANISM", 52, 63], ["CTS", "TREATMENT", 0, 3], ["past coronavirus infection", "PROBLEM", 47, 73], ["coronavirus", "OBSERVATION_MODIFIER", 52, 63], ["infection", "OBSERVATION", 64, 73]]], ["No evidence was found on the antiviral effect of corticosteroids alone in resisting SARS-CoV-2 in vivo and in vitro [58] [59] [60] .", [["corticosteroids", "CHEMICAL", 49, 64], ["SARS", "DISEASE", 84, 88], ["corticosteroids", "CHEMICAL", 49, 64], ["corticosteroids", "SIMPLE_CHEMICAL", 49, 64], ["SARS-CoV", "SPECIES", 84, 92], ["corticosteroids", "TREATMENT", 49, 64], ["CoV", "TEST", 89, 92]]], ["The dose of methylprednisolone varied, depending on disease severity.", [["methylprednisolone", "CHEMICAL", 12, 30], ["methylprednisolone", "CHEMICAL", 12, 30], ["methylprednisolone", "SIMPLE_CHEMICAL", 12, 30], ["methylprednisolone", "TREATMENT", 12, 30], ["disease severity", "PROBLEM", 52, 68]]], ["Moreover, administration of CST in the early phases of SARS-CoV-2 infection, is not recommended due to the increasing risk of superinfection and prolonged viral replication [61] .", [["SARS", "DISEASE", 55, 59], ["infection", "DISEASE", 66, 75], ["superinfection", "DISEASE", 126, 140], ["CST", "SIMPLE_CHEMICAL", 28, 31], ["SARS-CoV-2", "ORGANISM", 55, 65], ["SARS-CoV", "SPECIES", 55, 63], ["CST", "TREATMENT", 28, 31], ["SARS", "PROBLEM", 55, 59], ["CoV-2 infection", "PROBLEM", 60, 75], ["superinfection", "PROBLEM", 126, 140], ["prolonged viral replication", "TREATMENT", 145, 172], ["infection", "OBSERVATION", 66, 75], ["superinfection", "OBSERVATION", 126, 140]]], ["However, it has been demonstrated that methylprednisolone may be beneficial for patients with SARS-CoV-2 pneumonia who have developed ARDS on progression [62] .", [["methylprednisolone", "CHEMICAL", 39, 57], ["SARS-CoV-2 pneumonia", "DISEASE", 94, 114], ["ARDS", "DISEASE", 134, 138], ["methylprednisolone", "CHEMICAL", 39, 57], ["methylprednisolone", "SIMPLE_CHEMICAL", 39, 57], ["patients", "ORGANISM", 80, 88], ["SARS-CoV-2", "ORGANISM", 94, 104], ["patients", "SPECIES", 80, 88], ["methylprednisolone", "TREATMENT", 39, 57], ["SARS", "PROBLEM", 94, 98], ["CoV-2 pneumonia", "PROBLEM", 99, 114], ["ARDS", "PROBLEM", 134, 138], ["pneumonia", "OBSERVATION", 105, 114], ["ARDS", "OBSERVATION", 134, 138]]], ["The use of systemic CST in adults with SARS-CoV-2 and ARDS mechanically ventilated has been suggested by Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID- 19) of Surviving Sepsis Campaign (weak recommendation, low-quality evidence).", [["SARS", "DISEASE", 39, 43], ["ARDS", "DISEASE", 54, 58], ["Coronavirus Disease", "DISEASE", 164, 183], ["Sepsis", "DISEASE", 214, 220], ["CST", "MULTI-TISSUE_STRUCTURE", 20, 23], ["systemic CST", "TREATMENT", 11, 23], ["SARS", "PROBLEM", 39, 43], ["ARDS mechanically ventilated", "PROBLEM", 54, 82], ["Critically Ill Adults", "PROBLEM", 137, 158], ["Coronavirus Disease", "PROBLEM", 164, 183], ["COVID", "TEST", 190, 195], ["Surviving Sepsis Campaign", "PROBLEM", 204, 229], ["Sepsis", "OBSERVATION", 214, 220]]], ["Systemic CST are recommended for a short-term use (1 ~ 2 mg\u00b7kg \u00d7 3 ~ 5 days) [25, 63] .", [["Systemic CST", "TREATMENT", 0, 12]]], ["In patients on chronic dialysis or with renal transplant and rapid progression of SARS-CoV-2 disease the guidelines of the \"Brescia Renal Covid Task force\" indicate an initial dose of desametasone 20 mg/die for 5 days followed by a dose of 10 mg die for 5 days [3, 4] .Monoclonal antibodyTociluzumab.", [["renal", "ANATOMY", 40, 45], ["Renal", "ANATOMY", 132, 137], ["SARS", "DISEASE", 82, 86], ["desametasone", "CHEMICAL", 184, 196], ["Tociluzumab", "CHEMICAL", 288, 299], ["desametasone", "CHEMICAL", 184, 196], ["patients", "ORGANISM", 3, 11], ["renal", "ORGAN", 40, 45], ["desametasone", "SIMPLE_CHEMICAL", 184, 196], ["Monoclonal antibody", "PROTEIN", 269, 288], ["patients", "SPECIES", 3, 11], ["chronic dialysis", "TREATMENT", 15, 31], ["renal transplant", "TREATMENT", 40, 56], ["SARS", "PROBLEM", 82, 86], ["CoV-2 disease", "PROBLEM", 87, 100], ["desametasone", "TREATMENT", 184, 196], ["Monoclonal antibodyTociluzumab", "TREATMENT", 269, 299], ["chronic", "OBSERVATION_MODIFIER", 15, 22], ["dialysis", "OBSERVATION", 23, 31], ["renal", "ANATOMY", 40, 45], ["transplant", "OBSERVATION", 46, 56], ["Renal", "ANATOMY", 132, 137]]], ["Tociluzumab (TC) is a humanized monoclonal antibody (mAb) anti-human IL-6 receptor of the IgG1 subclass.", [["Tociluzumab", "CHEMICAL", 0, 11], ["TC", "CHEMICAL", 13, 15], ["Tociluzumab", "CHEMICAL", 0, 11], ["Tociluzumab", "SIMPLE_CHEMICAL", 0, 11], ["TC", "SIMPLE_CHEMICAL", 13, 15], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 69, 82], ["IgG1", "GENE_OR_GENE_PRODUCT", 90, 94], ["humanized monoclonal antibody (mAb) anti-human IL-6 receptor", "PROTEIN", 22, 82], ["IgG1 subclass", "PROTEIN", 90, 103], ["Tociluzumab (TC)", "TREATMENT", 0, 16], ["a humanized monoclonal antibody (mAb", "TREATMENT", 20, 56], ["anti-human IL", "TREATMENT", 58, 71]]], ["TC, interrupting IL-6 pathway, seems to be highly effective in reducing the inflammatory response through its pro-inflammatory effects and it has been successfully used for the treatment of rheumatologic diseases.", [["rheumatologic diseases", "DISEASE", 190, 212], ["TC", "SIMPLE_CHEMICAL", 0, 2], ["IL-6", "GENE_OR_GENE_PRODUCT", 17, 21], ["IL-6", "PROTEIN", 17, 21], ["the inflammatory response", "PROBLEM", 72, 97], ["rheumatologic diseases", "PROBLEM", 190, 212], ["inflammatory", "OBSERVATION", 76, 88], ["rheumatologic", "OBSERVATION", 190, 203]]], ["The use of TC for the treatment of SARS-CoV-2 infection has shown encouraging preliminary clinical results.", [["TC", "CHEMICAL", 11, 13], ["SARS", "DISEASE", 35, 39], ["infection", "DISEASE", 46, 55], ["TC", "SIMPLE_CHEMICAL", 11, 13], ["SARS-CoV-2", "ORGANISM", 35, 45], ["CoV-", "SPECIES", 40, 44], ["SARS-CoV-2", "SPECIES", 35, 45], ["TC", "TREATMENT", 11, 13], ["the treatment", "TREATMENT", 18, 31], ["SARS", "PROBLEM", 35, 39], ["CoV-2 infection", "PROBLEM", 40, 55]]], ["Nevertheless, the right time of therapy initiation, the duration and the recommended dose are not fully clear.", [["therapy initiation", "TREATMENT", 32, 50], ["right", "ANATOMY_MODIFIER", 18, 23], ["clear", "OBSERVATION", 104, 109]]], ["A multicenter, randomized controlled trial is ongoing in the investigation of the efficacy and safety of TC in the treatment of new coronavirus pneumonia [64] [65] [66] [67] .", [["TC", "CHEMICAL", 105, 107], ["coronavirus pneumonia", "DISEASE", 132, 153], ["TC", "SIMPLE_CHEMICAL", 105, 107], ["coronavirus", "ORGANISM", 132, 143], ["A multicenter, randomized controlled trial", "TREATMENT", 0, 42], ["TC", "TREATMENT", 105, 107], ["new coronavirus pneumonia", "PROBLEM", 128, 153]]], ["Moreover, a screening for tuberculosis and hepatitis B infection should be done before initiating TC.", [["tuberculosis", "DISEASE", 26, 38], ["hepatitis B infection", "DISEASE", 43, 64], ["hepatitis B", "ORGANISM", 43, 54], ["hepatitis B", "SPECIES", 43, 54], ["a screening", "TEST", 10, 21], ["tuberculosis", "PROBLEM", 26, 38], ["hepatitis B infection", "PROBLEM", 43, 64]]], ["The Brescia Renal COVID Task Force [3, 4] suggested a dose of 8 mg/Kg IV, repeatable after 12 h.Monoclonal antibodyEculizumab A multicenter trial (NCT04288713) is underway on Eculizumab (EZ), a humanized mAb that binds the complement component C5, which is required for formation of the membrane attack complex (MAC); MAC can cause organs' damage in other types of coronaviruses infection; therefore, modulation of this part of the immune response during SARS-CoV-2 infection can be helpful.", [["Renal", "ANATOMY", 12, 17], ["membrane", "ANATOMY", 287, 295], ["organs", "ANATOMY", 332, 338], ["Eculizumab", "CHEMICAL", 175, 185], ["EZ", "CHEMICAL", 187, 189], ["MAC", "CHEMICAL", 318, 321], ["organs' damage", "DISEASE", 332, 346], ["coronaviruses infection", "DISEASE", 365, 388], ["infection", "DISEASE", 466, 475], ["Eculizumab", "CHEMICAL", 175, 185], ["Eculizumab", "SIMPLE_CHEMICAL", 175, 185], ["EZ", "SIMPLE_CHEMICAL", 187, 189], ["complement component C5", "GENE_OR_GENE_PRODUCT", 223, 246], ["membrane", "CELLULAR_COMPONENT", 287, 295], ["organs", "ORGAN", 332, 338], ["coronaviruses", "ORGANISM", 365, 378], ["SARS-CoV-2", "ORGANISM", 455, 465], ["Monoclonal antibody", "PROTEIN", 96, 115], ["humanized mAb", "PROTEIN", 194, 207], ["complement component C5", "PROTEIN", 223, 246], ["membrane attack complex", "PROTEIN", 287, 310], ["SARS-CoV-2", "SPECIES", 455, 465], ["Monoclonal antibody", "TEST", 96, 115], ["Eculizumab", "TREATMENT", 115, 125], ["Eculizumab (EZ", "TREATMENT", 175, 189], ["a humanized mAb", "TREATMENT", 192, 207], ["the membrane attack complex", "PROBLEM", 283, 310], ["organs' damage", "PROBLEM", 332, 346], ["coronaviruses infection", "PROBLEM", 365, 388], ["SARS", "PROBLEM", 455, 459], ["CoV-2 infection", "PROBLEM", 460, 475], ["Renal", "ANATOMY", 12, 17], ["coronaviruses", "OBSERVATION_MODIFIER", 365, 378], ["infection", "OBSERVATION", 379, 388]]], ["In unvaccinated patients against Neisseria meningitides daily antimicrobial prophylaxis is mandatory (ceftriaxone iv) to avoid life-threatening infections.", [["Neisseria meningitides", "DISEASE", 33, 55], ["ceftriaxone", "CHEMICAL", 102, 113], ["infections", "DISEASE", 144, 154], ["ceftriaxone", "CHEMICAL", 102, 113], ["patients", "ORGANISM", 16, 24], ["Neisseria meningitides", "ORGANISM", 33, 55], ["ceftriaxone", "SIMPLE_CHEMICAL", 102, 113], ["patients", "SPECIES", 16, 24], ["Neisseria meningitides", "SPECIES", 33, 55], ["Neisseria meningitides", "TREATMENT", 33, 55], ["antimicrobial prophylaxis", "TREATMENT", 62, 87], ["ceftriaxone iv", "TREATMENT", 102, 116], ["life-threatening infections", "PROBLEM", 127, 154], ["infections", "OBSERVATION", 144, 154]]], ["EZ dose recommended is 900 mg IV every 7 days [65] .Monoclonal antibodySarilumab Sarilumab (SA) is a specific mAb for the interleukin-6 (IL-6) receptor; it may potentially contrast cytokine release syndrome in severely ill patients of COVID-19 disease [68, 69] .Monoclonal antibodyAnakinra.", [["EZ", "CHEMICAL", 0, 2], ["Sarilumab", "CHEMICAL", 81, 90], ["SA", "CHEMICAL", 92, 94], ["ill", "DISEASE", 219, 222], ["Anakinra", "CHEMICAL", 281, 289], ["Anakinra", "CHEMICAL", 281, 289], ["EZ", "SIMPLE_CHEMICAL", 0, 2], ["Sarilumab Sarilumab", "SIMPLE_CHEMICAL", 71, 90], ["SA", "SIMPLE_CHEMICAL", 92, 94], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 122, 135], ["IL-6", "GENE_OR_GENE_PRODUCT", 137, 141], ["patients", "ORGANISM", 223, 231], ["Anakinra", "SIMPLE_CHEMICAL", 281, 289], ["interleukin-6 (IL-6) receptor", "PROTEIN", 122, 151], ["cytokine", "PROTEIN", 181, 189], ["Monoclonal antibody", "PROTEIN", 262, 281], ["patients", "SPECIES", 223, 231], ["Monoclonal antibody", "TEST", 52, 71], ["the interleukin", "TEST", 118, 133], ["receptor", "TREATMENT", 143, 151], ["contrast cytokine release syndrome", "PROBLEM", 172, 206], ["COVID-19 disease", "PROBLEM", 235, 251], ["Monoclonal antibody", "TEST", 262, 281], ["Anakinra", "TREATMENT", 281, 289], ["severely", "OBSERVATION_MODIFIER", 210, 218], ["ill", "OBSERVATION_MODIFIER", 219, 222]]], ["Anakinra (AnK).", [["Anakinra", "CHEMICAL", 0, 8], ["AnK", "CHEMICAL", 10, 13], ["Anakinra", "CHEMICAL", 0, 8], ["AnK", "CHEMICAL", 10, 13], ["Anakinra", "GENE_OR_GENE_PRODUCT", 0, 8], ["AnK", "GENE_OR_GENE_PRODUCT", 10, 13], ["Anakinra (AnK)", "TREATMENT", 0, 14]]], ["AnK is a recombinant human interleukin-1 (IL-1) receptor antagonist.", [["AnK", "CHEMICAL", 0, 3], ["AnK", "GENE_OR_GENE_PRODUCT", 0, 3], ["human", "ORGANISM", 21, 26], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 27, 40], ["IL-1) receptor antagonist", "GENE_OR_GENE_PRODUCT", 42, 67], ["AnK", "PROTEIN", 0, 3], ["recombinant human interleukin-1 (IL-1) receptor", "PROTEIN", 9, 56], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["a recombinant human interleukin", "TREATMENT", 7, 38], ["receptor antagonist", "TREATMENT", 48, 67]]], ["NCT04324021 is a phase 3 randomized, open-label, multicenter trial on AnK.", [["AnK", "SIMPLE_CHEMICAL", 70, 73]]], ["Dose is 100 mg every 6 h (total of 400 mg daily) for 15 days [70] .Monoclonal antibodySince the elimination through the kidney of mAb is considered not significant, in CKD patients no dosage adjustment is required.Convalescent plasmaTreatment of acute severe pneumonia with immunoglobulin from healed patients could accelerate clinical recovery.", [["kidney", "ANATOMY", 120, 126], ["CKD", "DISEASE", 168, 171], ["pneumonia", "DISEASE", 259, 268], ["kidney", "ORGAN", 120, 126], ["mAb", "GENE_OR_GENE_PRODUCT", 130, 133], ["patients", "ORGANISM", 172, 180], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 274, 288], ["patients", "ORGANISM", 301, 309], ["Monoclonal antibody", "PROTEIN", 67, 86], ["mAb", "PROTEIN", 130, 133], ["immunoglobulin", "PROTEIN", 274, 288], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 301, 309], ["Monoclonal antibody", "TEST", 67, 86], ["CKD", "PROBLEM", 168, 171], ["dosage adjustment", "TREATMENT", 184, 201], ["acute severe pneumonia", "PROBLEM", 246, 268], ["immunoglobulin", "TREATMENT", 274, 288], ["kidney", "ANATOMY", 120, 126], ["mAb", "OBSERVATION", 130, 133], ["considered not", "UNCERTAINTY", 137, 151], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["acute", "OBSERVATION_MODIFIER", 246, 251], ["severe", "OBSERVATION_MODIFIER", 252, 258], ["pneumonia", "OBSERVATION", 259, 268], ["healed", "OBSERVATION_MODIFIER", 294, 300]]], ["Currently several trials are ongoing in China [71, 72] .Renal replacement therapiesIn some patients with SARS-CoV-2 infection, the systemic involvement should induce acute kidney injury (AKI) and MOF.", [["Renal", "ANATOMY", 56, 61], ["kidney", "ANATOMY", 172, 178], ["SARS-CoV-2 infection", "DISEASE", 105, 125], ["acute kidney injury", "DISEASE", 166, 185], ["AKI", "DISEASE", 187, 190], ["MOF", "DISEASE", 196, 199], ["Renal", "ORGAN", 56, 61], ["patients", "ORGANISM", 91, 99], ["SARS-CoV-2", "ORGANISM", 105, 115], ["kidney", "ORGAN", 172, 178], ["patients", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 105, 113], ["Renal replacement therapies", "TREATMENT", 56, 83], ["SARS", "PROBLEM", 105, 109], ["CoV-2 infection", "PROBLEM", 110, 125], ["the systemic involvement", "PROBLEM", 127, 151], ["acute kidney injury", "PROBLEM", 166, 185], ["AKI", "PROBLEM", 187, 190], ["MOF", "PROBLEM", 196, 199], ["replacement", "OBSERVATION", 62, 73], ["SARS", "OBSERVATION", 105, 109], ["infection", "OBSERVATION", 116, 125], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["kidney", "ANATOMY", 172, 178], ["injury", "OBSERVATION", 179, 185], ["AKI", "OBSERVATION", 187, 190]]], ["The cause of MOF in patients with SARS-CoV-2 pneumonia, similar to septic shock, is an uncontrolled inflammatory state or a subsequent immune-paralysis.", [["MOF", "DISEASE", 13, 16], ["SARS", "DISEASE", 34, 38], ["pneumonia", "DISEASE", 45, 54], ["septic shock", "DISEASE", 67, 79], ["paralysis", "DISEASE", 142, 151], ["patients", "ORGANISM", 20, 28], ["SARS-CoV-2", "ORGANISM", 34, 44], ["patients", "SPECIES", 20, 28], ["MOF", "PROBLEM", 13, 16], ["SARS", "PROBLEM", 34, 38], ["CoV", "PROBLEM", 39, 42], ["pneumonia", "PROBLEM", 45, 54], ["septic shock", "PROBLEM", 67, 79], ["an uncontrolled inflammatory state", "PROBLEM", 84, 118], ["paralysis", "PROBLEM", 142, 151], ["MOF", "OBSERVATION", 13, 16], ["pneumonia", "OBSERVATION", 45, 54], ["septic shock", "OBSERVATION", 67, 79], ["uncontrolled", "OBSERVATION_MODIFIER", 87, 99], ["inflammatory", "OBSERVATION", 100, 112], ["paralysis", "OBSERVATION", 142, 151]]], ["When pharmacological treatment is not effective, extracorporeal therapies offer a possibility to support different organs in a multiple organ dysfunction [73] .", [["extracorporeal", "ANATOMY", 49, 63], ["organs", "ANATOMY", 115, 121], ["organ", "ANATOMY", 136, 141], ["organ dysfunction", "DISEASE", 136, 153], ["organs", "ORGAN", 115, 121], ["organ", "ORGAN", 136, 141], ["pharmacological treatment", "TREATMENT", 5, 30], ["extracorporeal therapies", "TREATMENT", 49, 73], ["different organs", "PROBLEM", 105, 121], ["a multiple organ dysfunction", "PROBLEM", 125, 153]]], ["The indications for extracorporeal therapy in patients with SARS-CoV-2 infection and MOF include renal replacement therapy and sepsis.", [["renal", "ANATOMY", 97, 102], ["SARS-CoV-2 infection", "DISEASE", 60, 80], ["MOF", "DISEASE", 85, 88], ["sepsis", "DISEASE", 127, 133], ["patients", "ORGANISM", 46, 54], ["SARS-CoV-2", "ORGANISM", 60, 70], ["renal", "ORGAN", 97, 102], ["patients", "SPECIES", 46, 54], ["extracorporeal therapy", "TREATMENT", 20, 42], ["SARS", "PROBLEM", 60, 64], ["CoV-2 infection", "PROBLEM", 65, 80], ["MOF", "PROBLEM", 85, 88], ["renal replacement therapy", "TREATMENT", 97, 122], ["sepsis", "PROBLEM", 127, 133], ["infection", "OBSERVATION", 71, 80], ["renal", "ANATOMY", 97, 102], ["replacement", "OBSERVATION", 103, 114], ["sepsis", "OBSERVATION", 127, 133]]], ["AKI, in patients affected by SARS-CoV-2-related pneumonia, is uncommon, but it might result from a SIRS involving combined myocardial and kidney function.", [["myocardial", "ANATOMY", 123, 133], ["kidney", "ANATOMY", 138, 144], ["AKI", "DISEASE", 0, 3], ["SARS", "DISEASE", 29, 33], ["pneumonia", "DISEASE", 48, 57], ["SIRS", "DISEASE", 99, 103], ["myocardial and kidney function", "DISEASE", 123, 153], ["patients", "ORGANISM", 8, 16], ["SARS-CoV-2", "ORGANISM", 29, 39], ["myocardial", "MULTI-TISSUE_STRUCTURE", 123, 133], ["kidney", "ORGAN", 138, 144], ["patients", "SPECIES", 8, 16], ["AKI", "PROBLEM", 0, 3], ["SARS", "PROBLEM", 29, 33], ["pneumonia", "PROBLEM", 48, 57], ["a SIRS", "PROBLEM", 97, 103], ["combined myocardial and kidney function", "PROBLEM", 114, 153], ["pneumonia", "OBSERVATION", 48, 57], ["kidney", "ANATOMY", 138, 144]]], ["In sepsis, Ronco et al. observed the reduction of circulating levels of cytokines using cartridges containing highly biocompatible sorbents and microporous resins (ex.", [["sepsis", "DISEASE", 3, 9], ["cytokines", "PROTEIN", 72, 81], ["sepsis", "PROBLEM", 3, 9], ["cytokines using cartridges", "TREATMENT", 72, 98], ["highly biocompatible sorbents", "TREATMENT", 110, 139], ["microporous resins", "TREATMENT", 144, 162], ["sepsis", "OBSERVATION", 3, 9], ["reduction", "OBSERVATION_MODIFIER", 37, 46], ["biocompatible sorbents", "OBSERVATION", 117, 139], ["microporous resins", "OBSERVATION", 144, 162]]], ["Cytosorb).", [["Cytosorb", "SIMPLE_CHEMICAL", 0, 8]]], ["In dialysis patients with chronic kidney disease (CKD), Alberici et al. suggested expanded intermittent hemodialysis (HDx) whit medium cut-off (MCO) membrane to increase removal of inflammatory cytokines [3, 4] .Low molecular weight heparinHigh rate of pulmonary thromboembolism due to thrombophilic and inflammatory state has been reported.", [["kidney", "ANATOMY", 34, 40], ["membrane", "ANATOMY", 149, 157], ["pulmonary", "ANATOMY", 253, 262], ["chronic kidney disease", "DISEASE", 26, 48], ["CKD", "DISEASE", 50, 53], ["pulmonary thromboembolism", "DISEASE", 253, 278], ["thrombophilic", "DISEASE", 286, 299], ["patients", "ORGANISM", 12, 20], ["kidney", "ORGAN", 34, 40], ["membrane", "CELLULAR_COMPONENT", 149, 157], ["pulmonary", "ORGAN", 253, 262], ["inflammatory cytokines", "PROTEIN", 181, 203], ["patients", "SPECIES", 12, 20], ["dialysis", "TREATMENT", 3, 11], ["chronic kidney disease", "PROBLEM", 26, 48], ["CKD)", "PROBLEM", 50, 54], ["expanded intermittent hemodialysis (HDx", "TREATMENT", 82, 121], ["inflammatory cytokines", "PROBLEM", 181, 203], ["pulmonary thromboembolism", "PROBLEM", 253, 278], ["thrombophilic and inflammatory state", "PROBLEM", 286, 322], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["kidney", "ANATOMY", 34, 40], ["disease", "OBSERVATION", 41, 48], ["CKD", "OBSERVATION", 50, 53], ["intermittent", "OBSERVATION_MODIFIER", 91, 103], ["hemodialysis", "OBSERVATION", 104, 116], ["inflammatory", "OBSERVATION_MODIFIER", 181, 193], ["molecular weight", "OBSERVATION", 216, 232], ["pulmonary", "ANATOMY", 253, 262], ["thromboembolism", "OBSERVATION", 263, 278], ["thrombophilic", "OBSERVATION", 286, 299], ["inflammatory", "OBSERVATION", 304, 316]]], ["Therefore, the prophylactic use of low molecular weight heparin (LMWH) is indicated [75, 76] .DiscussionSince the SARS-CoV-2 outbreak began, last December 2019 in China, millions of people have been infected; SARS-CoV-2 should cause a large spectrum of clinical signs and symptoms ranging from mild to critical [1, 2] .", [["heparin", "CHEMICAL", 56, 63], ["LMWH", "CHEMICAL", 65, 69], ["SARS", "DISEASE", 114, 118], ["SARS", "DISEASE", 209, 213], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 35, 63], ["LMWH", "SIMPLE_CHEMICAL", 65, 69], ["people", "ORGANISM", 182, 188], ["SARS-CoV-2", "ORGANISM", 209, 219], ["people", "SPECIES", 182, 188], ["SARS-CoV", "SPECIES", 209, 217], ["low molecular weight heparin (LMWH)", "TREATMENT", 35, 70], ["clinical signs", "PROBLEM", 253, 267], ["symptoms", "PROBLEM", 272, 280], ["infected", "OBSERVATION", 199, 207], ["large", "OBSERVATION_MODIFIER", 235, 240]]], ["Currently, there are no vaccines or drugs approved for prevention and treatment of the infection.", [["infection", "DISEASE", 87, 96], ["vaccines", "TREATMENT", 24, 32], ["drugs", "TREATMENT", 36, 41], ["prevention", "TREATMENT", 55, 65], ["treatment", "TREATMENT", 70, 79], ["the infection", "PROBLEM", 83, 96], ["no", "UNCERTAINTY", 21, 23], ["vaccines", "OBSERVATION", 24, 32], ["infection", "OBSERVATION", 87, 96]]], ["Moreover, the kidney involvement of the SARS-CoV-2 infection should be associated with three different clinical settings.", [["kidney", "ANATOMY", 14, 20], ["SARS", "DISEASE", 40, 44], ["infection", "DISEASE", 51, 60], ["kidney", "ORGAN", 14, 20], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "SPECIES", 40, 48], ["the SARS", "PROBLEM", 36, 44], ["CoV-2 infection", "PROBLEM", 45, 60], ["kidney", "ANATOMY", 14, 20], ["involvement", "OBSERVATION", 21, 32], ["SARS", "OBSERVATION", 40, 44], ["CoV", "OBSERVATION_MODIFIER", 45, 48], ["infection", "OBSERVATION", 51, 60]]], ["The first includes patients with CKD, the second includes patients with AKI, the third includes immunosuppressed patients such as renal graft recipients or patients with glomerular diseases.", [["renal graft", "ANATOMY", 130, 141], ["glomerular", "ANATOMY", 170, 180], ["CKD", "DISEASE", 33, 36], ["AKI", "DISEASE", 72, 75], ["glomerular diseases", "DISEASE", 170, 189], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 113, 121], ["renal graft", "TISSUE", 130, 141], ["patients", "ORGANISM", 156, 164], ["glomerular", "TISSUE", 170, 180], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 156, 164], ["CKD", "PROBLEM", 33, 36], ["AKI", "PROBLEM", 72, 75], ["immunosuppressed patients", "TREATMENT", 96, 121], ["renal graft recipients", "TREATMENT", 130, 152], ["glomerular diseases", "PROBLEM", 170, 189], ["AKI", "OBSERVATION", 72, 75], ["immunosuppressed", "OBSERVATION", 96, 112], ["renal", "ANATOMY", 130, 135], ["graft", "OBSERVATION", 136, 141], ["glomerular diseases", "OBSERVATION", 170, 189]]], ["Moreover, it is known that kidney injury is associated with an increased risk of death in patients with influenza A virus subtype H1N1 and SARS [77, 78] .", [["kidney", "ANATOMY", 27, 33], ["kidney injury", "DISEASE", 27, 40], ["death", "DISEASE", 81, 86], ["influenza A virus subtype H1N1", "DISEASE", 104, 134], ["SARS", "DISEASE", 139, 143], ["kidney", "ORGAN", 27, 33], ["patients", "ORGANISM", 90, 98], ["influenza A virus subtype H1N1", "ORGANISM", 104, 134], ["patients", "SPECIES", 90, 98], ["influenza A virus", "SPECIES", 104, 121], ["kidney injury", "PROBLEM", 27, 40], ["death", "PROBLEM", 81, 86], ["influenza A virus subtype H1N1", "PROBLEM", 104, 134], ["kidney", "ANATOMY", 27, 33], ["injury", "OBSERVATION", 34, 40], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["In addition, a recent report suggested that the kidney involvement, in patients infected by SARS-CoV-2 at admission, is associated with a higher risk of in-hospital death [79] .", [["kidney", "ANATOMY", 48, 54], ["SARS", "DISEASE", 92, 96], ["death", "DISEASE", 165, 170], ["kidney", "ORGAN", 48, 54], ["patients", "ORGANISM", 71, 79], ["SARS-CoV-2", "ORGANISM", 92, 102], ["patients", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 92, 100], ["the kidney involvement", "PROBLEM", 44, 66], ["kidney", "ANATOMY", 48, 54], ["involvement", "OBSERVATION", 55, 66]]], ["AKI SARS-CoV-2 related is probably multifactorial, including a major role of inflammatory cytokines.", [["AKI", "DISEASE", 0, 3], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["inflammatory cytokines", "PROTEIN", 77, 99], ["AKI SARS", "PROBLEM", 0, 8], ["inflammatory cytokines", "PROBLEM", 77, 99], ["probably", "UNCERTAINTY", 26, 34], ["multifactorial", "OBSERVATION_MODIFIER", 35, 49], ["inflammatory cytokines", "OBSERVATION", 77, 99]]], ["In severe cases, cytokine storm causes a multiple organ failure syndrome, including kidney's disease [80] .", [["organ", "ANATOMY", 50, 55], ["kidney", "ANATOMY", 84, 90], ["multiple organ failure syndrome", "DISEASE", 41, 72], ["kidney's disease", "DISEASE", 84, 100], ["organ", "ORGAN", 50, 55], ["kidney", "ORGAN", 84, 90], ["cytokine", "PROTEIN", 17, 25], ["cytokine storm", "TREATMENT", 17, 31], ["a multiple organ failure syndrome", "PROBLEM", 39, 72], ["kidney's disease", "PROBLEM", 84, 100], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["cytokine storm", "OBSERVATION", 17, 31], ["multiple", "OBSERVATION_MODIFIER", 41, 49], ["organ", "ANATOMY", 50, 55], ["failure syndrome", "OBSERVATION", 56, 72], ["kidney", "ANATOMY", 84, 90]]], ["Kidney histology was examined in an autopsy series of 26 patients with evidence of acute tubular damage.", [["Kidney", "ANATOMY", 0, 6], ["tubular", "ANATOMY", 89, 96], ["acute tubular damage", "DISEASE", 83, 103], ["Kidney", "ORGAN", 0, 6], ["patients", "ORGANISM", 57, 65], ["tubular", "TISSUE", 89, 96], ["patients", "SPECIES", 57, 65], ["Kidney histology", "TEST", 0, 16], ["an autopsy series", "TEST", 33, 50], ["acute tubular damage", "PROBLEM", 83, 103], ["histology", "OBSERVATION", 7, 16], ["evidence of", "UNCERTAINTY", 71, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["tubular", "ANATOMY_MODIFIER", 89, 96], ["damage", "OBSERVATION", 97, 103]]], ["Nine biopsies were tested for intracellular virus and coronaviruses were identified in seven [81] .", [["biopsies", "ANATOMY", 5, 13], ["intracellular", "ANATOMY", 30, 43], ["biopsies", "CANCER", 5, 13], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["virus", "ORGANISM", 44, 49], ["coronaviruses", "ORGANISM", 54, 67], ["Nine biopsies", "TEST", 0, 13], ["intracellular virus", "PROBLEM", 30, 49], ["coronaviruses", "PROBLEM", 54, 67]]], ["To date, two cases were reported with collapsing glomerulopathy presenting with severe AKI and heavy proteinuria [82, 83] .DiscussionSince the clinical presentation of SARS-CoV-2 infection should be misleading until the severe stages, with rapid clinical deterioration, clinicians should pay more attention to renal patients, carrying out early treatment and intensive monitoring to improve the clinical outcome.", [["renal", "ANATOMY", 310, 315], ["glomerulopathy", "DISEASE", 49, 63], ["AKI", "DISEASE", 87, 90], ["proteinuria", "DISEASE", 101, 112], ["SARS-CoV-2 infection", "DISEASE", 168, 188], ["SARS-CoV-2", "ORGANISM", 168, 178], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 316, 324], ["SARS-CoV", "SPECIES", 168, 176], ["collapsing glomerulopathy", "PROBLEM", 38, 63], ["severe AKI", "PROBLEM", 80, 90], ["heavy proteinuria", "PROBLEM", 95, 112], ["SARS", "PROBLEM", 168, 172], ["CoV-2 infection", "PROBLEM", 173, 188], ["the severe stages", "PROBLEM", 216, 233], ["rapid clinical deterioration", "PROBLEM", 240, 268], ["early treatment", "TREATMENT", 339, 354], ["intensive monitoring", "TEST", 359, 379], ["glomerulopathy", "OBSERVATION", 49, 63], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["AKI", "OBSERVATION", 87, 90], ["heavy", "OBSERVATION_MODIFIER", 95, 100], ["proteinuria", "OBSERVATION", 101, 112], ["renal", "ANATOMY", 310, 315]]], ["Alberici et al. [3, 4] describe the experience of the Nephrology Ward of the University Hospital of Brescia in the northern of Italy, place of a dramatic COVID-19 outbreak, focusing the attention on dialysis and transplant patients.", [["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["a dramatic COVID", "PROBLEM", 143, 159], ["dialysis", "TREATMENT", 199, 207], ["transplant", "TREATMENT", 212, 222]]], ["Preliminary results on general population with mild symptoms suggested a synergic effect of HCL in combination with AZT, with a possible preventive effect of severe respiratory tract infections, in order to confirm the antiviral activity showed against SARS-CoV-1, Zika and Ebola viruses [45] [46] [47] [48] .", [["respiratory tract", "ANATOMY", 165, 182], ["HCL", "CHEMICAL", 92, 95], ["AZT", "CHEMICAL", 116, 119], ["respiratory tract infections", "DISEASE", 165, 193], ["Ebola viruses", "DISEASE", 274, 287], ["HCL", "CHEMICAL", 92, 95], ["AZT", "CHEMICAL", 116, 119], ["HCL", "SIMPLE_CHEMICAL", 92, 95], ["AZT", "SIMPLE_CHEMICAL", 116, 119], ["respiratory tract", "ORGANISM_SUBDIVISION", 165, 182], ["SARS-CoV-1", "ORGANISM", 253, 263], ["Zika", "ORGANISM", 265, 269], ["Ebola viruses", "ORGANISM", 274, 287], ["Ebola", "SPECIES", 274, 279], ["SARS-CoV-1", "SPECIES", 253, 263], ["Ebola viruses", "SPECIES", 274, 287], ["general population", "TEST", 23, 41], ["mild symptoms", "PROBLEM", 47, 60], ["HCL", "TREATMENT", 92, 95], ["AZT", "TREATMENT", 116, 119], ["severe respiratory tract infections", "PROBLEM", 158, 193], ["the antiviral activity", "TEST", 215, 237], ["SARS", "PROBLEM", 253, 257], ["CoV", "TEST", 258, 261], ["Zika and Ebola viruses", "PROBLEM", 265, 287], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["respiratory tract", "ANATOMY", 165, 182], ["infections", "OBSERVATION", 183, 193]]], ["On the basis of the latest toxicity warnings, when using CL and HCT, it is crucial to adapt the dosage to the renal function to avoid the overload and to carry out a close monitoring of the side effects, particularly cardiological ones.", [["renal", "ANATOMY", 110, 115], ["toxicity", "DISEASE", 27, 35], ["CL", "MULTI-TISSUE_STRUCTURE", 57, 59], ["renal", "ORGAN", 110, 115], ["CL", "TEST", 57, 59], ["HCT", "TEST", 64, 67], ["the overload", "PROBLEM", 134, 146], ["a close monitoring", "TEST", 164, 182], ["the side effects", "PROBLEM", 186, 202], ["renal", "ANATOMY", 110, 115], ["overload", "OBSERVATION", 138, 146]]], ["During this phase, nephrologist should consider the possibility to combine antiviral therapy and standard drugs, although in a recent trial, no benefit was observed with the association of lopinavir/ritonavir treatment [29] .", [["lopinavir/ritonavir", "CHEMICAL", 189, 208], ["lopinavir", "CHEMICAL", 189, 198], ["ritonavir", "CHEMICAL", 199, 208], ["lopinavir", "SIMPLE_CHEMICAL", 189, 198], ["ritonavir", "SIMPLE_CHEMICAL", 199, 208], ["antiviral therapy", "TREATMENT", 75, 92], ["standard drugs", "TREATMENT", 97, 111], ["lopinavir/ritonavir treatment", "TREATMENT", 189, 218]]], ["In severe cases of MOF and haemophagocitic syndrome, immunosuppressive strategies must be considered.", [["MOF", "DISEASE", 19, 22], ["haemophagocitic syndrome", "DISEASE", 27, 51], ["MOF", "PROBLEM", 19, 22], ["haemophagocitic syndrome", "PROBLEM", 27, 51], ["immunosuppressive strategies", "TREATMENT", 53, 81], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["MOF", "OBSERVATION", 19, 22], ["haemophagocitic syndrome", "OBSERVATION", 27, 51]]], ["The massive lung involvement and interstitial infiltrates with respiratory failure (PaO2/ FiO < 100) is usually considered the main life-threatening process of SARS-CoV-2 infection.", [["lung", "ANATOMY", 12, 16], ["interstitial infiltrates", "ANATOMY", 33, 57], ["respiratory", "ANATOMY", 63, 74], ["respiratory failure", "DISEASE", 63, 82], ["SARS", "DISEASE", 160, 164], ["infection", "DISEASE", 171, 180], ["lung", "ORGAN", 12, 16], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 33, 57], ["SARS-CoV-2", "ORGANISM", 160, 170], ["SARS-CoV", "SPECIES", 160, 168], ["The massive lung involvement", "PROBLEM", 0, 28], ["interstitial infiltrates", "PROBLEM", 33, 57], ["respiratory failure", "PROBLEM", 63, 82], ["PaO2/ FiO", "TEST", 84, 93], ["SARS", "PROBLEM", 160, 164], ["CoV", "PROBLEM", 165, 168], ["2 infection", "PROBLEM", 169, 180], ["massive", "OBSERVATION_MODIFIER", 4, 11], ["lung", "ANATOMY", 12, 16], ["involvement", "OBSERVATION", 17, 28], ["interstitial", "ANATOMY_MODIFIER", 33, 45], ["infiltrates", "OBSERVATION", 46, 57], ["respiratory failure", "OBSERVATION", 63, 82], ["SARS", "OBSERVATION", 160, 164], ["infection", "OBSERVATION", 171, 180]]], ["Moreover, the administration of high dose of steroids in association with monoclonal antibody as rescue procedures was strongly suggested [3, 4] .DiscussionUnfortunately, to date, a monoclonal antibody against SARS-CoV-2 has not been developed and TC is the most used in ongoing studies.", [["steroids", "CHEMICAL", 45, 53], ["SARS", "DISEASE", 210, 214], ["steroids", "CHEMICAL", 45, 53], ["steroids", "SIMPLE_CHEMICAL", 45, 53], ["SARS-CoV-2", "ORGANISM", 210, 220], ["monoclonal antibody", "PROTEIN", 74, 93], ["monoclonal antibody", "PROTEIN", 182, 201], ["SARS-CoV", "SPECIES", 210, 218], ["high dose of steroids", "TREATMENT", 32, 53], ["monoclonal antibody", "TREATMENT", 74, 93], ["rescue procedures", "TREATMENT", 97, 114], ["a monoclonal antibody", "TEST", 180, 201], ["SARS", "PROBLEM", 210, 214], ["CoV", "TEST", 215, 218], ["ongoing studies", "TEST", 271, 286]]], ["When SARS-CoV-2 infection causes AKI unresponsive to pharmacological treatment, renal replacement therapy is necessary.", [["renal", "ANATOMY", 80, 85], ["infection", "DISEASE", 16, 25], ["AKI", "DISEASE", 33, 36], ["SARS-CoV-2", "ORGANISM", 5, 15], ["renal", "ORGAN", 80, 85], ["SARS-CoV", "SPECIES", 5, 13], ["SARS", "PROBLEM", 5, 9], ["CoV-2 infection", "PROBLEM", 10, 25], ["AKI", "PROBLEM", 33, 36], ["pharmacological treatment", "TREATMENT", 53, 78], ["renal replacement therapy", "TREATMENT", 80, 105], ["AKI", "OBSERVATION", 33, 36], ["renal", "ANATOMY", 80, 85], ["replacement", "OBSERVATION", 86, 97]]], ["Moreover, in severely ill patients with sepsis/MOF or haemophagocitic syndrome, extracorporeal therapies with highly biocompatible resins are also used and seem to have a remarkable benefit in terms of hemodynamic support and organ function rescue [73, 74] .", [["extracorporeal", "ANATOMY", 80, 94], ["organ", "ANATOMY", 226, 231], ["sepsis", "DISEASE", 40, 46], ["MOF", "DISEASE", 47, 50], ["haemophagocitic syndrome", "DISEASE", 54, 78], ["patients", "ORGANISM", 26, 34], ["organ", "ORGAN", 226, 231], ["patients", "SPECIES", 26, 34], ["sepsis", "PROBLEM", 40, 46], ["MOF", "PROBLEM", 47, 50], ["haemophagocitic syndrome", "PROBLEM", 54, 78], ["extracorporeal therapies", "TREATMENT", 80, 104], ["highly biocompatible resins", "TREATMENT", 110, 137], ["hemodynamic support", "TREATMENT", 202, 221], ["organ function rescue", "TEST", 226, 247], ["severely", "OBSERVATION_MODIFIER", 13, 21], ["ill", "OBSERVATION_MODIFIER", 22, 25], ["sepsis", "OBSERVATION", 40, 46], ["MOF", "OBSERVATION", 47, 50], ["haemophagocitic syndrome", "OBSERVATION", 54, 78], ["biocompatible resins", "OBSERVATION", 117, 137]]], ["Convalescent plasma could be a promising approach in selected cases with severe disease [71, 72] .DiscussionIn renal transplant recipients and glomerulonephritis patients affected by SARS-CoV-2 infection, it is mandatory to verify the interactions of the drugs with immunosuppressive therapies to reduce and/or avoid harmful side effects.", [["plasma", "ANATOMY", 13, 19], ["renal", "ANATOMY", 111, 116], ["glomerulonephritis", "DISEASE", 143, 161], ["SARS-CoV-2 infection", "DISEASE", 183, 203], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["patients", "ORGANISM", 162, 170], ["SARS-CoV-2", "ORGANISM", 183, 193], ["patients", "SPECIES", 162, 170], ["SARS-CoV-2", "SPECIES", 183, 193], ["Convalescent plasma", "TEST", 0, 19], ["severe disease", "PROBLEM", 73, 87], ["renal transplant recipients", "TREATMENT", 111, 138], ["glomerulonephritis", "PROBLEM", 143, 161], ["SARS", "PROBLEM", 183, 187], ["CoV", "PROBLEM", 188, 191], ["2 infection", "PROBLEM", 192, 203], ["the drugs", "TREATMENT", 251, 260], ["immunosuppressive therapies", "TREATMENT", 266, 293], ["harmful side effects", "PROBLEM", 317, 337], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disease", "OBSERVATION", 80, 87], ["renal", "ANATOMY", 111, 116], ["transplant recipients", "OBSERVATION", 117, 138], ["glomerulonephritis", "OBSERVATION", 143, 161], ["infection", "OBSERVATION", 194, 203]]], ["Notably, it has been suggested to discontinue calcineurin inhibitors and antimetabolite in renal graft recipients, using only low doses of CST as anti-rejection therapies [3, 4] .", [["renal graft", "ANATOMY", 91, 102], ["calcineurin", "GENE_OR_GENE_PRODUCT", 46, 57], ["antimetabolite", "SIMPLE_CHEMICAL", 73, 87], ["renal graft", "TISSUE", 91, 102], ["CST", "SIMPLE_CHEMICAL", 139, 142], ["calcineurin", "PROTEIN", 46, 57], ["calcineurin inhibitors", "TREATMENT", 46, 68], ["antimetabolite", "TREATMENT", 73, 87], ["renal graft recipients", "TREATMENT", 91, 113], ["CST as anti-rejection therapies", "TREATMENT", 139, 170], ["renal", "ANATOMY", 91, 96], ["graft", "OBSERVATION", 97, 102]]], ["Pulmonary thromboembolism prophylaxis is useful in all patients with COVID-19 infection [75, 76] .DiscussionIn COVID-19 pediatric kidney patient, RDV is preferred to other agents.", [["Pulmonary", "ANATOMY", 0, 9], ["kidney", "ANATOMY", 130, 136], ["Pulmonary thromboembolism", "DISEASE", 0, 25], ["COVID-19", "CHEMICAL", 69, 77], ["infection", "DISEASE", 78, 87], ["RDV", "CHEMICAL", 146, 149], ["Pulmonary", "ORGAN", 0, 9], ["patients", "ORGANISM", 55, 63], ["kidney", "ORGAN", 130, 136], ["patient", "ORGANISM", 137, 144], ["patients", "SPECIES", 55, 63], ["patient", "SPECIES", 137, 144], ["Pulmonary thromboembolism prophylaxis", "TREATMENT", 0, 37], ["COVID", "TEST", 69, 74], ["infection", "PROBLEM", 78, 87], ["RDV", "TREATMENT", 146, 149], ["thromboembolism", "OBSERVATION", 10, 25], ["kidney", "ANATOMY", 130, 136]]], ["It is described a multisystem inflammatory syndrome (MIC-S) that shares clinical features with Kawasaki disease.", [["multisystem inflammatory syndrome", "DISEASE", 18, 51], ["Kawasaki disease", "DISEASE", 95, 111], ["a multisystem inflammatory syndrome", "PROBLEM", 16, 51], ["Kawasaki disease", "PROBLEM", 95, 111], ["multisystem", "OBSERVATION_MODIFIER", 18, 29], ["inflammatory syndrome", "OBSERVATION", 30, 51], ["Kawasaki disease", "OBSERVATION", 95, 111]]], ["Children who present with clinical features of MIS-C should be treated with steroid and if refractory, with monoclonal antibody (Anakinra, tocilizumab) [84] .DiscussionFinally, we would underline the nephrologists' role and its importance in the global clinical evaluation in kidney patients suffering from COVID-19 disease.", [["kidney", "ANATOMY", 276, 282], ["steroid", "CHEMICAL", 76, 83], ["steroid", "CHEMICAL", 76, 83], ["Children", "ORGANISM", 0, 8], ["MIS-C", "GENE_OR_GENE_PRODUCT", 47, 52], ["steroid", "SIMPLE_CHEMICAL", 76, 83], ["Anakinra", "SIMPLE_CHEMICAL", 129, 137], ["tocilizumab", "SIMPLE_CHEMICAL", 139, 150], ["kidney", "ORGAN", 276, 282], ["patients", "ORGANISM", 283, 291], ["monoclonal antibody", "PROTEIN", 108, 127], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 283, 291], ["MIS", "PROBLEM", 47, 50], ["steroid", "TREATMENT", 76, 83], ["monoclonal antibody (Anakinra, tocilizumab", "TREATMENT", 108, 150], ["the global clinical evaluation", "TEST", 242, 272], ["COVID-19 disease", "PROBLEM", 307, 323], ["kidney", "ANATOMY", 276, 282]]], ["Waiting for the availability of new drugs, nephrologists should contribute to choose the best therapy for renal patients in order to reserve the kidney function, to consider possible interactions between drugs and to avoid nephrotoxicity of combined therapies.", [["renal", "ANATOMY", 106, 111], ["kidney", "ANATOMY", 145, 151], ["nephrotoxicity", "DISEASE", 223, 237], ["patients", "ORGANISM", 112, 120], ["kidney", "ORGAN", 145, 151], ["patients", "SPECIES", 112, 120], ["new drugs", "TREATMENT", 32, 41], ["renal patients", "TREATMENT", 106, 120], ["the kidney function", "TEST", 141, 160], ["drugs", "TREATMENT", 204, 209], ["nephrotoxicity", "TREATMENT", 223, 237], ["combined therapies", "TREATMENT", 241, 259], ["renal", "ANATOMY", 106, 111], ["kidney", "ANATOMY", 145, 151]]], ["Furthermore, in unclear cases of renal function impairment, a kidney biopsy would be mandatory.ConclusionIn conclusion, the SARS-CoV-2 outbreaks therapy represents for clinicians one of the most difficult challenge.", [["renal", "ANATOMY", 33, 38], ["kidney", "ANATOMY", 62, 68], ["renal function impairment", "DISEASE", 33, 58], ["SARS", "DISEASE", 124, 128], ["renal", "ORGAN", 33, 38], ["kidney", "ORGAN", 62, 68], ["CoV-2", "ORGANISM", 129, 134], ["SARS-CoV", "SPECIES", 124, 132], ["renal function impairment", "PROBLEM", 33, 58], ["a kidney biopsy", "TEST", 60, 75], ["the SARS", "TEST", 120, 128], ["renal", "ANATOMY", 33, 38], ["function", "OBSERVATION", 39, 47], ["kidney", "ANATOMY", 62, 68], ["biopsy", "OBSERVATION", 69, 75]]], ["Within this setting, renal patients represent a population at high risk of morbidity and mortality, requiring a tailored therapeutic approach.", [["renal", "ANATOMY", 21, 26], ["renal", "CANCER", 21, 26], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["morbidity", "PROBLEM", 75, 84], ["a tailored therapeutic approach", "TREATMENT", 110, 141], ["renal", "ANATOMY", 21, 26], ["morbidity", "OBSERVATION", 75, 84]]], ["Moreover, it is well known that the therapeutic target to treat patients with CKD, AKI, and kidney transplant is complicated by pharmacodynamics and pharmacokinetics aspects, drug interactions, and extracorporeal therapies.", [["kidney", "ANATOMY", 92, 98], ["extracorporeal", "ANATOMY", 198, 212], ["CKD", "DISEASE", 78, 81], ["AKI", "DISEASE", 83, 86], ["patients", "ORGANISM", 64, 72], ["kidney", "ORGAN", 92, 98], ["patients", "SPECIES", 64, 72], ["CKD", "PROBLEM", 78, 81], ["AKI", "PROBLEM", 83, 86], ["kidney transplant", "TREATMENT", 92, 109], ["drug interactions", "TREATMENT", 175, 192], ["extracorporeal therapies", "TREATMENT", 198, 222], ["CKD", "OBSERVATION", 78, 81], ["AKI", "OBSERVATION", 83, 86], ["kidney", "ANATOMY", 92, 98], ["transplant", "OBSERVATION", 99, 109]]], ["Thus, there are no doubts that in renal patients, within the SARS-CoV-2 infection management, the role of nephrologists is useful in order to draw a balance between beneficial and potentially harmful effects of current treatment available.ConclusionAuthor contributions PR, LF, and DS conceived of the study and participated in its organization and coordination.", [["renal", "ANATOMY", 34, 39], ["SARS", "DISEASE", 61, 65], ["infection", "DISEASE", 72, 81], ["renal", "CANCER", 34, 39], ["patients", "ORGANISM", 40, 48], ["CoV-2", "ORGANISM", 66, 71], ["PR", "PROTEIN", 270, 272], ["patients", "SPECIES", 40, 48], ["SARS-CoV", "SPECIES", 61, 69], ["the SARS", "TEST", 57, 65], ["2 infection management", "TREATMENT", 70, 92], ["current treatment", "TREATMENT", 211, 228], ["the study", "TEST", 298, 307], ["no", "UNCERTAINTY", 16, 18], ["renal", "ANATOMY", 34, 39], ["patients", "OBSERVATION", 40, 48]]], ["LF, GG, CE, and NP contributed to the acquisition of scientific materials.", [["CE", "CHEMICAL", 8, 10], ["CE", "TEST", 8, 10], ["NP", "PROBLEM", 16, 18], ["GG", "OBSERVATION", 4, 6]]], ["LF, GG, CE, and DS drafted the manuscript.", [["GG", "OBSERVATION", 4, 6]]], ["All authors contributed to the interpretation of data, manuscript revisions, and read and approved the final manuscript.Conflict of interestThe author(s) declare that they have no conflict of interest.Conflict of interestEthical approval Not required for this paper.Conflict of interestInformed consent For this type of study, formal consent is not required.", [["interestEthical approval", "TREATMENT", 213, 237], ["study", "TEST", 320, 325]]]], "PMC7128695": [["The recent report1 of the first case of the Middle East respiratory syndrome (MERS) coronavirus infection from Seoul, South Korea, on May 20, 2015, has attracted global media attention.", [["Middle East respiratory syndrome (MERS) coronavirus infection", "DISEASE", 44, 105], ["Middle East respiratory", "ORGANISM", 44, 67], ["coronavirus", "SPECIES", 84, 95], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 44, 95], ["the Middle East respiratory syndrome", "PROBLEM", 40, 76], ["coronavirus infection", "PROBLEM", 84, 105], ["Middle", "ANATOMY_MODIFIER", 44, 50], ["respiratory syndrome", "OBSERVATION", 56, 76], ["coronavirus", "OBSERVATION_MODIFIER", 84, 95], ["infection", "OBSERVATION", 96, 105]]], ["The patient was a man aged 68 years who had travelled to the Middle East (Bahrain, United Arab Emirates, Saudi Arabia, and Qatar) from April 18, to May 3, 2015, and developed symptoms on his return to South Korea on May 11, 2015.", [["patient", "ORGANISM", 4, 11], ["man", "ORGANISM", 18, 21], ["patient", "SPECIES", 4, 11], ["man", "SPECIES", 18, 21], ["symptoms", "PROBLEM", 175, 183]]], ["This case could have passed unnoticed, since individual cases of MERS have been reported from all continents without major subsequent secondary spread.", [["MERS", "DISEASE", 65, 69], ["MERS", "CANCER", 65, 69], ["MERS", "PROBLEM", 65, 69], ["secondary", "OBSERVATION_MODIFIER", 134, 143], ["spread", "OBSERVATION", 144, 150]]], ["However, the subsequent major outbreak in Seoul, with 30 MERS cases (two deaths) reported as of June 3, is the largest case cluster of MERS outside the Middle East and a major cause for concern.", [["deaths", "DISEASE", 73, 79], ["major", "OBSERVATION_MODIFIER", 24, 29], ["outbreak", "OBSERVATION_MODIFIER", 30, 38], ["largest", "OBSERVATION_MODIFIER", 111, 118], ["Middle", "ANATOMY_MODIFIER", 152, 158]]], ["This outbreak gives us an opportunity to reflect on progress on global efforts being made to control MERS coronavirus since it was first detected in a patient who had died from a severe respiratory illness in June, 2012, in Jeddah, Saudi Arabia.2", [["respiratory", "ANATOMY", 186, 197], ["MERS coronavirus", "DISEASE", 101, 117], ["respiratory illness", "DISEASE", 186, 205], ["MERS coronavirus", "ORGANISM", 101, 117], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["MERS coronavirus", "SPECIES", 101, 117], ["MERS coronavirus", "PROBLEM", 101, 117], ["a severe respiratory illness", "PROBLEM", 177, 205], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["respiratory", "ANATOMY", 186, 197], ["illness", "OBSERVATION", 198, 205]]]]}